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PROTOCOL SYNOPSIS – BMT CTN PROTOCOL 0201 
 
A Phase III Randomized, Multicenter Study Comparing G-CSF Mobilized Peripheral 
Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
 
Principal Investigator: Claudio Anasetti, M.D. 
 
Study Design: The study is designed as a Phase III, randomized, open label, 
multicenter, prospective, comparative trial of granulocyte colony 
stimulating factor (G-CSF)-mobilized peripheral blood stem cells 
(PBSC) versus marrow from unrelated donors for transplantation in 
patients with hematologic malignancies.  Recipients will be stratified 
by transplant center and disease risk and will be randomized to either 
the PBSC or marrow arm in a 1:1 ratio. 
 
Primary Objective: The primary objective is to compare overall survival rates between 
patients in the two study arms using an intent-to-treat analysis. 
 
Secondary Objectives: Patients randomized to the two study arms and actually transplanted 
will be compared for the following endpoints (patients who do not 
receive a transplant will be excluded from the following analyses): 
survival, incidences of neutrophil and platelet engraftment, graft 
failure acute graft-versus-host disease (GVHD), chronic GVHD, 
time off all immunosuppressive therapy, relapse, infections, adverse 
events, immune reconstitution, and quality of life.  Donors in each 
arm of the study will be compared for time to return to baseline 
functional score, toxicity score, and CBC and WBC differential 
values after donation and quality of life. 
 
Eligibility Criteria: Eligible patients are up to 66.00 years of age, have acute leukemia, 
myelodysplasia, chronic myeloid leukemia, or other 
myeloproliferative disorders, adequate organ function, a 6/6 or 5/6 
HLA-A, B and DRB1 matched unrelated donor, and are able to give 
signed informed consent prior to enrollment.  Donors must be 18 
years of age, meet National Marrow Donor Program (NMDP) 
criteria for donor eligibility and give informed consent prior to 
enrollment. 
 
Treatment Description: Patients will receive one of three conditioning regimens and one of 
two GVHD prophylaxis regimens described in the protocol, at the 
discretion of  the transplant physician.  The transplant physician 
must choose among these regimens prior to randomization to the 
PBSC versus marrow arm.  Marrow cells will be collected from the 
donors using standard procedures.  PBSC donors will receive G-CSF 
10mcg/kg/d x 4-5 days and cells will be collected by a single large 
volume apheresis on Day 5, or two smaller volume apheresis 
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procedures on Days 5 and 6. Marrow or blood cells will not be T-
depleted or frozen.  
 
Accrual Objective: Patients who are candidates for transplantation of G-CSF–mobilized 
PBSC or marrow from HLA-compatible unrelated donors will be 
targeted for accrual.  Approximately 275 patients will be accrued per 
study arm (total of 550 patients). 
 
Accrual Period: The estimated accrual period is three years. 
 
Study Duration: Patients and donors will be followed for two years for evaluation of 
the primary endpoint, with additional follow-up to three years after 
transplantation or donation for evaluation of certain secondary 
endpoints. 
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CHAPTER 1 
 
 
1. BACKGROUND AND RATIONALE 
 
1.1. Rationale 
 
Many studies of allogeneic marrow transplantation have shown that a higher dose of marrow 
cells correlates with more robust hematopoietic engraftment and lower mortality from infectious 
complications.  Peripheral blood stem cells (PBSC) collected after mobilization with granulocyte 
colony stimulating factor (G-CSF) contain a larger number of CD34-positive (CD34) progenitors 
and total cells than bone marrow.  These observations led to the hypothesis that transplantation 
of PBSC would lead to lower mortality compared to transplantation of marrow.  In addition, 
PBSC grafts have a higher T cell content, predicting a possibly more powerful anti-leukemia 
effect.  However, the higher T cell content of PBSC may also lead to increased incidence and 
severity of acute and chronic graft-versus-host disease (GVHD).  This concern is especially 
serious when the donor is unrelated to the recipient.  This prospective, randomized, multi-center 
clinical trial of unrelated donor transplantation will test the hypothesis that transplantation of 
PBSC leads to similar patient survival compared to transplantation of marrow. 
 
1.2. Marrow Cell Dose Effect 
 
Early in the history of hematopoietic stem cell transplantation, marrow cell dose was recognized 
as a limiting factor for engraftment and patient survival.  In patients with aplastic anemia 
conditioned with cyclophosphamide and transplanted with marrow from HLA-identical siblings, 
infusion of fewer than 3 x 108 cells per kilogram (kg) was associated with increased risks of graft 
failure and death (1).  The authors of that report suggested: “The greatest possible amount of 
donor marrow, perhaps supplemented by stem cells derived from the peripheral blood, should be 
obtained.”  Subsequent studies have supported this concept. Improved survival was associated 
with transplantation of higher marrow cell doses in patients with acute myeloid leukemia (AML) 
in first remission (2).  The number of hematopoietic precursor cells in T-replete marrow grafts 
was associated with better survival after transplantation from HLA-identical siblings (3).  A 
higher number of CD34 cells, a population that includes hematopoietic progenitors, was 
associated with improved survival after T cell depleted (4), or T-replete marrow grafts from 
HLA-identical siblings (5). 
 
Cell dose is limiting with transplantation of HLA incompatible unrelated cord blood (6, 7), and 
with transplantation of HLA incompatible related donor marrow (8).  However engraftment 
across the HLA barrier was achieved with the use of T-depleted PBSC containing a large dose of 
CD34 cells (9). 
 
Studies of unrelated donor transplants have shown similar results.  In patients with acute 
leukemia receiving T-replete marrow from unrelated donors, transplantation of a marrow 
nucleated cell dose above 3.65 x 108/kg was associated with faster neutrophil and platelet 
engraftment, decreased incidence of severe GVHD, less non-leukemic deaths and better 
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leukemia-free survival (10, 11).  Similar findings were reported in children receiving unrelated 
donor transplants for chronic myeloid leukemia (CML) (12) or Hurler’s syndrome (13).  Thus, 
there is abundant evidence that marrow is a limiting source of hematopoietic progenitors for 
human transplantation.  This supports the hypothesis that cell doses higher than the average 
marrow harvest might improve transplant outcome. 
 
1.3. PBSC Characteristics 
 
Hematopoietic precursors circulate in the peripheral blood at a low steady state concentration.  
However, administration of a recombinant growth factor, such as G-CSF, causes a rapid increase 
in hematopoietic progenitors in the circulation.  Transplantation of G-CSF-mobilized PBSC can 
produce durable hematopoietic reconstitution when infused after myeloablative conditioning into 
autologous, syngeneic or allogeneic transplant recipients, and engraftment is more rapid with 
PBSC compared to marrow transplantation (14,15,16).  After transplantation, PBSC can 
differentiate into mature hepatocytes and epithelial cells in the skin and gastrointestinal tract, 
indicating that they contain true stem cells (17).  PBSC components collected after G-CSF 
administration contain two to five-fold greater numbers of CD34 cells compared to marrow, 10-
fold greater numbers of T cells (18), 24-fold greater numbers of monocytes, 13-fold greater 
numbers of natural killer (NK) cells (19), and 5-fold greater number of plasmacytoid dendritic 
cells (20).  Therefore, more rapid engraftment of PBSC compared to marrow grafts may not be 
entirely due to increased numbers of CD34 cells, but may result from altered properties of CD34 
cells, or from the infusion of more cells belonging to other lineages.  Clinical studies indicate 
that the risk of acute GVHD is perhaps increased after PBSC transplantation, but is definitely not 
as high as one would expect with the infusion of 1–2 logs more T cells as compared to marrow 
transplantation.  Possible explanations are that T cells are functionally altered in G-CSF-
mobilized PBSC or that infused accessory cells regulate T cell function (21, 22, 23).  Thus, there 
are multiple quantitative and qualitative differences between PBSC and marrow transplants. 
 
1.4. Safety of G-CSF in Normal Donors 
 
The advantages for the donor of PBSC apheresis over marrow harvesting include the avoidance 
of general anesthesia and surgical complications.  A randomized study of sibling transplantation 
demonstrated similar levels of physical discomfort for marrow and PBSC donors, but quicker 
resolution of symptoms for PBSC donors (24).  The administration of G-CSF in doses up to 16 
mcg/kg/day in normal donors has been associated with bone pain, malaise, myalgias, headache, 
leukocytosis and mild thrombocytopenia as common side-effects (25).  These are usually 
reversed within two days of discontinuing the drug.  Self-limited laboratory abnormalities 
include elevated alkaline-phosphatase, lactate dehydrogenase, uric acid, alanine 
aminotransferase, -glutamyl transpeptidase, and decreased potassium and magnesium. G-CSF 
also causes transient hemostatic changes, including increases in prothrombin fragment, 
thrombin–antithrombin complex and D-dimer (26).  Case reports have described rare events, 
such as myocardial infarction (27), or stroke (28), in association with G-CSF administration.  
These thrombotic complications have occurred in donors with a history of peripheral vascular 
disease or myocardial infarction and are unlikely to occur in healthy donors.  Spontaneous spleen 
rupture constitutes an unusual and rare adverse event following G-CSF administration for PBSC 
collection from normal donors (29, 30).  Preliminary National Marow Donor Program (NMDP) 
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experience with PBSC collection from unrelated donors indicates a favorable short-term safety 
profile (31).  The existence of late side-effects from G-CSF will not be known until many donors 
are evaluated for a long period of time. 
 
1.5. Results of Randomized Trials of PBSC versus Marrow from HLA-Identical Siblings 
 
1.5.1. Engraftment 
 
Eight randomized trials compared transplantation of mobilized PBSC and marrow from HLA-
identical sibling donors (32, 33, 34, 35, 36, 37, 38, 39).  Each of these trials enrolled 30 to 350 
patients.  Neutrophil engraftment occurred significantly earlier with PBSC in seven trials, and 
platelet engraftment occurred significantly earlier with PBSC in all trials. 
 
1.5.2. Acute GVHD 
 
The risks of acute grades II–IV GVHD were similar in seven trials, while the European Blood 
and Marrow Transplant (EBMT) study (40) noted a 13% greater incidence of grade II–IV GVHD 
and a 12% greater incidence of grade III–IV GVHD with PBSC.  The following are differences 
among the trials that might explain the reason for discrepant results: 
 
1. All trials utilized the combination of cyclosporine and methotrexate for GVHD 
prevention.  However, the EBMT study omitted the Day 11 methotrexate from the 
regimen while the next two largest trials in the U.S. (41) and Canada (42) included the 
Day 11 methotrexate.  In prior studies of marrow transplantation, the omission of Day 11 
methotrexate increased the risks of GVHD (43). 
 
2. The EBMT trial employed G-CSF post-transplant while the U.S. and the Canadian trials 
did not employ G-CSF.  There is no obvious relationship between post-transplant G-CSF 
and GVHD. 
 
3. The EBMT trial was the largest and therefore had the most statistical power to detect a 
difference. 
 
1.5.3. Chronic GVHD 
 
All trials suggested that PBSC transplantation was associated with more chronic GVHD, and 
three trials found a statistically significant increase of chronic GVHD with PBSC.  The Day 11 
dose of methotrexate was omitted in the three trials where PBSC led to a statistically significant 
increase in incidence of chronic GVHD.  While this observation does not directly explain a 
higher incidence of chronic GVHD, patients who have acute GVHD are more likely to develop 
chronic GVHD and patients who do not receive the Day 11 dose of methotrexate are more likely 
to develop acute GVHD. 
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1.5.4. Survival and Relapse 
 
The second and third largest trials, involving 228 and 172 patients in Canada and the United 
States (U.S.), respectively, showed statistically better survival or disease-free survival with 
PBSC.  In the U.S. study, the survival difference of 13% at 2 years was greatest among patients 
with advanced hematologic malignancies.  Both reduced transplant-related mortality and relapse 
contributed to the improved survival.  In comparison to the other trials, the U.S. study enrolled a 
larger number of patients with advanced hematologic malignancies, where it found a benefit for 
PBSC.  The U.S. trial failed to detect improved survival with PBSC in patients with early stage 
disease, perhaps because of the relatively small sample size or perhaps because both transplant-
related mortality and relapse are lower in this group regardless of graft source.  The Canadian 
trial enrolled patients with early leukemia, and found a significant survival advantage with PBSC 
of 10% at 2 years, primarily due to reduced non-relapse mortality.  The EBMT trial enrolled 
almost exclusively patients with early leukemia, but showed no differences in disease-free 
survival or overall survival.  Differences between the EBMT and the Canadian trials were 
discussed above.  One interpretation of the results of these randomized trials is that the 
administration of post-grafting methotrexate using the full dose and schedule may be critical to 
prevent acute and chronic GVHD after PBSC transplantation and to realize the potential for 
PBSC to improve patient survival by 10–13% at 2 years (44). 
 
1.6. Results of Phase II Studies of PBSC from Unrelated Donors 
 
1.6.1. European Studies 
 
Initial reports demonstrated the feasibility and potential safety of G-CSF-mobilized PBSC 
transplants from unrelated donors (45, 46, 47, 48).  In matched-cohort studies by Ringden (49) 
and Remberger (50), PBSC achieved faster neutrophil and platelet engraftment compared to 
marrow transplantation, but there was no difference in acute GVHD, relapse, treatment-related 
mortality, or survival.  Elmaagacli and colleagues (51) proposed that for patients with CML in 
chronic phase, PBSC transplants are associated with decreased relapse and improved survival 
when compared with bone marrow from HLA-compatible unrelated donors. 
 
1.6.2. Preliminary NMDP Phase II Data in Unrelated Donor PBSC Transplants 
 
A prospective study was conducted by the NMDP to test the feasibility of harvesting PBSC from 
volunteer donors and the safety of transplanting those PBSC to patients with hematological 
disorders.  Donors were treated daily with G-CSF 10 mcg/kg and PBSC were harvested on Days 
5 and 6.  Cells collected on Day 5 were stored at 2-8oC. The two-day collection was transported 
at 2-8oC and infused fresh into the recipient.  An interim analysis evaluated results of 222 
transplants facilitated by 55 apheresis centers and 57 transplant centers over the first year of 
study.  PBSC were obtained in a one-day (n=47) or two-day (n=175) collection.  The median 
blood volume processed was 12 liters per day, and 24 liters per total collection.  Transplant 
regimens varied according to institutional protocols.  The incidence of engraftment was 96%, 
acute GVHD grades II-IV 47%, acute GVHD grades III-IV 33%, extensive chronic GVHD 36%, 
mortality from causes other than relapse 18% at 100 days and 41% at one year, relapse 26%, 
survival 35% and disease-free survival 32% at one year.  Outcomes of PBSC and marrow 
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transplants conducted at the same institutions over the same period were compared.  Multivariate 
analyses were used to adjust for differences in patient age, gender, cytomegalovirus serology, 
performance status, diagnosis and stage, interval from diagnosis to transplant, donor age, HLA 
matching, transplant center, year of transplant, conditioning and immunosuppressive regimen.  
PBSC were associated with faster neutrophil and platelet engraftment, similar risk of GVHD 
grades II-IV, increased GVHD grades III-IV, and similar rates of relapse, survival and disease-
free survival (Table 1.6.2). 
 
 
Table 1.6.2. Multivariate analyses of unrelated donor transplant outcomes assessing the 
risks associated with PBSC compared to bone marrow. 
 
 Odds Ratio 95% Confidence Interval p value 
Neutrophil engraftment on Day 21 4.6 2.5-8.5 < 0.0001 
Platelet engraftment on Day 21 5.2 3.1-8.8 < 0.0001 
 
 Relative Risk 95% Confidence Interval p value 
Acute GVHD grades II-IV 1.3 0.9-1.7 0.12 
Acute GVHD grades III-IV  1.7 1.2-2.5 0.004 
Chronic extensive GVHD 1.3 0.8-1.9 0.26 
    
Relapse 1.0 0.7-1.4 0.85 
Disease-free survival  0.9 0.7-1.1 0.28 
 
Overall death 0.8 0.6-1.0 0.10 
Death first 100 days 0.6 0.4-0.8 0.003 
Death beyond 100 days 1.2 0.8-1.7 0.39 
 
 
Models were controlled for transplant center and year, recipient age, gender, diagnosis, Karnofsky 
score and CMV, donor age, HLA matching, conditioning and immunosuppressive regimens. 
 
Since the survival model did not meet criteria for hazard proportionality over time, two separate 
models tested the association between PBSC and survival.  Within the initial 100 days after 
transplantation, PBSC was associated with a lower hazard of death (RR 0.6, 95% C.I. 0.4-0.8, 
p=0.003), while after the 100 days there was no association (RR 1.2, 95% C.I. 0.8-1.7, p=0.39).  
When reduced-intensity transplants, defined by the use of whole body irradiation at a dose below 
800 cGy, or the use of mycophenolate mofetil were excluded from the analysis, the proportional 
hazards assumption was no longer violated and PBSC was associated with a small and not 
statistically significant survival advantage at 100 days (RR=0.7, p=0.10) and similar overall 
survival (RR=0.95, p=0.73).  A multivariable analysis restricted to PBSC recipients evaluated a 
potential association of CD34 cell dose with outcome.  The analysis found that the highest 
quintile of CD34 cell doses (i.e. > 107 per kg) was associated with an increased risk of chronic 
GVHD but had no association with survival.  The lowest dose of CD34 cells (i.e. < 4 x 106 per 
kg) was not associated with worse outcome. 
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We conclude that harvest and transplantation of PBSC from volunteer donors are feasible and, 
within the constraints of this initial study, appear at least as safe and effective as marrow grafts. 
Since this study was not randomized and the groups of patients who received PBSC and marrow 
differed for many variables, we cannot conclude with certainty that PBSC is better, worse, or the 
same as marrow.  Although the benefits and risks of PBSC transplants from unrelated donors are 
not proven, the utilization of unrelated donor PBSC in the U.S. is increasing: from 223 in the 
year 2000, to 372 in the year 2001, to 523 in the year 2002.  The continued rise in utilization of 
PBSC, in the absence of definitive data demonstrating any long-term advantages over marrow 
and concern about possible increased risks of chronic GVHD, supports the rationale for the 
timely conduct of a prospective randomized trial of PBSC versus marrow in unrelated donor 
transplantation. 
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CHAPTER 2 
 
 
2. STUDY DESIGN 
 
2.1. Study Overview 
 
This is a phase III randomized, open label, multicenter clinical trial sponsored by the NMDP and 
the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).  The objective of the 
trial is to test the null hypothesis that there is no difference in overall survival after PBSC versus 
marrow transplants from HLA compatible unrelated donors.  The study will compare G-CSF-
mobilized PBSC transplantation with bone marrow transplantation from HLA-compatible 
unrelated donors for patients with leukemia, myelodysplastic or myeloproliferative syndromes.  
Conditioning and GVHD prophylaxis regimens will vary by center but at each center will be the 
same for patients randomized to PBSC or marrow.  The primary endpoint of this trial is overall 
survival with two years of follow-up after randomization.  Secondary analyses will consider 
neutrophil and platelet recovery, acute and chronic GVHD, time off all immunosuppressive 
therapy, relapse, infections, adverse events and immune reconstitution.  The trial will include 
evaluation of patient and donor quality of life, composition of the graft, and immune 
reconstitution.  Accrual is anticipated for three years with a follow-up period of three years. 
 
2.2. Hypothesis and Specific Objectives 
 
2.2.1. Primary Hypothesis 
 
The null hypothesis of this randomized clinical trial is that there is no difference in the overall 
survival between PBSC and marrow transplantation.  The alternative statistical hypothesis is that 
survival after PBSC transplantation differs from survival after marrow transplantation; no 
assumption is made about the direction of the difference. 
 
2.2.2. Secondary Hypotheses 
 
PBSC recipients will have faster hematopoietic recovery, improved immune reconstitution, 
lower risks of infection and relapse, higher risks of grades III-IV acute GVHD and chronic 
GVHD, and longer requirement for immune suppressive medications than marrow recipients.  
There will be no detectable difference in the physical, functional, psycho-emotional quality of 
life and the rate of return to work between PBSC and marrow recipients.  There will be 
differences in the pattern of donor quality of life over time from donation between the groups, 
but no detectable differences in overall scores.  PBSC donors will experience more rapid 
recovery from the donation with fewer prolonged painful or disabling complications than 
marrow donors.  There will be no long-term impact on post-donation blood counts in either the 
PBSC or marrow group. 
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2.2.3. Study Objectives 
 
The primary objective of the trial is to compare overall survival rates of the two groups of 
patients starting from the time of randomization to the PBSC or marrow arm.  Secondary 
objectives include comparisons of survival rates after transplantation and incidences of 
neutrophil and platelet recovery, acute GVHD, chronic GVHD, time off all immunosuppressive 
therapy, relapse, infections, adverse events, immune reconstitution and quality of life.  
Additional secondary objectives are to compare donor donation experiences and recovery and 
donor quality of life.  In addition, the study will analyze variables affecting the composition of 
the graft, and assess the relationships between cell subsets in marrow or PBSC grafts and 
transplant outcomes. 
 
2.3. Patient Eligibility for Randomization 
 
2.3.1. Patient Inclusion Criteria 
 
1. Diagnoses to be included: 
1. Acute Myelogenous Leukemia at the following stages: 
 First Remission 
 Second Remission 
 Third or Subsequent Remission 
 Not in Remission 
 
Complete remission is defined as < 5% blasts in the marrow.   
 
2. Acute Lymphoblastic Leukemia at the following stages: 
 First Remission 
 Second Remission 
 Third or Subsequent Remission 
 Not in Remission 
 
Complete remission is defined as < 5% blasts in the marrow.   
 
3. Chronic Myelogenous Leukemia at the following stages: 
 Chronic Phase, defined by up to 10% blasts plus promyelocytes in marrow or blood; 
 Accelerated Phase, defined by > 10% and < 30% blasts plus promyelocytes in the 
marrow or blood; 
 Remission after Blast Phase, defined as < 5% blasts in the marrow, and no 
extramedullary leukemia; 
 Blast Phase, defined as > 30% promyelocytes plus blasts in the marrow or blood. 
4. Myelodysplastic syndromes at the following stages: 
 Refractory anemia 
 Refractory anemia with ringed sideroblasts 
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 Refractory cytopenia with multilineage dysplasia 
 Refractory cytopenia with multilineage dysplasia and ringed sideroblasts 
 Refractory anemia with excess blasts-1 (5-10% blasts) 
 Refractory anemia with excess blasts-2 (10-20% blasts) 
 Myelodysplastic syndrome, unclassified 
 MDS associated with isolated del (5q) 
5. Myeloproliferative diseases: 
 Chronic Myelomonocytic Leukemia 
 Agnogenic Myeloid Metaplasia with Myelofibrosis (Idiopathic Myelofibrosis) 
 Juvenile Myelomonocytic Leukemia 
6. Signed informed consent 
7. Age range: 0.00-66.00 years 
8. Transplant Center location in the United States (U.S.) 
 
2.3.2. Patient Exclusion Criteria 
 
1. Patients with prior allogeneic or autologous transplants using any hematopoietic stem cell 
source PBwill be excluded from this trial. 
2. Diseases to be excluded are: lymphoma (11% of 2001 NMDP transplants), other 
malignant disorders (6%), and non-malignant disorders (9%).  The diseases are excluded 
because they are rarely transplanted or are most often transplanted using reduced 
intensity regimens. 
 
2.4. Additional Patient Exclusion Criteria for Transplant Conditioning 
1. HIV infection 
2. Pregnancy (positive serum β-HCG) or breastfeeding  
3. Creatinine or bilirubin or ALT or AST greater than two times the upper limit of normal 
for the laboratory, whatever the etiology of the abnormal test except for isolated 
hyperbilirubinemia attributed to Gilbert’s Syndrome 
4. Pulmonary disease with FVC, FEV1 or DLCO parameters < 50% predicted 
5. Cardiac insufficiency or coronary artery disease requiring treatment 
6. Active infection requiring systemic antibiotic therapy with antibacterial, antifungal or 
antiviral agents 
7. Concomitant enrollment on Phase I study 
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2.5. Donor Selection Criteria 
 
The evaluation of donors shall be in accordance with existing NMDP Standards Policies and 
Procedures.  All donors shall meet the health criteria for both marrow and PBSC donation. 
 
2.5.1. Donor Inclusion 
1. Matched for HLA-A, B and DRB1 antigens 
 One antigen mismatch at HLA-A, B or DRB1 is acceptable with or without 
mismatch at HLA-C 
 Typing is by DNA techniques: intermediate resolution for A, B and C, and high 
resolution for DRB1.  HLA-C typing is mandatory but will not count in the match. 
2. Signed informed consent.  Donor must consent to both bone marrow harvest and G-CSF 
administration with apheresis.  Donor must provide written informed consent to 
randomization for either marrow or PBSC collection. 
3. Donor must have adequate peripheral venous access for leukapheresis or must consent to 
placement of a central catheter 
4. Donor center affiliation with NMDP 
5. General Donor inclusion criteria specified in the NMDP Standards and Donor Center 
Manual of Operations must be met 
 
2.5.2. Donor Exclusion 
1. Females who are pregnant (positive serum β-HCG) or breastfeeding 
2. Known allergy to G-CSF or to E. Coli-derived recombinant protein products 
3. History of autoimmune disorders 
4. History of deep vein thrombosis or venous thromboembolism 
5. History of iritis or episcleritis 
6. Thrombocytopenia (platelets < 150,000 per mcL) at baseline evaluation 
7. Current treatment with Lithium 
8. Positive Hemoglobin Solubility test for sickle cell trait 
9. Donors receiving experimental therapy or investigational agents 
 
2.6. Treatment Plan 
 
2.6.1. Conditioning Regimens 
 
Three broad groups of conditioning regimens will be included in the protocol: 
1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at 
least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI. 
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2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg 
busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a 
targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL 
at steady state and at least 120 mg/kg cyclophosphamide. 
3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of 
least 120 mg per m2 and a melphalan dose of at least 140 mg per m2. 
 
2.6.1.1. Additional drugs 
 
Additional drugs including anti-T cell antibodies may be added at the transplant center’s 
discretion with the exception of Alemtuzumab (Campath-1H) because of the impaired immune 
reconstitution and increased mortality observed with Alemtuzumab in combination with post-
grafting cyclosporine and methotrexate that will be employed in this study (52). 
 
2.6.1.2. Choice of conditioning regimen 
 
Transplant centers may use different regimens for patients with different diseases as required by 
institutional protocol.  However, the transplant center must declare before randomization what 
conditioning regimen and GVHD prophylaxis regimens will be used for each patient.  The 
specified regimens will be used for the patient whether randomized to receive PBSC or marrow, 
unless there is approval from the Protocol Chair to alter the regimen. 
 
2.6.1.3. Order of administration of cyclophosphamide and TBI 
 
The order of administration of cyclophosphamide and TBI is at the discretion of the transplant 
center.  Within each institution, all patients should receive the cyclophosphamide and TBI in the 
same order.  If cyclophosphamide is given last, there should be at least a one-day rest period 
before the marrow or PBSC infusion. 
 
2.6.1.4. TBI administration 
 
Fractionated TBI will be administered according to the schedules utilized by the participating 
clinical centers.  Radiation sources, dose rates, details of lung shielding, and sites receiving boost 
radiation will also be defined by the institution.  TBI may be delivered from either linear 
accelerator or Cobalt sources.  Lung shielding is preferred but not required during TBI.  For 
institutions using lung shielding, an electron boost to the chest wall should be used, if necessary, 
to achieve a rib dose within the desired therapeutic range. 
 
2.6.1.5. Cyclophosphamide administration 
 
Cyclophosphamide will be administered intravenously.  Mesna is allowed, but not required. 
 
2.6.1.6. Cyclophosphamide and busulfan dose adjustments 
 
Cyclophosphamide and busulfan dose adjustments for ideal body weight are recommended, but 
not required. 
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Ideal Body Weight Formulas: 
 
Patients Over 18 Years 
Males IBW = 50 kg + 2.3 kg/inch over 5 feet 
Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet 
 
Patients 1 to 18 Years of Age 
 
Less than 60 inches 
IBW = (ht2 x 1.65)/1000 where ht = cm, IBW = kg 
 
More than 60 inches 
Males IBW = 39.0 + [2.27 x (ht - 60)] where ht = inches, IBW = kg 
Females IBW = 42.2 + [2.27 x (ht - 60)] where ht = inches, IBW = kg 
 
2.6.1.7. Busulfan 
 
Busulfan may be administered either orally or intravenously.  Busulfan dose may be adjusted 
based on drug clearance estimated before or after starting the conditioning regimen. 
 
2.6.1.8. Fludarabine 
 
Fludarabine will be administered intravenously at the minimum total dose of 120 mg per m2, 
divided into three or more doses administered once daily. 
 
2.6.1.9. Melphalan 
 
Melphalan will be administered intravenously at the minimum dose of 140 mg per m2. 
 
2.6.1.10. Allopurinol 
 
Allopurinol is recommended for patients with high tumor bulk.  A common regimen employs 
allopurinol at the daily dose of 300 mg, beginning at least six hours before the start of 
conditioning and until the day before marrow or PBSC infusion. 
 
2.6.1.11. Intravenous hydration 
 
Intravenous hydration will begin at least 12 hours prior to the first dose of chemotherapy and 
continue for 24 hours following the last dose. 
 
2.6.1.12. Testicular irradiation 
 
Testicular irradiation with 400 cGy may be given to male patients with ALL or other acute 
leukemia according to local institutional practice. 
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2.6.1.13. Central Nervous System prophylaxis 
 
Central Nervous System (CNS) prophylaxis will be given according to institutional practice. 
 
2.6.2. GVHD Prophylaxis Regimen 
 
Two GVHD prophylaxis regimens will be offered and transplant centers can use either. 
1. Cyclosporine/methotrexate 
2. Tacrolimus/methotrexate 
 
Other agents (e.g., glucocorticosteroids) may NOT be added. 
 
The transplant center will declare before randomization what GVHD prophylaxis regimen will 
be used for the patient.  The specified regimen will be used whether the patient is randomized to 
receive PBSC or marrow. 
 
Dose and schedule of administration of cyclosporine, tacrolimus and methotrexate are as detailed 
in Sections 2.6.3 and 2.6.4. 
 
2.6.3. Cyclosporine or Tacrolimus Treatment Regimen 
 
Either cyclosporine or tacrolimus is administered beginning at least one day before 
transplantation for a minimum of six months.  The initial dose should be based on the ideal body 
weight of the recipient.  Subsequent doses are based on blood levels (see below).  
Determinations of blood levels should be performed at least once weekly for the initial three 
months.  Dose reductions should be made if toxicity is present or whole blood levels are above 
the recommended range, in the absence of toxicity.  Dose reductions for high levels without 
toxicity should be conservative, e.g. 25%, to avoid inadequate immunosuppression.   
 
If there is nausea and vomiting, the drug should be given intravenously.  Patients with severe 
intolerance of cyclosporine may be placed on tacrolimus and vice versa. 
 
2.6.3.1. Taper 
 
Fifty or more days after transplantation, in the absence of GVHD, the dose is slowly tapered over 
a minimum of 20 weeks and discontinued. 
 
2.6.3.2. Cyclosporine 
 
The cyclosporine regimen for GVHD prophylaxis will initially employ an intravenous total daily 
dose of 3 mg/kg/day.  Subsequent cyclosporine doses are adjusted to target whole blood levels 
between 150 and 450 ng/mL. 
 
Oral formulations of cyclosporine have variable bioavailability (intestinal absorption), and 
Neoral appears to have a higher and more predictable bioavailability than other formulations.  
When a patient is switched from intravenous cyclosporine to Neoral (preferred) or other oral 
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formulation, the dose is increased by 2.5-3 fold to adjust for the lower bioavailability of Neoral 
compared to intravenous cyclosporine. 
 
Drugs that may affect cyclosporine levels: 
1. Caspofungin, phenobarbital, phenytoin, rifampin, carbamazepine, rifabutin, St. John’s 
Wort (lowers levels) 
2. Glucocorticoids, fluconazole, voriconazole, ketoconazole, itraconazole, grapefruit juice, 
acetazolamide, amiodarone, amlodipine, amprenavir, bromocriptine, chloramphenicol, 
cimetidine, cisapride, clarithromycin, clotrimazole, danazol, diltiazem, erythromycin, 
ethinyl estradiol, metoclopramide, metronidazole, mibefradil, nefazodone, nelfinavir, 
tacrolimus, nifedipine, omeprazole, quinupristin/dalfopristin, ritonavir, saquinavir, 
theophylline, troleandomycin, verapamil (increases levels) 
 
2.6.3.3. Tacrolimus 
 
The tacrolimus regimen for GVHD prophylaxis will initially employ an intravenous total daily 
dose of 0.03 mg/kg.  Subsequent tacrolimus doses are adjusted to target whole blood levels 
between 5 and 15 nano (n) g/mL.  When a patient is switched from intravenous to oral 
tacrolimus, the dose is increased by 3-4 fold to adjust for the lower bioavailability of oral 
compared to intravenous tacrolimus. 
 
Drugs that may affect tacrolimus levels are: 
1. Caspofungin, phenobarbital, phenytoin, rifampin, carbamazepine, rifabutin, St. John’s 
Wort (lowers levels); 
2. Glucocorticoids, fluconazole, voriconazole, ketoconazole, itraconazole, grapefruit juice, 
amprenavir, bromocriptine, chloramphenicol, cimetidine, cisapride, clarithromycin, 
clotrimazole, danazol, diltiazem, erythromycin, ethinyl estradiol, metoclopramide, 
metronidazole, mibefradil, nefazodone, nelfinavir, nifedipine, omeprazole, 
quinupristin/dalfopristin, ritonavir, saquinavir, theophylline, troleandomycin, verapamil 
(increases levels). 
 
2.6.4. Methotrexate Treatment Regimen 
 
The regimen of methotrexate for GVHD prophylaxis will employ intravenous doses of 15 mg per 
m2 on Day 1 post-transplant, and 10 mg per m2 on Days 3, 6, and 11 post-transplant.  Third space 
syndromes with large accumulation of ascites or pleural effusions are a contraindication to the 
use of methotrexate.  Dose reductions should be made for renal, hepatic and mucosal toxicity.  
Determinations of blood levels are indicated 24-72 hours after administration in patients with 
impaired renal function.  Leucovorin rescue should be considered in patients with decreased 
clearance, severe toxicity or fluid accumulation/effusions. 
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Drugs that may increase methotrexate levels are: 
1. Non-steroidal anti inflammatory drugs 
2. Penicillins 
3. Diuretics 
 
2.6.5. PBSC Mobilization and Collection 
 
2.6.5.1. G-CSF Administration to Donors 
 
G-CSF (filgrastim, Amgen) will be administered to the donor at a dose of 10 mcg/kg/day 
subcutaneously for 5 consecutive days.  Daily dose shall not exceed 1200 mcg/day, and volume 
per injection site shall not exceed 2.0 mL.  G-CSF will be administered at approximately the 
same time each day for the first four days.  The fifth dose must be given at least one hour prior to 
aspheresis.  There will be no additional, sixth dose of G-CSF in cases where a second PBSC 
collection is performed on Day 6.  See Donor Companion Manual for G-CSF dose calculation 
and dose modification. 
 
2.6.5.2. PBSC Collection and Evaluation 
 
Apheresis shall begin on Day 5 of G-CSF administration. 
 
Apheresis Devices and Central Catheters - Apheresis shall be accomplished using a continuous-
flow apheresis device.  Bilateral peripheral venous access will be used whenever possible.  
Donors with insufficient peripheral access may undergo placement of a central venous catheter.  
Central catheters should be inserted on the day of collection. 
 
Anticoagulation - A citrate based anticoagulant such as acid citrate dextrose formula A (ACD-
A) should be used unless there is a contraindication or sensitivity to this agent.  Mononuclear cell 
apheresis collections are generally performed using citrate: whole blood ratios of 1:12 to 1:13.  If 
a citrate to whole blood ratio of less than 1:13 is used, then 15 mL of ACD-A should be added to 
the component bag either during apheresis or immediately after the procedure is completed. 
 
CD34 Cell Dose - Typical requested CD34 cell doses are between 5-10 x 106 per kg recipient 
body weight.  Quantitation of the CD34 cell content of the product by the Apheresis Center on 
the day of apheresis is recommended. 
 
Volume Processed – The volume processed shall be linked to the actual weight of the recipient 
as follows.  For recipients weighing less than or equal to 35 kg, a single 12-liter apheresis shall 
be performed.  For recipients weighing greater than 35 kg, the volume processed shall be 15 to 
24 liters.   
 
Single larger volume procedures are encouraged whenever possible.  In a prospective 
randomized study, a single 25-liter PBSC collection yielded the same number of CD34 cells as 
two consecutive daily 15-liter procedures, and was associated with a marked reduction in 
inconvenience and discomfort for the donor (53).  The following table provides a guide to 
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volume processed by weight of recipient.  Volume processed refers to true whole blood volume, 
not including anticoagulant (see Table 2.6.5). 
 
 
Table 2.6.5: Blood Volume Processed in Relation to Recipient Weight 
 
Recipient 
Weight (kg) 
Volume 
Processed (L) Procedure 
≤ 35 12 Single 12-liter apheresis 
36 - 45 15 Single 15-liter apheresis 
46 -55 18 Single 18-liter apheresis or two 12-liter procedures 
56 - 65 22 Single 22-liter apheresis or two 12-liter procedures 
>65 24 Single 24-liter apheresis or two 12-liter procedures 
 
 
Alternatively, centers may use an immediate pre-procedure blood CD34 cell count to determine 
the blood volume to be processed.  If such calculations are used, a CD34 cell dose of 5 x 106 
cells per kg recipient weight should be targeted as a minimum dose. 
 
If more than 5 million CD34 cells per kg recipient weight are collected in the first apheresis, a 
second collection will not be performed. 
 
Prevention of Citrate Toxicity - Apheresis procedures in which greater than 12 liters of blood 
are processed should incorporate a method to prevent severe citrate toxicity.  Such methods 
could include either (1) use of continuous infusion or intermittent bolus heparin administration, 
allowing use of lower citrate infusion rates, or (2) use of continuous infusion or bolus calcium 
salts (calcium chloride or calcium gluconate) (54).  Please refer to the Donor Companion Manual 
for suggested algorithms for heparin or calcium salt administration. 
 
Heparin should not be used in procedures requiring central venous catheter placement. 
 
Product Volume and Sampling - The product should have a minimal volume of 200 mL.  A 1.0 
mL sample for CBC should be obtained by the Apheresis Center from the long tubing tail 
attached to the bag. 
 
Processing, Storage and Shipment - If more than one PBSC procedure is performed, the first 
collection will be stored at 2-8o C overnight.  No processing or freezing of the PBSC product 
shall be done by the apheresis facility.  The transportation of PBSC components shall be in 
accordance with NMDP Standards. Recommended temperature during shipping is 2-8o C using 
cold packs, or similar material.  Dry ice shall not be used. 
 
PBSC components will be infused within 12 hours of arrival at the Transplant Center. 
 
Sample Collection - Each collection will be separately evaluated by the central reference 
laboratory for cellular composition in keeping with Appendix C and the BMT CTN Manual of 
Procedures (MOP) for graft characterization. 
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Records - Records of donation shall be maintained in accordance with NMDP Standards and 
shall include: 
1. Evaluation of donor health 
2. Dose of G-CSF administered per day 
3. Volume and type of anticoagulant administered 
4. Additional anticoagulant added to component 
5. Volume of blood processed, total cell and differential count in product 
6. Pre and post apheresis donor CBCs 
7. Details of storage and shipping 
 
2.6.6. Marrow Collection 
 
Donors randomized to the marrow arm will have marrow harvested on Day 0. 
 
Anesthesia - Either general or regional (epidural, spinal) anesthesia may be used. 
 
Anticoagulation of the Marrow Product - Reagents used, including salt solutions and 
anticoagulants, shall be approved by FDA or similar regulatory agency for human infusion.  
Recommended anticoagulation techniques are 10 U/mL of preservative-free heparin or 10% 
(volume/volume) ACD-A or a combination of both.  Anticoagulants to be used shall be agreed 
upon by the donor and transplant centers before initiation of the transplant conditioning regimen. 
 
Volume and Cell Dose - Requested marrow cell dose will be 4 x 108 nucleated cells per recipient 
actual body weight, as allowed by the weight of the donor.  The volume of marrow shall not 
exceed 20 mL per kg donor weight.  The volume to be collected shall be agreed upon by the 
donor and transplant centers before initiation of the transplant conditioning regimen. 
 
Blood Product Support - Donors shall store blood for autologous use in accordance with existing 
NMDP Standards. 
 
The transfusion of autologous or homologous blood should be in accordance with appropriate 
medical practice.  Homologous blood, if used, shall be irradiated to 2500 cGy. 
 
Processing of Bone Marrow Products - No processing of bone marrow, other than 
anticoagulation, filtration, packaging, and labeling in preparation for transportation, shall be 
performed by the collection center.  Processing of bone marrow for reduction of volume, plasma, 
red blood cells, or fat, may be performed by the transplant center. 
 
Shipping of Bone Marrow - The transportation of bone marrow shall be in accordance with 
NMDP Standards.  Recommended temperature during shipping is 2-8oC using cold packs, or 
similar material.  Dry ice shall not be used. 
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The marrow will be infused within 12 hours of arrival at the Transplant Center. 
 
Sample Collection - Each collection will be separately evaluated by the central reference 
laboratory for cellular composition in keeping with Appendix C and the BMT CTN Manual of 
Procedures (MOP) for graft characterization. 
 
Records - Records of donation shall be maintained in accordance with NMDP Standards and 
include: 
1. Evaluation of donor health 
2. Volume and type of anticoagulant added to component 
3. Volume of marrow, total cell and differential count in product 
4. Pre and post marrow harvest donor CBCs 
5. Details of storage and shipping 
 
2.6.7. PBSC or Marrow Infusion 
 
All patients will receive unmodified G-CSF mobilized PBSC or marrow on Day 0 with the 
following exceptions: plasma and red cell depletion are allowed for volume reduction or ABO 
incompatibility.  CD34 cell selection or T cell removal are not allowed.  PBSC or marrow is 
infused via a central venous catheter using standard blood infusion tubing. 
 
There is no minimum cell dose for CD34 cells or nucleated cells in either arm.  Similarly, there 
is no maximum cell dose.  It is recommended that all products are infused entirely, but this is not 
required.  Non-infusion of portion of the products will be documented.  No portion of the donor 
marrow or PBSC should be cryopreserved if the CD34 cell count is < 5 x 106 per kg recipient 
weight. 
 
In case that there is an unexpected change in the recipient’s condition and the PBSC or marrow 
harvest cannot be cancelled, the transplant center is required to obtain an approval from the 
NMDP prior to cell cryopreservation.  The patient and donor remain on study even if the 
transplant does not occur.   
 
2.6.8. No Blinding of Marrow and PBSC Infusions 
 
Rationale for Blinding - There are at least theoretical concerns that knowledge of the type of the 
stem cell product infused may influence the decision-making process of clinicians and nurses at 
the participating transplant centers.  Patient knowledge may have an impact as well.  This can 
introduce bias in the evaluation of transplant outcomes of interest.  This could be avoided by 
stem cell manipulation (ordinarily at the collection center) aimed at making the two products 
indistinguishable upon infusion and asking recipients to agree via the consent form to refrain 
from asking about the product type.  This was seemingly accomplished in at least one single-
center study (55). 
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Logistical Challenges - There are logistical challenges translating what was successfully carried 
out at a single center into procedures followed by many donor and transplant centers.  More 
importantly, blinding requires manipulation of the graft product and any additional stem cell 
manipulation introduces the potential for cell loss, clerical errors and infusion-related adverse 
events.  The related risks for patients are hard to justify.  Therefore, while acknowledging that 
blinding may be desirable, the decision was made not to pursue blinding in this phase III study. 
 
2.6.9. PBSC Collection or Marrow Harvesting for Additional Stem Cell Products 
 
In the event of primary or secondary graft failure, additional PBSC collection or marrow 
harvesting from the original donor may be requested by transplant centers following established 
NMDP policies.  The selection of PBSC or marrow for the second transplant is not bound to the 
randomization arm; it is the choice of the transplant center physician, and requires donor consent.  
If the same donor is selected, no less than 21 days should elapse between the two donations.  If 
the donor is unwilling or unavailable for a second PBSC or marrow collection, alternative 
management strategies including transplantation from a second donor must be considered by the 
treating physician at the transplant center. 
 
2.6.10. Supportive Care 
 
All supportive care will be given in keeping with BMT CTN MOP and local institutional 
practice. 
 
2.6.11. Growth Factors 
 
Patients must not receive post-transplant growth factors before Day +21, except in the case of 
serious infection where hastening neutrophil recovery by 1-3 days may be critical for survival.  
After Day 21, G-CSF or granulocyte-macrophage colony stimulating factor (GM-CSF) should be 
given for severe neutropenia (ANC < 500/mcL), or as necessary to keep ANC > 1000/mcL. 
 
2.6.12. Blood Products 
 
Transfusion thresholds for blood product support will be consistent with BMT CTN MOP and 
standard institutional guidelines.  All blood products will be irradiated.  Patients who are CMV 
negative will receive CMV negative or filtered blood products from study entry. 
 
2.6.13. Prophylaxis against Infections 
 
All patients will receive prophylaxis against bacterial, fungal and viral infections during the 
peritransplant period according to the BMT CTN MOP.  This will include: 
1. Anti-bacterial prophylaxis: In keeping with the BMT CTN MOP and local institutional 
standards for allogeneic transplants.  Prophylactic antibacterial antibiotics should be used 
for patients during the neutropenic (ANC < 500/mcL) period. 
2. Pneumocystis carinii: Prophylaxis will start at the time of engraftment or on Day 30 post-
transplant according to institutional preference.  Prophylaxis should be continued until 
immunosuppressive drugs are discontinued. 
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3. Antifungal therapy: Prophylaxis with fluconazole or other antifungal agents will begin 
with conditioning therapy and continue until at least Day 70 post-transplant. 
4. HSV/VZV: Prophylaxis will begin with conditioning therapy and continue up to one year 
post-allograft as directed by standard institutional practice. 
5. CMV: Monitoring and preemptive treatment strategy will be in accordance with the BMT 
CTN MOP and local institutional practice. 
 
2.6.14. Intravenous Immune Globulin (IVIG) 
 
IVIG administraion will be left to local institutional standard practice. 
 
2.6.15. Failure to Engraft 
 
If the ANC has not reached 500/mcL by Day 21, G-CSF, GM-CSF or other cytokines may be 
utilized. If the ANC is < 100/mcL on Day 28 post-transplant, the patient should be considered 
for a second infusion of stem cells from the original donor or retransplantation from a different 
donor using appropriate Transplant Center protocols. 
 
2.6.16. Post-transplant Donor Leukocyte Infusions (DLI) 
 
DLI may be given to patients for a recurrent or a second malignancy according to institutional 
practice and in accordance with the NMDP policy, if the donor is available and provides consent.  
The use of DLI will be recorded and analyzed as a secondary endpoint. 
 
2.6.17. Risks and Toxicities 
 
Recipients of marrow or PBSC transplants incur risks from pre-transplant conditioning, the graft 
itself, and post-transplant therapies.  All risks must be weighed against the risk of the malignancy 
for which the transplant is prescribed.  Major risks following transplantation include: 
1. Damage of any major organ may occur as a result of cumulative toxicity from anti-
neoplastic therapy, the conditioning regimen, drug toxicity, infection, or GVHD. 
2. Graft failure can result from genetic disparity between donor and recipient, insufficient 
immunosuppression of the recipient or poor cell dose. 
3. GVHD can be either acute or chronic; both types predispose to infection. 
4. Life-threatening infections may develop in patients with and without GVHD. These can 
be of a bacterial, viral, parasitic, or fungal nature. 
5. Relapse of the underlying disease may occur, especially in patients with far advanced 
disease status at time of transplant. 
6. All of these toxicities may be severe enough to result in death. 
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CHAPTER 3 
 
 
3. STUDY ENDPOINTS 
 
3.1. Primary Endpoint 
 
The primary endpoint is overall survival after two years follow up.  The event analyzed is 
death from any cause.  Patients alive at the time of last observation will be censored. 
 
3.2. Secondary Endpoints 
 
3.2.1. Overall Post-transplant Survival  
 
The endpoint is patient overall survival after two years of follow up.  Only patients who 
receive their transplant are included.  The event analyzed is death from any cause.  Patients alive 
at the time of last observation will be censored. 
 
3.2.2. Neutrophil Engraftment > 500/mcL 
 
This is defined as achieving ANC > 500/mcL for three consecutive measurements on different 
days.  The first of the three days will be designated the day of neutrophil engraftment.  This 
endpoint will be evaluated through 100 days. 
 
3.2.3. Primary Graft Failure 
 
This is defined by lack of neutrophil engraftment by 100 days in patients surviving a minimum 
of 14 days. 
 
3.2.4. Secondary Graft Failure 
 
This is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil 
counts < 500/mcL unresponsive to growth factor therapy. 
 
3.2.5. Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent 
 
This is defined as achieving platelet counts > 20,000 and 50,000/mcL for consecutive 
measurements over seven days without requiring platelet transfusions.  The first of the seven 
days will be designated the day of platelet engraftment.  This endpoint will be evaluated through 
100 days. 
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3.2.6. Acute GVHD of Grades II-IV and III-IV 
 
Acute GVHD is graded according to the BMT CTN MOP.  The first day of acute GVHD onset at 
a certain grade will be used to calculate cumulative incidence curves for that GVHD grade (e.g., 
if the onset of grade I acute GVHD is on Day 19 post-transplant and onset of grade III is on Day 
70 post-transplant, time to grade III is Day 70).  This endpoint will be evaluated through 100 
days. 
 
3.2.7. Chronic GVHD 
 
Chronic GVHD is scored according to the BMT CTN MOP.  The first day of chronic GVHD 
onset will be used to calculate cumulative incidence curves. 
 
3.2.8. Current Immunosuppressive (IS) Free Survival 
 
This function is an estimate of the chance that a patient is alive and not receiving 
immunosuppressive therapy at a given point in time for any reason.  This outcome measure takes 
into account subsequent immunosuppressive therapy that may occur following discontinuation of 
initial immunosuppressive therapy.  A similar approach has been used in analyzing the role of 
DLI following allogeneic transplants for CML where relapse is expected to be frequent but 
subsequent disease control is also expected after treatment of relapse with DLI (56).  A multi-
state model will estimate this with inputs being the patient’s immunosuppressive therapy and 
survival status at each potential examination time.  Immunosuppressive drugs include 
cyclosporine, tacrolimus, prednisone, methotrexate, azathioprine, mycophenolate mofetil, 
sirolimus, clofazimine, PUVA, anti-thymocyte globulin, OKT3, daclizumab, basilixumab, 
visilizumab, infliximab and alemtuzumab. 
 
3.2.9. Relapse of the Original Malignancy 
 
Relapse of Malignancy - Testing for recurrent malignancy in the blood, marrow or other sites 
will be used to assess relapse after transplantation.  For the purpose of this study, relapse is 
defined by either morphological or cytogenetic evidence of AML, ALL, CML, MDS, CMML, 
Myelofibrosis or JMML consistent with pre-transplant features.   
 
Minimal Residual Disease - Minimal residual disease is defined by the sole evidence of 
malignant cells by flow cytometry, or fluorescent in situ hybridization (FISH), or Southern blot, 
or Western blot, or polymerase chain reaction (PCR), or other techniques, in absence of 
morphological or cytogenetic evidence of disease in blood or marrow.  Since the frequency of 
testing for minimal residual disease is highly variable among centers, and the sensitivity is highly 
variable among laboratory techniques, evidence of minimal residual disease will not be sufficient 
to meet the definition of relapse in the context of this study, even if transplant physicians will 
utilize the information to alter therapy.  Data on tapering immunosuppression, infusing donor T 
cells, administering chemotherapy or biological agents to attempt reducing the tumor load will be 
captured in the case report forms. 
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Acute Leukemia - Relapse will be diagnosed when: 
1. Leukemic blasts (>25%) are documented in the blood or bone marrow after 
transplantation, or  
2. Leukemic blasts >5% and < 25% are documented in the blood or bone marrow 
and supported by reappearance of cytogenetic abnormality, or  
3. Leukemic blasts >5% and < 25% are documented in the blood or bone marrow on 
at least 2 occasions occasions, or  
4. There is leukemia detected at an extramedullary site.  
 
Chronic Myelogenous Leukemia (CML) -  
 
Hematologic relapse will be diagnosed when: 
1. Immature hematopoietic cells are persistently documented in the peripheral blood, 
or  
2. There is myeloid hyperplasia in the bone marrow in the absence of infection or 
hematopoietic growth factor therapy. 
 
Cytogenetic relapse will be diagnosed when:  
1. 50% of the metaphases exhibit the characteristic 9;22 translocation with at least 
ten metaphases analyzed, or 
2. At least one metaphase exhibits the 9;22 translocation on each of two separate 
consecutive examinations at least one month apart, regardless of number of 
metaphases analyzed. 
Myelodysplastic (MDS) and Myeloproliferative Syndromes (include CMML, AMM or 
Idiopathic Myelofibrosis, and JMML) - Relapse will be diagnosed when there is: 
1. Reappearance of pre-transplant morphologic abnormalities, detected in two 
consecutive bone marrow specimens taken at least one month apart, or 
2. Satisfying above criteria for evolution into acute leukemia, or   
3. Reappearance of pre-transplant cytogenetic abnormalities in at least 50% of 
metaphases with at least ten methaphases examined, or 
4. Reappearance of pre-transplant cytogenetic abnormality in at least one metaphase 
on each of two separate consecutive examinations at least one month apart, 
regardless of the number of metaphases analyzed. 
 
3.2.10. Donor Lymphocte Infusion (DLI) 
 
The indication for DLI will be collected, i.e., treatment of relapse of the original malignancy, 
treatment of a new malignancy, boost for immune reconstitution, reversal of graft failure, or 
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others.  Pretreatment of the recipient with chemotherapy or irradiation will be recorded.  
Pretreatment of the donor with G-CSF will be recorded. 
 
3.2.11. Infections 
 
Microbiologically documented infections will be reported by site of disease, date of onset, 
severity and resolution, if any.  For definitions, see Chapter 6 and the BMT CTN MOP. 
 
3.2.12. Immune Reconstitution 
 
This will be measured in all patients by: 
1. The rate of peripheral blood repopulation by CD3, CD4, CD8 and  T cells, NK cells, 
DC1, DC2, monocytes and B cells. 
2. The rate of blood repopulation by EBV or CMV-specific T cells measured by tetramer 
staining, and response to CMV, tetanus, pneumococcus and aspergillus antigens ex vivo. 
3. The rate of blood repopulation with recent thymus emigrants measured by T cell receptor 
excision circle-positive T cells. 
4. The serum levels of immunoglobulin G, A, and M and plasma levels of IL-2 and IL-7. 
5. Hepatitis A, Tetanus, Diphtheria and Pneumococcus antibody titers in response to 
immunization. 
 
3.2.13. Patient and Donor Quality of Life 
 
Details about these endpoints are given in Chapters 7 and 8. 
 
3.2.14. Donor Recovery to Baseline Functional Score 
 
Appropriate statistical methods to detect trends over the available spectrum of donor follow-up 
times will be employed for baseline functionality recovery to baseline endpoints.  
 
3.2.15. Donor Recovery to Baseline Toxicity Scores 
 
Appropriate statistical methods to detect trends over the available spectrum of donor follow-up 
times will be employed for baseline toxicity recovery to baseline endpoints.  
 
3.2.16. Donor Recovery to Baseline CBC and WBC Differential Values 
 
Appropriate statistical methods to detect trends over the available spectrum of donor follow-up 
time will be employed for baseline CBC recovery to baseline endpoints.  
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CHAPTER 4 
 
 
4. PATIENT AND DONOR REGISTRATION, ENROLLMENT AND EVALUATION 
 
4.1. Donor Search Initiation 
 
Transplant centers will initiate the donor search by submitting patient demographics, HLA, and 
disease information to the NMDP coordinating center, using standard NMDP forms and 
additional data entry mechanisms developed for this trial.  It is anticipated that 50-90% of the 
patients will have suitable donors identified as defined by HLA type, transplant center donor 
matching preferences, patient age, disease risk, and financial coverage (see step (1) in Figure 
4.1).  It is anticipated that the duration of the search will vary between two months and more than 
one year with a median time of approximately four months. 
 
Table 4.1 below highlights the event flow for recipients and donors in the trial.  The time scale is 
arbitrary beginning at the top and flowing downward.  Critical steps described in this Section are 
numbered (1) through (10). 
 
 
Figure 4.1 – Study Treatment 
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4.2. Approaching Patients About the Study 
 
Typically, transplant physicians first interact with the patient in a consultation session either 
before or, more likely, after initiation of the donor search, and in rare cases after a suitable donor 
has been identified.  During the initial consultation session, physicians explain the risks and 
benefits of transplant approaches and alternative therapies.  They also explain transplant 
modalities including the potential sources of hematopoietic cells for transplantation.  In such a 
setting, it will be appropriate for transplant physicians to approach eligible patients about their 
potential interest in the randomized trial of PBSC versus marrow transplantation.  Since most 
patients are affected by serious, rapidly progressing diseases and must proceed to transplantation 
as soon as possible, approaching patients for study participation at this stage will avoid ‘last 
minute’ pressure to obtain patient informed consent, and allow the required donor and patient 
procedures to be scheduled as soon as a suitable donor is identified. 
 
4.3. Screening for Patient Eligibility 
 
Transplant center physicians will evaluate the patient eligibility for randomization onto this study 
(Section 2.3).  For patients who cannot be seen at the transplant center, data to satisfy eligibility 
criteria will be obtained through direct communication with the patient and the patient's 
physician.  Eligibility criteria will be verified through the Internet Data Entry Systems (IDES).  
Patients that are not eligible will proceed off study and no further follow-up will be obtained. 
 
4.4. Patient Consent to Randomization 
 
Eligible patients who would like to participate in the trial will sign the appropriate Institutional 
Review Board (IRB) approved form, providing evidence of informed consent to proceed to 
randomization to PBSC or marrow, contingent upon finding a suitable donor willing to 
participate in the trial (see step (2) in Figure 4.1).  Patients will be informed that participation is 
dependent upon donor willingness to be randomized and upon the patient meeting specified 
eligibility criteria immediately prior to start of conditioning.  Alternate approaches in the event 
that either of these criteria is not met will be explained.  Patients who cannot travel to the 
transplant center because of medical contraindications or other reasons will be counseled by 
phone and will be allowed to mail the signed consent form.  Transplant center personnel will 
record the documentation of patient consent in IDES. 
 
4.5. Patient Registration 
 
Transplant center study coordinators will register eligible patients through IDES. 
 
4.6. Patient Refusal 
 
Patients who decline randomization on this study will proceed towards transplant off study.  
Transplant center personnel will record patient refusal in IDES. 
 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 1.0 dated June 17, 2003 
4-3 
4.7. Donor Selection and Work-Up 
 
As suitably matched donors are identified, the transplant center is notified. The transplant 
physician selects the best donor for the patient and requests donor ‘work-up’. Donor ‘work-up’ 
consists of a physical evaluation and an information session (see step (3) in Figure 4.1).  
Selection of the best donor occurs before the donor is approached for participation in this study. 
 
4.8. Donor Deferral 
 
If a candidate donor is found unsuitable to donate, an alternative donor will be sought. 
 
4.9. Donor Consent 
 
During the donor information session, the donor center physician explains the cell harvest 
procedures to the candidate donor.  Donors for patients who have consented to this study will be 
asked to participate in the study at this time (see step (4) in Figure 4.1).  Donors will express 
their consent to participate by signing an IRB-approved consent form.  Documentation of donor 
consent will be recorded in IDES. 
 
4.10. Donor Refusal 
 
If a donor refuses to participate in the study, the patient will be off study.  Donor refusal will be 
recorded in IDES.  The donor will be asked to donate either marrow or PBSC, according to 
transplant physician preference and standard NMDP policies.  
 
4.11. Transplant Protocol Registration 
 
Before randomization occurs, the transplant center must state through IDES which conditioning 
regimen and GVHD prophylaxis regimen will be used (see step (5) in Figure 4.1).  Such a 
registration step will avoid potential biases that preferential association of a certain regimen with 
one treatment arm could confer to the study.  At this stage, the transplant center will also verify 
that the patient is still a candidate for transplantation, and eligible for the trial. 
 
4.12. Randomization 
 
Once both patient and donor are deemed eligible and have given written informed consent, and 
the transplant center has confirmed patient eligibility and registered the patient’s conditioning 
and GVHD prevention protocols, randomization occurs (see step (6) in Figure 4.1). 
 
4.13. Treatment Scheduling 
 
Once the randomization arm is known, a transplant calendar is negotiated between the search-
coordinating unit, donor center and transplant center, and the transplant date is scheduled (see 
step (7) in Figure 4.1).  It is anticipated that 2-3 weeks will elapse between the randomization 
and the day of cell harvest and transplant.  This period is necessary to schedule the marrow or 
PBSC harvest.  During this period, donors may donate and store up to to 3 autologous red cell 
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units, if randomized to marrow, or receive G-CSF injections, if randomized to PBSC.  During 
this period, transplant center physicians will complete the patient evaluation. 
 
4.14. Patient Evaluation 
 
The patient pre-transplant evaluation will be completed during the three weeks preceding the 
transplant (see step (8) in Figure 4.1).  This step is necessary because patient organ function, 
infection status and status of malignancy may vary over time.  This evaluation will protect 
patients with a new contraindication to transplant from initiating transplant therapy at an unsafe 
time. 
 
4.15. Patient Final Eligibility Screening 
 
Within seven days before commencement of pre-transplant conditioning, patients will undergo a 
‘final’ eligibility screening (see Section 2.4 and step (9) in Figure 4.1).  Transplant center 
personnel will record the screening results in IDES. 
 
4.16. Patient Deferral 
 
Patients who meet exclusion criteria will be deferred.  One option is remaining on study and 
rescheduling the transplant when eligibility criteria are again met, for example after clearance of 
a serious infection.  Another option is proceeding to transplant or other treatment off study, if 
that is the best treatment option determined by the transplant physician for the patient.  Patients 
deferred will continue to be followed for the primary endpoint. 
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4.17. Study Monitoring 
 
A visit schedule based on transplant date is displayed for printing in IDES and is referred to as 
‘Follow-up Schedule.’. 
 
Table 4.17 — Follow-Up Schedule 
 
Study Visit Target Day Post-Transplant
1 week 7  2 days 
2 week 14  2 days 
3 week 21  2 days 
4 week 28  2 days 
5 week 35  2 days 
6 week 42  2 days 
7 week 49  2 days 
8 week 56  2 days 
9 week 63  2 days 
10 week 70  2 days 
11 week 77  2 days 
12 week 84  2 days 
13 week 91  2 days 
100 day 100 2 days 
6 month 180  28 days 
9 month 270  days 
12 month 365  28 days 
24 month 730  28 days 
36 month 1095  28 days 
 
 
4.17.1. Case Report Forms 
 
A description of the forms, the procedures required for forms completion and timeliness of 
submission can be found in the Data Management Handbook and User’s Guide.  Forms that are 
not received within the specified time are considered delinquent.  Transplant Centers can view 
submitted past due, and expected forms via IDES.  A missing form will continue to be requested 
either until the form is reported, or until an exception is granted. 
 
4.17.2. Reporting Patient Deaths 
 
Recipient death while at the transplant center must be reported to the BMT CTN Data 
Coordinating Center (DCC) within three business days of the event.  Death after the patient has 
left the transplant center must be reported within three business days of the event notification but 
no more than 30 days after the event.  If the cause of death is unknown, it need not be recorded at 
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the time of initial reporting.  However, once the cause of death is determined, the form must be 
updated. 
 
4.17.3. Reporting Serious Adverse Events 
 
4.17.3.1. Patient SAEs 
 
Reporting of patient serious adverse events (SAE) will be consistent with standard BMT CTN 
procedures.  Serious and unexpected adverse events should be reported within three working 
days.  Other SAEs will be tracked periodically as defined in the Form Submission Schedule, 
staged according to NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 
3.0 dated March 31, 2003.  The Data and Safety Monitoring Board will receive summary reports 
of all adverse experiences on at least an annual basis. 
 
4.17.3.2. Donor SAEs 
 
Marrow Donors - Reporting of SAEs following marrow donation will be consistent with 
standard BMT CTN procedures.  Serious and unexpected adverse events should be reported 
within three working days, and will include unexpected or life-threatening complications of 
anesthesia, and severe pain, debility, or incapacitation related to mechanical injury during 
marrow harvest.  Other SAEs, including prolonged hospitalization or hospital readmission, will 
be tracked, staged according to CTCAE, and reported on appropriate systems. 
 
PBSC Donors - Reporting of SAEs following G-CSF administration and apheresis donation will 
be consistent with NMDP policies and procedures.  Serious and unexpected adverse events 
should be reported within three working days, and will include complications of central line 
placement, and severe or life-threatening reactions to G-CSF administration or apheresis.  The 
Data and Safety Monitoring Board will receive summary reports of all adverse donor 
experiences on at least an annual basis. 
 
4.17.4. Patient Assessments 
 
Table 4.17.4 summarizes patient clinical assessments over the course of the study. 
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Table 4.17.4 – Summary of Patient Clinical Assessments 
 
Assessment Baseline Weeks 1–12 
1 
month 
3 
months
6 
months
7 
months
9 
months
11 
months
12 
months
24 
months
36 
months
60 
months8
History and physical 
exam, height, weight X X 
6   X    X X X  
Karnofsky or Lansky 
performance status X X 
6   X    X X X  
CBC and differential, 
platelet count X X 
1,2,3   X    X X X  
Blood chemistries 
(creatinine, bilirubin, 
alkaline phosphastase, 
AST, ALT) 
X X 4,5   X 
   
X X X 
 
Infectious disease titers 
(CMV, hepatitis panel, 
herpes simplex, varicella 
zoster, syphilis, HIV and 
HTLV1/2) 
X     
   
   
 
EKG X            
DLCO, FEV1 and FVC X            
Bone marrow aspirate 
(pathology, cytogenetics) X   X  
   X X X  
Bone marrow biopsy    X     X X X  
Patient anti-donor 
lymphocyte cross match 
(in mismatched 
transplants only) 
X     
   
   
 
Chest X-ray X            
β-HCG serum pregnancy 
test X     
       
GVHD and other 
morbidity  X 
6   X    X X X  
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Assessment Baseline Weeks 1–12 
1 
month 
3 
months
6 
months
7 
months
9 
months
11 
months
12 
months
24 
months
36 
months
60 
months8
5 mL sample from 
allograft for graft 
characterization 
X     
   
   
 
5 mL heparinized blood 
sample for HLA typing X     
       
Heparinized peripheral 
blood7 for immune 
reconstitution assays 
  X X X 
 
 
 
X X  
 
Plasma IL-7 and IL-2 
levels    X X 
   X X   
dT vaccination     X   X     
PCV7 vaccination      X X      
PPV23 vaccination        X     
Hep A vaccination     X   X     
dT Antibodies  X    X   X X X   
S. pneum. Ab and ops X    X   X X X   
Hep A Ab titer X    X   X X X   
Quantitative Ig X    X   X X X   
Peripheral blood T cell 
chimerism* X  X X  
   X X   
Patient quality of life 
interviews X    X 
   X X  X 
1 CBC performed three times weekly from Day 0 until ANC >500 mcL for three days after nadir. 
2 CBC performed twice weekly until Day 28. 
3 CBC performed weekly after Day 28 until 12 weeks post-transplant. 
4 Blood chemistries performed twice weekly until Day 28. 
5 Blood chemistries performed weekly after Day 28 until 12 weeks post-transplant. 
6 GVHD assessments performed weekly until Day 100 post-transplant. 
7 Immune reconstitution assays include: FACS analysis, tetramer assay, TREC analysis, plasma IL-2 and IL-7 levels, T cell responses, and post-vaccinations 
antibody titers. 
8 Will not be analyzed as part of the randomized trial. 
* Recommended but not mandatory. 
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4.17.4.1. Pre-Transplant Evaluations 
 
The following observations should be determined < 4 weeks before initiation of conditioning 
therapy: 
1. History, physical examination, height and weight. 
2. Karnofsky or Lansky performance status. 
3. CBC with differential and platelet count, creatinine, bilirubin, alkaline phosphatase, AST, 
ALT. 
4. CMV antibody test, hepatitis panel (HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), 
herpes simplex virus, varicella zoster virus, syphilis, HIV and HTLV1/2 antibody. 
5. EKG. 
6. DLCO, FEV1, and FVC. 
7. Bone marrow aspirates for pathology and cytogenetics. 
8. If the donor is HLA mismatched, patient anti-donor lymphocyte cross match must be 
performed to rule out donor-directed sensitization (57, 58). 
9. Chest X-ray. 
10. -HCG for serum pregnancy test (females only). 
11. Heparinized blood sample for post-transplant chimerism assay (recommended but not 
mandatory). 
12. Heparinized blood sample for retrospective HLA typing to the NMDP repository. A 
separate NMDP consent form is used for blood sample acquisition for the NMDP 
repository and HLA typing. 
13. Sample from the marrow or PBSC allograft for graft characterization. 
14. Quality of life survey. 
 
4.17.4.2. Post-Transplant Evaluations 
1. History and physical exam to assess GVHD and other morbidity weekly until Day 100 
post-transplant, then at six months, one year and then yearly until three years post-
transplant. GVHD evaluation and grading to be in keeping with BMT CTN MOP. 
2. Data on occurrence of infections will be collected as specified in Chapter 6. 
3. CBC at least three times a week from Day 0 until ANC > 500 mcL for 3 days after nadir 
reached. Thereafter CBC twice per week until Day 28, then weekly until 12 weeks, then 
six months, one year and then yearly until three years post-transplant. 
4. Creatinine, bilirubin, alkaline phosphatase, ALT, AST, twice a week until Day 28 (or 
four weeks) and then weekly until 12 weeks, six months, one year and then yearly until 
three years post-transplant. 
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5. Bone marrow aspirate and biopsy to pathology, aspirate to cytogenetics at 12 weeks, one 
year and then yearly until three years post transplant. 
6. Heparinized blood for quantitation of peripheral blood immune reconstitution at 1, 3, 6, 
12, and 24 months post-transplant. 
7. Serum for quantification of IgG, IgM and IgA, and antibody titers to diphtheria, tetanus, 
pneumococcus and hepatitis A at 6, 11, 12 and 24 months post-transplant. 
8. Quantitation of peripheral blood T cell chimerism at 1, 3, 12, and 24 months post-
transplant (recommended but not mandatory – see Appendix C). 
9. Quality of life surveys at 6 months, 1 year and 2 years. 
 
4.17.5. Required Observations for Donor  
 
Routine pre-allografting work-up in keeping with NMDP guidelines (see Donor Companion 
Manual for this protocol).  Work-up to include the following: 
1. Complete history and physical examination. 
2. HLA typing of heparinized peripheral blood sample to determine compatibility. 
3. Serologic testing for hepatitis B and C (HBsAg, anti-HBc, anti-HCV), CMV, syphilis, 
HIV1/2 and HTLV I/II. Molecular testing for HIV, HCV, and West Nile virus as 
recommended by the FDA. 
4. Hemoglobin solubility for sickle cell trait, if indicated. 
5. ABO Rh blood typing.  In the case of donor-recipient ABO incompatibility, the graft 
should be manipulated according to institutional practices. 
6. Heparinized blood samples for HLA typing to NMDP repository.  A separate NMDP 
consent form is used. 
7. Heparinized blood sample for Chimerism assays, if requested by the transplant center 
(not mandatory but recommended). 
8. Baseline functional score, toxicity scores, and CBC and WBC differential. 
9. Functional score and toxicity scores on each day of G-CSF administration. 
10. Number of autologous units collected prior to marrow donation. 
11. Type and duration of anesthesia, volume of marrow collected, pre- and post-marrow 
donation CBC and WBC differential, and number of autologous units infused. 
12. Pre- and post-leukapheresis CBC and WBC differential and volume of whole blood 
processed. 
13. Functional score and toxicity scores post-donation at two days, weekly until donor 
reports recovery from donation, one month, six month, and annually for a minimum of 
three years. 
14. CBC post-donation at one month, six months, and annually for a minimum of three years. 
15. Quality of life assessments as specified in Chapter 8.  
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CHAPTER 5 
 
 
5. STATISTICAL CONSIDERATIONS 
 
5.1. Study Design 
 
The study is designed as a Phase III, randomized, multicenter, prospective comparative study of 
G-CSF mobilized PBSC versus marrow transplantation in HLA compatible unrelated donors.  
The target enrollment is 550 patients. 
 
5.1.1. Accrual 
 
It is estimated that three years of accrual will be necessary to enroll the targeted sample size.  
Both Core and non-Core Centers will enroll patients on this study.  Details of accrual estimates 
follow in the sample size section. 
 
5.1.2. Randomization 
 
All patient-donor pairs who have consented to the randomization as detailed earlier will be 
randomized once the donor has been cleared for donation.  Randomization will be performed in a 
1:1 ratio using random block sizes for the PBSC and marrow arms.  Randomization will be 
stratified by transplant center and by disease risk (see Table 5.3). 
 
5.1.3. Primary Endpoint 
 
The primary endpoint is the overall survival, after two years of follow-up on all patients. 
 
5.1.4. Primary Hypothesis 
 
The primary statistical hypothesis of the study is that there will not be a difference in the overall 
survival with PBSC transplantation as compared to marrow transplantation.  The alternative 
statistical hypothesis is that the survival curves after PBSC versus marrow transplantation will 
differ. 
 
5.2. Sample Size and Power Considerations 
 
Overall survival between the standard and experimental therapy arms will be compared using the 
stratified log-rank test.  All patients who are randomized will be included in the analysis based 
on an intention to treat.  Survival times will be based on time since randomization, so that those 
patients who drop out of the study after randomization but before transplant can still be included.  
The final analysis will be performed after all patients have been followed for a minimum of two 
years post-transplant.  Based on the eligibility criteria, the estimated survival for the marrow 
transplant arm at 100 days, 1 year, 2 years, 3 years, 4 years, and 5 years are given in Table 5.3 
below.  A piecewise exponential survival curve was fitted to these data to determine the 
anticipated survival curve for patients actually receiving a marrow transplant.  Then a constant 
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relative risk was applied to this curve resulting in an improvement of 12.5% at two years.  This 
forms the anticipated survival curve for the patients who actually receive a PBSC transplant.  
Because randomization takes place prior to determination of a patient’s eligibility for transplant, 
NMDP experience indicates that 15% of the randomized patients in each arm will never receive 
a transplant.  These patients are typically high risk and are assumed to all die within six months.  
Therefore, the intent-to-treat populations to be compared in the primary analysis are assumed to 
be a mixture of 85% who receive the randomized stem cell source, and 15% who never receive a 
transplant.  A total sample size of 550 patients will have 80% power to detect the resulting 
difference in survival curves in the intent-to-treat populations, using a two-sided log-rank test 
with alpha=0.05. 
 
5.3. Accrual 
 
This study will accrue patients from U.S. Transplant Centers and donors from U.S. Donor 
Centers, according to the eligibilitiy criteria described in Chapter 2.  According to data from 
NMDP (based on 2002 numbers), there are approximately 350 patients who would be potentially 
eligible for this protocol transplanted in 14 non-Pediatric Blood and Marrow Transplant 
Corsortium (PBMTC) Core Centers per year.  Assuming an enrollment rate of 40%, the Network 
plans to accrue 140 patients annually from these Core Centers.  Among the PBMTC Centers 
doing at least 6 pediatric or at least 15 total unrelated donor peripheral blood or bone marrow 
transplants a year (N=9 centers), NMDP data indicate that there are about 125 potentially eligible 
for this study a year (70 under the age of 20 years).  Assuming an enrollment rate of 40%, the 
Network plans to accrue an additional 50 patients annually.  The Network plans to accrue an 
additional 40 patients a year from non-Core NMDP Centers.  In summary, we estimate accruing 
190 patients annually from 23 Core Centers and 40 from 5-8 non-Core centers.  These estimates 
were corroborated by surveys of Core Centers and non-Core Centers asking for the number of 
unrelated donor transplants done in the 12-month period from March 2001-March 2002.  
Although, this survey indicated a somewhat higher anticipated accrual, we chose to plan the 
study based on the conservative estimates given above because: 1) they are based on real data on 
actual numbers of NMDP-facilitated transplants in these centers; 2) participants may be lost 
based on either patient unwillingness to participate or donor unwillingness to participate; and, 3) 
about 20% of NMDP-facilitated transplants in the U.S. use donors from non-U.S. donor centers.   
 
Given these conservative estimates, it is anticipated that the accrual goal of 550 patients will be 
met in three years (see Figure 5.3 below).  Accrual will be closely monitored.  If necessary, the 
DCC will identify additional U.S. non-Core NMDP Centers that can contribute a minimum of 
three patients per year to the study.  Accrual will also be monitored to ascertain that enrolled 
patients reflect women, minorities and children in proportion to the numbers expected based on 
available NMDP data regarding general unrelated donor transplant recipients. 
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Table 5.3. – Outcome of U.S. Unrelated Donor Blood or Marrow Transplants – 1996-2001 
 
Risk 
Stratum 
Disease / 
Stage^ N 
100-day 
survival
1-year 
survival
2-year 
survival
3-year 
survival
4-year 
survival 
5-year 
survival 
# Tx’s 
2001* 
NMDP 
     
Good CML-CP 1097 75±3 59±3 53±3 50±3 47±3 42±4 61 (10%)
 CML-AP/ CP2+ 401 67±5 41±5 31±5 28±5 26±5 22±6 44 (7%)
 AML-CR1 357 67±5 43±5 36±6 32±6 32±6 32±6 83 (13%)
 AML-CR2 381 74±4 47±5 40±5 38±6 34±6 33±7 67 (11%)
 ALL-CR1 287 73±5 54±6 44±6 41±6 38±7 38±7 42 (7%)
 ALL-CR2 431 74±4 46±5 37±5 34±5 33±5 31±5 77 (12%)
 ALL-CR3 125 70±8 43±9 33±9 29±9 29±9 25±11 15 (2%)
 MDS-RA 121 69±8 45±9 42±9 36±10 25±11 25±11 17 (3%)
 MDS-RAEB 143 60±8 36±8 30±8 29±8 27±8 27±8 30 (5%)
 JCML (JMML) 25 68±18 48±20 43±20 43±20 34±22 34±22 0 (0%)
 MFMM 37 59±16 45±16 41±17 41±17 41±17 41±17 7 (1%)
 Total Good Risk 3405 72±2 50±2 42±2 39±2 37±2 34±2 443 (70%)
Poor CML-BP 72 56±12 25±10 15±9 13±8 13±8 9±9 10 (2%)
 AML-CR>2 38 45±16 26±14 18±12 18±12 18±12 18±12 6 (1%)
 AML-Not in CR 648 57±4 23±3 15±3 14±3 12±3 11±4 100 (16%)
 ALL-Not in CR 275 48±6 18±5 10±4 9±4 7±3 6±3 50 (7%)
 MDS-RAEBT 114 69±9 39±9 24±8 23±8 21±8 17±10 18 (3%)
 CMML 34 73±15 25±18 25±18 25±18 25±18 25±18 9 (1%)
 Total Poor Risk 1199 56±3 24±3 15±2 14±2 12±2 11±3 193 (30%)
 TOTAL 4604 68±1 43±1 35±1 33±1 31±2 28±2 636 (100%)
 * Includes all NMDP centers, U.S. and non-U.S., core and non-core centers. 
^ Abbreviations: CP = chronic phase; AP = accelerated phase; CR = complete remission; RA = 
refactory anemia; RAEB = refractory anemia with excess blasts; BP = blast phase; RAEBT = 
refractory anemia with excess blast in transformation. 
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Figure 5.3 – Anticipated Patient Accrual 
 
 
5.4. Interim Analyses and Statistical Stopping Guidelines 
 
Interim analyses will be conducted for safety at times coincident with regularly scheduled 
meetings of the The National Heart, Lung, and Blood Institute (NHLBI)-appointed Data and 
Safety Monitoring Board (DSMB).  Policies and composition of the DSMB are described in the 
BMT CTN MOP. 
 
Toxicity, adverse experiences, and other safety endpoints will be monitored regularly and 
reported to the DSMB at each interim analysis.  Treatment will be coded for all analyses unless 
the DSMB requests that the code be revealed. 
 
In addition, there will be periodic interim analyses approximately every six months to compare 
the toxicity of the two procedures in terms of their six-month mortality rates.  The stopping rule 
will only be applied to the estimated 470 patients who actually receive the randomized 
transplant, rather than the intent-to-treat population.  Because preliminary data from the NMDP 
indicates a potential for early survival differences between PBSC and marrow to dissipate by two 
years, a very conservative stopping rule is used.  The NMDP Phase II data indicated an early 
relative risk of 0.6 for PBSC versus marrow that resulted in no significant difference in survival 
at two years.  A relative risk of 0.6 throughout the first six months would yield a difference in 
six-month mortality rates of 15%.  Therefore, at each interim analysis the hypothesis that the 
difference in six-month mortality rates is less than or equal to 15% will be tested against the 
alternative that it is greater than 15%, using a two-sided alpha=0.05 level test.  If this hypothesis 
is rejected, all analyses will be sent to the DSMB for expedited review.  Operating characteristics 
of this interim analysis for safety are given below, as a function of the true difference in six-
month survival (Delta), assuming 55% survival at six months in the marrow arm.  As shown, this 
stopping rule will have good power to detect a large difference of 25-30% in six-month 
mortality, but will not stop often for smaller differences that may dissipate by two years. 
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Table 5.4. – Probability of Stopping 
 
Interim Analysis 1 2 3 4 5 6  
Patients Evaluable 78 156 234 312 390 468  
Delta Probability of stopping at interim analysis Total 
15% 1.9% 1.7% 1.1% 0.8% 0.8% 0.7% 7.1% 
20% 6.0% 5.8% 4.7% 4.9% 4.4% 4.6% 30.2% 
25% 14.0% 15.1% 13.8% 11.2% 9.9% 7.7% 71.7% 
30% 30.0% 28.8% 18.4% 10.6% 5.9% 3.2% 96.8% 
 
 
5.5. Demographic and Baseline Characteristics 
 
Demographics and baseline characteristics will be summarized for all patients, and for all 
patients who actually receive a transplant.  Between group comparisons will be performed for 
continuous variables via a t-test and for categorical variables, via the chi-square test. 
 
5.6. Analysis of the Primary Endpoint 
 
The primary analysis will be performed using the intention-to-treat principle so that all 
randomized patients will be included in the analysis.  The primary outcome of the trial is overall 
survival as measured from the time of randomization.  In the final analysis a stratified log-rank 
test will be used to compare survival between the two arms.  In addition, Kaplan-Meier survival 
curves will be constructed for each group.  Estimates of the difference between these survival 
curves and confidence bands for these differences will be constructed using the method of Zhang 
and Klein (59).  In the event that there are no significant differences between the two arms, a 
post hoc power analysis will be performed. 
 
5.7. Analysis of Secondary Endpoints 
 
Transplant-related event data will only be collected on patients who actually receive a transplant 
and do not drop out of the study.  Therefore, these comparisons will be made using the actually 
transplanted populations.  Because of the potential for unequal drop out between the two arms, 
adjustment for covariates will be used to make these groups comparable.  Event times for 
transplant-related events will be considered from the time of transplant rather than the time of 
randomization. 
 
5.7.1. Overall Survival among Transplanted Patients 
 
The overall survival after two years of follow-up will be compared between patients actually 
receiving the randomized transplant stem cell source, using a stratified log-rank test.  In addition, 
Cox proportional hazards regression may be used to adjust for patient characteristics which are 
unbalanced in the actually transplanted arms. 
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5.7.2. Neutrophil Engraftment > 500/mcL 
 
Rates of neutrophil engraftment, treating death prior to engraftment as a competing risk, will be 
compared between the two groups using a stratified log-rank test, and the cumulative incidence 
curves will be estimated for each group.  Cox regression will be performed to compare the 
groups after adjusting for covariates which may be imbalanced due to patient dropout. 
 
5.7.3. Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent 
 
Rates of platelet engraftment, treating death prior to engraftment as a competing risk, will be 
compared between the two groups using a stratified log-rank test, and the cumulative incidence 
curves will be estimated for each group.  Cox regression will be performed to compare the 
groups after adjusting for covariates that may be imbalanced due to patient dropout. 
 
5.7.4. Acute GVHD of Grades II-IV and III-IV 
 
The stratified log-rank test will be used to compare the cumulative incidence of acute GVHD of 
grades II-IV or III-IV by Day 100 between the treatment groups considering death as a 
competing risk.  Cox regression will be performed to compare the groups after adjusting for 
covariates which may be imbalanced due to patient dropout. 
 
5.7.5. Chronic GVHD 
 
Rates of chronic GVHD, treating death prior to occurrence of chronic GVHD as a competing 
risk, will be compared between the two groups using a stratified log-rank test, and the 
cumulative incidence curves will be estimated for each group.  Cox regression will be performed 
to compare the groups after adjusting for covariates which may be imbalanced due to patient 
dropout. 
 
5.7.6. Current Immunosuppressive (IS) Free Survival 
 
Patients on either arm may go off IS therapy, and then need to subsequently reinitiate therapy.  
The current immunosuppressive free survival is an estimate of the likelihood that a patient will 
be alive and not on immunosuppressive therapy at any given point in time. 
 
These survival curves will be compared between the two arms of the study across all time points 
using a technique found in Klein et al. (60). 
 
We will also estimate for each arm the probability a patient is alive and off IS therapy at 2, 6, 9, 
12, 15, 18, 21, 24, 30 and 36 months.  In the analysis at K months, the numerator for this 
estimate counts patients alive and off IS therapy, and the denominator counts all patients 
followed to K months, regardless of survival status.  These probabilities will be compared using 
standard tests for binomial proportions. 
 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 1.0 dated June 17, 2003 
5-7 
5.7.7. Relapse of the Original Malignancy 
 
Rates of relapse, treating death prior to relapse as a competing risk, will be compared between 
the two groups using a stratified log-rank test, and the cumulative incidence curves will be 
estimated for each group.  Cox regression will be performed to compare the groups after 
adjusting for covariates that may be imbalanced due to patient dropout. 
 
5.7.8. Donor Lymphocyte Infusion 
 
The use of DLI will be recorded and analyzed as a secondary endpoint. DLI will be a competing 
risk for evaluation of acute and chronic GVHD. 
 
5.7.9. Bacterial, Viral and Invasive Fungal Infection 
 
Infectious complications will be analyzed in relation to patients’ clinical risk with comparison of 
the two treatment cohorts (PBSC versus marrow) and adjusted by other relevant clinical risk 
factors.  These may include, but will not be limited to: pre-transplant infectious history and 
serostatus, time to neutrophil engraftment, and acute and chronic GVHD,.  Analysis of infection 
incidence (by cumulative incidence) and infection density (number of infections over time for 
patients with repeated infections), especially during later time periods, will be performed.  
Multivariate regression analysis will be performed to test for the contribution of stem cell source 
(PBSC versus marrow) and other relevant covariates to the incidence of infections.  Specific 
analyses using these techniques will be performed for bloodstream infections (bacteremia), 
systemic fungal infections, and viral infections (CMV, HSV, respiratory viruses), and infections 
that lead to added isolation precautions in the hospital setting (e.g., resistant enterococcus, 
Clostridium difficile, varicella zoster, adenovirus, rotavirus, respiratory viruses). 
 
5.7.10. Patient and Donor Quality of Life 
 
Details about these analyses will be given in the separate sections on quality of life. 
 
5.8. Safety Analysis 
 
All entered patients will be included in the safety analysis. 
 
5.8.1. Adverse Events 
 
All reported serious treatment related adverse events will be carefully examined with respect to 
the severity and relationship to study treatment.  Adverse events will be graded according to the 
NCI Common Terminology Criteria for Adverse Events, Version 3.0.  The incidence for each 
reported study group associated adverse experience delineated in Section 4.17 will be presented 
for each group. 
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5.9. Laboratory Tests 
 
Graft Characterization - Descriptive statistics will be computed on the cellular constituents of 
the graft, separately for each graft type.  These will be compared between graft types using 
nonparametric Wilcoxon rank sum tests.  Counts of the immune cells of different types in the 
graft (including donor CD34 and dendritic cells) as well as the graft type will be used to model 
post-transplant GVHD, relapse, and various measures of immune reconstitution through Cox 
regression, treating death prior to immune reconstitution, GVHD, or relapse as a competing risk. 
 
Immune Reconstitution - Descriptive statistics will be computed on the cellular constituents and 
Ig types separately by treatment arm.  These will be compared between treatment arms using 
nonparametric Wilcoxon rank sum tests.  Levels of IL-2 and IL-7 will be correlated using 
nonparametric measures with the levels of T cells in the blood.  Response to vaccinations will be 
compared between treatment arms using the binomial comparison of proportions.   
 
Chimerism - Chimerism results will be compared between the treatment arms using 
nonparametric Wilcoxon rank sum tests. 
 
5.10. Donor Recovery 
 
Donor Recovery to Baseline Functional Score - Appropriate statistical methods to detect trends 
over the available spectrum of donor follow-up time will be employed for baseline functionality 
recovery to baseline endpoints.  Such methods may include, but not necessarily be limited to: 
analysis of variance with repeated measures techniques, non-parametric paired comparisons, or 
other methods suitable for comparisons of correlated data. 
 
Donor Recovery to Baseline Toxicity Scores - Appropriate statistical methods to detect trends 
over the available spectrum of donor follow-up time will be employed for baseline toxicity 
recovery to baseline endpoints.  Such methods may include, but not necessarily be limited to: 
analysis of variance with repeated measures techniques, non-parametric paired comparisons, or 
other methods suitable for comparisons of correlated data. 
 
Donor Recovery to Baseline CBC and WBC Differential Values - Appropriate statistical 
methods to detect trends over the available spectrum of donor follow-up time will be employed 
for baseline CBC recovery to baseline endpoints.  Such methods may include, but not necessarily 
be limited to: analysis of variance with repeated measures techniques, non-parametric paired 
comparisons, or other methods suitable for comparisons of correlated data. 
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CHAPTER 6 
 
 
6. INFECTIOUS COMPLICATIONS OF TRANSPLANTATION 
 
The early neutropenia, mucocutaneous barrier disruption and extended period of 
immunodeficiency after allogeneic transplantation leave patients vulnerable to serious and life-
threatening infections.  Because engraftment as well as immune reconstitution rates may differ 
following PBSC versus marrow transplantation, in this trial individual infectious complications 
will be prospectively monitored and compared.  The primary question asked in this protocol 
component is whether there will be a significant difference in the incidence, severity and case-
fatality rate of microbiologically documented infections between the PBSC and the marrow arms 
of the trial. 
 
Regimens to prevent and treat infectous complications of transplantation have evolved over the 
last three decades and continue to evolve, as have diagnostic and monitoring tools.  Specific 
prophylactic, monitoring and therapeutic regimens also vary from center to center.  While the 
study randomization will be stratified by center, in part for this reason, knowledge of prevention 
regimens used at each center will assist with the interpretation of putative relationships between 
study arm and infectious complications on this trial. 
 
Infection prophylaxis and complication monitoring forms and instructions for completion of the 
forms are included in the Data Management Handbook and User's Guide. 
 
6.1. Required Data Elements for Collection 
 
6.1.1. Pretransplant infections that may have an impact on the transplant by recurrence 
 
Information regarding clinically significant fungal infections that occurred before transplant will 
be obtained based on the expected possibility of their reactivation during transplantation.  In 
addition, cytomegalovirus (CMV) serostatus of the donor and recipient, and herpes simplex 
(HSV) and varicella zoster virus (VZV) serostatus of the recipient will be collected.  The 
presence of fungal, bacterial and viral infections requiring treatment will also be captured as part 
of the pre-treatment eligibility screening form, as these infections are grounds for delaying or 
deferring the transplant. 
 
6.1.2. Infectious disease prophylaxis 
 
To determine what infection preventive measures were used, centers will be surveyed annually to 
report their infection prophylaxis protocols applicable to patients enrolled on this trial.  These 
center-defined, rather than patient-specific, data will be compiled for analysis.  The survey will 
include questions on: systemic bacterial, viral, fungal and pneumocystis prophylaxis, pre-
emptive therapy for positive CMV pp65 antigen or PCR tests.  Infection prophylaxis varies by 
time period post-transplant.   
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The center infection prophylaxis survey will include the following periods: 
1. Early neutropenia combined with mucocutaneous barrier disruption, weeks –1 through 
week +4 post-transplant; 
2. Resolution of early neutropenia combined with continuing recovery from mucocutaneous 
barrier disruption, from 4-12 weeks post-transplant; 
3. Extended period of immunodeficiency from 12-26 weeks post-transplant; and 
4. Extended period of immunodeficiency from 26-52 weeks post-transplant. 
 
Centers should indicate varying practices over time in their survey responses. 
 
6.1.3. Specific reporting of individual infections 
 
6.1.3.1. Data of Interest 
 
The objective of this protocol component is to capture microbiologically defined opportunistic 
infections.  These will include the following etiologies: 
1. Viruses 
2. Fungi 
3. Bacteria 
4. Protozoa 
5. Others 
 
For the case definition for each infectious syndrome please refer to the CTN Infectious Diseases 
MOP included in the Data Management Handbook and User's Guide.  Case definitions specify 
clinical manifestations of disease and microbiological data.  Micobiological data will be captured 
from evidence of microbiology isolates, as well as genetic or antibody probes tested on fluid or 
tissue samples.  Clinical manifestations specific for each infectious disease syndrome will be 
captured by the case report forms using data from clinical source documents. 
 
Specific microbiology information about Candida and Aspergillus species will be included in the 
Case Report Form, as this emerging and serious infection class is now being managed with 
multiple alternate antifungal agents. 
 
6.1.3.2. Tempo of data acquisition and reporting 
 
To enhance the reporting of all individual infections, infections forms should be filed as soon as 
possible after diagnosis.  Patient charts should be reviewed on Days 28, 100, 180, 365 and 730 to 
ensure that all clinically significant infections were captured between these reporting time 
periods.  If no clinically significant infections have occurred, that negative information will be 
reported. 
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CHAPTER 7 
 
 
7. PATIENT QUALITY OF LIFE 
 
7.1. Background and Significance 
 
7.2. Overview and Rationale 
 
Quality of life (QOL) refers to every dimension of life except for its length, and includes 
physical abilities, symptoms, social well-being, psycho-emotional status, and spiritual/existential 
qualities.  It reflects how well people feel, what they can accomplish, how satisfied they are with 
their lives, and whether their lives have meaning and purpose.  Within this broad concept, health-
related quality of life (HRQOL) refers to aspects of QOL that are attributable to health, disease 
or medical treatment (for simplicity, the abbreviation QOL will be used in this protocol).  
Following hematopoietic stem cell transplantation (HSCT), QOL can range from perfect, with no 
physical, emotional or social sequelae and a greater appreciation for life, to severely 
compromised with physical disability, pain and psychological despair.  Of course, most patients 
who have undergone HSCT fall within this spectrum. 
 
The figure below shows an example of QOL taxonomy. Global QOL (“Overall, how is your 
quality of life?”) is made up of several domains such as physical symptoms and functioning, 
emotional well-being, social relationships etc.  HSCT survivors generally report high global 
quality of life following HSCT, but many specific symptoms (61, 62, 63, 64, 65, 66, 67) and 
limitations on their daily activities (68).  However, despite many problematic long-term 
complications, almost all patients indicate they would undergo the procedure again given similar 
circumstances (69, 70, 71, 72).  In addition, for some common problems after HSCT such as 
fatigue, sleep and sexual functioning, documented dissatisfaction is also high in the general 
population and chemotherapy-treated patients (73, 74). 
 
 
 
The purpose of the QOL component of this trial comparing unrelated PBSC versus marrow as a 
stem cell source is to understand the long-term QOL implications of one graft source versus 
another.  While the trial is powered with survival as the primary endpoint, QOL will be an 
especially important secondary endpoint if survival is not statistically different, or if the 
incidence of chronic GVHD is higher in one group.  It is also possible that immunologic 
recovery, peri-transplant experiences and complications, speed of physical recovery, and 
expectations may influence ultimate QOL. 
 
It is very important that data collection is centralized, patients’ response burden is minimized and 
QOL assessments are fully integrated into the trial to maximize the chance of complete data 
 
PHYSICAL 
fatigue 
pain 
SOCIAL
family
friends
EMOTIONAL
anxiety
depression
FUNCTIONAL
work
sleep
Global QOL 
SPIRITUAL
religion 
meaning 
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collection.  With this goal in mind, the number of data instruments will be minimized and 
focused on answering the research question, assuming that other psychological, social etc. 
factors are balanced by the randomization process.  Specifically, associations between QOL and 
specific clinical events or patient characteristics will not be investigated.  Other ongoing studies 
fully address those issues. 
 
7.3. Preliminary Work 
 
NHLBI has sponsored a randomized trial of T cell depletion vs. immunosuppressive medications 
for acute GVHD prophylaxis in unrelated donor marrow transplantation (TCD).  Accrual and 
follow-up are complete.  Dr. John Wingard and the International Bone Marrow Transplant 
Registry (IBMTR) have concluded a large, cross-sectional study of QOL and relationships 
incorporating patients, spouses and controls.  Both these studies have shown the feasibility of a 
centralized, telephone data collection strategy using mailed surveys followed by phone 
interviews.  Overall and item completion rates were excellent, and anecdotally, the personal 
contact was much appreciated by the patients.  Results are not yet available from these studies, 
but completion rates in the NHLBI trials were excellent (baseline – 91%, 100 days – 59%, 6 
months – 64%, one year – 73%, 3 years – 84%).  However, compliance varied and improved as 
the study progressed.  In addition, a pediatric component was planned but closed early due to 
poor compliance.  In order to facilitate comparison of the current study with the NHLBI and 
IBMTR studies, every effort has been made to include similar instruments and assessment times. 
 
7.4. Specific Aims 
 
The overall aim is to compare the QOL of patients undergoing unrelated donor marrow 
transplantation with that of patients undergoing unrelated donor PBSC transplantation.  Other 
aims include: 
1. To compare chronic GVHD symptom burden (as measured by the chronic GVHD 
symptom scale) between the two treatment groups. 
2. To compare physical, functional, and transplant-specific QOL modules (as measured by 
the Trial Outcome Index [TOI] of the Functional Assessment of Chronic Illness Therapy 
[FACT-BMT] and the rate of return to work) between the two groups. 
3. To compare the positive and negative psycho-emotional aspects of transplantation (as 
measured by the Mental Health Inventory) between the two groups. 
 
7.5. Hypotheses 
1. There will be greater chronic GVHD symptom burden in recipients of PBSC transplants 
at one-year post-transplantation. 
2. There will be no difference in the physical, functional, and transplant-specific QOL 
between the two groups over time through two years post-transplantation.  
3. There will be no difference in rate of return to work at two years. 
4. There will be no difference in the positive and negative psycho-emotional aspects of 
transplantation, as measured by the Mental Health Inventory. 
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7.6. Eligibility and Exclusion Criteria 
 
7.6.1. Inclusion Criteria: 
1. Enrollment in the randomized clinical trial. 
2. At least 16 years of age. 
3. Signed informed consent. 
 
7.6.2. Exclusion Criteria: 
1. Inability to communicate in English or Spanish. 
2. Inability to participate in interviews due to cognitive, linguistic or emotional difficulties. 
3. Current uncontrolled psychiatric illness. 
4. No telephone or access to a telephone. 
5. This study will not be offered to children and their parents based on the experience with 
the NHLBI TCD study.  In addition, QOL considerations and instruments differ between 
adult and pediatric patients necessitating a separate analysis.  It is anticipated that 
minority representation will mirror that in the randomized study. 
 
7.7. Study Procedures 
 
7.7.1. Study Design 
 
Patients will be enrolled in the QOL study at the time they provide first consent for the 
randomized trial.  Once a donor is confirmed, the patient will be sent a QOL study packet 
including a cover letter, copy of the QOL interview, and information to schedule the time for a 
pre-transplant interview. Interviews will be conducted in either English or Spanish.  
 
Interviewers will read the verbatim questions to the subject, who will indicate their answers.  
Interviewers will record those answers.  If a patient wishes to stop and continue later or another 
day, that is permissible.  Three contacts with the patient will be allowed with his/her permission 
to obtain complete data at each time point.  In addition, a toll-free line will be established for 
patient questions or in case it is easier for the patient to complete the surveys at another phone 
(e.g., at a clinic appointment or a friend’s house). 
 
Patients will be surveyed prior to transplantation (within 1 month of admission), and at 6 months, 
1 year and 2 years.  Post-transplant interviews may occur +/- 1 month from the scheduled time 
point. Permission will also be sought for QOL assessment at 5 years post-transplantation, 
although these data will not be analyzed as part of the randomized controlled trial. 
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7.7.2. Study Endpoints 
 
The four study endpoints of the QOL component will be: 
1. The chronic GVHD symptom scale. 
2. The Trial Outcome Index of the FACT-BMT. 
3. Occupational functioning. 
4. The Psychological Distress and Psychological Well-Being Subscales of the Mental 
Health Inventory. 
 
7.7.3. Instruments 
 
Table 7.7.3 – Description of Instruments 
 
Instrument Domains Rationale 
Sociodemographics Race/ethnicity, Age, 
Gender, Education, 
Income 
 
Global quality of life Karnofsky 
performance status 
Perception of 
overall health, 
Perception of 
overall QOL, Rating 
scale 
Assesses patient self-perceived global quality of life 
and functioning 
FACT-BMT Physical, 
Emotional, Social 
Functional, 
Transplant-specific 
Collected in NHLBI TCD and IBMTR QOL study. 
Allows comparison with other cancer populations 
Mental Health Inventory 
(MHI) 
MHI Index , 
Psychological 
distress, 
Psychological well-
being 
Measures depression, anxiety, positive affect, 
emotional ties and loss of behavioral and emotional 
control. Includes the mental subscale from the SF36. 
Occupational functioning Occupational 
functioning 
Only about 75% of surviving patients return to work, 
and return to work is associated with better QOL. This 
instrument was used in NHLBI study. 
Chronic GVHD module Chronic GVHD 
summary score 
Anticipated rates of cGVHD are 50-90%. Measures 
cGVHD problems with skin, energy, lung, nutrition, 
psychological, eye, and mouth 
Alternative contacts  Contact information for two alternative individuals 
Distress assessment  Measures distress caused by survey administration 
 
Sociodemographics: Eight standardized questions will assess ethnicity (Hispanic/Non-
Hispanic), race (White, Black, Asian, American Indian/Alaskan Native, Native Hawaiian or 
other Pacific Islander, Multiracial), age, sex, education, work status and occupation, and family 
income. 
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Global Quality of Life: Four standard questions will assess patient self-assessed Karnofsky 
performance status, overall health and overall quality of life (excellent, very good, good, fair, 
poor), and a rating scale for overall quality of life (where 0 equals death and 100 equals perfect 
quality of life). 
 
FACT-BMT: The FACT-BMT is a 37-item instrument composed of the FACT-G and 
transplant-specific subscale.  The FACT-G is comprised of 4 domains, physical (7 items), social 
(7 items, including sexual satisfaction), emotional (6 items) and functional (7 items, including 
work, sleep and leisure activities).  The transplant-specific module (10 scored items) includes 
appetite, appearance, mobility, fatigue (75,76).  Higher scores indicate better functioning.  The 
Trial Outcome Index (TOI) is composed of the physical, functional, and transplant-specific 
modules (77).  Data from 132 observations in unrelated donor recipients post-transplantation (6-
60 months) showed a mean of 66.76, SD 19.53, range 11.8-96.0. 
 
Mental Health Inventory (MHI): Thirty-eight items divided into two summary scores and five 
subscales measure anxiety, depression, positive affect, emotional ties, and loss of behavioral and 
emotional control (this instrument includes the entire mental subscale of the SF36).  As 
transplantation has been associated with both positive and negative psycho-emotional sequelae, it 
is important that the instrument detects both.  Psychological well-being is measured by 14 items 
with a reported mean of 59.16 and SD 12.16 in a general population sample of 5,000 individuals.  
Cronbach’s alpha is 0.92, one year test-retest 0.63, and higher scores indicate better functioning. 
On the 24 item psychological distress scale, mean is 47.54, SD 15.39, Cronbach’s alpha 0.94, 
one-year test-retest 0.62, and higher scores indicate more distress (78, 79).  The MHI was 
sensitive to changes associated with azacytidine treatment in MDS patients, and baseline scores 
were very similar to that of the general population. 
 
Occupational Functioning: Occupational functioning was measured in the NHLBI TCD trial 
using 6 items that assess current job status, type of work (will be captured using Hollingshead 
categories), number of hours of paid and unpaid work, school, importance of work and change in 
work goals. 
 
Chronic GVHD Symptom Scale: The 30 item cGVHD symptom scale measures degree of 
bother of cGVHD manifestations in skin, energy, lung, nutrition, psychological, eye and mouth.  
Responses are captured on a five-point Likert scale (“no symptoms, or not bothered at all”, 
“slightly bothered,” “moderately bothered,” “bothered quite a bit,” or “extremely bothered”).  
Scores for each domain are converted to a 0-100 scale where higher scores indicate more bother.  
Mean (SD) was 12 (9) for patients with mild (N=55), 18 (13) for patients with moderate (N=39), 
and 34 (13) for patients with severe (N=13) disease.  Although the SF-36 and FACT-BMT were 
sensitive to changes in overall health, only the chronic GVHD symptom scale was sensitive to 
changes in patient-perceived chronic GVHD severity (80).  
 
Alternative Contact Information: The names of two people who do not live with the subject, 
but would be able to locate the patient in case of phone number change, move etc. will be 
obtained.  Names, addresses and phone numbers of these alternative contacts will be collected. 
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Distress Assessment: Two items will assess distress at the conclusion of each survey 
administration.  One question measures level of comfort with the questions (very comfortable, 
comfortable, a little uncomfortable, very uncomfortable) and degree of stress caused by the 
questions (a great deal, a lot, some, a little, none).  These questions were modified from studies 
of bereaved family members.  Responses of “very uncomfortable” with questions or “a great 
deal” or “a lot” of stress caused by the survey leads to follow-up questions and an offer of 
referral.  Actual referral or the need to notify the transplant center Principal Investigator due to 
distress caused by the survey administration will constitute an unexpected serious adverse event. 
 
7.7.4. Required Data 
 
Table 7.7.4. – Required Data 
 
Instrument N items Pre 6 mos 
1 & 2 
yrs 5 years
Sociodemographics 8 X    
Global quality of life 4 X X X X 
FACT-BMT 37 X X X X 
Mental Health Inventory (MHI) 38 X X X X 
Occupational functioning 6 X  X X 
Chronic GVHD module 31  X X  
Alternative contacts 2 X X X  
Distress assessment 2 X X X X 
TOTAL N ITEMS  97 114 120 87 
ANTICIPATED TIME  20 min 20 min 25 min 15 min 
 
 
7.8. Description of Study Process 
 
7.8.1. Identification of Eligible Patients 
 
Upon provision of informed consent for participation in the randomized clinical trial, patients 
will also complete a Patient Contact Form to allow the QOL interviewer to reach them.  This 
form will capture name, address, home phone number, email address and alternative contact 
information.  Site coordinators will provide hospital name, physician and nurse name, contact 
phone numbers, date of admission, hospital record number, and NMDP identification number.  
This information will be faxed to the QOL coordinating center and entered into a password-
protected database.  Upon receipt of this information, patients will be mailed a packet of 
information including a cover letter explaining more about the QOL survey procedures, the first 
survey for their review, and contact information for more questions. 
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7.8.2. Informed Consent 
 
Consent for QOL data collection is contained in the informed consent document for the trial.  
Procedures between the QOL coordinating center and the BMT CTN Data Coordinating Center 
(DCC) will ensure that a copy of the informed consent is on file before collection of the QOL 
data. 
 
7.8.3. Collection of QOL data 
 
QOL interviewers will call the patient at a day and time that is convenient for them, or patients 
may call a toll-free number at a predetermined time.  Baseline data will be collected within one 
month prior to graft infusion and after an admission date is scheduled.  For each subsequent 
contact, the QOL coordinator will call or email the clinical contact person associated with the 
patient within a month of contact in order to prevent contact attempts with deceased patients.  
Once confirmation of survival is obtained, the QOL coordinator will mail the patient a packet of 
information, and call the patient to schedule the QOL interview.  The post-transplant interviews 
may occur +/- 1 month from the scheduled time.  At the conclusion of each survey 
administration, patients will be reminded of the next date of contact and the procedures that will 
be followed. 
 
7.8.4. Location of Missing Patients 
 
If patients cannot be located through the contact information provided, or through the transplant 
center, then the alternative contacts will be used to locate the patient.  With the patient’s 
permission, updated contact information will be forwarded to the transplant center for their 
records. 
 
7.8.5. Withdrawal of Consent for QOL Data Collection 
 
If patients wish to discontinue participation in the QOL study, the QOL interviewer will notify 
the Principal Investigator at the transplant center immediately.  In approximately one week, the 
Principal Investigator will call the patient back to make an attempt to keep the patient in the 
study by explaining the goals of the study and the required data needs.  Should the patient still 
wish to drop out of the QOL study, no further contact will be attempted.  However, QOL data 
will be removed from the database only when specifically requested by the patient. 
 
7.8.6. Fifth Year Contact 
 
Although the fifth year will not be officially part of the randomized controlled study or the 
analysis, consenting patients for long-term follow-up allows important long-term data to be 
collected.  Similar procedures as for the two-year survey will be followed. 
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7.8.7. Letter of Appreciation and Communication of Findings 
 
At the conclusion of the study, a letter of appreciation will be sent to all surviving patients 
thanking them for their participation.  If a patient dies, a letter will NOT be sent to the next of 
kin.   
 
7.8.8. Management of Adverse Reactions 
 
Patients enrolled in this study will undergo up to five interviews.  At the start of each interview, 
patients will be told clearly that they may skip over any interview questions they wish and may 
withdraw from the study at any time.  Despite our best efforts, it is conceivable that some 
patients may find the process upsetting.  Names and phone numbers of local people to contact 
will be listed in the consent form and provided at the end of each interview.  Notification of the 
transplant center Principal Investigator based on distress caused by participation in the study will 
be considered an unexpected, serious adverse event and will be reported to the Principal 
Investigator, the IRB and the DCC.  However, distress incidentally detected will be reported to 
physicians and noted in the research file, but will not be considered an adverse event.  Section 
7.11.1 details study procedures in case distress is detected with potential to cause injury to self or 
others. 
 
7.9. Statistical Considerations 
 
7.9.1. Sample Size 
 
As quality of life is a secondary endpoint for the randomized clinical trial, the available sample 
size is predetermined by the primary endpoint of survival.  Thus, statistical considerations will 
focus on the power to detect differences given the enrollment and likely survival of the treatment 
arms. 
 
The available sample size at two years will be 60 for marrow and 81 for PBSC, based on 
expected accrual and the following additional assumptions: 
1. 90% of patients are adults (age > 18 years) who communicate in English or Spanish. 
2. Compliance with QOL assessments is 80%. 
3. Survival is 45% in the PBSC and 35% in the marrow group at two years. 
 
The hypothesis related to chronic GVHD symptoms pertains only to the one-year time point, and 
return to work applies to the two-year assessment.  All other hypotheses address differences 
between the two groups (marrow versus PBSC) over four potential time points: pre-transplant, 
six months, one year and two years.  For illustrative purposes, there is 64% power to detect a 0.5 
SD difference in the scores of interest at the two year time point (assuming 81 PBSC and 60 
marrow eligible survivors) and with a Bonferroni correction p=0.01 and two-sided testing. These 
detectable differences are presented in Table 7.9.1. 
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Table 7.9.1. – Detectable Differences 
 
Outcome Raw scores 0.5 SD 
CGVHD Symptoms 12 vs. 18.5 6.5 
Trial Outcome Index 60 vs. 70 10 
Psychological Well-Being 56 vs. 62 6 
Psychological Distress 44 vs. 52 8 
 
 
Differences in QOL between the two groups will be assessed in two main ways.  First, the 
marginal QOL scores given that a patient is alive will be compared at the specific time points 
described above using simple t-tests/confidence intervals.  Each of these time point comparisons 
will be done using the patients alive at that time.  Additionally, a second analysis will be done 
using the Integrated Quality Adjusted Survival to compare the two treatments on an aggregated 
assessment of QOL over the entire period of observation.  This second analysis will account for 
potential differences in the survival rates between the two groups. 
 
7.9.2. Missing Data 
 
Missing data is a common problem in survey and/or longitudinal studies.  Reasons of missing 
data are multifold: death, relapse, drop-out, early termination, or missing assessments.  Death 
rates are expected to be substantial based on the underlying disease states and the nature of 
unrelated donor transplantation, and will be accounted for by the Quality Adjusted Survival, as 
discussed above.  For comparison of QOL among survivors, every effort will be made to collect 
all measurements from all eligible patients to minimize missing data from survivors.  However, 
as experience with the TCD trial suggests, there appear to be fewer problems with missing data 
at later time points because initial toxicity has diminished.  If missing data occur, we will 
diagnose the mechanism and pattern of missing data based on information provided by the site 
and we will perform missing data analysis.  Since prior studies suggest that missing data in 
HSCT studies is associated with poor QOL (81) (i.e., informative right censoring, non-ignorable 
missing), we will explore the generalized Schlucter model (82), which is a joint model for 
longitudinal and survival data, where the survival component of the model acts as a missing data 
mechanism using software developed at the Dana-Farber Cancer Institute (83).  This model 
essentially allows missing QOL measurements at a specific time point of interest to be imputed 
based on how soon after that time the patient dies.  Note that use of subsequent survival 
information to input the QOL scores is primarily useful when comparing QOL at earlier time 
points, because the survival times will be observed until two years for each patient, while at later 
time points there may be less additional time for which the patient’s survival status is recorded.  
Therefore this should be a reasonable approach to dealing with the missing data related to QOL. 
 
7.9.3. Modified Intent-to-Treat 
 
A modified intent-to-treat analysis is planned using all randomized patients who are transplanted 
according to their randomization assignment. 
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7.10. Risks and Discomforts 
 
No medical treatment will be delivered as part of the QOL component. Participation is limited to 
completion of the surveys.  It is possible that some of the questions may be upsetting, although 
they are all validated instruments used on thousands of patients.  Patients will be reminded 
before every survey administration that they may skip items if they wish.  Distress will be 
assessed at the completion of each survey, and distress attributable to participation in the study 
(as opposed to distress detected incidentally) will be considered a severe adverse event 
reportable to the IRB. 
 
7.10.1. Potential Risks to Research Subjects 
 
As this is an observational study, there are no associated physical risks.  It is possible that the 
survey questions could cause emotional distress, but the risk is likely to be minimal.  Distress 
will be assessed after every contact with patients, and if we detect a high level of distress, the 
transplant center Principal Investigator will be notified. 
 
7.10.2. Adequacy of Protection Against Risks 
 
The informed consent document clearly outlines the QOL procedures, assessment points, time 
commitment and goals of this portion of the trial and must be signed by the patient.  Study 
participants may withdraw their consent to participate at any time or may refuse to participate in 
any aspect of the study.  This withdrawal will not compromise their medical care in any way. 
 
Confidential and emotionally sensitive material will be collected from the patients.  These data 
will be kept in locked research areas.  Access to all data will be limited to study personnel.   
 
7.10.3. Sources of Research Materials 
 
For the QOL component, potentially identifiable information on patients will consist of 
completed surveys.  Patient sociodemographics, quality of life, functional status, employment 
status, mental health and chronic GVHD symptoms will be measured.  Permission to collect all 
data will be obtained through the informed consent document, and will be obtained specifically 
for research purposes.  However, if a high level of emotional distress is detected, the transplant 
center Principal Investigator will be notified. 
 
7.10.4. Potential Benefits 
 
Patients participating in this study are not expected to obtain any direct benefit although some 
patients do report feeling better after participation in other QOL studies. 
 
7.10.5. Potential Benefits of the Proposed Research to the Subjects and Others 
 
This study will involve minimal risk to participants.  No benefits to the patients, as a result of 
participation in the study, is anticipated.  However it is hoped that future patients will benefit.  
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The risks of the study to participants are minimal whether measured absolutely or relative to 
what will be learned to benefit future patients. 
 
7.11. Monitoring and Quality Assurance 
 
7.11.1. Patient Tracking 
 
Patient tracking will be accomplished through a master file maintained by the QOL interviewers.  
Every four months, a progress report with total number of contacts attempted, total number of 
surveys successfully collected, and barriers to complete data collection will be produced.  In this 
way, response rates will be constantly monitored with the ability to enhance data collection 
procedures if inadequate QOL participation is detected. 
 
If serious distress is detected (suicidal, homicidal or psychotic features), the Principal 
Investigator at the patient’s transplant center will be notified for the patient’s own protection.  
This safeguard will be clearly outlined in the patient consent form, “Your answers to the quality 
of life interviews will be kept private and not included in your medical records nor shared with 
your physicians or other caregivers.  Your answers will be coded with a study number only and 
kept in password-protected electronic files or locked in file cabinets.  Only study personnel will 
have access to your information.  However, if any of your answers lead us to believe you are 
seriously depressed or in danger of hurting yourself, your physician will be notified.” 
 
7.11.2. Oversight of Project Staff 
 
Prior to patient contact, all study staff will be able to: 
1. Administer QOL surveys over the phone under appropriate supervision 
2. Demonstrate basic knowledge about the medical procedures under study and know where 
to refer patients who have questions about their medical conditions 
3. Explain and answer questions about the standardized instruments 
4. Know how to recognize and refer patients experiencing distress to the study investigators 
 
Ongoing quality will be maintained through random monitoring of interviews and additional 
training provided as necessary. 
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CHAPTER 8 
 
 
8. DONOR QUALITY OF LIFE 
 
8.1. Background and Significance 
 
Although both bone marrow harvest and PBSC collection are fairly well tolerated by donors (see 
Chapter 1), there may be significant differences between the procedures in terms of their impact 
on donor quality of life.  In a French study (84), researchers performed a prospective evaluation 
of anxiety, pain, and inconvenience.  Patients were randomly assigned to apheresis or bone 
marrow harvest for collection of stem cells in preparation for an autologous hematopoietic cell 
transplant.  Marrow donor patients experienced more anxiety and pain than PBSC patients.  
Patients undergoing PBSC collection experienced more positive judgments toward the collection 
procedure than bone marrow donor patients.  Patients who had a venous catheter placed for 
collection of stem cells experienced more pain than those from whom stem cells were collected 
by peripheral venous access. 
 
A group in Norway (85) also conducted a randomized study of safety and complaints of PBSC or 
marrow donation of stem cells.  They found a striking difference in the total burden of 
complaints, duration of hospital stay, and sick leave in the two groups of donors, favoring PBSC 
donors.  Interestingly, they found that PBSC donors used more analgesics than marrow donors.  
They hypothesized that these differences may have been due to the nature of the discomfort and 
the expectation that PBSC donors would continue to work during their daily injections of growth 
factor.  They indicated that the method used for informing donors may have influenced 
expectations, possibly impacting the post-procedure assessment.  However, they do not elaborate 
this point. 
 
Switzer et al., (86) compared the physical and psychosocial experiences of marrow and PBSC 
donors donating cells a second time.  Although the study was cross-sectional and retrospective, 
attainment of results from donors who have experienced both procedures makes this study 
unique.  Results were similar to the aforementioned studies; a greater proportion of marrow 
donors reported post-donation physical side effects as compared to PBSC donors.  A greater 
proportion of marrow donors reported using pain medications.  Individuals who donated marrow 
for their first donation and PBSCs for their second reported PBSC donation as less physically 
difficult, time-consuming, and inconvenient as compared to marrow donation. 
 
Rowley et al., (87) compared the experiences of marrow and PBSC donors participating in a 
randomized trial, and did not find significant differences in symptom burden or emotional status 
between collection methods.  They found that pain levels and duration were similar for the two 
groups, although they peaked at different times.  Both marrow and PBSC donors reported 
minimal fluctuations in emotional status.  However, as emotional status was measured with only 
a single, global item, these results should be interpreted with caution. The most significant 
difference between the groups was that recovery time was faster for PBSC donors. 
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Given the few studies conducted and their somewhat contradictory results, further investigation 
is warranted to better describe the potential differences in quality of life following marrow versus 
PBSC donation. 
 
8.2. Specific Aims and Hypotheses 
 
Our overall goal is compare the QOL of marrow donors with PBSC donors.  We are interested in 
knowing if the physical and psychosocial symptom burdens, recovery time, inconvenience, 
concerns, and satisfaction levels of marrow and PBSC donors differ depending on the donation 
method.  Specific aims include: 
1. To compare the physical side effects, functional ability, and recovery time between the 
two donation methods. 
2. To compare the psychosocial side effects between the two donation methods. 
3. To compare the inconvenience and restriction of activities between the two groups. 
4. To compare the level of concern about donation of each group. 
5. To compare levels of satisfaction reported by each type of donor. 
 
8.2.1. Hypotheses 
1. PBSC donors will report fewer numbers of side effects and greater functional ability 
overall, but a greater degree of bone pain, than marrow donors.  PBSC donors will 
recover to baseline functioning faster than marrow donors. 
2. PBSC donors will report less anxiety about donation than marrow donors. 
3. PBSC donors will report lower levels of inconvenience and restriction of daily activities 
than marrow donors. 
4. PBSC donors will report fewer concerns about donation than marrow donors. 
5. PBSC donors will report greater satisfaction levels than marrow donors. 
 
8.3. Eligibility and Exclusionary Criteria 
 
8.3.1. Inclusion criteria 
1. Enrollment in the randomized clinical trial. 
2. Signed informed consent. 
 
8.3.2. Exclusion Criteria 
1. Inability to read and write in English, because instruments in other languages have not 
been validated. 
2. Inability to complete questionnaires due to cognitive, linguistic, or emotional difficulties. 
3. No telephone access or failure to provide telephone contact number. 
4. Age less than 18 years. 
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8.4. Study Procedures 
 
8.4.1. Study Design 
 
Donors will be enrolled upon completion of their evaluations and agreement to the study 
randomization.  Sociodemographic information will be obtained at the time of consent. 
 
Within four weeks prior to marrow donation or initiation of G-CSF administration donors will 
complete the baseline questionnaire.  Every attempt will be made to administer the baseline 
questionnaire as close to donation or G-CSF administration as possible. 
 
Donors will be surveyed within 48 hours after donation, then weekly until they indicate a return 
to normal functioning.  Long-term assessment will occur at 6 and 12 months.  PBSC donors will 
have an additional assessment at Day 4 of G-CSF administration, since the preparatory 
procedures for PBSC donation are considered part of the donation process and include 
experiences that likely affect QOL. 
 
All questionnaires will be administered by phone by an independent interviewer.  Donors will be 
sent a copy of the questionnaires to review before contact with the interviewer.  Medical 
information will be obtained by the donor center following standard NMDP procedures and 
forms.  Information will include the need for central venous catheter placement, hospitalization 
and reason, and any serious adverse event. 
 
Permission will be sought for repeated QOL and satisfaction assessment yearly for five years.  
These data will not be included as part of this randomized trial. 
 
8.4.2. Study Endpoints 
 
Study endpoints include physical recovery, including symptoms, functioning, and recovery time, 
psychological and social functioning, degree of inconvenience experienced, and concerns about 
donation, and satisfaction with donation. 
 
8.4.3. Measures 
 
Sociodemographic Questions: Age, sex, marital status, education level, and work status will be 
assessed. Race/ethnicity will be identified using NIH categories. 
 
Physical Recovery: Physical side effects will be measured by a series of questions used by 
Switzer et al., in their 2001 study of second-time donors.  These questions include assessment of 
fever, overall pain, and specific side effects.  These questions will be supplemented with similar 
questions contained on the standard NMDP forms, which assess side effects, complications, 
medication use, and discomfort in specific parts of the body, as well as evaluation of return to 
baseline functioning.  Four additional items will assess highest pain intensity, average pain, 
amount of pain, and pain’s effect on sleep using visual analog scales used previously by Rowley 
et al., 87.  Functional status will be measured by Performance Status, which is standard on the 
NMDP forms. 
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Psychological Functioning: Psychological status will be measured by the Profile of Mood 
States-Short Form (88).  This is a 30-item measure that produces an overall distress score, as 
well as scores on six subscales: depression, anxiety, anger, confusion, fatigue, and vigor.  This 
scale has been shown to have good reliability and validity 88 and has been used extensively in 
the assessment of psychological aspects of quality of life. 
 
Convenience: The degree to which the procedure interferes with daily activities, and requires 
that special arrangements be made for coverage of work or domestic responsibilities, the number 
of days off from work, and the restriction of leisure activities will be assessed with items from 
the standard NMDP forms and items used in previous studies (89). 
 
Concerns about Donation: The degree to which donors are concerned about short- and long-
term health effects of donation will be assessed with questions used in previous studies (89). 
 
Satisfaction with Donation: Donors’ level of satisfaction with their donation experience will be 
assessed with questions used in previous studies (89). 
 
Clinical Data: Number of analgesic tablets needed to reduce pain is regularly assessed via 
NMDP forms and will be used to corroborate self-reported pain levels.  Number of blood 
transfusions given, requirement for a central line, number and duration of leukapheresis 
procedures, duration of hospitalization, sick leave, and number of days with restricted activities 
will also be assessed via NMDP forms. 
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Table 8.4.3 – Data Collection Timeline 
 
Measures N items Pre 
Day 4-
PBSC 
only 
Within 
48 hours 
donation
Weekly 
until full 
recovery 
6 & 12 
mos 
Sociodemographics and 
background information 
13 X     
Influence of Others 4 X     
Concerns about donation 5 X 
(7 items) 
X X X X 
Preparedness 5 X     
Physical Symptom Scale 12 X X X X X 
Pain 4 X X X X X 
Profile of Mood States 30 X X X X X 
Satisfaction and feelings 
about donation 
9   X X X 
Response of Others 3   X X X 
Side Effects 7  X 
(6 items)
X X X 
Inconvenience 5  X 
(4 items)
X X X 
Concerns about the 
recipient 
5   X X X 
TOTAL N ITEMS  75 61 80 80 80 
ANTICIPATED TIME  12 min 10 min 15 min 15 min 15 min 
 
 
8.5. Description of Study Process 
 
8.5.1. Contact Information 
 
Refer to Donor Companion Manual. 
 
8.5.2. Informed Consent 
 
A copy of the signed informed consent will be kept in a secure location to ensure confidentiality. 
 
8.5.3. Collection of QOL data 
 
All questionnaires will be administered by phone by an independent interviewer.  Donors will be 
sent a copy of the questionnaires to review before contact with the interviewer.  Medical 
information will be obtained by the donor center following standard NMDP procedures and 
forms. 
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8.5.4. Withdrawal of Consent for QOL Data Collection 
 
If a donor wishes to discontinue participation, every attempt will be made to ascertain the reason 
for discontinuation.  The interviewer will briefly review the procedures to make certain that the 
cause of withdrawal is not misunderstanding of study procedures. 
 
8.5.5. Letter of Appreciation and Summary of Results 
 
At the close of the study, thank you letters will be sent to each participant.  A summary of study 
results will be made available upon request. 
 
8.6. Statistical Considerations 
 
8.6.1. Sample Size 
 
As donor quality of life is a secondary endpoint for this randomized trial, the sample size is 
predetermined by the primary endpoint of patient survival. 
 
8.6.2. Group Comparisons 
 
All demographic variables will be summarized and the PBSC and marrow groups will be 
compared with chi-squared tests as appropriate.  All outcome variables will be compared 
between the two groups at each time point using t-tests for continuous outcomes, nonparametric 
Wilcoxon tests for ordinal outcomes, chi-square tests for nominal categorical variables, and chi-
square trend tests for ordinal categorical variables, as appropriate.  A significance level of 0.01 
will be used as an ad-hoc protection against multiplicity due to a large number of outcome 
variables and time points examined.  In addition, because physical recovery and psychological 
functioning are assessed both at baseline and subsequent times, adjustment for baseline 
measurements will be considered.  Symptom reporting (three categories) will be compared 
between the two groups at each time point using chi-squared trend tests, and may be adjusted for 
baseline symptom levels, by treating them as strata variables.  Pain and psychological 
functioning will be compared between the two groups using mixed models for repeated measures 
data.  Clinical data will be compared between the two groups using nonparametric Wilcoxon 
tests or chi-squared tests as appropriate. 
 
8.6.3. Missing Data 
 
Missing data will be assumed to be missing at random, and therefore no adjustment will be made 
to the mixed models analysis across time.  Separate tests performed at each time point will be 
done with the complete data at that time. 
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8.7. Risks and Discomforts 
 
QOL data collection involves non-invasive survey procedures that pose no risk to the 
participants.  It is possible, although highly improbably, that completion of the survey items 
could elicit distress.  However, participants are instructed to leave blank any questions that they 
feel uncomfortable answering.  Donors also are informed that they may withdraw from study 
participation at any time without penalty.  Should high levels of distress be detected during donor 
contacts, the interviewer will attempt to determine the nature and intensity of the distress, and 
will ask the donor if they wish to receive a follow up call from the donor center Principal 
Investigator.  If the donor says yes, the Principal Investigator, or his or her representative, will 
make every attempt to contact the donor by phone within 24 hours. 
 
8.8. Potential Benefits 
 
There are no direct benefits to participating in this study.  However, participants may experience 
positive feelings associated with sharing their experiences and/or contributing to research that 
may help others in the future. 
 
8.9. Monitoring and Quality Assurance 
 
The QOL data is confidential and will be kept in secure areas accessible only to study personnel.  
The study will be approved by the IRBs of all participating centers.  Standard operating 
procedures to respond to any adverse event are delineated above.   
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APPENDIX A – RATIONALE FOR THE STUDY DESIGN 
 
 
In creating this study, the protocol team held extensive discussions about the proper approach to 
donor and recipient enrollment.  The study is complicated because two research subjects, the 
hematopoietic stem cell (HSC) donor and the HSC recipient, must be managed 
contemporaneously.  Between these two, the recipients are inherently more unstable and more 
likely to shift in their eligibility status over short periods of time. 
 
The selected management schema is depicted in Figure 1.  Here the recipient eligibility is 
divided into two components, eligibility for randomization and eligibility for transplantation.  
The donor will be selected, enrolled and cleared for donation prior to randomization.  The 
recipient should be confirmed eligible for randomization prior to donor work-up (using the 
somewhat abbreviated criteria described in Section 2.3, with information that can be obtained by 
phone or mail for patients remote from the transplant center), but must be confirmed eligible on 
full evaluation at the transplant center after randomization but before conditioning therapy is 
initiated. 
 
Once the pair is randomized, the recipient will undergo work-up to determine final eligibility for 
transplantation.  Simultaneously, the donor will be prepared for the assigned donation, bone 
marrow or mobilized peripheral blood.  The donor’s preparation will require 2 – 3 weeks, during 
which time the recipient will be confirmed eligible for transplantation (Figure 1). 
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The major disadvantage of this approach is that a certain proportion of recipients will be found 
ineligible for transplant after randomization.  Based upon NMDP data, this is expected to be 15% 
or less, and has led to appropriate adjustment in the sample size (see Section 5.2).  The intent to 
treat analysis is discussed in the protocol. 
 
Several alternative approaches were considered.  The first of these involved performing work-up 
of both the donor and recipient prior to randomization (Figure 2).  
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This schema has the advantage of ensuring that the recipient is fully eligible for the study and 
transplantation prior to randomization.  The problem here is that following randomization the 
donor must still be prepared for donation.  During this 2 - 3 week preparation, the recipient will 
have ample time to change in status.  Complete or partial rework-ups would be needed for some 
recipients.  Also a consideration, long-distance recipients, i.e., those living far from the 
transplant center, would need to travel back and forth or stay in the transplant center city for 
several weeks before transplant. 
 
A modified version of schema II was also considered at the request of some donor center medical 
directors (Figure 3).  It was reasoned that donor enrollment would be greatly simplified if the 
randomization assignment was known at the time of donor work-up request. 
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Thus, the recipient would be randomized to a treatment arm and the donor invited to participate 
in the study by agreeing to provide the assigned product.  This model was discarded because it 
further aggravated the time delay for recipients between randomization and transplantation.  In 
addition, there were concerns because it could be argued (strongly) that donors were being 
randomized prior to their enrollment. 
 
The ideal randomization schema would place randomization as close as possible to the start of 
therapy.  This model is shown in Figure 4.  This model, unfortunately, would require that donors 
be prepared for both PBSC and marrow donation during the days prior to randomization.  Thus it 
would be necessary to schedule collection time in both the operating room and apheresis center.  
In all likelihood, donors eventually randomized to PBSC would still need to provide autologous 
blood before the randomization.  This model was rejected because it is too complex, it ties up 
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resources that do not belong to the donor centers (operating room and apheresis time) and it 
would be prohibitively costly (Figure 4). 
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RECIPIENT CONSENT FORM and ATTACHMENTS 
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 Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
If you are a parent or guardian of a patient younger than 18 years old and have been asked to read and 
sign this form, the “you” in this document refers to the patient. 
 
This is a consent form for a research study.  This form is to help you decide if you want to participate in 
this study.   
 
Patients like you may be treated with a transplant of either bone marrow or peripheral blood stem cells 
(PBSC) from unrelated donors.  Physicians have been successfully using either bone marrow or PBSC 
transplants for the treatment of blood disorders including leukemia and myelodysplasia.  The goal of this 
study is to see if patients have better results using a bone marrow transplant or a PBSC transplant from 
unrelated donors.  The study may also find that patients have similar results with either type of transplant. 
 
The results that are important to the study include: 
 Blood counts after transplant 
 Infection levels 
 Graft-versus-host disease (GVHD) 
 Return of cancer 
 How long you live after transplant 
 Your quality of life  
 
This study will give more information to doctors about future treatment choices.  In addition: 
 You will not be paid to be in this study.   
 You or your insurance company will pay for all medical bills for your treatment. 
 You will not be charged for research tests. 
 You will also face the same risks and benefits as any other transplant patient. 
 
Before you decide to join the study, please read the information below.  Feel free to ask questions to 
understand your rights.  It is your choice to take part in this study.  You and your doctor will discuss other 
treatment options if you decide not to be in this study. 
 
1. Title of Research Study 
A Phase III, Randomized, Open Label, Multi-center Clinical Trial Comparing Transplantation with 
Peripheral Blood Stem Cells versus Marrow from Unrelated Donors 
 
2. Principal Investigator Contact Information at your Institution  
Name/Title/Phone number/ 
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3. Contact information for emergencies after hours or on weekends or holidays: 
Name/Phone number/ 
 
4.  Sponsors and Source of Funding or Other Material Support 
This research study is paid for by the National Institutes of Health (NIH) and the National Marrow Donor 
Program ® (NMDP).  The NMDP ® and the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN) will direct the research study.  This study will be done at many different medical centers, 
including [Center Name/Location]. 
 
5. What is the purpose of this study? 
This study will look at two kinds of blood stem cell transplants, bone marrow and peripheral blood 
stem cells (PBSC), and their side effects.  At this time, doctors use both types of stem cells for 
transplant.  The goal is to see which type of stem cells (bone marrow or PBSC) transplant has better 
treatment results.  This study may find that one type of stem cells has better results for patients, or that 
there is no difference. 
 
The study will also look at what vaccinations after transplantation can do for you. 
 
An important part of this study will look at how well you feel after your transplant.  This part of the study 
will follow you up to five years after your transplant.  Researchers want to know what side effects, both 
good and bad, are from each type of stem cells used for the transplant and how long they might last. 
 
Good side effects might include: Bad side effects might include: 
 Quick recovery from transplant  Long recovery or no recovery 
 Low or no return of cancer  Return of cancer 
 High cure rates  Severe graft-versus-host disease 
 Few infections  Serious infections 
 Able to return to important activities in life  Low quality of life 
 
The information collected from this study will help doctors make better treatment choices for their future 
patients. 
 
6. What will be done if you take part in this research study? 
The transplant process has many steps.  A matched donor must be found.  Both you and the donor 
will need to be tested before you can have the transplant.  You and the donor will need to give 
permission to join this study.  A donor may refuse to participate in this study, but continue to be 
available for transplantation.  You may decide to transplant using this donor, but not join this study or 
to find another donor who does want to join this study. 
This study looks at the results of two different kinds of transplants, called bone marrow and 
peripheral blood stem cell (PBSC).  The kind of transplant a patient gets is decided by random, like a 
coin toss.  Neither you nor your doctor choose the type of transplant.  Half of the patients in the study 
will have a bone marrow transplant.  The other half will receive a PBSC transplant.  Participation in 
the study means that you are willing to accept either type of transplant. 
You will get vaccinations for diphtheria, tetanus, hepatitis A and pneumococcus.  Blood will be 
drawn for medical tests to make sure the vaccinations are working. 
You will need to take many drugs and have other medical treatments as part of your transplant.  Your 
doctor will explain these during discussion of your medical care. 
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The study coordinators at your center will collect information from your medical chart about you and 
your health over three years.  They will collect information every week for 100 days, then at 6 
months, 1 year, 2 years, and 3 years. 
 
Another part of the study will ask questions about your physical and emotional health if you are 16 
years of age or older (younger people will not participate in this part of the study).  A trained 
interviewer will contact you before your transplant, then 6 months, 1 year, 2 years and 5 years after 
your transplant.  These interviews will last approximately 15-25 minutes and will be done at a 
convenient time for you.  They will include questions about side effects, health problems and how 
well you can do things that are important to you.  You may skip any questions you wish. 
 
7. Will you provide blood samples for research? 
We will collect blood samples to see if infection-fighting cells are working. 
 
If you agree, a small blood sample (3-9 teaspoons or 15-45 ml) will be taken from you a maximum of 
nine times over two years (up to a total of 81 teaspoons or 405 ml for the entire study).  The samples 
will be saved for future testing.  This will not require any extra procedures.  The blood can usually be 
drawn from your central line at the time of other blood collections.  If this is not possible, then it can 
be drawn directly from a vein.  Any unused blood will be destroyed. 
You are free not to take part in this future research and still take part in the other parts of the 
study.  There will be no change in your care if you choose not to give these extra samples.  Please 
mark your choice(s) below:  
 No, I do not wish samples of my blood to be used for research. 
 I agree to donate extra samples of my blood for any additional research and further testing.  For 
example, future tests for infectious diseases or return of working blood cells. 
 I agree to a limited use of extra samples of my blood for any additional research and further testing. 
Please specify limits:__________________________________________________ 
 
____________________________________                             _______________________ 
 Signature                                                                               Date 
 
8. What are the possible discomforts and risks? 
You will face risks from the transplant itself, and from treatments given before and after the 
transplant.  Your doctor thinks these risks are less than the risk from your cancer.  
 
Your heart, lungs, liver, bladder, kidneys, brain or other organs may be damaged by the 
chemotherapy or irradiation, or by other drugs given to you after the transplant.  We expect this risk 
to be the same whether you receive marrow or PBSCs. 
 
Failure of the donor cells to grow (graft failure) may result from a mismatch with the donor, a 
reduced effect of pre-transplant drugs on your body, or not enough cells in the graft.  This risk may be 
less with PBSCs, since PBSCs contain more blood-forming cells than marrow. 
 
GVHD is a frequent problem after unrelated-donor transplantation.  The new cells react against your 
body, especially your skin, liver or gut.  GVHD can occur soon after transplant (within 100 days).  It 
can be mild or very painful and it can kill you.  GVHD also occurs late after transplant (up to several 
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years) and can cause long-term problems.  Drugs to control GVHD also make it harder to fight 
infections.  The chance of getting GVHD may be increased with PBSCs, since PBSC transplants 
contain more donor cells. 
 
Infections after transplant can be from bacteria, viruses, parasites, or fungi.  The risk of getting an 
infection might be less after a PBSC transplant, because the blood counts return faster than with 
marrow.  However, the risk of infections might be increased in PBSC transplants, because GVHD 
might be worse and last longer. 
Relapse of your cancer might occur after transplant, especially in patients with advanced disease.  
This risk may be decreased by PBSC transplantation. 
Completion of the quality of life interviews will not cause you any physical discomfort, although it is 
possible that you will find some of the questions or topics upsetting.  If you do, there is always 
someone available to speak with you.  They will be able to refer you to appropriate counselors or 
other support people. 
Refer to Appendix A, B and C for additional risks and toxicities. 
 
9. As with any treatment, there may be yet unknown and/or unexpected side effects from a 
marrow or PBSC transplant.  
We may learn about new things about marrow or PBSC transplants that might make you want to stop 
being in the study. We will let you know if this happens. You can decide if you want to continue in 
the study. 
 
10. What other alternatives or treatments are available if you do not want to be in this study? 
Participation in this study is entirely voluntary.  You are free to refuse to be in the study, and your 
refusal will not affect current or future health care you receive at this institution.  You and your doctor 
will discuss any other teatment options available to you including: 
 No treatment 
 Chemotherapy 
 A transplant using your own bone marrow or PBSC 
 A transplant of bone marrow or PBSC from a relative 
 A transplant of cord blood cells 
 You may decide to receive a transplant of bone marrow or PBSC from an unrelated donor and not 
participate in this study. 
 
11. What are the possible benefits to you? 
You may receive no direct benefits from this study.  You may or may not benefit from the scheduled 
medical assessments required for this study, and extra support from personnel working for this study. 
 
12. What are the possible benefits to others? 
You may be helping other patients get better treatment in the future. 
 
13. If you choose to take part in this study, will it cost you anything? 
You and/or your insurance company will pay all medical expenses relating to, or arising from 
transplantation of either PBSC or marrow.  Research tests will not be charged to you.  
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For questions about your costs, financial responsibilities, and/or medical insurance coverage for your 
transplant and this study, please contact /Center/ Financial Counselor at /Number/. 
 
14. Will you be paid for taking part in this research study? 
 
No. 
 
15. What if you are injured because of the study? 
If you are injured or become ill while taking part in this study, medical care will be provided at this 
center.  No funds have been set aside to pay you if you are injured.  You or your insurance company 
will be charged for ongoing medical care and/or hospitalization. 
 
Contact your doctor or one of the people listed at the start of this form if you are concerned about a 
research-related injury. 
 
16. How can you withdraw from this research study? 
You may decide to quit this study at any time, for any reason, without notice.  However, if you quit 
after you have had some or all of the treatment but before the bone marrow or PBSCs are given, then 
your blood counts may not return and you could die. 
 
If you decide to quit, we ask that you tell [the Principal Investigator] in writing (his/her address is on 
the front page of this form). If you do take back your consent, there will be no penalty and you will 
not lose anything you are entitled to and will continue to receive medical care. 
 
If you have any questions about your rights as a study subject, you may phone the Institutional Review 
Board (IRB) office at /number/. 
 
17. If you quit the study, can information about you still be collected and used? 
If you quit the study, we ask that you let us continue using all information that was already collected.  We 
also ask that you let your doctor continue to tell us about your progress until 5 years after your transplant.  
You may say no at any time. 
 
18. Can the Principal Investigator withdraw you from this research study? 
You can be taken off the study (with or without your consent) for any of these reasons: 
 Staying in the study would be harmful to you. 
 You need treatment not allowed in this study. 
 You do not follow directions. 
 The study is cancelled.  
 
19. How will your privacy and the confidentiality of your research records be protected? 
The centers and doctors in charge of this study will keep your personal information as private as possible.  
They will do their best to see that it is shared only when required by state or federal law or the terms of 
this consent.  It is impossible to promise total privacy.   
 
In addition to following state and federal law, the organizations listed below may read or copy your 
records to make sure the study information is correct.  Your research and medical records will have your 
name on them.  They will include things such as your medical history, results of your blood tests and 
exams, as well as reports about your treatment and office visits. 
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In order to understand the results of the study, people from the /Center Name/, the NMDP and the 
Blood Marrow Transplant Clinical Trials Network (BMT CTN) will need to see medical records with 
your name on them.  These people include: 
 Doctors in the study 
 Transplant center committees 
 People (who are not doctors) who check the safety and progress of studies 
 Members of the Institutional Review Board (this committee safe-guards the rights of persons 
taking part in research), and 
 People from the government (the National Institutes of Health and the Food and Drug 
Administration) might also need to see medical records with your name on them. 
 
Your research and medical records may be shown to these organizations:  
 /Institution/ 
 The National Institutes of Health (NIH) 
 Office of Human Research Protection (OHRP) 
 The Food and Drug Administration (FDA)  
 Institutional Review Board (IRB) 
 Data and Safety Monitoring Board (DSMB), not part of /Institution/ 
 The National Marrow Donor Program (NDMP) 
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 
 
We will do all we can to keep your medical records private.  Your name will not be used in any report 
of study results.   
 
Your answers to the quality of life interviews will be kept private and not included in your medical 
records, nor shared with your physicians or other caregivers.  Your answers will be coded with a 
study number only and kept in password-protected electronic file or locked file cabinets.  Only study 
personnel will have access to your information.  However, if any of your answers lead us to believe 
you are seriously depressed or in danger of hurting yourself, your physician will be notified. 
 
For questions about access to your medical records, please contact /name / at/number/. 
 
20. What is the expiration date for keeping your records? 
Study records will be kept indefinitely by the transplant center for re-analysis and follow-up. 
 
If you have questions about the keeping of your research records or access to your files, please call 
/name/at /number/. 
 
21. How will the researcher(s) benefit from you being in this study? 
The researchers have no money invested in this study.  But, in general, presenting research results helps 
the career of a scientist.  Therefore, the Principal Investigator may benefit if the results of this study are 
presented at scientific meetings or in the scientific press.  In addition, the Principal Investigator is being 
paid a small amount to cover the cost of the study. 
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22. Consent and Assent Instructions 
 
Consent: People 18 years and older must sign on the subject line below. 
For people under 18, consent is provided by the Legally Authorized Representative. 
 
Assent: Is required for people under the age of 18, using the Assent form. 
 
I have been informed about this study’s purpose, procedures, possible benefits and risks.  I have been 
given a chance to ask questions.  I am satisfied with the answers I have gotten to my questions.  I 
understand that I can ask more questions at any time. 
 
I voluntarily agree to take part, or to allow my child to take part, in this study. 
 
By signing this consent form, I have not given up any of the legal rights which, I (my child) otherwise 
would have as a subject in a research study. 
 
 
 
            
Subject‘s Signature      Date 
 
 
If you are not the subject, please print your name      
and indicate one of the following: 
 
  The subject’s parent        The subject’s guardian 
  A surrogate         A durable power of attorney 
  A proxy         Other, please explain: ________________ 
 
 
 
            
Legally Authorized Representative Signature  Date 
 
 
As a representative of this study, I have explained the purpose, the procedures, the potential benefits, 
and the risks that are involved in this research study: 
 
 
 
            
Signature of person conducting informed consent   Date 
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Attachment A – Additional Risks and Toxicities 
Regimen – Total Body Irradiation and Cyclophosphamide 
There are more risks involved with transplantation, and there may be more side-effects.  Most of these 
risks and side-effects are listed below, but they will vary from person to person.  Your doctor may give 
you drugs to lessen some of the side effects.  
 
Central Venous Catheter (Central line): When a central venous catheter is put into one of the large 
veins in your chest, it may cause bleeding or infection.  Rarely, one of your lungs could collapse.  This 
would require putting another tube into your chest until the lung is fully re-expanded.  While you have a 
central line in place, you have an increased chance of infection in the tissues around it or in your blood.  
This would require treatment with antibiotics, and possible removal of the catheter.  Another catheter 
would then need to be placed.  Rarely, a blood clot can form on the tip of the catheter, break off, and go 
into the lungs (pulmonary embolus), which could cause shortness of breath and pain. 
 
Cyclophosphamide (Cytoxan) is a common anti-cancer drug.  It is an alkaloid (type) drug that kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause diarrhea (loose stools), 
nausea (sick to your stomach), vomiting (throwing up), short-term hair loss, short-term bladder problems, 
and, at times, bleeding from the bladder.  A few patients may have bladder damage and bleeding for a 
longer time.  You will be given large amounts of sterile water through your central line to protect your 
bladder.  A bladder catheter (thin plastic tube) may be inserted into your bladder, if your physician thinks 
that it can help you.  Cyclophosphamide slows the making of new red blood cells, white blood cells, and 
platelets.  This causes a risk of infection and/or severe bleeding until the transplanted cells begin to work.  
You will get blood transfusions as needed.  Cyclophosphamide also lowers your defense system.  This 
may lead to more infections for several months after transplant.  Cyclophosphamide may cause heart 
damage in a small number of patients.  Cyclophosphamide may result in sterility (you can’t have 
children).  Even if sterility does not occur, there is a major risk of genetic damage to any future children.  
It is not known whether the use of Cyclophosphamide will cause more side effects or problems with your 
health in the future. 
 
Total Body Irradiation (TBI) may cause diarrhea (loose stools), nausea (sick to your stomach), 
vomiting (throwing up), and painful swelling of the parotid gland (a gland under the chin) for a few days.  
Short-term hair loss also occurs.  TBI kills both sick and normal marrow, leading to a lack of red blood 
cells, white blood cells, and platelets.  The short-term loss of these blood cells could cause anemia, 
infection, and/or bleeding.  This will continue until the transplant begins to work.  You will get blood 
transfusions as needed.  There is a risk that cataracts (cloudiness) may develop in the eyes.  This may 
mean partial loss of vision, and you may need contact lenses or surgery to remove the cataracts.  The 
irradiation dose used will probably result in sterility (you can’t have children.)  Even if sterility does not 
occur, there is a major risk of genetic damage to any future children.  It is not known whether the use of 
total body irradiation will cause more side effects or problems with your health in the future. 
 
Peripheral Blood Stem Cell Transplant/ Marrow Transplant: The infusion of PBSC or marrow 
usually has few side effects.  Once in a while it may cause a headache, chest pain or trouble breathing, a 
slight fever, or blood in the urine.  Very rarely, it may cause an allergic reaction (which shows up as a 
severe drop in blood pressure and may cause loss of consciousness).   
 
The graft contains stem cells, which allow your blood counts (red blood cells, white blood cells, and 
platelets) to recover.  Stem cells make all the blood cells in the bone marrow and serve the entire body.  It 
is possible that your marrow will not work well enough after the stem cells recover and you will be at an 
increased risk of infections and even death.  Blood counts will be done often to track marrow recovery.  
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 1.0 dated June 17, 2003 
B-10 
You will get platelets and red cells as needed to keep your counts at a healthy level.  There is a risk that 
stem cells may not grow after being given to you.  This is called graft failure.  Graft failure can be fatal 
unless you have a second transplant.  
 
Graft-versus-host Disease:  After the graft begins to function, there is a further risk of a reaction of the 
graft against your tissues.  This reaction is called graft-versus-host disease (GVHD) and may cause a skin 
rash, or abnormalities of the liver, or stomach.  GVHD may cause nausea, vomiting, lack of appetite, 
stomach cramps, diarrhea, and bleeding of the gut.  Chronic GVHD may occur later after transplantation 
and may involve problems with the eyes, mouth, lips, throat and liver.  Early (acute) or late (chronic) 
GVHD may become severe enough to result in death.  GVHD is treated with drugs that weaken the 
immune system, and therefore make you more susceptible to infections. 
 
Cyclosporine or Tacrolimus will be used to try to prevent GVHD.  These drugs have similar side 
effects. The immediate side effects may include nausea or vomiting when given orally.  Other side effects 
may include the possibility of developing high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  These effects are generally 
reversible upon decreasing the dose of the drug.  An occasional patient has had a seizure.  Patients may 
experience a change of liver or kidney function, in which case the dose will be reduced or possibly even 
withheld.  This effect on kidneys seems to increase when other drugs, which might cause kidney problems 
are given at the same time, especially antibiotics. Occasionally, the kidney damage caused may require 
the use of an artificial kidney machine (hemodialysis). 
 
Some patients given intravenous cyclosporine for the treatment of GVHD experience a painful sensation 
in their hands or feet or both.  The pain decreases or goes away with the improvement of GVHD or when 
the cyclosporine is switched from the intravenous to the oral form. 
 
Some patients given tacrolimus experience diabetes and require insulin during the time the drug is 
administered. 
 
Methotrexate is also a drug used to try to prevent GVHD.  Methotrexate causes damage to cells, and 
therefore can affect many different tissues of the body.  It may cause or can worsen the mouth sores or 
inflammation of the oral mucous membranes (mucositis) which may have already been caused by the 
procedures and drugs used to prepare the patient for transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation.  It can worsen kidney function if the kidney is already 
damaged for other reasons.  Methotrexate can cause liver damage.  If kidney damage does occur, the 
methotrexate dose may be reduced or not administered. 
 
Cyclosporine, Tacrolimus and Methotrexate cause suppression of the immune system, which in turn 
may result in an increased risk of infection for several months after transplant, especially viral infections 
and pneumonia.  
 
Glucocorticoids (or steroids) are hormones used to treat cancer and GVHD, including 
prednisone (when taken by mouth) and methylprednisolone (when taken by vein).  Potential 
side effects of steroid therapy include swelling, fluid retention, high blood sugar, 
gastrointestinal (stomach, gut) bleeding, changes in behavior or mood, insomnia and 
softening of bones (aseptic necrosis).  In addition, you can be at of increased risk of 
developing an infection.  Steroids may also cause increases in blood pressure and seizures in 
some patients.  As with any drug there may be unanticipated negative effects.  All patients 
will be followed closely for these possible complications and if a serious problem occurs, the 
steroids will be stopped as quickly as possible.
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Consent to Total Body Irradiation and Cyclophosphamide Regimen (Attachment A) 
 
Consent: People 18 years and older must sign on the subject line below. 
For people under 18, consent is provided by the Legally Authorized Representative. 
 
I have been informed about this study’s purpose, procedures, possible benefits and additional risks 
involved with transplantation, total body irradiation and cyclophosphamide.  I have been given a 
chance to ask questions.  I am satisfied with the answers I have gotten to my questions.  I understand 
that I can ask more questions at any time. 
 
I voluntarily agree to take part, or to allow my child to take part, in this study. 
 
By signing this consent form, I have not given up any of the legal rights which, I (my child) otherwise 
would have as a subject in a research study. 
 
 
 
            
Signature       Date 
 
 
If you are not the subject, please print your name      
and indicate one of the following: 
 
  The subject’s parent        The subject’s guardian 
  A surrogate         A durable power of attorney 
  A proxy         Other, please explain: ________________ 
 
 
 
            
Legally Authorized Representative Signature  Date 
 
 
As a representative of this study, I have explained the purpose, the procedures, the potential benefits, 
and the risks that are involved in this research study: 
 
 
 
            
Signature of person conducting informed consent   Date 
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Attachment B – Additional Risks and Toxicities 
Regimen – Busulfan and Cyclophosphamide 
There are more risks involved with transplantation, and there may be more side effects.  Most of these 
risks and side effects are listed below, but they will vary from person to person.  Your doctor may be able 
to give you medications to lessen some of the side effects.  
 
Central Venous Catheter (Central line): When a central venous catheter is put into one of the large 
veins in your chest, it may cause bleeding or infection.  Rarely, one of your lungs could collapse.  This 
would require putting another tube into your chest until the lung is fully re-expanded.  While you have a 
central line in place, you have an increased chance of infection in the tissues around it or in your blood.  
This would require treatment with antibiotics, and possible removal of the catheter.  Another catheter 
would then need to be placed.  Rarely, a blood clot can form on the tip of the catheter, break off, and go 
into the lungs (pulmonary embolus), which could cause shortness of breath and pain. 
 
Cyclophosphamide (Cytoxan) is a common anticancer drug.  It is an alkaloid (type) drug that kills cancer 
cells by stopping them from growing.  Cyclophosphamide may cause diarrhea (loose stools), nausea (sick 
to your stomach), vomiting (throwing up), short-term hair loss, short term bladder problems, and, at 
times, bleeding from the bladder.  A few patients may have bladder damage and bleeding for a longer 
time.  You will be given large amounts of sterile water through your central line to protect your bladder.  
A bladder catheter (thin plastic tube) may be inserted into your bladder, if your physician thinks that it 
can help you.  Cyclophosphamide slows the making of new red blood cells, white blood cells, and 
platelets.  This causes a risk of infection and/or severe bleeding until the transplanted cells begin to work.  
You will get blood transfusions as needed.  Cyclophosphamide also lowers your defense system.  This 
may lead to more infections for several months after transplant.  Cyclophosphamide may cause heart 
damage in a small number of patients.  Cyclophosphamide may result in sterility (you can’t have 
children).  Even if sterility does not occur, there is a major risk of genetic damage to any future children.  
It is not known whether the use of Cyclophosphamide will cause more side effects or problems with your 
health in the future. 
 
Busulfan is a drug that disrupts the growth of cancer cells, which are then destroyed.  Likely side effects 
of busulfan are: diarrhea (loose stools), nausea (sick to your stomach), vomiting (throwing up), lower 
white blood cell count that increases your risk of infection, lower platelet count that increases your risk of 
bleeding, hair loss, stopping of menstrual periods in women, temporary reduced or no sperm production 
in men.  Less likely side effects are: fatigue, sores in mouth or on lips, fever, rash, loss of appetite, 
changes in color of the skin, seizure.  Rare side effects are: damage to your lungs causing a cough, trouble 
breathing, and being short of breath, changes in liver function.  
 
Peripheral Blood Stem Cell Transplant/ Marrow Transplant: The infusion of PBSC or marrow 
usually has few side effects.  Once in a while it may cause a headache, chest pain or trouble breathing, a 
slight fever, or blood in the urine.  Very rarely, it may cause an allergic reaction (which shows up as a 
severe drop in blood pressure and may cause loss of consciousness). 
 
The graft contains stem cells, which allow your blood counts (red blood cells, white blood cells, and 
platelets) to recover.  Stem cells make all the blood cells in the bone marrow and serve the entire body.  It 
is possible that your marrow will not work well enough after the stem cells recover and you will be at an 
increased risk of infections and even death.  Blood counts will be done often to track marrow recovery.  
Platelets and red cells will be given as needed to keep your counts at a healthy level.  There is a risk that 
stem cells may not grow after being given to you.  This is called graft failure.  Graft failure can be fatal 
unless you have a second transplant.  
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Graft-versus-host Disease:  After the graft begins to function, there is a further risk of a reaction of the 
graft against your tissues.  This reaction is called graft-versus-host disease (GVHD) and may cause a skin 
rash, or abnormalities of the liver, or stomach.  GVHD may cause nausea, vomiting, lack of appetite, 
stomach cramps, diarrhea, and bleeding of the gut.  Chronic GVHD may occur later after transplantation 
and may involve abnormalities of the eyes, mouth, lips, throat and liver.  Early (acute) or late (chronic) 
GVHD may become severe enough to result in death.  GVHD is treated with drugs that weaken the 
immune system, and therefore make you more susceptible to infections. 
 
Cyclosporine or Tacrolimus will be used to try to prevent GVHD.  These drugs have similar side 
effects.  The immediate side effects may include nausea or vomiting when given orally.  Other side 
effects may include the possibility of developing high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  These effects are generally 
reversible upon decreasing the dose of the drug.  An occasional patient has had a seizure.  Patients may 
experience a change of liver or kidney function, in which case the dose will be reduced or possibly even 
withheld.  This effect on kidneys seems to increase when other drugs, which might cause kidney problems 
are given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require 
the use of an artificial kidney machine (hemodialysis). 
 
Some patients given intravenous cyclosporine for the treatment of GVHD experience a painful sensation 
in their hands or feet or both.  The pain decreases or goes away with the improvement of GVHD or when 
the cyclosporine is switched from the intravenous to the oral form. 
 
Some patients given tacrolimus experience diabetes and require insulin during the time the drug is 
administered. 
 
Methotrexate is also a drug used to try to prevent GVHD.  Methotrexate causes damage to cells, and 
therefore can affect many different tissues of the body. It may cause or can worsen the mouth sores or 
inflammation of the oral mucous membranes (mucositis) which may have already been caused by the 
procedures and drugs used to prepare the patient for transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation.  It can worsen kidney function if the kidney is already 
damaged for other reasons.  Methotrexate can cause liver damage.  If kidney damage does occur, the 
methotrexate dose may be reduced or not administered. 
 
Cyclosporine, Tacrolimus and Methotrexate cause suppression of the immune system, which in turn 
may result in an increased risk of infection for several months after transplant, especially viral infections 
and pneumonia.  
 
Glucocorticoids are hormones used to treat cancer and GVHD, including prednisone (when taken 
by mouth) and methylprednisolone (when taken by vein).  Potential side effects of steroid therapy 
include swelling, fluid retention, high blood sugar, gastrointestinal (stomach, gut) bleeding, changes 
in behavior or mood, insomnia and softening of bones (aseptic necrosis). In addition, you can be at 
of increased risk of developing an infection.  Steroids may also cause increases in blood pressure 
and seizures in some patients. As with any drug there may be unanticipated negative effects.  All 
patients will be followed closely for these possible complications and if a serious problem occurs, 
the steroids will be stopped as quickly as possible. 
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Consent to Busulfan and Cyclophosphamide Regimen (Attachment B) 
 
Consent: People 18 years and older must sign on the subject line below. 
For people under 18, consent is provided by the Legally Authorized Representative. 
 
I have been informed about this study’s purpose, procedures, possible benefits and additional risks 
involved with transplantation, busulfan and cyclophosphamide.  I have been given a chance to ask 
questions.  I am satisfied with the answers I have gotten to my questions.  I understand that I can ask 
more questions at any time. 
 
I voluntarily agree to take part, or to allow my child to take part, in this study. 
 
By signing this consent form, I have not given up any of the legal rights which, I (my child) otherwise 
would have as a subject in a research study. 
 
 
 
            
Signature       Date 
 
 
If you are not the subject, please print your name      
and indicate one of the following: 
 
  The subject’s parent        The subject’s guardian 
  A surrogate         A durable power of attorney 
  A proxy         Other, please explain: ________________ 
 
 
 
            
Legally Authorized Representative Signature  Date 
 
 
As a representative of this study, I have explained the purpose, the procedures, the potential benefits, 
and the risks that are involved in this research study: 
 
 
 
            
Signature of person conducting informed consent   Date 
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Attachment C – Additional Risks and Toxicities 
Regimen – Fludarabine and Melphalan 
There are more risks involved with transplantation, and there may be more side effects.  Most of these 
risks and side effects are listed below, but they will vary from person to person.  Your doctor may be able 
to give you medications to lessen some of the side effects.  
 
Central Venous Catheter (Central line): When a central venous catheter is put into one of the large 
veins in your chest, it may cause bleeding or infection.  Rarely, one of your lungs could collapse.  This 
would require putting another tube into your chest until the lung is fully re-expanded.  While you have a 
central line in place, you have an increased chance of infection in the tissues around it or in your blood.  
This would require treatment with antibiotics, and possible removal of the catheter.  Another catheter 
would then need to be placed.  Rarely, a blood clot can form on the tip of the catheter, break off, and go 
into the lungs (pulmonary embolus), which could cause shortness of breath and pain. 
 
Fludarabine is a drug used to treat cancer.  It has been used in stem cell transplants to reduce the risk of 
rejection.  Likely side effects are: low white blood cell count with increased risk of infection, low platelet 
count with increased risk of bleeding, feeling tired or sleepy, anemia (low red blood cell count).  An 
occasional patient has experienced confusion or coma, trouble seeing or problems with your eyes, trouble 
breathing, diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), 
pneumonia, agitation, numbness and tingling of the fingertips and toes, and kidney problems. 
 
Melphalan disrupts the growth of cancer cells, which are then destroyed.  Expected side effects include: 
nausea (feeling sick to stomach), hair loss, low white blood cell count which may lead to infection.  Less 
likely side effects include: diarrhea (loose stools), mouth ulcers, low platelet count with increased risk of 
bleeding.  A severe allergic reaction is a rare side effect.  Symptoms include itching, hives (bumps on 
your skin), flushing (redness), wheezing, chest tightness, skin rashes, fever, chills, muscle stiffening, 
severe breathing problems, and loss of appetite. 
 
Peripheral Blood Stem Cell Transplant/ Marrow Transplant: The infusion of PBSC or marrow 
usually has few side effects.  Once in a while it may cause a headache, chest pain or trouble breathing, a 
slight fever, or blood in the urine.  Very rarely, it may cause an allergic reaction (which shows up as a 
severe drop in blood pressure and may cause loss of consciousness).   
 
The graft contains stem cells, which allow your blood counts (red blood cells, white blood cells, and 
platelets) to recover.  Stem cells make all the blood cells in the bone marrow and serve the entire body.  It 
is possible that your marrow will not work well enough after the stem cells recover and you will be at an 
increased risk of infections and even death.  Blood counts will be done often to track marrow recovery.  
Platelets and red cells will be given as needed to keep your counts at a healthy level.  There is a risk that 
the stem cells may not grow after being given to you.  This is called graft failure.  Graft failure can be 
fatal unless you have a second transplant.  
 
Graft-versus-host Disease:  After the cells in the graft begin to grow, there is a risk that the graft may 
react against your body.  This is called graft-versus-host disease (GVHD) and may show up as a skin rash, 
or liver or stomach problems.  GVHD may cause nausea (feeling sick to your stomach), vomiting 
(throwing up), lack of appetite, stomach cramps, diarrhea (loose stools), and bleeding of the gut.  Chronic 
GVHD may occur later after transplantation and may involve problems with the eyes, mouth, lips, throat 
and liver.  Early (acute) or late (chronic) GVHD may be bad enough to cause death.  GVHD is treated 
with drugs that weaken the body’s defense system, and thus make you more likely to get an infection. 
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Cyclosporine or Tacrolimus will be used to try to prevent GVHD.  These drugs have similar side 
effects, which may include nausea (feeling sick to your stomach) or vomiting (throwing up) when given 
by mouth.  Other side effects may include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and not thinking clearly.  These usually go away after the dose of the drug 
is decreased.  An occasional patient has had a seizure.  Patients may show liver or kidney problems, in 
which case the dose will be reduced or not given.  The effect on the kidneys seems worse when other 
drugs known to cause kidney problems (especially antibiotics) are given at the same time.  Once in a 
while, the kidney problems may require the use of an artificial kidney machine (hemodialysis). 
 
Some patients given cyclosporine by vein to treat GVHD have pain in their hands or feet or both.  The 
pain is less or goes away when GVHD gets better or when the cyclosporine is changed from by-vein to 
by-mouth. 
 
Some patients given tacrolimus get diabetes and need insulin at the same time. 
 
Methotrexate is a drug used to try to prevent GVHD.  Methotrexate damages healthy cells, and thus can 
affect many parts of the body.  It may cause mouth sores (mucositis) or make mouth sores caused by the 
procedures and drugs used before transplant worse.  Methotrexate may slow down the return of blood 
cells after transplantation.  Methotrexate can cause liver damage.  It can worsen kidney function if the 
kidney is already damaged.  If kidney damage occurs, the methotrexate dose may be reduced or not given.   
 
Glucocorticoids (also called steroids) are hormones used to treat cancer and GVHD.  Prednisone is taken 
by mouth and methylprednisolone is taken by vein.  Possible side effects include swelling, retaining fluid, 
high blood sugar, gastrointestinal (stomach, gut) bleeding, changes in behavior or mood, not being able to 
sleep and softening of bones (aseptic necrosis).  Steroids may also raise blood pressure and cause seizures 
in some patients.  As with any drug there may be unexpected bad effects.  All patients will be followed 
closely for possible side effects.  If a serious problem occurs, the steroids will be stopped as quickly as 
possible. 
 
Cyclosporine, Tacrolimus, Methotrexate, and steroids interfere with the body’s defense system (the 
immune system).  This may lead to more infections (especially viral infections and pneumonia) for 
several months after transplant. 
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Consent to Fludarabine and Melphalan Regimen (Attachment C) 
 
Consent: People 18 years and older must sign on the subject line below. 
For people under 18, consent is provided by the Legally Authorized Representative. 
 
I have been informed about this study’s purpose, procedures, possible benefits and additional risks 
involved with transplantation, fludarabine and melphalan.  I have been given a chance to ask 
questions.  I am satisfied with the answers I have gotten to my questions.  I understand that I can ask 
more questions at any time. 
 
I voluntarily agree to take part, or to allow my child to take part, in this study. 
 
By signing this consent form, I have not given up any of the legal rights which, I (my child) otherwise 
would have as a subject in a research study. 
 
 
 
            
Signature      Date 
 
 
If you are not the subject, please print your name      
and indicate one of the following: 
 
  The subject’s parent        The subject’s guardian 
  A surrogate         A durable power of attorney 
  A proxy         Other, please explain: ________________ 
 
 
 
            
Legally Authorized Representative Signature  Date 
 
 
As a representative of this study, I have explained the purpose, the procedures, the potential benefits, 
and the risks that are involved in this research study: 
 
 
 
            
Signature of person conducting informed consent   Date 
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NATIONAL MARROW DONOR PROGRAM® (NMDP) 
A RANDOMIZED TRIAL OF FILGRASTIM-MOBILIZEDBLOOD STEM CELLS  
AND BONE MARROW 
 
DONOR/SUBJECT RESEARCH CONSENT FORM 
 
I. INVITATION AND PURPOSE 
You are invited to participate in a research study of the NMDP and the Blood and Marrow 
Transplant Clinical Trials Network (BMT CTN).  This study is designed to see whether there is a 
difference in the results of unrelated donor transplants depending on whether the stem cells are 
collected from the donor’s blood stream or bone marrow.  This study is also designed to see if 
there are differences in donor experiences depending on whether the donor donates blood stem 
cells or bone marrow.  You are invited to participate in this study because you have been 
matched with a potential recipient.  You should read this form and ask any questions you may 
have before agreeing to participate in the study. 
The main goal of this study is to find out if there are differences in the outcomes of unrelated 
donor transplants if stem cells are collected from the blood stream (blood stem cells) or from the 
bone marrow.  Stem cells, which are found in bone marrow, are required for transplantation, but 
only a few stem cells are normally found in the blood.  In the past, stem cells were always 
collected from the bone marrow.  However, it is now known that a drug called “Filgrastim” can 
increase the number of stem cells in the blood so greatly that transplants can be performed using 
stem cells collected from the blood.  When the NMDP compared the survival of recipients who 
received an unrelated donor marrow transplant with recipients who received an unrelated donor 
blood stem cell transplant, there was no difference in survival between the two groups.  This may 
have been because the recipients in each group did not have the same characteristics (different 
ages, different disease stages).  In this study, the donor and recipient will be randomly assigned 
(much like the toss of a coin) to either the blood stem cell group or the bone marrow group.  By 
randomly assigning the recipients to receive either blood stem cells or bone marrow, the 
characteristics of the recipients in each group should be similar.  With similar types of recipients 
in each group, we should be able to find out if recipients who receive one type of product do 
better after transplant than recipients who receive the other product, or if recipients in both 
groups have similar results from their transplant. 
Another goal of this study is to find out if blood stem cell donors and bone marrow donors 
experience different physical side effects, and have different quality of life issues such as how 
the donation experience affected daily life. 
 
It is not possible to predict for certain the chances of a successful transplant for a potential 
recipient.  It is possible that the recipient will suffer fatal complications from the transplant 
or that the recipient’s disease will not be cured by the procedure.  You cannot control the 
success of the transplant, so it is important that you not feel personally responsible for its 
outcome. 
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This study is being conducted by: Dr. _______________ ___________________ (Donor Center 
Medical Director), and Dr. Dennis Confer, Chief Medical Officer of the NMDP. 
 
III. STUDY PROCEDURES 
A. Medical Evaluation 
If you agree to participate, you will undergo: 
 a medical evaluation, 
 a series of standard laboratory tests, 
 testing for infectious diseases such as hepatitis and HIV, 
 screening for hemoglobin S (sickle hemoglobin), and 
 if you are female, a pregnancy test. 
 
These will determine if you might experience unexpected risks by donating blood stem cells or 
bone marrow and also if the recipient of your blood stem cells or bone marrow might experience 
unexpected risks.  If your medical evaluation discloses any abnormalities, you will be informed.  
The NMDP or your Donor Center may also be required by law to notify your state public health 
agency if you test positive for hepatitis B, hepatitis C, the virus that causes AIDS (HIV) or other 
infectious diseases.  If anything abnormal is found during the medical evaluation, it is possible 
that you may not be permitted to donate one product or the other product, or it is also possible 
that you will not be able do donate either blood stem cells or bone marrow.  
There have been reports of severe reactions to Filgrastim in persons with sickle cell disease.  
You will be tested for sickle hemoglobin.  This test may result in genetic information that is new 
to you.  If your blood tests positive for sickle hemoglobin, you will not be able to participate in 
this study. You may still be asked to donate bone marrow for this recipient. 
You must not take Filgrastim if you are pregnant.  This medication could cause serious problems 
for an unborn child.  You will be required to take a pregnancy test before getting Filgrastim.  
You must ensure that you do not get pregnant while taking Filgrastim and for 48 hours after the 
last shot. 
 
B. Randomization 
Once your medical evaluation is completed and it has been decided that you may donate, you 
and your recipient will be randomly assigned (much like the toss of the coin) to either the blood 
stem cell group or the bone marrow group.  You will go through certain procedures depending 
on which product you’ve been randomized to donate.  The following sections describe the 
procedures for donating blood stem cells and bone marrow. 
 
C. Procedures for Blood Stem Cells 
Preparation for Donating Blood Stem Cells 
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If you are randomized to donate blood stem cells, you will receive Filgrastim injections under the 
skin once a day for four or five days.  These injections will increase the number of stem cells in 
your bloodstream.  Before each Filgrastim injection, you will be asked about any symptoms you 
may have.  You will also have blood samples drawn from a vein in your arm on the first day of 
Filgrastim.  Seven to 14 milliliters (½ to 1 tablespoon) of blood will be drawn each time to 
measure your blood cell counts. 
Filgrastim, also called “G-CSF” and marketed in the U.S. as Neupogen® , has been approved by 
the Food and Drug Administration (FDA) to collect blood stem cells from patients receiving 
transplants of their own stem cells.  It is also approved to treat patients with cancer getting 
chemotherapy, for patients getting bone marrow transplants and for patients with diseases 
causing very low white blood counts. 
The physicians at the transplant center where the recipient is being treated may also ask for some 
additional blood from you before the transplant.  If this blood is requested, you will not be asked 
to give any more than 100 mLs (approximately 7 tablespoons) of blood.  The blood will be 
drawn from a vein in your arm.  The blood will be used at the transplant center for tests 
necessary for treatment of the recipient.  For example, DNA from your blood may be stored to 
help identify which blood cells growing in the recipient after the transplant came from the 
donor’s (your) cells, and which came from the recipient’s cells.  This blood cannot be used for 
research without additional consent from you. 
 
Blood Stem Cell Donation 
To collect blood stem cells, you will have a needle placed in a vein in each arm.  Blood is 
removed from one arm and passed through a special machine called a blood cell separator.  This 
process is called “apheresis.”  The machine collects your blood stem cells, and the rest of your 
blood is given back through the needle in your other arm.  You will make one or two blood stem 
cell donations, depending on the size of the recipient.  During each donation you will need to lie 
relatively still in a recliner chair for four to six hours. 
The blood stem cell donation procedure requires that a needle be placed in a vein in each arm.  If 
your arm veins are not big enough for these needles, you may be asked to have a special blood-
drawing tube, called a “central line,” placed in a larger vein in your body.  Based on the NMDP’s 
experience, 18% of women and 2.5% of men require a central line placement.  Your veins will 
be evaluated at the medical evaluation, but a decision to place a central line may be made at the 
time of the blood stem cell collection as well.   
Central line placement is a surgical procedure that requires local anesthesia.  If a central line is 
requested, you will be asked to sign another consent form that will explain the risks of the central 
line placement.  If a central line is placed, a peripheral blood stem cell collection over two days 
may require you to stay overnight in the hospital.  If a central line is recommended, you are free 
to decline.  If you decline a central line placement, you may be asked to consider bone marrow 
donation instead.  
With each blood stem cell donation, 10 milliliters (¾ tablespoon) of blood will be taken at the 
start and at the end of the procedure to measure your blood cell counts.  The blood stem cells 
may be tested after they are collected to determine the number and types of cells, and other 
factors that may be important to the transplant.   
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D. Procedures for Bone Marrow 
Preparation for Donating Bone Marrow 
Depending on how much bone marrow you are asked to donate, you may need to have one to 
three units of your blood drawn and stored prior to the bone marrow collection.  You will be 
asked to sign a separate consent form each time you give a unit (approximately two cups) of 
blood.  If your blood counts are low after the bone marrow collection, your stored blood will be 
given back to you by transfusion. 
The physicians at the transplant center where the recipient is being treated may also ask for 
additional blood from you before the transplant.  If this blood is requested, you will not be asked 
to give more than 100 mLs (approximately 7 tablespoons) of blood.  The blood will be drawn 
from a vein in your arm.  The blood will be used at the transplant center for tests necessary for 
treatment of the recipient.  For example, DNA from your blood may be stored to help identify 
which blood cells growing in the recipient after the transplant came from the donor’s (your) 
cells, and which came from the recipient’s cells.  This blood cannot be used for research without 
additional consent from you. 
 
Bone Marrow Donation 
Bone marrow is collected in an operating room.  You will be given either general anesthesia or 
spinal anesthesia. Prior to the bone marrow collection, you will meet with a physician to discuss 
the type of anesthesia that will be used for the collection.  (This consent form is not for the 
anesthesia or the actual bone marrow collection.  At the hospital you will be asked to sign 
another consent form for the anesthesia and the bone marrow collection.)  Your bone marrow 
will be removed from your iliac crest (pelvic bone).  The physician collecting the bone marrow 
will make at least two, and possibly more, very small cuts in the skin covering the pelvic bones. 
Needles will be inserted through these cuts into the bone.  After the needle is placed in the 
marrow cavity of the bone, a syringe will be attached to the needle and the marrow will be 
removed.  The amount of bone marrow collected depends on the size of the person for whom you 
are donating, however, no more than two teaspoons of bone marrow per pound of your body 
weight will be removed (for example, if a donor weighs 150 pounds, no more than 6 cups of 
bone marrow would be collected).  Once the bone marrow is collected, the anesthetic will be 
allowed to wear off and you will be returned to your hospital room.  
 
E. Follow-up Visits for Blood Stem Cells and Bone Marrow Donors 
Two days after the blood stem cell or bone marrow collection, you will be asked questions by 
telephone about how you are feeling (symptom assessment).  You will be asked these questions 
by phone again one week after the blood or bone marrow stem cells are collected, and then 
weekly after that until you feel back to normal.  You will also be asked to donate a blood sample 
(7 milliliters or ½ tablespoon) one month and six months after your donation and then yearly to 
measure your blood cell counts.  These follow-up visits will be used to assess your recovery 
from the donation. 
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Summary of pre-donation, donation and follow-up visits for blood stem cell donation 
In summary, your scheduled visits for Filgrastim administration, blood stem cell donations, and 
blood draws are given in the following table (an X marks what will happen on each visit): 
 
Visits Symptom Assessment 
Filgrastim 
Shot 
Blood Stem Cell 
Donation 
Blood 
Draws 
Screening X   X 
Preparation, Day 1 X X   
Preparation, Day 2 X X   
Preparation, Day 3 X X   
Preparation, Day 4 X X   
First donation X X1 X X 
Second donation1 X  X X 
2 days after donation X    
1 week after donation2 X    
1 month after donation X   X 
6 months after donation X   X 
1 year after donation 
2 years after donation 
3 years after donation 
Yearly visits after 
donation 
X 
X 
X 
X 
  
X 
X 
X 
X 
1 If necessary, based on size of the recipient.  
2 Will continue weekly until complete recovery from donation is reported. 
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Summary of pre-donation, donation and follow-up visits for bone marrow donation 
In summary, your scheduled visits for autologous blood units, bone marrow donation, and 
follow-up visits are given in the following table (an X marks what will happen on each visit): 
 
Visits Symptom Assessment 
Donor’s blood 
drawn and 
stored 
Bone Marrow 
Donation 
Blood 
Draws 
Screening X   X 
Pre-donation blood draw 
1 X X  X 
Pre-donation blood draw 
1 X X   
Pre-donation blood draw 
1 X X   
Bone marrow donation X  X  
2 days after donation X    
1 week after donation2 X    
1 month after donation X   X 
6 months after donation X   X 
1 year after donation 
2 years after donation 
3 years after donation 
Yearly visits after 
donation 
X 
X 
X 
X 
  X 
X 
X 
X 
1 This item depends on how much bone marrow will be collected. 
2 Will continue weekly until complete recovery from donation is reported. 
 
F. QUALITY OF LIFE STUDIES 
In addition to donating either blood stem cells or bone marrow, this study includes a quality of 
life study.  If you read and write English, have access to a telephone, and have the ability to 
complete a questionnaire, you will be included in the quality of life study.  
If you are included in the quality of life study, your name, telephone number and address will be 
given to the research team conducting the quality of life study.  As part of the quality of life 
study, you will be asked to complete a questionnaire at specific time points before and after the 
donation.  You will be asked questions about your physical recovery, how well you are doing 
emotionally, how much the donation affected your daily activities, and how you feel about the 
donation experience.  In addition, you will be asked questions about your age, gender, race, 
marital status, work status and how much education you have had.  You will be asked these 
questions either by phone or in-person.  The answers to your questions are confidential and will 
be kept in a secure place only open to study members working on the quality of life study. 
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Schedule for Questionnaires: 
 4 weeks prior to donation 
 Day 4 of Filgrastim injection (only for blood stem cell donors) 
 2 days after the donation 
 Weekly until complete recovery from the donation 
 6 months after the donation 
 Annually for five years after the donation 
 
These quality of life questionnaires are in addition to the physical assessments that are done as 
part of the donation (see Section III.E of this consent form). 
Since the quality of life study only involves answering questions, there are no physical risks to 
participating in the quality of life study.  However, some people may experience emotional 
discomfort at having to answer personal questions.  You do not have to answer any questions 
that you do not wish to answer.  This study will not benefit you, but the knowledge gained from 
the study may help people in the future who are asked to donate stem cells. 
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IV. POSSIBLE RISKS AND BENEFITS TO BEING IN THIS STUDY 
Depending on whether you were randomized to donate blood stem cells or bone marrow, you 
will experience different possible risks.  
 
A. Risks Associated With Donating Blood Stem Cells 
Side Effects of Filgrastim 
Filgrastim will be injected under the skin, which may be painful.  Most people will have aching 
pain in their bones while getting Filgrastim.  This pain is usually relieved by acetaminophen 
(Tylenol™) or ibuprofen (Motrin™, Advil™).  If you have pain that is not relieved by 
acetaminophen or ibuprofen, you should contact the Donor Center Coordinator, 
_____________________ at (       ) _______________, and the dose of Filgrastim may be 
reduced.  During the blood stem cell donation, your platelet count may be decreased because 
platelets are collected with the stem cells.  Taking aspirin when your platelet count is lowered 
may increase your chance of developing bleeding.  Therefore, aspirin or aspirin-containing 
drugs must not be taken while getting Filgrastim and for two weeks after blood stem cell 
donation without physician approval. 
Besides aching bones, other less frequent side effects of Filgrastim include headaches, muscle 
aches, tiredness, nausea and vomiting, and trouble sleeping.  All symptoms usually go away 
within two or three days after stopping Filgrastim. 
Filgrastim will cause your white blood cell count to be very high, which will not cause additional 
symptoms.  White blood cell counts usually return to normal levels within several days to several 
weeks following the discontinuation of Filgrastim. 
Filgrastim may cause your platelet count to be lower than normal.  Two out of 1400 NMDP 
donors experienced very low platelet counts that required close monitoring.  Although one donor 
was hospitalized during the monitoring period, neither developed symptoms from the low 
platelet count and both recovered.  Your platelet count will be measured on Day 5, prior to the 
first blood stem cell donation procedure.  If your platelet count is less than 80% of the lower 
limit of a normal platelet count, you will be informed.  In this case, depending on the actual 
value of your platelet count, you may be asked to consider donating bone marrow instead of 
blood stem cells, or the blood stem cell donation procedure may be delayed for a day. 
The NMDP is aware of four healthy related donors who developed pain and bleeding from the 
spleen while receiving Filgrastim.  In two cases the spleen was removed by surgery.  All four 
recovered.  Symptoms of this side effect are pain in the upper left-side just below the rib cage.  If 
you feel pain in this area you should contact your Donor Center immediately as this is a 
potentially serious side effect.  There is a small (estimated 1 in 10,000) risk of pain and bleeding 
from the spleen. 
Rare side effects of Filgrastim include allergy symptoms like rapid heart rate, dizziness, 
shortness of breath, itching or rash. 
If you think you are having any unexpected symptoms, contact the Donor Center immediately at 
(       ) ___________________________. 
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Long-term safety data on Filgrastim given to healthy people are limited; however, to date, no 
long-term adverse effects of Filgrastim have been observed. 
 
Side Effects of the Blood Stem Cell Donation Procedure 
To collect blood stem cells, a needle will be placed in a vein in each arm.  Pain and bruising 
could occur in both arms, but severe bleeding in the arm is rare. Should the blood cell separator 
machine break down, which is rare, you could lose up to 300 milliliters (1½ cups) of blood. 
To prevent clotting, your blood will be mixed with a liquid called an “anticoagulant” during the 
blood stem cell donation.  The anticoagulant sometimes causes temporary numbness and tingling 
of the fingertips or around the mouth.  If you experience numbness and tingling, you must tell 
the nurse operating the machine.  These symptoms are easily treated with calcium, but if not 
corrected could progress to muscle cramps.  Other possible side effects of the donation procedure 
include lightheadedness, nausea or, more rarely, fainting due to temporary lowering of the blood 
pressure, as well as becoming chilled during the procedure. 
In addition to collecting blood stem cells, the blood cell separator also collects platelets.  
Platelets help stop bleeding.  If your platelet count after the first donation is too low, the second 
donation may be cancelled.  Platelet counts usually return to normal levels within two to four 
weeks following collection of blood stem cells. 
Donating blood stem cells can cause intense emotions; especially if the transplant is not 
successful.  These emotions may range from general stress to post-donation elation or blues. 
You may be asked to donate again for the recipient if the donated cells do not grow in the 
recipient, or if the recipient’s disease is not cured.  If you are asked to donate again, you are free 
to decline. 
 
B. Risks Associated With Donating Bone Marrow 
Pre-donation Risks 
Prior to the bone marrow donation you will give several samples of blood.  There are minimal 
risks associated with giving a blood sample.  You may experience bruising around the site of the 
blood draw, fainting, or more rarely, infection at the puncture site.  
Risk of the Bone Marrow Donation 
There are certain risks associated with donating bone marrow.  For several hours after the bone 
marrow collection, you may feel groggy and nauseated from the anesthetic.  You will not be 
allowed to eat food or to get out of bed until you are wide awake and all the anesthetic has worn 
off.  Even after the anesthetic has worn off, you may still be nauseated and lightheaded for a 
period of time.  You should expect to feel some discomfort from the collection of the bone 
marrow.  Most donors experience soreness in their lower back, like a back strain, that lasts for a 
few weeks.  You may find it difficult to sit in a chair for long periods of time or to climb stairs.  
You will probably be less active than usual for the first two weeks following the collection. 
More serious complications from bone marrow collection are rare but could occur.  These more 
serious complications can be due to an unexpected reaction to the anesthetics or from problems 
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with the bone marrow collection procedure.  Anesthetics, for example, can sometimes cause high 
fevers, allergic reactions, or the inability to urinate.  Infection at the bone marrow collection site 
may occur, requiring antibiotic treatment.  Sometimes bone marrow collection will cause pain or 
numbness in a leg, bleeding at the collection site, or more severe pain than usual.  Bone, nerve or 
other tissue damage may occur and may require additional medical treatment or physical therapy. 
Although life-threatening reactions from collecting bone marrow are extremely rare, you should 
be aware that fatal complications can occur. 
Donating bone marrow can cause intense emotions; especially if the transplant is not successful.  
These emotions may range from general stress to post-donation elation or blues. 
You may be asked to donate again for the recipient if the donated cells do not grow in the 
recipient, or if the recipient’s disease is not cured.  If you are asked to donate again, you are free 
to decline. 
 
C. Potential Benefits From Donating Blood Stem Cells or Bone Marrow 
You will receive no direct benefits from participating in this study.  However, participating in 
this study may help the recipient of your cells and may provide information on the value of 
unrelated donor transplantation that will benefit future recipients and donors.  
 
V. CONFIDENTIALITY 
Your participation in this research study will be kept private and confidential.  Your blood stem 
cells or bone marrow and all records associated with this study will be labeled only with a nine-
digit identification number.  Your name or other identifying information will not appear on the 
blood stem cells or bone marrow or on any study records maintained outside the Donor Center. 
Your Donor Center ________________________, and the NMDP will not disclose your 
participation by any means of communication to any person or organization, except by your 
written request or permission, or unless required by federal, state or local laws, or regulatory 
agencies. 
Individuals authorized by the NMDP, the BMT CTN and the Food and Drug Administration 
(FDA) may request access to your donor medical charts (i.e., the donor and medical charts 
maintained on you as a donor).  In agreeing to participate, you consent to such inspections and to 
the copying of excerpts from these records, if required by their authorized representatives. 
Scientific and medical findings resulting from the study may be presented at meetings or 
published so that the information can be useful to others.  Nothing in such presentations or 
publications would reveal your identity or participation in this study.  
 
VI.  AUTHORIZATION TO USE AND DISCLOSE HEALTH INFORMATION FOR 
RESEARCH PURPOSES 
By signing this consent form, you authorize _____________________________ (name of Donor 
Center) to give to the National Marrow Donor Program® (NMDP) your demographic information 
(for example, gender, age and ethnic background) and health information that was collected as 
part of the donation process (for example, results from infectious disease testing and the physical 
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exam and information on recovery from the donation).  This information will be used by the 
NMDP to evaluate operation of the registry, to report to its funding agencies, and to conduct 
research.  In addition, researchers approved by the NMDP may use this information for research 
purposes. 
 
This authorization does not have an expiration date.  You have the right to cancel this 
authorization at any time b notifying the NMDP in writing that you are canceling the 
authorization.  The address for the NMDP is 3001 Broadway Street, NE, Suite 500, Minneapolis, 
MN 55413.  If you cancel this authorization, any identifiable health information will be removed 
from the NMDP research database.  If you cancel your authorization, this will not affect your 
right or access to healthcare or any other services you are entitled to receive at 
_____________________________ (name of Donor Center). 
 
The NMDP has processes in place to keep your identity confidential.  While it is unlikely, there 
is a minimal risk that your identity could become known to an investigator who receives your 
demographic and health information as part of a research study. 
 
VII. REIMBURSEMENT AND COSTS 
You will not be paid for participating in this study or for donating blood stem cells or bone 
marrow.  You will not be charged for any expenses resulting from your blood stem cell or bone 
marrow donation. 
 
VIII. IN THE EVENT OF INJURY DURING THE COURSE OF THE STUDY 
The risk of serious injury associated with this study is considered small.  However, if an injury 
does occur, treatment (including first aid, emergency treatment and other necessary care) will be 
available.  The NMDP will pay for this treatment.  Please call your Donor Center coordinator 
immediately at (       ) __________________if you are injured. 
You do not waive any liability rights for personal injury by signing this form. 
 
IX. VOLUNTARY NATURE OF THE STUDY AND YOUR RIGHT TO WITHDRAW 
If you decide to participate, you are free to withdraw at any time.  If you withdraw after your 
blood stem cells or bone marrow have already been collected, the cells may still be given to the 
intended recipient.  It is important for you to know that if you decline to donate after the intended 
recipient has begun treatments in preparation for the transplant, he or she will most likely die.  If 
you have questions regarding this statement, please ask your Donor Center Medical Director to 
discuss this with you.  Your decision to withdraw will not affect your participation with your 
Donor Center or the NMDP. 
If you choose not to participate in this study, this decision will not affect your right or access to 
health care or any other services that you are entitled to receive at your Donor Center. 
If you decline to participate, the NMDP will not remove you from the Registry unless you ask 
for this to be done.  No matter what you decide, now or in the future, your decision will not 
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affect your relationship with the NMDP in any way or result in any penalty or loss of benefits to 
which you would otherwise be entitled. 
 
X. POSSIBILITY OF FUTURE REQUESTS 
If you choose not to participate in this study, you may be asked to consider either a blood stem 
cell or bone marrow donation for this same recipient.  In this case, there would be no 
randomization, and you would know right away which product you would be asked to donate.  
Unless you ask to be removed from the Registry, we may at some future time ask you to consider 
a bone marrow or blood stem cell donation for another recipient.  You may at any time decline to 
participate in this program and decline any future requests made of you. 
 
XI. QUESTIONS, CONCERNS or ILLNESS/ADVERSE REACTIONS 
The researchers conducting this study are Dr. _________________________ (Donor Center 
Medical Director) and Dr. Dennis L. Confer, NMDP Chief Medical Officer.  If you have 
questions or concerns, please contact Dr.________________________ at 
____________________________________________________________________ or Dr. 
Confer at 800-526-7809.  For questions concerning your rights as a research subject, please 
contact Roberta King, IRB Administrator, at the NMDP at 800-526-7809.  You will be given a 
copy of this consent form for your records. 
 
XII. DONOR/SUBJECT STATEMENT OF CONSENT  
My signature below indicates that I have read this consent form, I have been given the 
opportunity to ask questions, and I voluntarily agree to participate in this study and to donate 
blood stem cells. 
 
____________________________________ ______________________________ 
Donor/Subject Signature    Date 
 
____________________________________ ______________________________ 
Print Name of Donor/Subject    Date 
 
 
Certification of Counseling Healthcare Professional 
I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this research study have been explained to the above individual and that any 
questions about this information have been answered. 
 
____________________________________ ______________________________ 
Counseling Healthcare Professional   Date 
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APPENDIX B-3 
 
ASSENT TO PARTICIPATE FORM 
 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 1.0 dated June 17, 2003 
B-32 
Assent to Participate in Research 
 
 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III, Randomized, Open Label, Multi-center Clinical Trial Comparing Transplantation with 
Peripheral Blood Stem Cells versus Marrow from Unrelated Donors 
 
2. Principal Investigator Contact Information at your Institution  
Name/Title/Phone number/ 
 
3. Contact information for emergencies after hours or on weekends or holidays: 
Name/Phone number/ 
 
 
You have a disease in your blood and the disease makes you very sick.  To try to help you get better, the 
doctors will have to give you strong medicines that will kill the disease and thin your blood.   
 
These medicines may make you throw up, lose your hair and have mouth sores.   
 
You will get a transplant that will make new and healthy blood.  The transplant is from a donor you do 
not know and is outside your family.   
 
The transplant may come from the donor bone or from the donor blood.  Your doctors are trying to find 
out if the donor bone or the donor blood is better for transplant.  So this transplant is a study.  Right now, 
they think that the two are the same.  You will receive one or the other transplant.   
 
Your parents, doctors, and nurses will explain what happens with the transplant.  You should ask them 
about anything you do not understand.  They will answer your questions. 
 
Patient’s Statement 
 
I have been told what I will be asked to do if I am in this study.  I have been told that I don’t have to be in 
this study.  I may quit the study at any time, and no one will be mad at me.  I have had a chance to discuss 
the study and ask questions.  My questions have been answered.  I agree to be in the study and do what I 
am asked to do so long as I stay in the study. 
 
 
 
             
Signature of Minor (age 7 – 13 years)      Date     
Age (years) 
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Study Personnel 
 
I have explained the purposes, procedures, potential benefits and risks involved in this research study in 
detail to: 
 
 
           ,           
Print name(s) of Parents/Authorized Consenting Party, and Print child’s name 
The signature of both parents is required 
 
 
who in my opinion IS/ IS NOT capable of assenting to participate in this study. 
 
 
 
              
Signature of Person Conducting Assent     Date 
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APPENDIX C --LABORATORY PROCEDURES 
 
 
 
The laboratory procedures performed under this protocol include: 
1. HLA Typing 
2. Characterization of Graft 
3. Immune Reconstitution 
4. Chimerism 
5. Laboratory Specimen Collection, Storage and Shipping Procedures 
 
LABORATORY PROCEDURES 
 
1. HLA TYPING 
 
Before Transplantation: HLA typing will be performed for all patients and donors in American 
Society of Histocompatibility and Immunogenetics (ASHI)-approved laboratories designated by 
the transplant centers.  HLA typing must be performed by DNA methods for HLA-A, -B, and -C 
at intermediate resolution, and DRB1 at high resolution, consistent with NMDP standard 
procedures. 
 
After Transplantation: High resolution HLA typing of cryopreserved patient and donor 
samples is conducted as an ongoing research study by the NMDP.  Data will be shared with the 
CTN. 
 
 
2. GRAFT CHARACTERISTICS 
 
2.1 Rationale: The impact of the cellular constituents of the graft on post-transplant outcome 
is likely a complex effect that is a function of the absolute numbers of immune cells in the graft 
(T cells, NK-cells, B-cells, monocytes, and dendritic cells) as well as interactions among these 
different donor cells, and their interactions with residual host cells.  Storek et al. has noted that 
the kinetics of CD45RAbright “naïve” CD4 T cells is most correlated to the numbers of 
CD45RAbright CD4 T cells in the allograft marrow or PBSC allo-graft from HLA matched 
siblings (Storek 2001).  A detailed analysis of the cellular constituents of the graft in patients 
receiving allogeneic marrow or PBSC could help validate or reject the hypothesis that the 
content of donor CD34 and donor dendritic cells are significant factors in regulating post-
transplant immune reconstitution and the incidences of post-transplant GvHD and relapse.  
Recent reports have suggested that the content of donor dendritic cells are associated with the 
incidences of chronic GVHD, and relapse (Waller, 2001), and that the number of transplanted 
CD34 cells is associated with the incidence of acute and chronic GVHD (Przepiorka, 1999).  
Other reports have shown that mobilization of PBSC with G-CSF results in a relative increase in 
the frequency of type 2 dendritic cell progenitors (DC2p) compared with un-stimulated blood 
mononuclear cells (Arpinati 2000).  Thus it is likely that the content of donor CD34 and type 2 
dendritic cells will vary significantly between allogeneic marrow grafts and PBSC grafts that are 
collected after G-CSF stimulation. 
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2.2 Assays: Studies will be conducted in keeping with CTN MOP on graft characterization.  
Samples of the marrow or PBSC graft will be sent to a central reference laboratory for flow 
cytometric analysis of the content of CD34 cells, the CD38-negative subset of CD34 cells, 
ALDH-bright progenitor cells, T cells, B-cells, NK-cells, monocytes, and dendritic cells.  The 
test samples will be shipped to the reference laboratory at the same time that the graft is shipped 
from the collection center to the transplant center, so that the analysis of the cell content will be 
performed at approximately the same time as the graft is infused into the recipient.  Samples will 
be shipped at 2-8oC on “cold-packs” in order to prevent accidental over-heating that may impair 
cell viability. Pilot experiments storing samples of  marrow or PBSC grafts at 2-8oC versus 20oC 
have not shown any significant differences in recovery of viable CD34 cells or the recovery of 
various subsets of immune cells (Table 1).  The flow cytometric analysis will be performed using 
a panel of flow cytometry assays, each containing multiple fluorescently labeled monoclonal 
antibodies.  The FACS panel that will be used is shown in Table 2. 
 
2.3 Calculation of absolute cell counts for manipulated products: Some products are 
manipulated between the time of arrival at the transplant center and infusion.  In some cases, 
plasma or red cells are depleted, while in others a subset of the product is cryopreserved.  For 
such products, the doses of cell subsets transplanted can be estimated by adjusting the cell subset 
count at the reference lab multiplied by the proportion of total cells infused divided by the total 
cell received by the transplant center.  Such a method assumes that travel and manipulation of 
the product did not affect any cell subset in a selective manner. 
 
 
3. MEASUREMENTS OF POST-TRANSPLANT IMMUNE RECONSTITUTION 
 
3.1 Sample shipping and analysis: Twenty five cc heparinized blood samples will be 
shipped at 2o-8o C to a central reference laboratory for measurement of peripheral T cell subsets, 
the numbers of T cell receptor excision circles (TREC)-positive CD4 and CD8 T cells, and the 
frequencies of anti-viral T cells using the tetramer assay and the pattern of cytokine synthesis by 
intracellular staining and flow cytometric assays.  Plasma samples will be analyzed for IL2 and 
IL7 levels.  Serum samples will be analyzed at the transplant center for quantitative 
immunoglobulin levels, and serum samples from 15 mL of blood will be shipped to the reference 
laboratory for analysis of standard antibody titers to diptheria toxin and tetanus antigen (dT).  
Serum for measuring pneumococcal antibodies, Hepatitis A antibody as well as the titers of 
opsonophagocytic antibodies to pnuemococcus will be sent to the central reference laboratory.  
The schedule for obtaining and shipping samples is listed in Table 4.2 of the protocol and Table 
4 of Appendix C below. 
 
3.2 Rationale and methods for measuring post-transplant T cell function: PBSC grafts 
contain more donor immune cells than marrow grafts and therefore may lead to improved 
reconstitution.  Storek, et al. compared the kinetics of immune reconstitution among 115 cancer 
patients randomly assigned to receive either marrow or PBSC allografts from HLA matched 
siblings (Storek 2001).  Recovery of CD4 T cells was slower among recipients of marrow versus 
PBSC allografts while proliferative responses of T cells to HSV, VZV, or PHA in vitro did not 
differ between recipients of marrow versus PBSC transplants.  There was a significant difference 
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in the incidence of post-transplant infections, with recipients of marrow grafts experiencing a 2.4 
fold higher rate of severe infections.  The rate of fungal infections was 10/46 among recipients of 
marrow grafts and 2/36 among recipients of PBSC grafts (Storek 2001).  The frequency of T 
cells, NK cell, B cells and dendritic cells will be measured in the blood of transplant recipients in 
order to test the hypothesis that the content of donor CD34 cells and donor immune cells in the 
graft has a material impact on the kinetics and quality of post-transplant immune reconstitution.  
Tetramer staining and flow cytometric assays will measure anti-CMV and anti-EBV CD8 T cells 
in samples from A2+ and/or B7+ recipients (circa 60% of patients).  The frequency of functional 
anti-CMV specific T cells will be measured by the frequency of T cells that synthesize TNF in 
response to in vitro exposure to CMV antigens.  The frequency of anti-aspergillus T cells will be 
assessed by measuring cytokine (-IFN and IL-4) synthesis following incubation with aspergillus 
antigen in-vitro.  Plasma IL-7 and IL-2 levels will be measured by ELISA or chemiluminesence 
assays from the heparinized tube of blood used to measure peripheral blood T cells.  The levels 
of IL-2 and IL-7 will be correlated with the levels of T cells in the blood to test the hypothesis 
that poor cellular immune reconstitution may be due, in part, to low blood levels of these 
cytokines (Okamoto 2002).  
 
3.3 Rationale and methods for measuring post-transplant B-cell function: Comparison 
of recovery of serum immunoglobulin levels among a 115 patients randomized to receive 
marrow or PBSC allo-grafts from HLA matched siblings did not reveal any significant difference 
in the levels of serum Ig or circulating B-cells post-transplant (Storek 2001).  Of note, this study 
did not compare humoral responses to vaccines, but did find lower rates of infections among the 
recipients of the PBSC grafts.  In order to compare in vivo functional humoral immunity between 
the PBSC and marrow recipients, the response to vaccination with the heptavalent pneumococcal 
conjugate vaccine and to Hepatitis A will be measured.  Pneumococcal infections are a long-term 
risk after transplant and, given the increased prevalence of penicillin resistant S. pneumonia, 
penicillin prophylaxis is not universally effective (Kulkarni 2000).  However, polysaccharide 
epitopes such as those in the 23-valent pneumovax vaccine, are T cell independent antigens.  As 
such, the pneumovax vaccine is not highly immunogenic, especially when administered in the 
first year after transplantation.  Conjugate vaccines, which are T cell dependent and provide 
longer lasting immunity have been found to be more immunogenic in both infants and bone 
marrow transplant recipients (Barra 1992).  A recent study adminstered the heptavalent 
pneumococcal conjugate vaccine (Prevnar, Wyeth Lederle Laboratories) to recipients (and half 
of the donors) at 3, 6, and 12 months after a repleted allogeneic transplant plant (Molrine 2002).  
By month 12, over 60% of recipients had protective immunity to all 7 serotypes, although at 
month 3 and 6, humoral responses remained low in the half of patients whose donors had not 
been immunized.  An increase in the frequency of patients with protective antibodies was seen 
following the third vaccination with PPV23 at 12 months, indicating that multiple early 
vaccinations with the protein conjugate vaccine can elicit protective humoral antibody responses 
when given within the first year post-transplant (Molrine 2003).  Since the Wyeth vaccine is 
conjugated to a nontoxic variant of diphtheria toxin (CRM), an attractive strategy to augment 
humoral responses to the glycoprotein polysaccharide vaccines in adults within the first year 
post-transplant would be to sequentially immunize transplant recipients with the carrier protein 
(diptheria toxin) followed by vaccination with the pneumococcal conjugate vaccine (7 valent) 2 
weeks later, and finally the 23-valent polysaccharide pneumococcal vaccine a few months later.  
Immunization with Hepatitis A will serve as a potentially informative “neo-antigen” for the circa 
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40-50% of donor-recipient pairs that are both sero-negative to test the integrity of the primary 
humoral immune response post-transplant and responding patients may be protected from 
infection.  The hypothesis would be that recipients of PBSC would receive more donor T cells 
and may respond to vaccinations starting at six months post-transplant at a higher frequency than 
recipients of marrow allografts.  Demonstration of immune-responsiveness among transplant 
recipients receiving vaccine starting at six months post-transplant could lead to a reduction of 
some of the morbidity and mortality due to infection seen within the first year post-transplant.  
Local and systemic reactions to the vaccines will be compared between groups. 
 
3.4 Immunophenotype assays of lymphoid subsets and dendritic cells:  Samples of 
heparinized peripheral blood (ca. 2 mL) will be obtained from patients at 1, 3, 6, 12 and 24 
months post-transplant.  Aliquots of peripheral blood will be stained with the panels described in 
Table 3 by the central reference laboratory, and the percentage of nucleated cells with each 
phenotype determined using standard Cell-Quest (or similar) analysis templates.  The reference 
laboratory will send back to the transplant and coordinating centers the results from a CBC with 
differential performed on the shipped sample as well as the calculated numbers of cells/mcL of 
each phenotype as determined by the results of the FACS analysis.  The reference laboratory will 
calculate the absolute numbers of subsets of immune cells in the blood based upon the absolute 
number of leukocytes in the blood and the percentage of leukocytes that are T, B, NK, monocyte, 
or dendritic cells subsets as defined by multiparameter flow cytometry.  
 
3.5 Assays for antigen-specific T cells: Additional 23 mL heparinized blood samples 
patients who receive transplants from donors who have the HLA A2 or B7 allele will be obtained 
at 3, 6, 12 and 24 months post-transplant.  These will be shipped to the central reference 
laboratory for FACS analysis of the frequency of anti-CMV and anti-EBV specific T cells using 
a tetramer FACS assay on the mononuclear cell fraction obtained from fresh (not frozen) 
samples.  Tetramers will be incubated with PBMC obtained from transplant recipients at the time 
points described above, and the frequency of CD3, CD8, tetramer+ T cells will be assessed by 
flow cytometry (Altman, 1996).  A subset of approximately 60% of transplant patients are 
predicted to be either A2+ and/or B7+, but they should be evenly distributed between the two 
arms.  Phycoerythrin-labeled HLA A2 and HLA B7 tetramers that stain antigen specific T cells 
that recognize immunogenic CMV peptides will be synthesized by the tetramer core facility at 
the central reference laboratory.  HLA-B0702 tetramers loaded with (TPRVTGGGAM), the 
amino acid number 417-426 of lower matrix protein pp65-of CMV) and HLA-A 0201 tetramers, 
loaded with (NLVPMVATV), the amino acid number 495-503 of the pp65 protein will be used 
to identify CMV specific T cells from patients transplanted with HLA A2 and HLA B7 donors, 
respectively (Singhal, 2000; Keenan, 2001).  EBV specific T cells will be assayed using 
phycoerythrin-labeled HLA A2 tetramers loaded with the EBV/BMLF1 peptide containing aa 
280-288 (GLCTLVAML, Chen, 2001).  In addition, the presence and number of aspergillus-
specific, CMV-specific, pneumococcal-sepcific, and tetanus-specific T cells will be determined 
by secreted cytokines (-IFN, TNF, IL-4, and IL10) measured by ELISA and FACS following 
in-vitro incubation with antigens at 3, 6, 9, and 12 months after transplant (Centeno-Lima 2002; 
Hebart 2002).  
 
3.6 TREC assay for de novo T cell generation: The central reference laboratory will 
prepare a mononuclear cell suspension from the blood samples and freeze PBMC in aliquots for 
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batch analysis of signal joint T cell receptor excised circles (TRECs). IL-7 and IL-2 levels will 
be measured by the central reference laboratory using ELISA or chemiluminesence assays on 
samples of plasma obtained from the tubes of blood used to measure T cell numbers.  The levels 
of IL2 and IL7 will be correlated with the numbers TREC CD4 and CD8 (Okamoto 2002).  A 
summary of post-transplant studies in cellular immune reconstitution is shown in Table 4.  
 
3.7 Immunoglobulin levels: Quantitative immunoglobulin levels will be determined on 6, 
12 and 24 months post-transplant by the reference laboratory (Table 4).  
 
3.8 Vaccination schedule: In order to increase the effectiveness of the pneumococcal 23 
valent polysaccharide vaccine administered post-transplant, transplant recipients will receive 
sequential vaccination with Td (tetanus diphtheria toxoid) at 6 months post-transplant followed 
by the heptavalent pneumococcal conjugate vaccine (PCV7) four weeks later at 7 months, and 
again at 9 months post-transplant, and then the 23-valent polysaccharide vaccine (PPV23) at 11 
months post-transplant (Table 4).  The goal will be to evaluate the safety and the 
immunogenicity of the pneumococal vaccine when it is administered after boosting with the Td 
carrier vaccine followed by sequential vaccination using the PCV7 and PPPV23 vaccines. 
ELISA and functional type-specific pneumococcal antibodies will be measured.  Diphtheria and 
tetanus antibody will be measured prior to the first vaccination and prior to the PPV23 vaccine.  
Approximately 60% of recipients are predicted to be sero-negative for Hepatitis A. 
Immunization with the Hepatitis A vaccine will be used a neo-antigen, in order to assess immune 
response to primary antigen.  The Hepatitis A vaccine will be administered at 6 months and 11 
months after transplant, and antibody titers at 6, 11, 12 and 24 months will be determined to 
compare responses in the PBSC and bone marrow recipients.  Donor and pre-transplant recipient 
serum will be collected to measure antibody titers with the same assays.  
 
3.9 Laboratory assays for antibody titers:. 
 
i) ELISA for diphtheria antibody and tetanus antibody will be performed at a 
commercial laboratory. 
 
ii) ELISA for S. pneumoniae antibody. IgG antibody levels for specific serotypes of S. 
pneumoniae will be assayed by a protocol developed by George Carlone, Ph.D. at CDC.  
These studies will be conducted at the central reference laboratory.  Serotypes that are 
present in the 7 valent and the 23 valent vaccines will be measured. 
 
iii) Functional antibodies for S. pneumoniae.  Functional antibodies will be measured by 
an opsonophagocytic assay using HL-60 cells. Opsonophagocytic titers will be expressed 
as the reciprocal of the serum dilution with 50% killing compared with growth in the 
complement control wells.  These studies will be conducted at the central reference 
laboratory. 
 
iv) Hepatitis A antibody: These will be measured using ELISA kits at the central reference 
laboratory. 
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v) Stored serum and subsequent assays.  If, during the conduct of the study, investigators 
wish to analyze additional antibody assays, samples from frozen serum samples will be 
sent to the outside lab with no identifying information, except for a unique study number.  
All serum specimens will be stored for a 2-year period following enrollment of the last 
patient on the study.  Specimens will be stored in a locked freezer at –80C. 
 
 
4. CHIMERISM 
 
Recommendations for chimerism assay: Demonstration of donor cells in lymphoid and 
myeloid lineages can assess the relative engraftment potential of PBSC compared to marrow.  
Since all patients on this trial will receive myeloablative conditioing regimens, we hypothesize 
that there will be little if any difference in donor chimerism between PBSC recipients and 
marrow recipients.  Therefore, chimerism testing will not be mandatory in this study. However, 
routine chimerism data generated by transplant center laboratories will be reported.  Chimerism 
results will be reported as “percent donor DNA.” 
 
 
5. LABORATORY SPECIMEN COLLECTION, STORAGE AND SHIPPING 
PROCEDURES 
 
Standard procedures for collection, storage, and shipping of specimens will be followed 
according to the NMDP and the NHLBI guidelines. 
 
Table 1 -- Effect of Storage Time and Storage Temperature on the Numbers of Viable 
CD34 Cells, T cells, and Dendritic Cells in Blood and Marrow Grafts 
 
Analyses after 72 
hours: Median 
percentages of initial 
value 
2-8C Marrow 
HPC 
Room Temp 
Marrow HPC 
2-8C Blood 
HPC 
Room Temp 
Blood PBSC 
Viable CD34 100% 100% 40% 16% 
Viable CD3 60% 51% 54% 48% 
Viable DC2p 74% 54% 67% 32% 
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Table 2 -- Flow Cytometry for Graft Characterization 
 
Tube 
# 
Class of 
Cells Cell Types 
Measured Blood Cell 
Subsets Antibodies 
1 Progenitor 
Cell  
Viable CD34 
cells 
Viable nucleated cells 
CD34 cells 
CD34/CD38- cells/kg 
anti-CD45 (FITC) 
anti-CD34 (PE) 
anti-CD38(APC) 
7AAD 
2 Progenitor 
Cell  
ALDHbright 
cells 
ALDHbright CD34 cells 
ALDHbright CD34-negative 
cells/kg 
BAAA (FITC) 
anti-CD34 (APC) 
anti-CD45(PE) 
3 Progenitor 
Cell  
ALDH 
negative 
control 
Negative control for 
BAAA staining 
BAAA (FITC) + DEAB 
IgG1-(APC negative control) 
IgG1-(PE negative control) 
4 Progenitor 
Cell  
ALDH 
compensation 
BAAA control BAAA 
IgG1 (APC negative control) 
IgG1-(PE negative control) 
5 Progenitor 
Cell  
ALDH 
compensation 
PE control BAAA 
IgG1-(APC negative control) 
CD3-(PE) 
6 Progenitor 
Cell  
ALDH 
compensation 
APC control BAAA 
CD3-(APC) 
IgG1-(PE negative control) 
7 Lymphoid 
Subsets 
T cell subsets CD4 
CD8 
CD25+ 
anti-CD4 (PerCP) 
anti-CD8 (FITC) 
anti-CD25 (PE) 
anti-CD3 (APC) 
8 Lymphoid 
Subsets 
NK and  T 
cells 
CD56+ 
  T cells 
anti-CD56 (PE) 
anti- TCR (FITC) 
anti-CD16 (PerCP) 
anti-CD3 (APC) 
9 Lymphoid 
Subsets 
B-cells & 
monocytes 
CD5+ B-cells  
CD14+ monocytes 
anti-CD5 (PerCP) 
anti-CD14(PE) 
anti-CD2 (FITC) 
anti-CD19 (APC) 
10 Dendritic 
Cell 
Subsets 
DC subsets DC1 and DC2 subsets anti-lineage (FITC) 
anti-CD123(PE) 
anti-HLADR (PerCP) 
anti-CD11c(APC) 
11 Isotype 
Controls 
Isotype Ig Non-specific staining irrelevant (FITC) (PE) (PerCP) (APC) 
conjugates to murine monoclonal Ab 
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Table 3 -- Flow Cytometry for Immune Reconstitution 
 
Tube 
# 
Class of 
Cells Cell Types 
Measured Blood Cell 
Subsets Antibodies 
1 Lymphoid 
Subsets 
T cells CD4 
CD8 
CD25+  
anti-CD4(PerCP) 
anti-CD8 (FITC) 
anti-CD25 (PE) 
anti-CD3(APC) 
2 Lymphoid 
Subsets 
NK and  T 
cells 
CD56+  
 T cells 
anti-CD56 (PE) 
anti- TCR (FITC) 
anti-CD16 (PerCP) 
anti-CD3 (APC) 
3 Lymphoid 
Subsets 
CD8 T cell 
Subsets 
Naïve and activated 
CD8 T cells 
anti-CD8 (APC) 
anti-Ki67(FITC) 
anti-CD62L (PE) 
anti-CD45RA (TC) 
4 Lymphoid 
Subsets 
CD4 T cell 
Subsets 
Naïve and activated 
CD4 T cells 
anti-CD4 (APC) 
anti-Ki67(FITC) 
anti-CD62L(PE) 
anti-CD45RA (TC) 
5 Lymphoid 
Subsets 
B-cells & 
monocytes 
CD5+ 
CD27 
B cells 
CD14+ monocytes 
anti-CD5 (PerCP) 
anti-CD27 (FITC) 
anti-CD14(PE) 
anti-CD19 (APC) 
6 Dendritic 
Cell Subsets 
DC subsets DC1 and DC2 subsets anti-lineage (FITC) 
anti-CD123(PE) 
anti-HLADR (PerCP) 
anti-CD11c(APC) 
7 Isotype 
Controls 
Isotype Ig Non-specific staining irrelevant (FITC) (PE) (PerCP) 
(APC) conjugates to murine 
monoclonal Ab 
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Table 4 -- Schedule for Drawing Blood Samples and Vaccination of Recipients Post-transplant 
 
 
 Baseline:  
Patient 
and donor
1 m 3 m 6 m 7 m 9 m 11 m 12 m 24 m 
  
Measures of Cellular Immunity (30 cc heparinized blood)  
FACS analysis   X X X    X X 
Tetramers assay   X X    X X 
TREC analysis   X X    X X 
Plasma IL-7 and IL-2 levels   X X    X X 
T-cell responses to tetanus, 
CMV, pneumococcal, and 
Aspergillus antigens  
  X X    X X 
  
Vaccination Schedule  
dT vaccine    X   X   
PCV7 vaccine     X X    
PPV23 vaccine       X   
Hep A vaccine    X   X   
          
Immunoglobulin and Antibody Titers (serum from 15 cc blood)  
dT Antibodies  X   X   X X X 
S. pneum. Ab and ops X   X   X X X 
Hep A Ab titer X   X   X X X 
Quantitative Ig X   X   X X X 
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APPENDIX D – HUMAN SUBJECTS 
 
 
Subject consent: Candidates for the study will be identified as described in Section 4.  The PI or 
his/her designee at each transplant or donor center will contact the candidates, provide 
information about the purpose of the study, obtain consent and register them onto the study.  A 
template of the consent form will be provided by the network for each center customization to 
the local requirements, review and approved by the local IRB. 
 
Confidentiality: Confidentiality will be maintained by assigning patients and donors identifier 
codes.  The keys relaying to the patient’s or donor's identity with the ID code will be kept at each 
Center and at the NMDP separately from the research database.  
 
Participation of women and minorities, children and other populations: Women and ethnic 
minorities will be included in this study.  There is no lower age for participants. 
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APPENDIX E – DONOR MANAGEMENT 
 
 
Donor eligibility will be confirmed as described in Section 2.5 of the protocol.  In addition, 
donor management will be in accordance with the NMDP Donor Center Manual of Operations. 
 
Donors’ eligibility determinations and enrollments will occur following issuance of a work-up 
request.  Because none of the work-up requirements are unique to the protocol, the donor consent 
decision may be made at any time prior to donor clearance.  However, the invitation to 
participate in the protocol must be extended at the donor information session.  At any time 
during the work-up procedure, if the donor declines to participate in the protocol, this decision 
must be communicated immediately to the NMDP Search and Transplant Services Department.  
At the donor information session, the following information will be provided: 
 
PURPOSE OF THE TRIAL 
This trial has been undertaken to compare the established blood stem cell source, bone marrow, 
against the newer source, PBSC.  In making this comparison, we are interested in both donor and 
recipient experiences (outcomes).  There is no foregone conclusion that one product is better 
than the other (for either donors or recipients), if that were the case, the trial would not be 
necessary.  While some experts may have opinions about the comparison, these opinions cannot 
be verified by facts.  The purpose of this trial is to provide scientifically valid information to 
allow a comparison. 
 
POTENTIAL ADVANTAGES OF EACH PRODUCT 
Donors will be informed about what is being compared to determine the potential advantages of 
each product for themselves and their recipients.  The major outcome for donors is the incidence 
of adverse events and serious adverse events.  We are also interested, however, in the donors’ 
quality of life experiences with each type of donation.  For transplant recipients, we will be 
measuring engraftment, graft-versus-host disease, risk of relapse and survival.  
 
The NMDP has been conducting a non-randomized comparison of bone marrow and PBSC since 
July 1999.  This comparison suggests, but does not prove, the following associations. 
 
For Donors1 –  
Symptoms from donation Similar in both groups. PBSC donors experience most 
of their symptoms before donation, but bone marrow 
donors have symptoms after donation. 
Recovery from donation PBSC donors recover faster after donation.  
Satisfaction with donation Both bone marrow and PBSC donors are comfortable 
with their decisions to donate and both groups feel the 
donation experience was positive. 
 
                                                 
1 Data provided by Galen Switzer who has conducted an NMDP-funded comparison of donor experiences following 
bone marrow and PBSC donation. 
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For Recipients –  
Engraftment of neutrophils and 
platelets 
Clearly occurs earlier with PBSC, but no difference in 
overall engraftment 
Risk of graft-versus-host 
disease 
May be higher with PBSC, particularly chronic GVHD 
Immune reconstitution May be faster with PBSC 
Risk of relapse No obvious differences 
Survival  No obvious differences 
 
 
RECIPIENT DROPOUT 
Donors should receive information about the enrollment process for donors and recipients.  They 
should understand that the recipient has consented to participate in the clinical trial, but will 
ultimately be confirmed eligible only in the days immediately preceding the start of conditioning 
therapy.  It is anticipated by the study investigators that up to 15% of enrolled donor-recipient 
pairs will be removed from study before the start of conditioning. In this instance, participation 
in the study will be terminated.  Donors should understand that they may still be asked to provide 
a blood stem cell product for the recipient if an alternative approach to transplantation is 
available.  But, in such cases, the transplant and the results of the transplant will not be included 
in the clinical study. 
 
DONOR EDUCATIONAL MATERIALS 
The NMDP has developed educational materials for donors considering the randomized clinical 
trial.  These materials should be provided prior to the donor’s consent decision.  Questions from 
donors may be directed to donor center personnel or to Dr. Dennis Confer, NMDP Chief Medical 
Officer (612-362-3425, dconfer@nmdp.org) or Dr. Chatchada Karanes, NMDP Medical Director 
(612-617-8354, ckaranes@nmdp.org). 
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BMT CTN PROTOCOL #0201 MODIFICATIONS 
 
I. RESPONSE TO DSMB QUESTIONS FOR BMT CTN PROTOCOL #0201 BASED 
ON THE JULY 3, 2003 DATA AND SAFETY MONITORING BOARD REVIEW 
 
1. The donor exclusion criteria have been revised to clarify that donors with sickle 
hemoglobin are excluded (Section 2.5.2). 
 
The criterion in item 8, section 2.5.2 has been changed to the following:  “Presence of sickle 
hemoglobin as demonstrated by appropriate testing such as hemoglobin electrophoresis.” 
 
2. Covariates that will be used for the ad hoc analysis in sections 5.7.2 – 5.7.5 have been 
specified. 
 
The analysis of secondary endpoints is restricted to those patients in the trial who actually 
receive transplants.  Because of the potential for unequal dropout between the two arms, 
adjustment for covariates will be used to make the groups comparable.  Covariates have been 
specified in section 5.7 and include transplant center, year of transplant, preparative regimen, 
GvHD prophylaxis, recipient characteristics (age, sex, body mass index [BMI], race, 
Karnofsky/Lansky, diagnosis, disease stage, time from diagnosis to transplant, CMV status, 
comorbid disease) and donor characteristics (age, sex, BMI, race, CMV status and parity), 
and HLA Match.   
 
3. Clarify the percent difference in survival curves in the intent-to-treat analysis (p5-2) 
and include a range of values 
 
Careful consideration of the primary analysis after the DSMB review led us to decide that the 
test statistic for the intent-to-treat analysis was not precise enough.  The prior version of the 
protocol proposed a log-rank test to compare the survival curves; this actually compares the 
entire survival curves, not just the two-year survival rates, and is only appropriate when the 
hazard rates of the two groups do not cross.  Instead, we propose to use just the point 
estimate of two-year survival as the primary endpoint. 
There are two reasons for this change.  First, recent NMDP data suggests that the hazard rates 
and even the survival curves may cross prior to two years, in which case the log-rank test will 
be less powerful and may even give inconsistent results from the two-year pointwise survival 
comparison.  Second, the new primary endpoint will be more consistent with the stopping 
rule for six-month mortality.  The stopping rule was designed anticipating that an early 
benefit to PBSC at six months may dissipate or even reverse by two years, which would only 
be the case if the hazard rates had crossed.  Therefore, we changed the primary analysis of 
two-year survival from a stratified log-rank test to a stratified binomial comparison (Mantel-
Haenszel test).  This would only compare the two-year survival probabilities and not the 
entire survival curves. 
 2 
There is a slight loss in power by making this change, which would result in larger required 
sample sizes (315 patients per arm, for a total of 630 patients).  However, the assumption 
about the proportion of patients never receiving a transplant was felt to be overly 
conservative (15%) in the prior version of the protocol.  When this is relaxed to 5-15%, the 
original sample size of 550 patients is adequately powered to detect the targeted 12.5% 
difference in 2 year survival.  We plan to monitor the rate of patients not receiving a 
transplant throughout the trial.  If we find that 10% is an underestimate of this rate, we will 
consider extending accrual up to 630 patients to obtain adequate power. 
In conclusion: this section of the protocol has been substantially amended to make the 
primary endpoint more precise (2 year survival vs. entire survival curves), the detectable 
survival differences have been clarified (12.5% difference), the power calculations have been 
redone, and a range of values for the difference have been included in the power analysis 
(10%, 12.5%, and 15%).  
 
Revised Section 5.2 Sample Size and Power Considerations 
 
Overall survival between the standard and experimental therapy arms will be compared 
using the stratified binomial comparison (Mantel-Haenszel test).  All patients who are 
randomized will be included in the analysis based on an intention to treat.  Survival 
times will be based on time since randomization, so that those patients who drop out of 
the study after randomization but before transplant can still be included.  The final 
analysis will be performed after all patients have been followed for a minimum of two 
years post-transplant.  Based on the eligibility criteria, the estimated survival for the 
marrow transplant arm at 2 years is 35% as detailed in Table 5.3 below.    The study is 
powered to detect an improvement of 12.5% over the two- year survival rate of 35% 
among patients who actually receive a transplant.  Because randomization takes place 
prior to determination of a patient’s eligibility for transplant, NMDP experience 
indicates that between 5-15% of the randomized patients in each arm will never receive 
a transplant.  These patients are typically high risk and are assumed to all die within six 
months.  Therefore, the intent-to-treat populations to be compared in the primary 
analysis are assumed to be a mixture of 85-95% who receive the randomized stem cell 
source, and 5-15% who never receive a transplant.  The resulting two-year survival 
rates for the intent-to-treat populations are given in the table below, as well as the 
powers to detect these differences, for sample sizes of 275 per group (550 total) and 
315 per group (630 total), and for differences of Delta=10%, 12.5%, and 15%.  A total 
sample size of 550 patients will have approximately 80% power to detect the targeted 
difference of 12.5% in two year survival rates for dropout rates between 5-10%, using a 
two-sided binomial comparison with alpha=0.05. 
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Table 5.2 – Power to Reject the Null Hypothesis under Various Scenarios1 
 
Intention to Treat Population 
Delta Source  
Transplanted 
Population 5% Dropout 10% Dropout 15% Dropout 
  Marrow 2 Yr. Survival 35.0% 33.3% 31.5% 29.7%
12.5% PB 2 Yr. Survival 47.5% 45.1% 42.8% 40.4%
  Power (N=550) 81% 78% 74%
    Power (N=630) 86% 83% 80%
10% PB 2 Yr. Survival 45.0% 42.8% 40.5% 38.3%
  Power (N=550) 63% 59% 56%
    Power (N=630) 69% 65% 62%
15% PB 2 Yr. Survival 50.0% 47.5% 45.0% 42.5%
  Power (N=550) 92% 90% 88%
  Power (N=630) 95% 93% 91%
1The table has been simplified for interpretability.  Power calculations are based on a two-sided test. 
 
4. Clarify that time to recovery will be used in the analysis of neutrophil engraftment. 
 
The time to recovery is not measurable for patients who are censored or who die prior to 
engraftment; therefore, the statistical comparison is done by comparing the rates of 
engraftment over time using the log-rank test.  The protocol has been modified (section 
5.7.2.1 as shown below) to reflect that the rates of engraftment will be compared over time 
(utilizing the entire time to recovery information) rather than at a fixed point in time. 
 
5.7.2.1  Neutrophil Engraftment > 500/mcL 
 
Rates of neutrophil engraftment over time, treating death prior to engraftment as a 
competing risk, will be compared between the two groups using a stratified log-rank test, 
and the cumulative incidence curves will be estimated for each group.  Cox regression will 
be performed to compare the groups after adjusting for covariates which may be 
imbalanced due to patient dropout. 
 
5. Add a disease subgroup analysis plan to the statistical section 
 
Section 5.11 has been added describing subgroup analysis for pediatric patients.   
 
5.11  Subgroup Analyses: 
 
Subgroup analyses will be performed on the following subgroups: pediatric patients (<16), 
disease risk (High vs. Low, as defined in Table 5.3), and HLA Matching status (Matched 
on HLA-A,B,C,DRB1 vs. Mismatched).  First the direction and magnitude of the treatment 
effect in the subgroup will be compared with the rest of the sample to look for qualitative 
differences.  In addition, statistical hypothesis testing will be performed on endpoints of 
interest to look for significant interactions between the treatment and each subgroup of 
interest.  However, because of the greatly reduced sample sizes in such subgroups, these 
tests are underpowered and not anticipated to reach statistical significance in most cases.  
They will be used only to note very strong interactions and to generate hypotheses. 
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6. Clarify that Kaplan Meier estimates will be used for interim analysis 
 
The protocol has been clarified in section 5.4.1.4 and the stopping rules repeated below to 
indicate that Kaplan Meier estimates of 6 month survival will be used for the interim 
analyses.    In making these changes, it was realized that the previous version of the stopping 
rule had a sixth interim analysis after all patients had been enrolled, which would not be 
useful in closing enrollment early.  Therefore, the number of interim analyses was reduced to 
5 and spaced approximately every 6 months starting with the ninth month.  The power of the 
revised stopping rules was not affected much (i.e. less than 3% decrease) by the changes.  
The timing of the interim analyses, the number of patients enrolled at each interim analysis, 
and the operating characteristics have been updated in the protocol to reflect these 
modifications.   
 
Revised Section 5.4: 
 
In addition, there will be periodic interim analyses approximately every six months 
beginning nine months after the study opens  to compare the toxicity of the two 
procedures in terms of their six-month mortality rates.  The stopping rule will only be 
applied to the estimated 470 495 patients who actually receive the randomized transplant, 
rather than the intent-to-treat population.  Because preliminary data from the NMDP 
indicates a potential for early survival differences between PBSC and marrow to dissipate 
by two years, a very conservative stopping rule is used.  In addition, the conservatism of 
the six month mortality stopping rule lessens the impact on the type I error rate 
relating for the final analysis of the primary endpoint(two-year survival).  The NMDP 
Phase II data indicated an early relative risk of 0.6 for PBSC versus marrow that resulted 
in no significant difference in survival at two years.  A relative risk of 0.6 throughout the 
first six months would yield a difference in six-month mortality rates of 15%.  Therefore, 
at each interim analysis the hypothesis that the difference in six-month mortality rates 
between the two arms is less than or equal to 15% will be tested against the alternative that 
the difference is greater than 15%, using a two-sided alpha=0.05 level test.  This test will 
be done by comparing the Kaplan-Meier estimates of six-month mortality, and using 
Greenwood’s formula for the variance in each group. If this hypothesis is rejected, all 
analyses will be sent to the DSMB for expedited review.  Operating characteristics of this 
interim analysis for safety are given below, as a function of the true difference in six-
month survival (Delta), assuming an exponential survival curve with 55% or 
55%+Delta survival at six months in the marrow or PB arms respectively, and 
assuming uniform accrual over three years .  As shown, this stopping rule will have 
good power to detect a large difference of 25-30% in six-month mortality, but will not 
stop often for smaller differences that may dissipate by two years. 
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Table 5.4. – Probability of Stopping 
 
Interim Analysis 1 2 3 4 5 
Accrual Month 9 15 21 27 33 
Patients 
Enrolled 124 206 289 371 454 
Delta Probability of Stopping Total 
15% 3.3% 1.6% 1.2% 1.1% 0.9% 8.1% 
20% 8.5% 7.1% 5.5% 5.2% 4.9% 31.2% 
25% 18.1% 16.7% 14.4% 11.4% 8.5% 69.1% 
30% 34.6% 28.9% 17.3% 9.5% 4.9% 95.2% 
 
7. Explicitly describe the TRM stopping rule to clarify the guidelines 
 
See #6 above. 
 
II. OTHER PROTOCOL MODIFICATIONS 
 
Substantive Changes 
 
1. Added "History of serious adverse reaction to anesthesia" to the donor exclusion criteria.  
(Section 2.5.2) 
2. Added "Deaths are to be reported in 24 hours". (Section 4.17.3.1) 
3. Changed "log rank test" to "binomial comparison (Mantel-Haenszel test)" (Section 5.2) 
4. Updated Section 5.2 as described above 
5. Added "In addition, the rate of patients enrolling in the study and not receiving a transplant 
will be closely monitored and compared with our target rate of 5-15%.  If the observed rate 
appears to be higher than 15%, increasing accrual to up to 630 patients will be considered." 
(Section 5.3) 
6. Updated Section 5.4 as described above. 
7. Changed "log rank test" to "binomial comparison (Mantel-Haenszel test)" (Section 5.6) 
8. Changed "log rank test" to "Mantel-Haenszel test" (Section 5.7.1) 
9. Added Section 5.11 as described above 
10. Added summary table of cytokines (new Table 1) to Appendix C. 
 
Minor Changes: 
 
1. Updated several sections to change the primary endpoint of overall survival from the time of 
randomization to two-year survival from the time of randomization. (Synopsis, Sections 2.1, 
2.2.1, 2.2.3, 3.1, 5.1.3, 5.1.4, 5.6) 
2. Added a comma after graft failure in the Synopsis. 
3. Removed the typographical error of "PB". (Section 2.3.2) 
4. Divided donor inclusion criteria # 2 into two criteria. (Section 2.5.1) 
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5. Changed donor inclusion criteria "…consent to placement of a central catheter" to "…agree 
to placement of a central catheter". (section 2.5.1) 
6. Changed "Positive Hemoglobin Solubility test for sickle cell trait" to "Presence of sickle 
hemoglobin as demonstrated by appropriate testing such as hemoglobin electrophoresis". 
(Section 2.5.2) 
7. Changed "Recommended temperature during shipping is 2-8o C using cold packs, or similar 
material." to "Products will be shipped in an NMDP-approved container that is charged with 
cold packs or similar material to provide an initial ambient temperature of  
2-8 o C." (Section 2.6.5) 
8. Changed "Requested marrow cell dose will be 4 x 108 nucleated cells per recipient actual 
body weight, as allowed by the weight of the donor." to "Requested marrow cell dose will be 
4 x 108 nucleated cells per kg of recipient body weight". (Section 2.6.6) 
9. Changed "Recommended temperature during shipping is 2-8o C using cold packs, or similar 
material." to "Products will be shipped in an NMDP-approved container that is charged with 
cold packs or similar material to provide an initial ambient temperature of  
2-8 o C." (Section 2.6.6) 
10. Changed title Section 3.2.1 from "Overall Post-transplant Survival" to "Two-year Post-
transplant Survival". 
11. Changed "The endpoint is patient overall survival after two years of follow up" to "The 
endpoint is two-year survival from the time of transplant." (Section 3.2.1)  
12. Removed pneumococcus from Section 3.2.12 item #2 
13. Added Section 3.2.14 Three-year survival 
14. Changed "The target enrollment is 550 patients." to "The target enrollment is 550 patients, 
with a provision to increase enrollment to 630 patients depending on the observed rate of 
patients dropping out without receiving a transplant." (Section 5.1) 
15. Changed "Transplant-related event data will only be collected on patients who actually 
receive a transplant and do not drop out of the study." to "Transplant-related event data will 
only be collected on patients who actually receive a transplant and will use event times 
calculated from the time of transplantation." (Section 5.7) 
16. Added "Covariates have been specified in section 5.7 and include transplant center, year of 
transplant, preparative regimen, GvHD prophylaxis, recipient characteristics (age, sex, body 
mass index [BMI], race, Karnofsky/Lansky, diagnosis, disease stage, time from diagnosis to 
transplant, CMV status, comorbid disease) and donor characteristics (age, sex, BMI, race, 
CMV status and parity), and HLA Match." (Section 5.7) 
17. Changed the title of Section 5.7.1  from "Overall Survival among Transplanted Patients" to  
"Two-year Survival among Transplanted Patients" 
18. Added "over time" (Section 5.7.2 and 5.7.3) 
19. Re-worded third paragraph Section 5.7.6. 
20. Added Section 5.7.11 Three-year Survival 
21. Added editorial changes to Section 8.1, specifically 
1st paragraph - added (QOL) 
3rd paragraph - replaced "attainment of results" with "examination of quality of life 
outcomes" 
4th paragraph - replaced "faster" with "shorter" 
22. Replaced "…between the two donation methods" with "…of donors randomized to PBSC or 
marrow donation".  (Section 8.2) 
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23. Added paragraph "Potential study participants will be the 550 donors (~275 each of PBSC 
and marrow) recruited to participate in the randomized clinical trial (RCT).  Donors must (a) 
meet the standard NMDP requirement for donor eligibility, (b) be selected for participation in 
the RCT, (c) meet the inclusion and exclusion criteria listed below, and (d) give signed 
informed consent to participate in both the RCT and the Donor Quality of Life study." 
(Section 8.3) 
24. Added "parent" to 8.3.1 item #1 
25. Added editorial changes to Section 8.3.2, specifically 
Item #1  - Replaced "Inability to read and write in English, because instruments in other 
languages have not been validated." with "Inability to read and speak in English, because (a) 
consent for the parent study will require that the participant be able to read English and (b) 
the instruments to be used in the Quality of Life study have not all been validated in other 
languages." 
Item #2 - Replaced "Inability to complete questionnaires due to cognitive, linguistic, or 
emotional difficulties." with "Inability to complete telephone interview due to cognitive or 
linguistic difficulties." 
Item #3 - Replaced "No telephone access or failure to provide telephone contact number." 
with " Lack of telephone access." 
26. Added editorial changes to Section 8.4.1, specifics are indicated in redline/strikeout below 
Pre-donation.  Donors will be enrolled upon completion of their evaluations and agreement 
to the study randomization.  Sociodemographic information will be obtained at the time of 
consent. 
Within four weeks prior to marrow donation or initiation of G-CSF administration donors for 
PBSC donors, participants will complete the baseline interview questionnaire.  Every 
attempt will be made to administer the baseline questionnaire interview as close to donation 
or G-CSF administration as possible.  PBSC donors will have an additional assessment at 
Day 4 of G-CSF administration, since the preparatory procedures for PBSC donation are 
considered part of the donation process and include experiences that likely affect QOL. 
Post-donation. Donors will be surveyed within 48 hours after donation, then weekly until 
they indicate a return to normal functioning for a period of three consecutive weeks.  Long-
term assessment will occur at 6 and 12 months. All questionnaires will be administered by 
phone by an independent interviewer.  Donors will be sent a copy of the questionnaires to 
review before contact with the interviewer.  Basic medical information will be obtained 
directly from donors  by the donor center following standard NMDP procedures and forms.  
Information will include the need for central venous catheter placement, hospitalization and 
reason, and any serious adverse event. 
Permission will be sought for repeated QOL and satisfaction assessment yearly for five years.  
These data will not be included as part of this randomized trial. 
 
27. Added "ECOG" before "performance status" (Section 8.4.3) 
28. Added the following paragraph to Section 8.4.3  
General Physical, Social, and Emotional Functioning: Global physical, social, and 
emotional functioning will be assessed with the 12-item Medical Outcomes Survey Short-
Form 12v2 (88).  The SF-12v2 is widely used, reliable and a well-validated instrument that is 
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appropriate for individuals with a broad range of functional limitations.  It has the advantage 
of being linked to a substantial body of normative data. 
29. Replaced "Clinical Data: Number of analgesic tablets needed to reduce pain is regularly 
assessed via NMDP forms and will be used to corroborate self-reported pain levels.  Number 
of blood transfusions given, requirement for a central line, number and duration of 
leukapheresis procedures, duration of hospitalization, sick leave, and number of days with 
restricted activities will also be assessed via NMDP forms." with " Clinical Data: Number of 
blood transfusions given, requirement for a central line and the number and duration of 
leukapheresis procedures will also be assessed via NMDP forms." (Section 8.4.3) 
30. Table 8.4.3 was updated. 
31. Added "Center" (Section 8.5.1) 
32. Changed Section 8.5.3 as indicated below 
All questionnaires interviews  will be administered by telephone by an trained independent 
interviewer.  Donors will be sent a copy of the questionnaires to review before contact with 
the interviewer.  If donors wish, they can receive a mailed copy of the interviewer's 
questionnaire before the telephone interview.  Medical information will be obtained by the 
donor center following standard NMDP procedures and forms. 
33. Added editorial changes to Section 8.5.4, specifically 
The interviewer In general, the project coordinator or the study principal investigator 
will briefly review the procedures to make certain that the cause of withdrawal is not 
misunderstanding of study procedures. 
34. Added "A total sample size of 550 will provide more than adequate power to examine group-
level differences between PSBC and marrow donors." (Section 8.6.1) 
35. Replaced "….level of 0.01 will be used as an ad hoc protection…." with "…level of 0.01 will 
be used as protection…" (Section 8.6.2) 
36. Replaced "…chi-squared trend test…" with "…chi-squared test…" (Section 8.6.2) 
37. Added editorial changes to Section 8.6.3, specifically 
Missing data will initially be assumed to be missing at random, and therefore requiring no 
adjustment will be made to the mixed models analysis across time.  Separate If this is the 
case, separate tests performed at each time point will be done with the complete data at that 
time. However, missing cases will be examined to determine whether data are missing 
systematically by key sociodemographic indicators. 
38. Editorial changes were made to Section 8.7, specifically 
QOL data collection involves non-invasive survey procedures that pose no risk to the 
participants.  It is possible, although highly improbabley, that completion of the survey items 
could elicit distress.  However, participants are instructed to leave blank not to answer any 
questions that make them uncomfortablethey feel uncomfortable answering.  Donors also are 
informed that they may withdraw from study participation at any time without penalty.  
Should high levels of distress be detected during donor contacts, the interviewer will attempt 
to determine the nature and intensity of the distress, and will ask the donor if they wish to 
receive a follow up call from their local donor coordinator, the donor center Principal 
Investigator of the RCT or from a member of the Donor Services Staff at the NMDP.  If 
the donor says yes, the interviewer will contact the appropriate individual within 12 hours. 
Principal Investigator, or his or her representative, That individual, in turn, will make every 
attempt to contact the donor by telephone within 24 hours. 
39. Updated table number references in Appendix C 
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40. Removed that results would be sent to the transplant centers. (Appendix C - Section 3.4) 
41. Clarified the assays to be performed Appendix C Section 3.5 to, specifically 
In addition, the presence and number of aspergillus-specific, CMV-specific, pneumococcal-
sepcific, and tetanus-specific T cells will be determined by secreted cytokines (g-IFN, TNF, 
IL-4, and IL10) measured by ELISA and FACS following in-vitro incubation with antigens 
at 3, 6, 9, and 12 and 24 months after transplant (Centeno-Lima 2002; Hebart 2002). For 
CMV, the assays will include FACS for cytoplasmic IL2, IFN-g and TNF-a, and no 
ELISA.  For Aspergillus, the assays will only include ELISA for IL2, IL4, IL10 and 
IFN-g and no FACS.  For Tetanus, the assays will include FACS for cytoplasmic IL2 
and ELISA for IL-2, IL-4, IL-10 and IFN-g.  Appropriate controls should be included 
in the assays.  See Table 1 below.  
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BMT CTN PROTOCOL #0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized 
Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible 
Unrelated Donors  
 
 
Major Changes/Clarifications to Version 2.0 of the Protocol: 
 
 
Appendix B 
· The informed consent forms contained in Appendix B have been reworded.  A 
summary of the risks related to the transplant procedure has been added to 
Attachment A, B, and C of the informed consent form.   
The two significant changes to the informed consent form are: 
1. The addition of Section 20 that clarifies the use of blood samples for 
research. 
2. The reduction of the number of options for providing blood samples for 
research from three to two.  The two options now offered to subjects are “I 
agree to have blood drawn for research purposes” and “I do not agree to 
have blood drawn for research purposes.”   
These changes should be made to the transplant center’s informed consent form 
and the revised informed consent form should be submitted to the transplant 
center IRB for approval. 
 
Appendix C 
· In Appendix C, § 3.3, added the following paragraph: 
“Antibody response to the conjugated vaccine, however, represents a best-case 
scenario.  If patients do not respond to the conjugated vaccine, they will not 
respond to the unconjugated vaccine or wild type infection.  Unfortunately, the 
ability to respond to the conjugated vaccine does not predict for response to 
bacterial carbohydrate antigens.  To evaluate the recipient’s ability to produce an 
antibody response to wild type bacterial carbohydrate antigens, we will test for 
Haemophilus influenzae type B-specific IgG antibodies that cross-react against E. 
coli K-100 present in gut flora.” 
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· In Appendix C, § 3.1 modified the fourth sentence to indicate that serum will be 
analyzed for Haemophilus influenzae type B-specific IgG antibodies.   
· In Appendix C, added a § 6, LABORATORY CONTRACTS AND REMAINING 
SAMPLES, to read the following: 
“All laboratory studies will be performed at laboratories under contract with the 
NMDP on behalf of the BMT CTN.  The laboratory contract specifies that any 
remaining serum must be stored at the laboratory for the duration of the study.  If 
the investigators choose to perform additional studies on these remaining samples, 
a formal amendment will be made to the protocol.  Any amendments to the 
protocol are subject to the DSMB and IRB approval process. 
At the end of the study, the BMT CTN will either instruct the laboratory to 
destroy any remaining samples or to transfer the remaining samples to the NHLBI 
sample repository in Maryland.  These samples will be paired with the respective 
donor or recipient sample and given unique bar code designations that cannot be 
linked back to the donor or the recipient.  An NHLBI Biologic Specimen 
Repository Utilization Committee will advise the Institute on requests for 
specimens to perform research with these anonymous samples.  If an investigator 
request for these samples is approved by the committee, the NHLBI may provide 
a panel of the specimens requested using unique code numbers.  Laboratory test 
results, clinical information, etc., associated with the coded samples are provided 
to the investigator only after completion of his/her research protocol.  Samples 
sent to researchers cannot be linked with any remaining sample at the repository. 
After completion of all cellular assays, the samples will be destroyed.  Only 
serum samples remaining from the laboratory assays for antibody titers will be 
shipped to the NHLBI sample repository.”   
 
Appendix D 
· In Appendix D, added a detailed subsection, entitled “Justification for including 
minors”, included in pages D-2 to D-4 of the protocol.   
 
Minor Changes/Clarifications to Version 2.0 of the Protocol: 
 
· The word “study” was changed to “trial” in the protocol title. 
· Corrected spelling and grammatical errors. 
 
Chapter 2 
· In §2.3.1, added definition of Chronic Phase of Chronic Myelogenous Leukemia 
with the following: 
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o Stable, not hematologic remission: blasts present in marrow and/or PB, but 
disease does not qualify as accelerated or blast phase 
o Hematological remission: no blast cells or precursor cells in the blood or 
marrow 
o Partial cytogenetic remission: Ph+ metaphases >0% but <35% 
o Complete cytogenetic remission: absence of Ph+ metaphases 
· In §2.3.1, added definition of Accelerated Phase of Chronic Myelogenous 
Leukemia with “any one of the following symptoms: 
o WBC difficult to control (>50 x 109/L despite therapy) 
o Rapid doubling of WBC (<5 days) 
o 10% blasts in blood or marrow 
o 20% blasts and/or promyelocytes in blood or marrow 
o 20% basophils and/or eosinophils in blood 
o Anemia or thrombocytopenia unresponsive to standard treatment 
o Persistent thrombocytosis (>1000 x 109/L) 
o Cytogenetic abnormalities in addition to Ph+ 
o Increasing splenomegaly 
o Marrow fibrosis 
· In §2.3.1, replaced the “Remission after Blast Phase, defined as < 5% blasts in the 
marrow, and no extramedullary leukemia;” with the following: 
o More than 30% blasts and/or promyelocytes in blood or bone marrow 
o More than 20% blasts 
· In § 2.4, number 4, added “(corrected for hemoglobin)” to describe parameters. 
· In §2.5.1, added number 5 “Donor center affiliation with NMDP.” to Donor 
Inclusion list. 
· In § 2.5.1 changed number 5 to number 6 and modified to read “General donor 
inclusion criteria specified in the Donor Companion Manual.” 
· In § 2.6.1.6, changed ht2 to ht2  
· In § 2.6.3.2, defined nano (n) g/mL as ng/mL 
· In § 2.6.5.2, in the Anticoagulation section, changed the third sentence to indicate 
that it is “optional” to add ACD-A if the citrate to whole blood ratio is less than 
1:13. 
 
Chapter 3 
· In § 3.2.8, added “Patients will be censored for this endpoint at the time of 
relapse.” 
· In § 3.2.9, changed number 2 under Chronic Myelogenous Leukemia (CML) 
from “There is myeloid hyperplasia in the bone marrow in the absence of 
infection or hematopoietic growth factor therapy.” to “There is myeloid 
hyperplasia in the bone marrow in the presence of cytogenetics relapse.” 
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Chapter 4 
· Modified table 4.17 to include a 7-month and an 11-month study visit. 
· In § 4.17.3.1, added “grades 3-5” before adverse events.  Added the sentence “All 
grades 3-5 adverse reactions to vaccines should be reported within three working 
days. 
· Modified table 4.17.4 to specify assessments by days post transplant. 
· In § 4.17.4.1, added number 13 “Serum for quantification of IgG, IgM and IgA, 
and antibody titers to diptheria, tetanus, and hepatitis A.  Serum for antibody titers 
to H. influenzae type B at 6, 12, and 24 months post-transplant.” to reflect table 
4.17.4.   Renumbered 13 and 14 to 14 and 15. 
· In § 4.17.4.2, added number 7 “dT, PPV23, and Hepatitis A vaccines at 6 and 11 
months post-transplant and PCV7 vaccine at 7 and 9 months post-transplant.” to 
reflect table 4.17.4.   
· In § 4.17.5, changed number 4 from “Hemoglobin solubility for sickle cell trait, if 
indicated.” to “Sickle cell trait testing.”  Added number 8, “Serum for Hepatitis A 
antibody titer.” to reflect table 4.17.4.   
 
Chapter 5 
· In § 5.2, added the following: “Sample size calculations are based on the analysis 
of the primary endpoint of two year survival.”  Changed “Overall survival 
between the standard and experimental therapy arms will be compared using the 
stratified binomial comparison (Mantel-Haenszel test).” to “The standard and 
experimental therapy arms will be compared using the stratified binomial 
comparison (Mantel-Haenszel test).” 
· In § 5.7.6, added the following: “Patients will be censored for this endpoint at the 
time of relapse.” 
 
Chapter 8 
· In § 8.4.3, corrected the references for the following subsections: Physical 
Recovery; Psychological Functioning; Convenience; Concerns about Donation; 
Satisfaction with Donation. 
 
Appendix C 
· In Appendix C, § 3.1 changed the volume of the blood sample from 25 cc to 40cc.  
Modified the third sentence to indicate that the analysis will be performed at a 
central reference laboratory, not the transplant center.   
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· In Appendix C, § 3.8, added the following sentence: “Haemophilus influenzae 
type B-specific IgG antibody measurements will also be performed on samples 
collected at 6, 12 and 24 months post transplant to assist in evaluating the 
recipient’s ability to produce T cell independent immune responses to 
polysaccharide antigens.”   
· In Appendix C, § 3.9, section ii), added the following: “Serotypes that are PCV7 
heptavalent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F &23F) and 
a subset of serotypes present in the PPV23-valent polysaccharide vaccine (1, 3, 5, 
7F, 15B) vaccines will be measured at 6, 11, 12 and 24 months post-transplant.”  
In section iii), added the following: “The opsonophagocytic assay will be 
performed only on 11 and 12 month post-transplant patient samples that show 
demonstrable IgG antibodies directed against one or more of the twelve S. 
pneumoniae serotypes evaluated in this study.  The measurement of functional 
antibodies will be limited to the analysis of the two serotype-specific antibodies 
(one serotype, if IgG antibody detected to only one serotype) exhibiting the 
highest IgG titers.”  In section iv) added the following: “Analysis will be 
performed on baseline donor and patient serum samples and on patient samples 
collected at 6, 11, 12 and 24 months post-transplant (Table 5).”  In section v), 
added the following: “ELISA for Haemophilus influenzae antibodies.  
Quantitative total IgG antibody levels against H. influenzae Type B (HIB) 
capsular polysaccharide will be measured using ELISA/EIA kits at the central 
reference laboratory.  Analysis will be performed on patient serum samples 
collected at 6, 12 and 24 months post-transplant.” 
· In Appendix C, § 5 added the following: “Samples will be given a unique 
alphanumeric code that contains no personal identifiers.  Transplant Center 
Coordinators will hold the link to the code.  Laboratory staff will not have access 
to the link.” 
· In Appendix C, § 3.1 removed the reference to Table 5.2 in the protocol. 
· In Appendix C, § 3.4 and § 3.5 removed blood sample amount and preparation. 
· Modified the first two sentences to include details from Table 5 regarding the 
time points at which the analysis will be performed and further details about the 
analysis (“Cell separations will be performed to isolate CD3+/CD4+ and 
CD3+/CD8+ cell subsets for batch analysis of signal joint T cell receptor excised 
circles (TRECs).”) 
· In Appendix C, § 3.7, modified the sentence to include details from Table 5 
regarding the time points at which the analysis will be performed and which lab 
will be performing the analysis. 
· In Appendix C, § 3.8 removed “safety” from the goal of evaluating the vaccine.  
Modified the final sentence to reference Table 5. 
· In Appendix C, § 3.9, section i) changed “commercial laboratory” to “central 
laboratory.”   
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· In Appendix C, table 5, split “Baseline: Patient and donor” column into two 
columns: “Baseline Donor” and “Baseline Recipient.”  Only “Hep A Ab titer” is 
checked for “Baseline Donor” and “dT Antibodies”, “Hep A Ab titer”, and 
“Quantitative Ig” are all checked for “Baseline Recipient.”  Added “H. influenzae 
B Ab Titer” which will be collected at 6, 12, and 24 months to reflect §3.9 of 
Appendix C. 
 
 
 
 
 
 
BMT CTN PROTOCOL #0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem 
Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
 
Major Changes/Clarifications to Version 3.0 of the Protocol: 
 
Protocol Synopsis 
• Changed the number of conditioning regimens from three to four. 
Chapter 2 
• In §2.6.1, changed the number of conditioning regimens that are available from three to four.  The 
fourth regimen is as follows: 4.  Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that 
include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 
busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG.  Institutional 
standards should be followed for targeting plasma levels. 
• Added §2.6.1.10 ATG.  It reads:  ATG will be administered at a dose of at least 40 mg/kg equine or 4 
mg/kg rabbit.  The Physician Desk Reference’s manufacturer’s guidelines should be followed for 
administration of ATG. 
Chapter 3 
• In §3.2.12, number 5, replaced Hepatitis A with Hepatitis B. 
Chapter 4 
• In Table 4.17.4 and §4.17.4.2, replaced the Hepatitis A vaccine with the Hepatitis B vaccine to be 
given at 6, 7, and 11 months post-transplant. 
• In §4.17.5, replaced the Hepatitis A antibody titer sample with the Hepatitis B antibody titer sample. 
• Table 4.17.4, §4.17.4.1, §4.17.4.2, and §4.17.5 were updated to reflect the blood sample for natural 
killer cell receptors acquisition ancillary study to be collected at baseline and Days 84, 180, and 365 
for the patient and pre-donation (prior to G-CSF if PBSC) for the donor. 
Chapter 5 
• The safety monitoring rule for six-month survival was replaced with an interim analysis plan for 
overall survival. 
Appendix B 
• In all informed consent forms, replaced references to the Hepatitis A vaccination or antibody titer 
with Hepatitis B vaccination or antibody titer. 
• Added “Attachment D: Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Busulfan Conditioning Regimen.”
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• To reflect the additional samples required for the natural killer cell receptor acquisition ancillary 
study, modified the “Blood Samples For Research Purposes” in all patient informed consent forms to 
read “provide blood samples up to 7 times (10-100 mL each time or approximately 1-7 tablespoons) 
between the time transplant is initiated and two years after (up to a total for all 7 blood draws of 430 
mL or approximately 2 cups).” 
• To reflect the additional samples required for the natural killer cell receptor acquisition ancillary 
study, modified §II.A of the donor consent to read “40 mLs (approximately 3 tablespoons) of blood 
will be drawn from a vein in your arm…Tests will also be done on the blood to help better understand 
tissue matching between donors and recipients in this study.” 
Appendix C 
• Added §5 Acquisition of Natural Killer Cell Receptors in Recipients of Unrelated Transplants. 
 
Minor Changes/Clarifications to Version 3.0 of the Protocol: 
• Changed all references to the “Internet Data Entry System” to “Advantage EDCSM” 
• Added City of Hope Samaritan and St. Louis Children’s Hospital (PBMTC) to the list of Core Study 
Participants and Roswell Park Cancer Institute to the list of Non-Core Study Participants. 
• Corrected spelling and grammatical errors. 
Protocol Synopsis 
• Under secondary objectives, removed reference to a functional score at baseline for the donors. 
• Clarified that PBSC donors will receive G-CSF for five days. 
• Clarified that marrow or blood cells should not be frozen prior to transplantation. 
Chapter 2 
• In §2.1, clarified that the study is sponsored by the National Institutes of Health. 
• In §2.1, clarified that the conditioning and GVHD prophylaxis regimens will vary by center “and 
within centers, however, the center must declare before randomization what regimens will be used for 
each patient.”   
• In §2.5.1, added number 6 “Donor must be 18 years of age or older.” to the Donor Inclusion list. 
• In §2.5.2, clarified that female donors are excluded if their breastfeeding is “uninterruptible.” 
• In §2.6.1.8, added “Fludarabine is not recommended for patients with severe renal impairment, i.e., a 
creatinine clearance (CrCl) less than 30 milliliters/minute/1.73 square meter (mL/min/1.73 m2).  For 
patients with moderate renal impairment (CrCl of 30 to 70 mL/min/1.73 m2), the fludarabine dose 
should be reduced by 20% to 50%.” to clarify dose reduction of fludarabine for patients in renal 
failure.  Also clarified dose adjustment based on body weight. 
• In §2.6.3.2, added “When initiating therapy with voriconazole in patients already receiving 
cyclosporine, it is recommended that the cyclosporine dose be reduced to one-half of the original dose 
and followed with frequent monitoring of the cyclosporine blood levels.  Increased cyclosporine 
levels have been associated with nephrotoxicity.  When voriconazole is discontinued, cyclosporine 
levels should be frequently monitoring and the dose increased as necessary.” 
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• In §2.6.3.3, added “When initiating therapy with voriconazole in patients already receiving 
tacrolimus, it is recommended that the tacrolimus dose be reduced to one-third of the original dose 
and followed with frequent monitoring of the tacrolimus blood levels.  Increased tacrolimus levels 
have been associated with nephrotoxicity.  When voriconazole is discontinued, tacrolimus levels 
should be frequently monitoring and the dose increased as necessary.” 
• Modified §2.6.1.12 Intravenous hydration was changed from “Intravenous hydration will begin at 
least 12 hours prior to the first dose of chemotherapy and continue for 24 hours following the last 
dose.” to “Intravenous hydration is recommended to prevent tumor lysis syndrome in patients with 
bulky tumor and to prevent hemorrhagic cystitis in patients treated with cyclophosphamide.  
Hydration should begin at least 12 hours prior to the first dose of chemotherapy and continue for 24 
hours following the last dose.” 
• In §2.6.3.3, changed the initial intravenous total daily dose of tacrolimus from “0.03 mg/kg” to “0.03 
mg/kg/day.”  
• In §2.6.13, changed the antifungal therapy from “Prophylaxis with fluconazole or other antifungal 
agents will begin with conditioning therapy and continue until at least Day 70 post transplant.” to “In 
keeping with the BMT CTN MOP and local institutional standards for allogeneic transplants.” 
Chapter 3 
• In §3.2.9, replaced the acute leukemia relapse definition with the following: 
“Relapse will be diagnosed when: 
o The reappearance of leukemia blast cell in the peripheral blood, or 
o >5% blasts in the marrow, not attributable to another cause (e.g., bone marrow regeneration), or 
o The appearance of new dysplastic changes within the bone marrow, or 
o No circulating blasts, but the marrow contains 5-20% blasts, a repeat bone marrow ≥1 week later 
with >5% blasts is necessary to meet the criteria for relapse, or 
o The development of extramedullary leukemia or leukemic cells in the cerebral spinal fluid.” 
• Added “Relapse will be defined to occur in the absence of the evidence above if specific therapy, 
such as infusion of donor lymphocytes, use of interferon, or second transplant, is initiated for relapse 
reversal.” to §3.2.9. 
• Removed §3.2.15 Donor Recovery to Baseline Functional Score, which read “Appropriate statistical 
methods to detect trends over the available spectrum of donor follow-up times will be employed for 
baseline functional recovery to baseline endpoints.” 
Chapter 4 
• In §4.6, removed the line “Transplant center personnel will record patient refusal in IDES.” 
• In §4.10, removed the line “Donor refusal will be recorded in IDES.” 
• In §4.17.2, changed the first sentence to indicate that deaths should be reported within 24 hours of the 
event. 
• In §4.17.13, modified the text to read “Unexpected, grade 3-5 adverse events (AE) will be reported 
through an expedited AE reporting system.  Unexpected, grade 4-5 AEs must be reported within 24 
hours of knowledge of the event.  Unexpected, grade 3 AEs must be reported within three business 
days of knowledge of the event.  All grade 3-5 adverse reactions to vaccines should be reported 
within three working days.  Expected AEs will be reported using NCI’s Common Toxicity Criteria 
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for Adverse Events (CTCAE) Version 3.0 at regular intervals as defined on the Form Submission 
Schedule.” in order to match the text in all other BMT CTN protocols. 
• In Table 4.17.4 and in §4.17.4.2, added “Vaccinations should be given ±1 week of the scheduled 
date.” and “Antibody titers should be drawn just before vaccination.” 
• In Table 4.17.4 and in §4.17.4.1, §4.17.4.2, and §4.17.5 , indicated which assessments are generally 
performed for transplant patients and which assessments are required for this study. 
• In Table 4.17.4, indicated that the history and physical exam are required weekly until Day 100. 
• In §4.17.4.2, clarified that the PPV23 vaccination is only given at 11 months post-transplant and not 
at 6 months post-transplant. 
Chapter 8 
• In §8.3.2, removed the line “(a) consent for the parent study will require that the participant be able to 
read English.” 
Appendix B 
• In §20 of the Informed Consent to Participate in Research and in the Legal Guardian Informed 
Consent to Participate in Research and in §13 of the Assent to Participate in Research (Ages 12 to 17 
years old), in the first line of the section, added that the patient will be asked to provide blood samples 
“to help better understand tissue matching between donors and recipients in this study.” 
• In §17 of the Informed Consent to Participate in Research and in the Legal Guardian Informed 
Consent to Participate in Research added the following to the list of organizations with access to 
research and medical information: 
o Quality of Life staff at the Center on Outcomes, Research, and Education at Evanston 
Northwestern Healthcare 
o Laboratory staff at Dr. Edmund Waller’s laboratory at Emory University 
o Laboratory staff at Esoterix, Inc. 
o Laboratory staff at Dr. Jeffrey Miller’s laboratory at the University of Minnesota 
• In §III.A.1, removed the line “In this case, depending on the actual value of your platelet count, you 
may be asked to consider donating bone marrow instead of blood stem cells, or the blood stem cell 
donation procedure may be delayed for a day.” and added “In this case, depending on the actual value 
of your platelet count, a physician will discuss with you the possible courses of action that might be 
taken. These include: 
o Monitoring the platelet count throughout the apheresis procedure. 
o Shortening the apheresis procedure. 
o Delaying the apheresis procedure for a day. 
o Canceling the blood stem cell donation. 
o Asking you to consider a standard marrow donation. 
o Asking you to consider some other course of action that is agreeable to you.  
Appendix C 
• Added “Vaccinations should be given ±1 week of the scheduled date.” to §3.8. 
• Changed all references of “cc” to “mL” 
• Added Table 6 and Table 7 to clarify the collection and shipping procedures and the collection 
schedule for patient and donor blood and product samples. 
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BMT CTN PROTOCOL #0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem 
Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
 
Major Changes/Clarifications to Version 4.0 of the Protocol: 
 
Chapter 2 
• In §2.6.4, the use of mini-methotrexate regimens is now permitted.  The following sentence has been 
added, “The dose of methotrexate may be decreased per institutional standard practice to no less than 
5 mg per m2 on Days 1, 3, 6, and 11 post-transplant.”  
 
Minor Changes/Clarifications to Version 4.0 of the Protocol: 
 
• Added Texas Transplant Institute to the list of Non-Core Study Participants. 
Chapter 2 
• In §2.4, added the exclusion criteria “Patients with prior malignancies except resected basal cell 
carcinoma or treated carcinoma in-situ.  Cancer treated with curative intent < 5 years previously will 
not be allowed unless approved by the Medical Monitor or Protocol Chair. Cancer treated with 
curative intent > 5 years previously will be allowed.” to be consistent with other BMT CTN 
protocols. 
• In §2.4, changed the exclusion criteria of “Pulmonary disease with FVC, FEV1 or DLCO parameters 
< 50% predicted (corrected for hemoglobin)” to “Pulmonary disease with FVC, FEV1 or DLCO 
parameters < 45% predicted (corrected for hemoglobin).” 
Chapter 4 
• In §4.17.4.1, clarified that a β-HCG for serum pregnancy test is only required for women of 
childbearing potential, to be consistent with other BMT CTN protocols. 
• In §4.17.5, clarified which donor evaluations are required pre-collection, on the day of collection, and 
post-collection.  Clarified that a toxicity assessment and product CBC are required on the day of 
collection.  Clarified that a product sample for cellular composition testing is required for this 
protocol. 
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BMT CTN PROTOCOL #0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem 
Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
Minor Changes/Clarifications to Version 6.0 of the Protocol: 
 
• Added Baylor College of Medicine, University of Alabama at Birmingham, University of Maryland, 
University of Pittsburgh, Loyola University Medical Center, and Tulane University Hospital to the 
list of Non-Core Study Participants. 
• Removed Children’s Memorial – Northwestern and Memorial Sloan-Kettering Cancer Center from 
the list of Core Center Participants and removed Georgetown BMT and Arthur G. James Cancer 
Hospital from the list of Non-Core Center Study Participants. 
Chapter 2 
• In §2.6.5.1, changed the verbiage regarding administration of the fifth dose of G-CSF: “The fifth dose 
must should be given at least one hour prior to apheresis.”  This change was made to maintain 
consistency with the NMDP PBSC protocol. 
• In §2.6.5.2, changed the verbiage regarding quantitation of the CD34 cell dose: “Quantitation of the 
CD34 cell content of the product by the Apheresis Center on the day of apheresis is recommended 
required.”  This change was made to maintain consistency with the NMDP PBSC protocol. 
• In §2.6.5.2, the italicized text was added to the paragraph regarding volume and cell dose: “Requested 
marrow cell dose will be 4 x 108 nucleated cells per kg of recipient body weight.  This dose will be 
unattainable for many recipients because of donor and/or recipient factors, e.g., body size 
mismatches.  The volume of marrow shall not exceed 20 mL per kg donor weight.  The volume to be 
collected The estimated cell dose and a planned donor marrow volume shall be agreed upon by the 
donor and transplant centers before initiation of the transplant conditioning regimen.”  This change 
was made to provide clarification of requested cell dose versus collected cell dose. 
Appendix B – Donor Consent Form 
• In §II.C.2 of the donor consent form, clarified that if a central line is placed, a peripheral blood stem 
cell collection over two days will require the donor to stay overnight in the hospital.  This change was 
made to maintain consistency with the NMDP PBSC protocol. 
• In §III.A.2, added the following text regarding side effects of filgrastim “Normal individuals are at 
risk for developing cancer, including leukemia, lymphoma or other blood diseases throughout their 
life time.  It is unknown whether filgrastim either increases or decreases an individual’s risk of 
developing cancer.  The data being collected during follow-up will help establish if there are any 
positive or negative long-term effects from receiving filgrastim.”  This change was made to maintain 
consistency with the NMDP PBSC protocol.  
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BMT CTN PROTOCOL #0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem 
Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
Major Changes/Clarifications to Version 7.0 of the Protocol: 
Chapter 2 
• In §2.3.1, added the following diagnosis to be included: “Patients with therapy-related AML or MDS 
whose prior malignancy has been in remission for at least 12 months.  If the remission is less than 12 
months, medical monitor or protocol chair approval is required.” 
• In §2.3.2, added the following text regarding patients with prior transplants: “Patients with secondary 
malignancies who have had a prior autologous transplant will be eligible for participation in this trial.  
The prior autologous transplant must have been performed for the primary malignancy (such as 
lymphoma) and must have occurred twelve or more months prior to enrollment. 
• In §2.6.11, modified the text to indicate that the use of growth factor use prior to Day 21 post-
transplant is not prohibited, but it is also not recommended.  Also added the following text regarding 
the use of growth factors prior to Day 21: “If a transplant center chooses to give growth factors prior 
to Day 21 post-transplant, they should be given to all patients, regardless of whether receiving bone 
marrow or peripheral blood stem cells. 
Minor Changes/Clarifications to Version 7.0 of the Protocol: 
• Updated protocol team member list. 
• Added CancerCare Manitoba, Ottawa General Hospital, Queen Elizabeth II Health Sciences Centre, 
Tom Baker Cancer Centre, McGill University, University of Toronto/Princess Margaret Hospital, 
Hôpital Maisonneuve – Rosemont, Hamilton Health Sciences, Saskatoon Cancer Centre, CHA 
Hôpital Enfant-Jésus, and Centre Hospitalier L’hotel Dieu de Quebec to the list of Non-Core Study 
Participants. 
• Removed Johns Hopkins University from the list of Core Center Study Participants. 
• Removed Mt. Sinai Medical Center and Tulane University Hospital from the list of Non-Core Center 
Study Participants. 
Chapter 2 
• In §2.3.1, indicated that the transplant center may also be located in Canada. 
• In §2.4, added “or O2 saturation < 92% of room air” to the pulmonary disease exclusion criterion to 
be consistent with other BMT CTN protocols. 
• In §2.6.5.2, changed the text regarding blood volume processing from “If such calculations are used, 
a CD34 cell dose of 5 x 106 cells per kg recipient weight should be targeted as the minimum dose. If 
more than 5 million CD34 cells per kg recipient weight are collected in the first apheresis, a second 
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collection will not be performed.” to “If such calculations are used, the transplant center requested 
CD34 cell dose should be targeted as the minimum dose.  If the requested CD34 dose is collected in 
the first apheresis procedure, a second collection will not be performed.” to ensure consistency with 
the NMDP PBSC protocols. 
• In §2.6.12, changed the text regarding blood products from “All blood products will be irradiated.” to 
“All cellular blood products will be irradiated.” per the request of the NMDP IRB. 
Chapter 4 
• In §4.1 through 4.14, added text to provide more detailed instructions on where patient and donor 
eligibility data is collected in AdvantageEDC and clarified the timing of completion of the patient 
pre-transplant assessments. 
Appendix B 
• The Donor Consent Form has been reformatted and written with a lower reading level. 
Appendix D 
• Added the sentence “Minor assent must be documented by a signature on the assent form for 
participation in the study.” to the section regarding assent of children. 
Appendix E 
• Replaced Dr. Chatchada Karanes’ contact information with Dr. John Miller’s contact information for 
questions regarding donor educational materials. 
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BMT CTN PROTOCOL #0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem 
Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
Major Changes/Clarifications to Version 8.0 of the Protocol: 
Chapter 2 
• In §2.6.2, modified the GVHD prophylaxis to allow for multiple regimens rather than just the 
previously specified two regimens.  Specifically the section now states: 
2.6.2 GVHD Prophylaxis Regimen 
 
The choice of GVHD prophylaxis regimen is by institutional preference.  Any regimen or 
protocol may be used, with the exception that Phase I GVHD prophylaxis protocols are not 
allowed.  The regimen and dosing employed must not be dependent on graft source assignment, 
i.e., marrow or PBSC. 
 
The two most commonly used GVHD prophylaxis regimens following unrelated donor 
transplantation are: 
1. Cyclosporine/methotrexate 
2. Tacrolimus/methotrexate 
 
The recommended doses and schedule of administration of cyclosporine, tacrolimus and 
methotrexate are as detailed in Sections 2.6.3 and 2.6.4.  This information is provided only as a 
guideline. 
 
Alternative or additional agents/dosing may be used per institutional preference.  However, the 
use of Phase I agents is prohibited.  
 
The transplant center will declare before randomization what GVHD prophylaxis regimen will 
be used for that particular patient.  The declared regimen must be used whether the patient is 
randomized to receive PBSC or marrow.  There is no requirement for the institution to use the 
same regimen for each subsequent patient enrolled. 
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Minor Changes/Clarifications to Version 8.0 of the Protocol: 
 
Synopsis 
• Modified Treatment Description to state: “The GVHD prophylaxis regimen will be per institutional 
standard, but may not contain any Phase I agents.” 
Appendix B 
• Modified all the recipient consent form and legal guardian consent form attachments to include the 
following:”If other agents are used for GVHD prophylaxis then analogous paragraphs describing 
risks of those agents must be added to your version of the consent form.” 
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PROTOCOL SYNOPSIS – BMT CTN PROTOCOL 0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood 
Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
 
Principal Investigator: Claudio Anasetti, M.D. 
 
Study Design: The study is designed as a Phase III, randomized, open label, 
multicenter, prospective, comparative trial of granulocyte colony 
stimulating factor (G-CSF)-mobilized peripheral blood stem cells 
(PBSC) versus marrow from unrelated donors for transplantation in 
patients with hematologic malignancies.  Recipients will be stratified 
by transplant center and disease risk and will be randomized to either 
the PBSC or marrow arm in a 1:1 ratio. 
 
Primary Objective: The primary objective is to compare two-year survival probabilities 
between patients in the two study arms using an intent-to-treat 
analysis. 
 
Secondary Objectives: Patients randomized to the two study arms and actually transplanted 
will be compared for the following endpoints (patients who do not 
receive a transplant will be excluded from the following analyses): 
survival, incidences of neutrophil and platelet engraftment, graft 
failure, acute graft-versus-host disease (GVHD), chronic GVHD, 
time off all immunosuppressive therapy, relapse, infections, adverse 
events, immune reconstitution, and quality of life.  Donors in each 
arm of the study will be compared for time to return to baseline 
toxicity score, CBC and WBC differential values after donation and 
quality of life. 
 
Eligibility Criteria: Eligible patients are up to 66.00 years of age, have acute leukemia, 
myelodysplasia, chronic myeloid leukemia, or other 
myeloproliferative disorders, adequate organ function, a 6/6 or 5/6 
HLA-A, B and DRB1 matched unrelated donor, and are able to give 
signed informed consent prior to enrollment.  Donors must be 18 
years of age, meet National Marrow Donor Program (NMDP) 
criteria for donor eligibility and give informed consent prior to 
enrollment. 
 
Treatment Description: Patients will receive one of four conditioning regimens as described 
in the protocol, at the discretion of the transplant physician.  The 
GVHD prophylaxis regimen will be per institutional standard, but 
may not contain Phase I agents.  The transplant physician must 
declare the conditioning and GVHD prophylaxis regimens prior to 
randomization to the PBSC versus marrow arm.  Marrow cells will 
be collected from the donors using standard procedures.  PBSC 
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donors will receive G-CSF ~10mcg/kg/d x 5 days and cells will be 
collected by a single large volume apheresis on Day 5, or two 
smaller volume apheresis procedures on Days 5 and 6. Marrow or 
blood cells will not be T-depleted or frozen prior to transplantation.  
 
Accrual Objective: Patients who are candidates for transplantation of G-CSF–mobilized 
PBSC or marrow from HLA-compatible unrelated donors will be 
targeted for accrual.  Approximately 275 patients will be accrued per 
study arm (total of 550 patients). 
 
Accrual Period: The estimated accrual period is three years. 
 
Study Duration: Patients and donors will be followed for two years for evaluation of 
the primary endpoint, with additional follow-up to three years after 
transplantation or donation for evaluation of certain secondary 
endpoints. 
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CHAPTER 1 
 
 
1. BACKGROUND AND RATIONALE 
 
1.1. Rationale 
 
Many studies of allogeneic marrow transplantation have shown that a higher dose of marrow 
cells correlates with more robust hematopoietic engraftment and lower mortality from infectious 
complications.  Peripheral blood stem cells (PBSC) collected after mobilization with granulocyte 
colony stimulating factor (G-CSF) contain a larger number of CD34-positive (CD34) progenitors 
and total cells than bone marrow.  These observations led to the hypothesis that transplantation 
of PBSC would lead to lower mortality compared to transplantation of marrow.  In addition, 
PBSC grafts have a higher T cell content, predicting a possibly more powerful anti-leukemia 
effect.  However, the higher T cell content of PBSC may also lead to increased incidence and 
severity of acute and chronic graft-versus-host disease (GVHD).  This concern is especially 
serious when the donor is unrelated to the recipient.  This prospective, randomized, multicenter 
clinical trial of unrelated donor transplantation will test the hypothesis that transplantation of 
PBSC leads to similar patient survival compared to transplantation of marrow. 
 
1.2. Marrow Cell Dose Effect 
 
Early in the history of hematopoietic stem cell transplantation, marrow cell dose was recognized 
as a limiting factor for engraftment and patient survival.  In patients with aplastic anemia 
conditioned with cyclophosphamide and transplanted with marrow from HLA-identical siblings, 
infusion of fewer than 3 x 108 cells per kilogram (kg) was associated with increased risks of graft 
failure and death (1).  The authors of that report suggested: “The greatest possible amount of 
donor marrow, perhaps supplemented by stem cells derived from the peripheral blood, should be 
obtained.”  Subsequent studies have supported this concept. Improved survival was associated 
with transplantation of higher marrow cell doses in patients with acute myeloid leukemia (AML) 
in first remission (2).  The number of hematopoietic precursor cells in T-replete marrow grafts 
was associated with better survival after transplantation from HLA-identical siblings (3).  A 
higher number of CD34 cells, a population that includes hematopoietic progenitors, was 
associated with improved survival after T cell depleted (4), or T-replete marrow grafts from 
HLA-identical siblings (5). 
 
Cell dose is limiting with transplantation of HLA incompatible unrelated cord blood (6, 7), and 
with transplantation of HLA incompatible related donor marrow (8).  However engraftment 
across the HLA barrier was achieved with the use of T-depleted PBSC containing a large dose of 
CD34 cells (9). 
 
Studies of unrelated donor transplants have shown similar results.  In patients with acute 
leukemia receiving T-replete marrow from unrelated donors, transplantation of a marrow 
nucleated cell dose above 3.65 x 108/kg was associated with faster neutrophil and platelet 
engraftment, decreased incidence of severe GVHD, less non-leukemic deaths and better 
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leukemia-free survival (10, 11).  Similar findings were reported in children receiving unrelated 
donor transplants for chronic myeloid leukemia (CML) (12) or Hurler’s syndrome (13).  Thus, 
there is abundant evidence that marrow is a limiting source of hematopoietic progenitors for 
human transplantation.  This supports the hypothesis that cell doses higher than the average 
marrow harvest might improve transplant outcome. 
 
1.3. PBSC Characteristics 
 
Hematopoietic precursors circulate in the peripheral blood at a low steady state concentration.  
However, administration of a recombinant growth factor, such as G-CSF, causes a rapid increase 
in hematopoietic progenitors in the circulation.  Transplantation of G-CSF-mobilized PBSC can 
produce durable hematopoietic reconstitution when infused after myeloablative conditioning into 
autologous, syngeneic or allogeneic transplant recipients, and engraftment is more rapid with 
PBSC compared to marrow transplantation (14, 15, 16).  After transplantation, PBSC can 
differentiate into mature hepatocytes and epithelial cells in the skin and gastrointestinal tract, 
indicating that they contain true stem cells (17).  PBSC components collected after G-CSF 
administration contain two to five-fold greater numbers of CD34 cells compared to marrow, 10-
fold greater numbers of T cells (18), 24-fold greater numbers of monocytes, 13-fold greater 
numbers of natural killer (NK) cells (19), and 5-fold greater number of plasmacytoid dendritic 
cells (20).  Therefore, more rapid engraftment of PBSC compared to marrow grafts may not be 
entirely due to increased numbers of CD34 cells, but may result from altered properties of CD34 
cells, or from the infusion of more cells belonging to other lineages.  Clinical studies indicate 
that the risk of acute GVHD is perhaps increased after PBSC transplantation, but is definitely not 
as high as one would expect with the infusion of 1–2 logs more T cells as compared to marrow 
transplantation.  Possible explanations are that T cells are functionally altered in G-CSF-
mobilized PBSC or that infused accessory cells regulate T cell function (21, 22, 23).  Thus, there 
are multiple quantitative and qualitative differences between PBSC and marrow transplants. 
 
1.4. Safety of G-CSF in Normal Donors 
 
The advantages for the donor of PBSC apheresis over marrow harvesting include the avoidance 
of general anesthesia and surgical complications.  A randomized study of sibling transplantation 
demonstrated similar levels of physical discomfort for marrow and PBSC donors, but quicker 
resolution of symptoms for PBSC donors (24).  The administration of G-CSF in doses up to  
16 mcg/kg/day in normal donors has been associated with bone pain, malaise, myalgias, 
headache, leukocytosis and mild thrombocytopenia as common side effects (25).  These are 
usually reversed within two days of discontinuing the drug.  Self-limited laboratory 
abnormalities include elevated alkaline-phosphatase, lactate dehydrogenase, uric acid, alanine 
aminotransferase, γ-glutamyl transpeptidase, and decreased potassium and magnesium. G-CSF 
also causes transient hemostatic changes, including increases in prothrombin fragment, 
thrombin–antithrombin complex and D-dimer (26).  Case reports have described rare events, 
such as myocardial infarction (27), or stroke (28), in association with G-CSF administration.  
These thrombotic complications have occurred in donors with a history of peripheral vascular 
disease or myocardial infarction and are unlikely to occur in healthy donors.  Spontaneous spleen 
rupture constitutes an unusual and rare adverse event following G-CSF administration for PBSC 
collection from normal donors (29, 30).  Preliminary National Marrow Donor Program (NMDP) 
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experience with PBSC collection from unrelated donors indicates a favorable short-term safety 
profile (31).  The existence of late side effects from G-CSF will not be known until many donors 
are evaluated for a long period of time. 
 
1.5. Results of Randomized Trials of PBSC versus Marrow from HLA-Identical Siblings 
 
1.5.1. Engraftment 
 
Eight randomized trials compared transplantation of mobilized PBSC and marrow from HLA-
identical sibling donors (32, 33, 34, 35, 36, 37, 38, 39).  Each of these trials enrolled 30 to 350 
patients.  Neutrophil engraftment occurred significantly earlier with PBSC in seven trials, and 
platelet engraftment occurred significantly earlier with PBSC in all trials. 
 
1.5.2. Acute GVHD 
 
The risks of acute grades II–IV GVHD were similar in seven trials, while the European Blood 
and Marrow Transplant (EBMT) study (40) noted a 13% greater incidence of grade II–IV GVHD 
and a 12% greater incidence of grade III–IV GVHD with PBSC.  The following are differences 
among the trials that might explain the reason for discrepant results: 
 
1. All trials utilized the combination of cyclosporine and methotrexate for GVHD 
prevention.  However, the EBMT study omitted the Day 11 methotrexate from the 
regimen while the next two largest trials in the U.S. (41) and Canada (42) included the 
Day 11 methotrexate.  In prior studies of marrow transplantation, the omission of Day 11 
methotrexate increased the risks of GVHD (43). 
 
2. The EBMT trial employed G-CSF post-transplant while the U.S. and the Canadian trials 
did not employ G-CSF.  There is no obvious relationship between post-transplant G-CSF 
and GVHD. 
 
3. The EBMT trial was the largest and therefore had the most statistical power to detect a 
difference. 
 
1.5.3. Chronic GVHD 
 
All trials suggested that PBSC transplantation was associated with more chronic GVHD, and 
three trials found a statistically significant increase of chronic GVHD with PBSC.  The Day 11 
dose of methotrexate was omitted in the three trials where PBSC led to a statistically significant 
increase in incidence of chronic GVHD.  While this observation does not directly explain a 
higher incidence of chronic GVHD, patients who have acute GVHD are more likely to develop 
chronic GVHD and patients who do not receive the Day 11 dose of methotrexate are more likely 
to develop acute GVHD. 
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1.5.4. Survival and Relapse 
 
The second and third largest trials, involving 228 and 172 patients in Canada and the United 
States (U.S.), respectively, showed statistically better survival or disease-free survival with 
PBSC.  In the U.S. study, the survival difference of 13% at 2 years was greatest among patients 
with advanced hematologic malignancies.  Both reduced transplant-related mortality and relapse 
contributed to the improved survival.  In comparison to the other trials, the U.S. study enrolled a 
larger number of patients with advanced hematologic malignancies, where it found a benefit for 
PBSC.  The U.S. trial failed to detect improved survival with PBSC in patients with early stage 
disease, perhaps because of the relatively small sample size or perhaps because both transplant-
related mortality and relapse are lower in this group regardless of graft source.  The Canadian 
trial enrolled patients with early leukemia, and found a significant survival advantage with PBSC 
of 10% at 2 years, primarily due to reduced non-relapse mortality.  The EBMT trial enrolled 
almost exclusively patients with early leukemia, but showed no differences in disease-free 
survival or overall survival.  Differences between the EBMT and the Canadian trials were 
discussed above.  One interpretation of the results of these randomized trials is that the 
administration of post-grafting methotrexate using the full dose and schedule may be critical to 
prevent acute and chronic GVHD after PBSC transplantation and to realize the potential for 
PBSC to improve patient survival by 10–13% at 2 years (44). 
 
1.6. Results of Phase II Studies of PBSC from Unrelated Donors 
 
1.6.1. European Studies 
 
Initial reports demonstrated the feasibility and potential safety of G-CSF-mobilized PBSC 
transplants from unrelated donors (45, 46, 47, 48).  In matched-cohort studies by Ringden (49) 
and Remberger (50), PBSC achieved faster neutrophil and platelet engraftment compared to 
marrow transplantation, but there was no difference in acute GVHD, relapse, treatment-related 
mortality, or survival.  Elmaagacli and colleagues (51) proposed that for patients with CML in 
chronic phase, PBSC transplants are associated with decreased relapse and improved survival 
when compared with bone marrow from HLA-compatible unrelated donors. 
 
1.6.2. Preliminary NMDP Phase II Data in Unrelated Donor PBSC Transplants 
 
A prospective study was conducted by the NMDP to test the feasibility of harvesting PBSC from 
volunteer donors and the safety of transplanting those PBSC to patients with hematological 
disorders.  Donors were treated daily with G-CSF 10 mcg/kg and PBSC were harvested on Days 
5 and 6.  Cells collected on Day 5 were stored at 2-8oC. The two-day collection was transported 
at 2-8oC and infused fresh into the recipient.  An interim analysis evaluated results of 222 
transplants facilitated by 55 apheresis centers and 57 transplant centers over the first year of 
study.  PBSC were obtained in a one-day (n=47) or two-day (n=175) collection.  The median 
blood volume processed was 12 liters per day, and 24 liters per total collection.  Transplant 
regimens varied according to institutional protocols.  The incidence of engraftment was 96%, 
acute GVHD grades II-IV 47%, acute GVHD grades III-IV 33%, extensive chronic GVHD 36%, 
mortality from causes other than relapse 18% at 100 days and 41% at one year, relapse 26%, 
survival 35% and disease-free survival 32% at one year.  Outcomes of PBSC and marrow 
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transplants conducted at the same institutions over the same period were compared.  Multivariate 
analyses were used to adjust for differences in patient age, gender, cytomegalovirus serology, 
performance status, diagnosis and stage, interval from diagnosis to transplant, donor age, HLA 
matching, transplant center, year of transplant, conditioning and immunosuppressive regimen.  
PBSC were associated with faster neutrophil and platelet engraftment, similar risk of GVHD 
grades II-IV, increased GVHD grades III-IV, and similar rates of relapse, survival and disease-
free survival (Table 1.6.2). 
 
 
Table 1.6.2: Multivariate Analyses of Unrelated Donor Transplant Outcomes Assessing 
the Risks Associated with PBSC Compared to Bone Marrow 
 
 Odds Ratio 95% Confidence Interval p value 
Neutrophil engraftment on Day 21 4.6 2.5-8.5 < 0.0001 
Platelet engraftment on Day 21 5.2 3.1-8.8 < 0.0001 
 
 Relative Risk 95% Confidence Interval p value 
Acute GVHD grades II-IV 1.3 0.9-1.7 0.12 
Acute GVHD grades III-IV  1.7 1.2-2.5 0.004 
Chronic extensive GVHD 1.3 0.8-1.9 0.26 
    
Relapse 1.0 0.7-1.4 0.85 
Disease-free survival  0.9 0.7-1.1 0.28 
 
Overall death 0.8 0.6-1.0 0.10 
Death first 100 days 0.6 0.4-0.8 0.003 
Death beyond 100 days 1.2 0.8-1.7 0.39 
 
 
Models were controlled for transplant center and year, recipient age, gender, diagnosis, Karnofsky 
score and CMV, donor age, HLA matching, conditioning and immunosuppressive regimens. 
 
Since the survival model did not meet criteria for hazard proportionality over time, two separate 
models tested the association between PBSC and survival.  Within the initial 100 days after 
transplantation, PBSC was associated with a lower hazard of death (RR 0.6, 95% C.I. 0.4-0.8, 
p=0.003), while after the 100 days there was no association (RR 1.2, 95% C.I. 0.8-1.7, p=0.39).  
When reduced-intensity transplants, defined by the use of whole body irradiation at a dose below 
800 cGy, or the use of mycophenolate mofetil were excluded from the analysis, the proportional 
hazards assumption was no longer violated and PBSC was associated with a small and not 
statistically significant survival advantage at 100 days (RR=0.7, p=0.10) and similar overall 
survival (RR=0.95, p=0.73).  A multivariable analysis restricted to PBSC recipients evaluated a 
potential association of CD34 cell dose with outcome.  The analysis found that the highest 
quintile of CD34 cell doses (i.e. > 107 per kg) was associated with an increased risk of chronic 
GVHD but had no association with survival.  The lowest dose of CD34 cells (i.e. < 4 x 106 per 
kg) was not associated with worse outcome. 
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We conclude that harvest and transplantation of PBSC from volunteer donors are feasible and, 
within the constraints of this initial study, appear at least as safe and effective as marrow grafts. 
Since this study was not randomized and the groups of patients who received PBSC and marrow 
differed for many variables, we cannot conclude with certainty that PBSC is better, worse, or the 
same as marrow.  Although the benefits and risks of PBSC transplants from unrelated donors are 
not proven, the utilization of unrelated donor PBSC in the U.S. is increasing: from 223 in the 
year 2000, to 372 in the year 2001, to 523 in the year 2002.  The continued rise in utilization of 
PBSC, in the absence of definitive data demonstrating any long-term advantages over marrow 
and concern about possible increased risks of chronic GVHD, supports the rationale for the 
timely conduct of a prospective randomized trial of PBSC versus marrow in unrelated donor 
transplantation. 
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CHAPTER 2 
 
 
2. STUDY DESIGN 
 
2.1. Study Overview 
 
This is a Phase III randomized, open label, multicenter clinical trial sponsored by the NMDP and 
the National Institutes of Health (NIH).  The objective of the trial is to test the null hypothesis 
that there is no difference in overall survival after PBSC versus marrow transplants from HLA 
compatible unrelated donors.  The study will compare G-CSF-mobilized PBSC transplantation 
with bone marrow transplantation from HLA-compatible unrelated donors for patients with 
leukemia, myelodysplastic or myeloproliferative syndromes.  Conditioning and GVHD 
prophylaxis regimens will vary by center and within centers, however, the center must declare 
before randomization what regimens will be used for each patient.  The primary endpoint of this 
trial is two-year survival following randomization.  Secondary analyses will consider neutrophil 
and platelet recovery, acute and chronic GVHD, time off all immunosuppressive therapy, 
relapse, infections, adverse events and immune reconstitution.  The trial will include evaluation 
of patient and donor quality of life, composition of the graft, and immune reconstitution.  
Accrual is anticipated for three years with a follow-up period of three years. 
 
2.2. Hypothesis and Specific Objectives 
 
2.2.1. Primary Hypothesis 
 
The null hypothesis of this randomized clinical trial is that there is no difference in the two-year 
survival between PBSC and marrow transplantation.  The alternative statistical hypothesis is that 
survival after PBSC transplantation differs from survival after marrow transplantation; no 
assumption is made about the direction of the difference. 
 
2.2.2. Secondary Hypotheses 
 
PBSC recipients will have faster hematopoietic recovery, improved immune reconstitution, 
lower risks of infection and relapse, higher risks of grades III-IV acute GVHD and chronic 
GVHD, and longer requirement for immune suppressive medications than marrow recipients.  
There will be no detectable difference in the physical, functional, psycho-emotional quality of 
life and the rate of return to work between PBSC and marrow recipients.  There will be 
differences in the pattern of donor quality of life over time from donation between the groups, 
but no detectable differences in overall scores.  PBSC donors will experience more rapid 
recovery from the donation with fewer prolonged painful or disabling complications than 
marrow donors.  There will be no long-term impact on post-donation blood counts in either the 
PBSC or marrow group. 
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2.2.3. Study Objectives 
 
The primary objective of the trial is to compare two-year survival rates of the two groups of 
patients starting from the time of randomization to the PBSC or marrow arm.  Secondary 
objectives include comparisons of survival rates after transplantation and incidences of 
neutrophil and platelet recovery, acute GVHD, chronic GVHD, time off all immunosuppressive 
therapy, relapse, infections, adverse events, immune reconstitution and quality of life.  
Additional secondary objectives are to compare donor donation experiences and recovery and 
donor quality of life.  In addition, the study will analyze variables affecting the composition of 
the graft, and assess the relationships between cell subsets in marrow or PBSC grafts and 
transplant outcomes. 
 
2.3. Patient Eligibility for Randomization 
 
2.3.1. Patient Inclusion Criteria 
 
Diagnoses to be included: 
1. Acute Myelogenous Leukemia at the following stages: 
• First Remission 
• Second Remission 
• Third or Subsequent Remission 
• Not in Remission 
Complete remission will be defined as all of the following according to the revised 
recommendations of the international working group:52 
• A bone marrow aspirate containing spicules with < 5% blasts with a count of at 
least 200 nucleated cells and no Auer rods seen.  If spicules are absent in the 
aspirate, a bone marrow biopsy should confirm that < 5% blasts are present. 
• No evidence of a persistently abnormal leukemic population by flow cytometry. 
• ANC > 1,000 µL and platelet count > 100,000 µL. 
• No extramedullary leukemia. 
• No blasts in peripheral blood. 
2. Acute Lymphoblastic Leukemia at the following stages: 
• First Remission 
• Second Remission 
• Third or Subsequent Remission 
• Not in Remission 
Complete remission will be defined as all of the following according to the revised 
recommendations of the international working group:52 
• A bone marrow aspirate containing spicules with < 5% blasts with a count of at 
least 200 nucleated cells and no Auer rods seen.  If spicules are absent in the 
aspirate, a bone marrow biopsy should confirm that < 5% blasts are present. 
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• No evidence of a persistently abnormal leukemic population by flow cytometry. 
• ANC > 1,000 µL and platelet count > 100,000 µL. 
• No extramedullary leukemia. 
• No blasts in peripheral blood. 
3. Chronic Myelogenous Leukemia at the following stages: 
• Chronic Phase: 
o Stable, not hematologic remission: blasts present in marrow and/or PB, but 
disease does not qualify as accelerated or blast phase 
o Hematological remission: no blast cells or precursor cells in the blood or marrow 
o Partial cytogenetic remission: Ph+ metaphases >0% but < 35% 
o Complete cytogenetic remission: absence of Ph+ metaphases 
• Accelerated Phase - any one of the following symptoms: 
o WBC difficult to control (> 50 x 109/L despite therapy) 
o Rapid doubling of WBC (< 5 days) 
o ≥ 10% blasts in blood or marrow 
o ≥ 20% blasts and/or promyelocytes in blood or marrow 
o ≥ 20% basophils and/or eosinophils in blood 
o Anemia or thrombocytopenia unresponsive to standard treatment 
o Persistent thrombocytosis (> 1000 x 109/L) 
o Cytogenetic abnormalities in addition to Ph+ 
o Increasing splenomegaly 
o Marrow fibrosis 
• Blast Phase: 
o More than 30% blasts and/or promyelocytes in blood or bone marrow 
o More than 20% blasts 
4. Myelodysplastic syndromes at the following stages: 
• Refractory anemia 
• Refractory anemia with ringed sideroblasts 
• Refractory cytopenia with multilineage dysplasia 
• Refractory cytopenia with multilineage dysplasia and ringed sideroblasts 
• Refractory anemia with excess blasts-1 (5-10% blasts) 
• Refractory anemia with excess blasts-2 (10-20% blasts) 
• Myelodysplastic syndrome, unclassified 
• MDS associated with isolated del (5q) 
5. Myeloproliferative diseases: 
• Chronic Myelomonocytic Leukemia 
• Agnogenic Myeloid Metaplasia with Myelofibrosis (Idiopathic Myelofibrosis) 
• Juvenile Myelomonocytic Leukemia 
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6. Patients with therapy-related AML or MDS whose prior malignancy has been in 
remission for at least 12 months.  If the remission is less than 12 months, Medical 
Monitor or Protocol Chair approval is required. 
7. Signed informed consent 
8. Age range: 0.00-66.00 years 
9. Transplant Center location in the United States (U.S.) or Canada 
 
2.3.2. Patient Exclusion Criteria 
 
1. Patients with prior allogeneic or autologous transplants using any hematopoietic stem cell 
source will be excluded from this trial.  Patients with secondary malignancies who have 
had a prior autologous transplant will be eligible.  The prior autologous transplant must 
have been performed for the primary malignancy (such as lymphoma) and must have 
occurred 12 or more months prior to enrollment. 
2. Diseases to be excluded are: lymphoma (11% of 2001 NMDP transplants), other 
malignant disorders (6%), and non-malignant disorders (9%).  The diseases are excluded 
because they are rarely transplanted or are most often transplanted using reduced 
intensity regimens. 
 
2.4. Additional Patient Exclusion Criteria for Transplant Conditioning 
 
1. HIV infection 
2. Pregnancy (positive serum β-HCG) or breastfeeding  
3. Creatinine or bilirubin or ALT or AST greater than two times the upper limit of normal 
for the laboratory, whatever the etiology of the abnormal test except for isolated 
hyperbilirubinemia attributed to Gilbert’s Syndrome 
4. Pulmonary disease with FVC, FEV1 or DLCO parameters < 45% predicted (corrected for 
hemoglobin) or O2 saturation < 92% of room air 
5. Cardiac insufficiency or coronary artery disease requiring treatment 
6. Active infection requiring systemic antibiotic therapy with antibacterial, antifungal or 
antiviral agents 
7. Concomitant enrollment on Phase I study 
8. Patients with prior malignancies except resected basal cell carcinoma or treated 
carcinoma in-situ.  Cancer treated with curative intent < 5 years previously will not be 
allowed unless approved by the Medical Monitor or Protocol Chair.  Cancer treated with 
curative intent > 5 years previously will be allowed. 
 
2.5. Donor Selection Criteria 
 
The evaluation of donors shall be in accordance with existing NMDP Standards Policies and 
Procedures.  All donors shall meet the health criteria for both marrow and PBSC donation. 
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2.5.1. Donor Inclusion 
 
1. Matched for HLA-A, B and DRB1 antigens 
• One antigen mismatch at HLA-A, B or DRB1 is acceptable with or without mismatch 
at HLA-C 
• Typing is by DNA techniques: intermediate resolution for A, B and C, and high 
resolution for DRB1.  HLA-C typing is mandatory but will not count in the match. 
2. Signed informed consent.  Donor must consent to both bone marrow harvest and G-CSF 
administration with apheresis.  Donor must provide written informed consent to 
randomization for either marrow or PBSC collection. 
3. Donor must have adequate peripheral venous access for leukapheresis or must agree to 
placement of a central catheter. 
4. Donor center affiliation with NMDP. 
5. Donor must be 18 years of age or older. 
6. General donor inclusion criteria specified in the Donor Companion Manual. 
 
2.5.2. Donor Exclusion 
 
1. Females who are pregnant (positive serum β-HCG) or uninterruptible breastfeeding 
2. Known allergy to G-CSF or to E. Coli-derived recombinant protein products 
3. History of autoimmune disorders 
4. History of deep vein thrombosis or venous thromboembolism 
5. History of iritis or episcleritis 
6. History of serious adverse reaction to anesthesia 
7. Thrombocytopenia (platelets < 150,000 per mcL) at baseline evaluation 
8. Current treatment with lithium 
9. Presence of sickle hemoglobin as demonstrated by appropriate testing such as 
hemoglobin electrophoresis 
10. Donors receiving experimental therapy or investigational agents 
 
2.6. Treatment Plan 
 
2.6.1. Conditioning Regimens 
 
Four broad groups of conditioning regimens will be included in the protocol: 
1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at 
least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI. 
2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg 
busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a 
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targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL 
at steady state and at least 120 mg/kg cyclophosphamide. 
3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of 
least 120 mg per m2 and a melphalan dose of at least 140 mg per m2. 
4. Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a 
fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 
busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG.  
Institutional standards should be followed for targeting plasma levels. 
 
2.6.1.1. Additional drugs 
 
Additional drugs including anti-T cell antibodies may be added at the transplant center’s 
discretion with the exception of Alemtuzumab (Campath-1H) because of the impaired immune 
reconstitution and increased mortality observed with Alemtuzumab in combination with post-
grafting cyclosporine and methotrexate that will be employed in this study (53). 
 
2.6.1.2. Choice of conditioning regimen 
 
Transplant centers may use different regimens for patients with different diseases as required by 
institutional protocol.  However, the transplant center must declare before randomization what 
conditioning regimen and GVHD prophylaxis regimens will be used for each patient.  The 
specified regimens will be used for the patient whether randomized to receive PBSC or marrow, 
unless there is approval from the Protocol Chair to alter the regimen. 
 
2.6.1.3. Order of administration of cyclophosphamide and TBI 
 
The order of administration of cyclophosphamide and TBI is at the discretion of the transplant 
center.  Within each institution, all patients should receive the cyclophosphamide and TBI in the 
same order.  If cyclophosphamide is given last, there should be at least a one-day rest period 
before the marrow or PBSC infusion. 
 
2.6.1.4. TBI administration 
 
Fractionated TBI will be administered according to the schedules utilized by the participating 
clinical centers.  Radiation sources, dose rates, details of lung shielding, and sites receiving boost 
radiation will also be defined by the institution.  TBI may be delivered from either linear 
accelerator or Cobalt sources.  Lung shielding is preferred but not required during TBI.  For 
institutions using lung shielding, an electron boost to the chest wall should be used, if necessary, 
to achieve a rib dose within the desired therapeutic range. 
 
2.6.1.5. Cyclophosphamide administration 
 
Cyclophosphamide will be administered intravenously.  Mesna is allowed, but not required. 
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2.6.1.6. Cyclophosphamide and busulfan dose adjustments 
 
Cyclophosphamide and busulfan dose adjustments for ideal body weight are recommended, but 
not required. 
 
Ideal Body Weight Formulas: 
 
Patients Over 18 Years 
Males IBW = 50 kg + 2.3 kg/inch over 5 feet 
Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet 
 
Patients 1 to 18 Years of Age 
 
Less than 60 inches 
IBW = (ht2 x 1.65)/1000 where ht = cm, IBW = kg 
 
More than 60 inches 
Males IBW = 39.0 + [2.27 x (ht - 60)] where ht = inches, IBW = kg 
Females IBW = 42.2 + [2.27 x (ht - 60)] where ht = inches, IBW = kg 
 
2.6.1.7. Busulfan 
 
Busulfan may be administered either orally or intravenously.  Busulfan dose may be adjusted 
based on drug clearance estimated before or after starting the conditioning regimen. 
 
2.6.1.8. Fludarabine 
 
Fludarabine will be administered intravenously at the minimum total dose of 120 mg per m2, 
divided into three or more doses administered once daily.  Fludarabine is not recommended for 
patients with severe renal impairment, i.e., a creatinine clearance (CrCl) less than  
30 milliliters/minute/1.73 square meter (mL/min/1.73 m2).  For patients with moderate renal 
impairment (CrCl of 30 to 70 mL/min/1.73 m2), the fludarabine dose should be reduced by 20% 
to 50% (54).  Fludarabine administration should be dosed based on the patient’s actual body 
weight.  It is recommended, though not required, that for patients weighing more than 100% of 
their IBW, fludarabine be dosed based on the adjusted ideal body weight (AIBW). 
 
 Ideal Body Weight Formulas: 
 See Section 2.6.1.6 
 
 Adjusted Ideal Body Weight Formula: 
 AIBW = IBW + [(0.25) x (ABW - IBW)] 
 
2.6.1.9. Melphalan 
 
Melphalan will be administered intravenously at the minimum dose of 140 mg per m2. 
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2.6.1.10. ATG 
 
ATG will be administered at a dose of at least 40 mg/kg equine or 4 mg/kg rabbit.  The Physician 
Desk Reference’s manufacturer’s guidelines should be followed for administration of ATG. 
 
2.6.1.11. Allopurinol 
 
Allopurinol is recommended for patients with high tumor bulk.  A common regimen employs 
allopurinol at the daily dose of 300 mg, beginning at least six hours before the start of 
conditioning and until the day before marrow or PBSC infusion. 
 
2.6.1.12. Intravenous hydration 
 
Intravenous hydration is recommended to prevent tumor lysis syndrome in patients with bulky 
tumor and to prevent hemorrhagic cystitis in patients treated with cyclophosphamide.  Hydration 
should begin at least 12 hours prior to the first dose of chemotherapy and continue for 24 hours 
following the last dose. 
 
2.6.1.13. Testicular irradiation 
 
Testicular irradiation with 400 cGy may be given to male patients with ALL or other acute 
leukemia according to local institutional practice. 
 
2.6.1.14. Central Nervous System prophylaxis 
 
Central Nervous System (CNS) prophylaxis will be given according to institutional practice. 
 
2.6.2. GVHD Prophylaxis Regimen 
 
The choice of GVHD prophylaxis regimen is by institutional preference.  Any regimen or 
protocol may be used, with the exception that Phase I GVHD prophylaxis protocols are not 
allowed.  The regimen and dosing employed must not be dependent on graft source assignment, 
i.e., marrow or PBSC. 
 
The two most commonly used GVHD prophylaxis regimens following unrelated donor 
transplantation are: 
1. Cyclosporine/methotrexate 
2. Tacrolimus/methotrexate 
 
The recommended doses and schedule of administration of cyclosporine, tacrolimus and 
methotrexate are as detailed in Sections 2.6.3 and 2.6.4.  This information is provided only as a 
guideline. 
 
Alternative or additional agents/dosing may be used per institutional preference.  However, the 
use of Phase I agents is prohibited.  
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The transplant center will declare before randomization what GVHD prophylaxis regimen will 
be used for that particular patient.  The declared regimen must be used whether the patient is 
randomized to receive PBSC or marrow.  There is no requirement for the institution to use the 
same regimen for each subsequent patient enrolled. 
 
2.6.3. Cyclosporine or Tacrolimus Treatment Regimen 
 
Either cyclosporine or tacrolimus is administered beginning at least one day before 
transplantation for a minimum of six months.  The initial dose should be based on the ideal body 
weight of the recipient.  Subsequent doses are based on blood levels (see below).  
Determinations of blood levels should be performed at least once weekly for the initial three 
months.  Dose reductions should be made if toxicity is present or whole blood levels are above 
the recommended range, in the absence of toxicity.  Dose reductions for high levels without 
toxicity should be conservative, e.g. 25%, to avoid inadequate immunosuppression.   
 
If there is nausea and vomiting, the drug should be given intravenously.  Patients with severe 
intolerance of cyclosporine may be placed on tacrolimus and vice versa. 
 
2.6.3.1. Taper 
 
Fifty or more days after transplantation, in the absence of GVHD, the dose is slowly tapered over 
a minimum of 20 weeks and discontinued. 
 
2.6.3.2. Cyclosporine 
 
The cyclosporine regimen for GVHD prophylaxis will initially employ an intravenous total daily 
dose of 3 mg/kg/day.  Subsequent cyclosporine doses are adjusted to target whole blood levels 
between 150 and 450 nano (n)g/mL. 
 
Oral formulations of cyclosporine have variable bioavailability (intestinal absorption), and 
Neoral appears to have a higher and more predictable bioavailability than other formulations.  
When a patient is switched from intravenous cyclosporine to Neoral (preferred) or other oral 
formulation, the dose is increased by 2.5-3 fold to adjust for the lower bioavailability of Neoral 
compared to intravenous cyclosporine. 
 
Drugs that may affect cyclosporine levels: 
1. Caspofungin, phenobarbital, phenytoin, rifampin, carbamazepine, rifabutin, St. John’s 
Wort (lowers levels) 
2. Glucocorticoids, fluconazole, voriconazole, ketoconazole, itraconazole, grapefruit juice, 
acetazolamide, amiodarone, amlodipine, amprenavir, bromocriptine, chloramphenicol, 
cimetidine, cisapride, clarithromycin, clotrimazole, danazol, diltiazem, erythromycin, 
ethinyl estradiol, metoclopramide, metronidazole, mibefradil, nefazodone, nelfinavir, 
tacrolimus, nifedipine, omeprazole, quinupristin/dalfopristin, ritonavir, saquinavir, 
theophylline, troleandomycin, verapamil (increases levels) 
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Per the voriconazole package insert, when initiating therapy with voriconazole in patients 
already receiving cyclosporine, it is recommended that the cyclosporine dose be reduced to one-
half of the original dose and followed with frequent monitoring of the cyclosporine blood levels.  
Increased cyclosporine levels have been associated with nephrotoxicity.  When voriconazole is 
discontinued, cyclosporine levels should be frequently monitored and the dose increased as 
necessary (55). 
 
2.6.3.3. Tacrolimus 
 
The tacrolimus regimen for GVHD prophylaxis will initially employ an intravenous total daily 
dose of 0.03 mg/kg/day.  Subsequent tacrolimus doses are adjusted to target whole blood levels 
between 5 and 15 ng/mL.  When a patient is switched from intravenous to oral tacrolimus, the 
dose is increased by 3-4 fold to adjust for the lower bioavailability of oral compared to 
intravenous tacrolimus. 
 
Drugs that may affect tacrolimus levels are: 
1. Caspofungin, phenobarbital, phenytoin, rifampin, carbamazepine, rifabutin, St. John’s 
Wort (lowers levels); 
2. Glucocorticoids, fluconazole, voriconazole, ketoconazole, itraconazole, grapefruit juice, 
amprenavir, bromocriptine, chloramphenicol, cimetidine, cisapride, clarithromycin, 
clotrimazole, danazol, diltiazem, erythromycin, ethinyl estradiol, metoclopramide, 
metronidazole, mibefradil, nefazodone, nelfinavir, nifedipine, omeprazole, 
quinupristin/dalfopristin, ritonavir, saquinavir, theophylline, troleandomycin, verapamil 
(increases levels). 
 
Per the tacrolimus package insert, when initiating therapy with voriconazole in patients already 
receiving tacrolimus, it is recommended that the tacrolimus dose be reduced to one-third of the 
original dose and followed with frequent monitoring of the tacrolimus blood levels.  Increased 
tacrolimus levels have been associated with nephrotoxicity.  When voriconazole is discontinued, 
tacrolimus levels should be carefully monitored and the dose increased as necessary.(55) 
 
2.6.4. Methotrexate Treatment Regimen 
 
The regimen of methotrexate for GVHD prophylaxis will employ intravenous doses of 15 mg per 
m2 on Day 1 post-transplant, and 10 mg per m2 on Days 3, 6, and 11 post-transplant.  The dose of 
methotrexate may be decreased per institutional standard practice to no less than 5 mg per m2 on 
Days 1, 3, 6, and 11 post-transplant.  Third space syndromes with large accumulation of ascites 
or pleural effusions are a contraindication to the use of methotrexate.  Dose reductions should be 
made for renal, hepatic and mucosal toxicity.  Determinations of blood levels are indicated 24-72 
hours after administration in patients with impaired renal function.  Leucovorin rescue should be 
considered in patients with decreased clearance, severe toxicity or fluid accumulation/effusions. 
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Drugs that may increase methotrexate levels are: 
1. Non-steroidal anti inflammatory drugs 
2. Penicillins 
3. Diuretics 
 
2.6.5. PBSC Mobilization and Collection 
 
2.6.5.1. G-CSF Administration to Donors 
 
G-CSF (filgrastim, Amgen) will be administered to the donor at a dose of ~10 mcg/kg/day 
subcutaneously for 5 consecutive days.  Daily dose shall not exceed 1200 mcg/day, and volume 
per injection site shall not exceed 2.0 mL.  G-CSF will be administered at approximately the 
same time each day for the first four days.  The fifth dose should be given at least one hour prior 
to apheresis.  There will be no additional, sixth dose of G-CSF in cases where a second PBSC 
collection is performed on Day 6.  See Donor Companion Manual for G-CSF dose calculation 
and dose modification. 
 
2.6.5.2. PBSC Collection and Evaluation 
 
Apheresis shall begin on Day 5 of G-CSF administration. 
 
Apheresis Devices and Central Catheters - Apheresis shall be accomplished using a continuous-
flow apheresis device.  Bilateral peripheral venous access will be used whenever possible.  
Donors with insufficient peripheral access may undergo placement of a central venous catheter.  
Central catheters should be inserted on the day of collection. 
 
Anticoagulation - A citrate based anticoagulant such as acid citrate dextrose formula A (ACD-
A) should be used unless there is a contraindication or sensitivity to this agent.  Mononuclear cell 
apheresis collections are generally performed using citrate: whole blood ratios of 1:12 to 1:13.  If 
a citrate to whole blood ratio of less than 1:13 is used, then additional ACD-A may be added to 
the component bag, either during apheresis or immediately after the procedure is completed. 
 
CD34 Cell Dose - Typical requested CD34 cell doses are between 5-10 x 106 per kg recipient 
body weight.  Quantitation of the CD34 cell content of the product by the Apheresis Center on 
the day of apheresis is required. 
 
Volume Processed – The volume processed shall be linked to the actual weight of the recipient 
as follows.  For recipients weighing less than or equal to 35 kg, a single 12-liter apheresis shall 
be performed.  For recipients weighing greater than 35 kg, the volume processed shall be 15 to 
24 liters.   
 
Single larger volume procedures are encouraged whenever possible.  In a prospective 
randomized study, a single 25-liter PBSC collection yielded the same number of CD34 cells as 
two consecutive daily 15-liter procedures, and was associated with a marked reduction in 
inconvenience and discomfort for the donor (56).  The following table provides a guide to 
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volume processed by weight of recipient.  Volume processed refers to true whole blood volume, 
not including anticoagulant (see Table 2.6.5). 
 
 
Table 2.6.5:  Blood Volume Processed in Relation to Recipient Weight 
 
Recipient 
Weight (kg) 
Volume 
Processed (L) Procedure 
≤ 35 12 Single 12-liter apheresis 
36 - 45 15 Single 15-liter apheresis 
46 -55 18 Single 18-liter apheresis or two 12-liter procedures 
56 - 65 22 Single 22-liter apheresis or two 12-liter procedures 
> 65 24 Single 24-liter apheresis or two 12-liter procedures 
 
 
Alternatively, centers may use an immediate pre-procedure blood CD34 cell count to determine 
the blood volume to be processed.  If such calculations are used, the transplant center requested 
CD34 cell dose should be targeted as the minimum dose.  If the requested dose is collected in the 
first apheresis procedure, a second collection will not be performed. 
 
Prevention of Citrate Toxicity - Apheresis procedures in which greater than 12 liters of blood 
are processed should incorporate a method to prevent severe citrate toxicity.  Such methods 
could include either (1) use of continuous infusion or intermittent bolus heparin administration, 
allowing use of lower citrate infusion rates, or (2) use of continuous infusion or bolus calcium 
salts (calcium chloride or calcium gluconate) (57).  Please refer to the Donor Companion Manual 
for suggested algorithms for heparin or calcium salt administration. 
 
Heparin should not be used in procedures requiring central venous catheter placement. 
 
Product Volume and Sampling - The product should have a minimal volume of 200 mL.  A 1.0 
mL sample for CBC should be obtained by the Apheresis Center from the long tubing tail 
attached to the bag. 
 
Processing, Storage and Shipment - If more than one PBSC procedure is performed, the first 
collection will be stored at 2-8o C overnight.  No processing or freezing of the PBSC product 
shall be done by the apheresis facility.  The transportation of PBSC components shall be in 
accordance with NMDP Standards.  Products will be shipped in an NMDP-approved container 
that is charged with cold packs or similar material to provide an initial ambient temperature of  
2-8 o C.  Dry ice shall not be used. 
 
PBSC components will be infused within 12 hours of arrival at the Transplant Center. 
 
Sample Collection - Each collection will be separately evaluated by the central reference 
laboratory for cellular composition in keeping with Appendix C and the BMT CTN Manual of 
Procedures (MOP) for graft characterization. 
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Records - Records of donation shall be maintained in accordance with NMDP Standards and 
shall include: 
1. Evaluation of donor health 
2. Dose of G-CSF administered per day 
3. Volume and type of anticoagulant administered 
4. Additional anticoagulant added to component 
5. Volume of blood processed, total cell and differential count in product 
6. Pre and post apheresis donor CBCs 
7. Details of storage and shipping 
 
2.6.6. Marrow Collection 
 
Donors randomized to the marrow arm will have marrow harvested on Day 0. 
 
Anesthesia - Either general or regional (epidural, spinal) anesthesia may be used. 
 
Anticoagulation of the Marrow Product - Reagents used, including salt solutions and 
anticoagulants, shall be approved by FDA or similar regulatory agency for human infusion.  
Recommended anticoagulation techniques are 10 U/mL of preservative-free heparin or 10% 
(volume/volume) ACD-A or a combination of both.  Anticoagulants to be used shall be agreed 
upon by the donor and transplant centers before initiation of the transplant conditioning regimen. 
 
Volume and Cell Dose - Requested marrow cell dose will be 4 x 108 nucleated cells per kg of 
recipient body weight.  This dose will be unattainable for many recipients because of donor 
and/or recipient factors, e.g., body size mismatches.  The volume of marrow shall not exceed  
20 mL per kg donor weight.  The estimated cell dose and a planned donor marrow volume shall 
be agreed upon by the donor and transplant centers before initiation of the transplant 
conditioning regimen. 
 
Blood Product Support - Donors shall store blood for autologous use in accordance with existing 
NMDP Standards. 
 
The transfusion of autologous or homologous blood should be in accordance with appropriate 
medical practice.  Homologous blood, if used, shall be irradiated to 2500 cGy. 
 
Processing of Bone Marrow Products - No processing of bone marrow, other than 
anticoagulation, filtration, packaging, and labeling in preparation for transportation, shall be 
performed by the collection center.  Processing of bone marrow for reduction of volume, plasma, 
red blood cells, or fat, may be performed by the transplant center. 
 
Shipping of Bone Marrow - The transportation of bone marrow shall be in accordance with 
NMDP Standards.  Products will be shipped in an NMDP-approved container that is charged 
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with cold packs or similar material to provide an initial ambient temperature of  
2-8 o C.  Dry ice shall not be used. 
 
The marrow will be infused within 12 hours of arrival at the Transplant Center. 
 
Sample Collection - Each collection will be separately evaluated by the central reference 
laboratory for cellular composition in keeping with Appendix C and the BMT CTN Manual of 
Procedures (MOP) for graft characterization. 
 
Records - Records of donation shall be maintained in accordance with NMDP Standards and 
include: 
1. Evaluation of donor health 
2. Volume and type of anticoagulant added to component 
3. Volume of marrow, total cell and differential count in product 
4. Pre and post marrow harvest donor CBCs 
5. Details of storage and shipping 
 
2.6.7. PBSC or Marrow Infusion 
 
All patients will receive unmodified G-CSF mobilized PBSC or marrow on Day 0 with the 
following exceptions: plasma and red cell depletion are allowed for volume reduction or ABO 
incompatibility.  CD34 cell selection or T cell removal are not allowed.  PBSC or marrow is 
infused via a central venous catheter using standard blood infusion tubing. 
 
There is no minimum cell dose for CD34 cells or nucleated cells in either arm.  Similarly, there 
is no maximum cell dose.  It is recommended that all products are infused entirely, but this is not 
required.  Non-infusion of portion of the products will be documented.  No portion of the donor 
marrow or PBSC should be cryopreserved if the CD34 cell count is < 5 x 106 per kg recipient 
weight. 
 
In the case that there is an unexpected change in the recipient’s condition and the PBSC or 
marrow harvest cannot be cancelled, the transplant center is required to obtain an approval from 
the NMDP prior to cell cryopreservation.  The patient and donor remain on study even if the 
transplant does not occur.   
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2.6.8. No Blinding of Marrow and PBSC Infusions 
 
Rationale for Blinding - There are at least theoretical concerns that knowledge of the type of the 
stem cell product infused may influence the decision-making process of clinicians and nurses at 
the participating transplant centers.  Patient knowledge may have an impact as well.  This can 
introduce bias in the evaluation of transplant outcomes of interest.  This could be avoided by 
stem cell manipulation (ordinarily at the collection center) aimed at making the two products 
indistinguishable upon infusion and asking recipients to agree via the consent form to refrain 
from asking about the product type.  This was seemingly accomplished in at least one single-
center study (58). 
 
Logistical Challenges - There are logistical challenges translating what was successfully carried 
out at a single center into procedures followed by many donor and transplant centers.  More 
importantly, blinding requires manipulation of the graft product and any additional stem cell 
manipulation introduces the potential for cell loss, clerical errors and infusion-related adverse 
events.  The related risks for patients are hard to justify.  Therefore, while acknowledging that 
blinding may be desirable, the decision was made not to pursue blinding in this Phase III study. 
 
2.6.9. PBSC Collection or Marrow Harvesting for Additional Stem Cell Products 
 
In the event of primary or secondary graft failure, additional PBSC collection or marrow 
harvesting from the original donor may be requested by transplant centers following established 
NMDP policies.  The selection of PBSC or marrow for the second transplant is not bound to the 
randomization arm; it is the choice of the transplant center physician, and requires donor consent.  
If the same donor is selected, no less than 21 days should elapse between the two donations.  If 
the donor is unwilling or unavailable for a second PBSC or marrow collection, alternative 
management strategies including transplantation from a second donor must be considered by the 
treating physician at the transplant center. 
 
2.6.10. Supportive Care 
 
All supportive care will be given in keeping with BMT CTN MOP and local institutional 
practice. 
 
2.6.11. Growth Factors 
 
It is recommended that patients not receive post-transplant growth factors before Day 21, except 
in the case of serious infection where hastening neutrophil recovery by 1-3 days may be critical 
for survival.  If a transplant center chooses to give growth factors prior to Day 21 post-transplant, 
they should be given to all patients, regardless of whether receiving bone marrow or peripheral 
blood stem cells.  After Day 21, G-CSF or granulocyte-macrophage colony stimulating factor 
(GM-CSF) should be given for severe neutropenia (ANC < 500/mcL), or as necessary to keep 
ANC > 1000/mcL. 
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2.6.12. Blood Products 
 
Transfusion thresholds for blood product support will be consistent with BMT CTN MOP and 
standard institutional guidelines.  All cellular blood products will be irradiated.  Patients who are 
CMV negative will receive CMV negative or filtered blood products from study entry. 
 
2.6.13. Prophylaxis against Infections 
 
All patients will receive prophylaxis against bacterial, fungal and viral infections during the 
peritransplant period according to the BMT CTN MOP.  This will include: 
1. Anti-bacterial prophylaxis: In keeping with the BMT CTN MOP and local institutional 
standards for allogeneic transplants.  Prophylactic antibacterial antibiotics should be used 
for patients during the neutropenic (ANC < 500/mcL) period. 
2. Pneumocystis carinii: Prophylaxis will start at the time of engraftment or on Day 30 post-
transplant according to institutional preference.  Prophylaxis should be continued until 
immunosuppressive drugs are discontinued. 
3. Antifungal therapy: In keeping with the BMT CTN MOP and local institutional standards 
for allogeneic transplants. 
4. HSV/VZV: Prophylaxis will begin with conditioning therapy and continue up to one year 
post-allograft as directed by standard institutional practice. 
5. CMV: Monitoring and preemptive treatment strategy will be in accordance with the BMT 
CTN MOP and local institutional practice. 
 
2.6.14. Intravenous Immune Globulin (IVIG) 
 
IVIG administration will be left to local institutional standard practice. 
 
2.6.15. Failure to Engraft 
 
If the ANC has not reached 500/mcL by Day 21, G-CSF, GM-CSF or other cytokines may be 
utilized. If the ANC is < 100/mcL on Day 28 post-transplant, the patient should be considered for 
a second infusion of stem cells from the original donor or retransplantation from a different 
donor using appropriate Transplant Center protocols. 
 
2.6.16. Post-transplant Donor Leukocyte Infusions (DLI) 
 
DLI may be given to patients for a recurrent or a second malignancy according to institutional 
practice and in accordance with the NMDP policy, if the donor is available and provides consent.  
The use of DLI will be recorded and analyzed as a secondary endpoint. 
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2.6.17. Risks and Toxicities 
 
Recipients of marrow or PBSC transplants incur risks from pre-transplant conditioning, the graft 
itself, and post-transplant therapies.  All risks must be weighed against the risk of the malignancy 
for which the transplant is prescribed.  Major risks following transplantation include: 
1. Damage of any major organ may occur as a result of cumulative toxicity from anti-
neoplastic therapy, the conditioning regimen, drug toxicity, infection, or GVHD. 
2. Graft failure can result from genetic disparity between donor and recipient, insufficient 
immunosuppression of the recipient or poor cell dose. 
3. GVHD can be either acute or chronic; both types predispose to infection. 
4. Life-threatening infections may develop in patients with and without GVHD. These can 
be of a bacterial, viral, parasitic, or fungal nature. 
5. Relapse of the underlying disease may occur, especially in patients with far advanced 
disease status at time of transplant. 
6. All of these toxicities may be severe enough to result in death. 
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CHAPTER 3 
 
 
3. STUDY ENDPOINTS 
 
3.1. Primary Endpoint 
 
The primary endpoint is two-year survival from the time of randomization after two years of 
follow-up.  The event analyzed is death from any cause.  Patients alive at the time of last 
observation will be censored. 
 
3.2. Secondary Endpoints 
 
3.2.1. Two-Year Post-transplant Survival  
 
The endpoint is two-year survival from time of transplant.  Only patients who receive their 
transplant are included.  The event analyzed is death from any cause.  Patients alive at the time of 
last observation will be censored. 
 
3.2.2. Neutrophil Engraftment > 500/mcL 
 
This is defined as achieving ANC > 500/mcL for three consecutive measurements on different 
days.  The first of the three days will be designated the day of neutrophil engraftment.  This 
endpoint will be evaluated through 100 days. 
 
3.2.3. Primary Graft Failure 
 
This is defined by lack of neutrophil engraftment by 100 days in patients surviving a minimum 
of 14 days. 
 
3.2.4. Secondary Graft Failure 
 
This is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil 
counts < 500/mcL unresponsive to growth factor therapy. 
 
3.2.5. Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent 
 
This is defined as achieving platelet counts > 20,000 and 50,000/mcL for consecutive 
measurements over seven days without requiring platelet transfusions.  The first of the seven 
days will be designated the day of platelet engraftment.  This endpoint will be evaluated through 
100 days. 
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3.2.6. Acute GVHD of Grades II-IV and III-IV 
 
Acute GVHD is graded according to the BMT CTN MOP.  The first day of acute GVHD onset at 
a certain grade will be used to calculate cumulative incidence curves for that GVHD grade (e.g., 
if the onset of grade I acute GVHD is on Day 19 post-transplant and onset of grade III is on Day 
70 post-transplant, time to grade III is Day 70).  This endpoint will be evaluated through 100 
days. 
 
3.2.7. Chronic GVHD 
 
Chronic GVHD is scored according to the BMT CTN MOP.  The first day of chronic GVHD 
onset will be used to calculate cumulative incidence curves. 
 
3.2.8. Current Immunosuppressive (IS) Free Survival 
 
This function is an estimate of the chance that a patient is alive and not receiving 
immunosuppressive therapy at a given point in time for any reason.  This outcome measure takes 
into account subsequent immunosuppressive therapy that may occur following discontinuation of 
initial immunosuppressive therapy.  Patients will be censored for this endpoint at the time of 
relapse.  A similar approach has been used in analyzing the role of DLI following allogeneic 
transplants for CML where relapse is expected to be frequent but subsequent disease control is 
also expected after treatment of relapse with DLI (59).  A multi-state model will estimate this 
with inputs being the patient’s immunosuppressive therapy and survival status at each potential 
examination time.  Immunosuppressive drugs include cyclosporine, tacrolimus, prednisone, 
methotrexate, azathioprine, mycophenolate mofetil, sirolimus, clofazimine, PUVA, anti-
thymocyte globulin, OKT3, daclizumab, basilixumab, visilizumab, infliximab and alemtuzumab. 
 
3.2.9. Relapse of the Original Malignancy 
 
Relapse of Malignancy - Testing for recurrent malignancy in the blood, marrow or other sites 
will be used to assess relapse after transplantation.  For the purpose of this study, relapse is 
defined by either morphological or cytogenetic evidence of AML, ALL, CML, MDS, CMML, 
Myelofibrosis or JMML consistent with pre-transplant features.   
 
Minimal Residual Disease - Minimal residual disease is defined by the sole evidence of 
malignant cells by flow cytometry, or fluorescent in situ hybridization (FISH), or Southern blot, 
or Western blot, or polymerase chain reaction (PCR), or other techniques, in absence of 
morphological or cytogenetic evidence of disease in blood or marrow.  Since the frequency of 
testing for minimal residual disease is highly variable among centers, and the sensitivity is highly 
variable among laboratory techniques, evidence of minimal residual disease will not be sufficient 
to meet the definition of relapse in the context of this study, even if transplant physicians will 
utilize the information to alter therapy.  Data on tapering immunosuppression, infusing donor T 
cells, administering chemotherapy or biological agents to attempt reducing the tumor load will be 
captured in the case report forms. 
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Acute Leukemia - Relapse will be diagnosed when there is: 
1. The reappearance of leukemia blast cells in the peripheral blood, or 
2. > 5% blasts in the marrow, not attributable to another cause (e.g., bone marrow 
regeneration), or 
3. The appearance of new dysplastic changes within the bone marrow, or 
4. No circulating blasts, but the marrow contains 5-20% blasts, a repeat bone marrow ≥ one 
week later with > 5% blasts is necessary to meet the criteria for relapse, or 
5. The development of extramedullary leukemia or leukemic cells in the cerebral spinal 
fluid. 
 
Chronic Myelogenous Leukemia (CML) -  
 
Hematologic relapse will be diagnosed when: 
1. Immature hematopoietic cells are persistently documented in the peripheral blood, 
or  
2. There is myeloid hyperplasia in the bone marrow in the presence of cytogenetics 
relapse. 
 
Cytogenetic relapse will be diagnosed when:  
1. 50% of the metaphases exhibit the characteristic 9;22 translocation with at least 
ten metaphases analyzed, or 
2. At least one metaphase exhibits the 9;22 translocation on each of two separate 
consecutive examinations at least one month apart, regardless of number of 
metaphases analyzed. 
Myelodysplastic (MDS) and Myeloproliferative Syndromes (include CMML, AMM or 
Idiopathic Myelofibrosis, and JMML) - Relapse will be diagnosed when there is: 
1. Reappearance of pre-transplant morphologic abnormalities, detected in two 
consecutive bone marrow specimens taken at least one month apart, or 
2. Satisfying above criteria for evolution into acute leukemia, or   
3. Reappearance of pre-transplant cytogenetic abnormalities in at least 50% of 
metaphases with at least ten methaphases examined, or 
4. Reappearance of pre-transplant cytogenetic abnormality in at least one metaphase 
on each of two separate consecutive examinations at least one month apart, 
regardless of the number of metaphases analyzed. 
Relapse will be defined to occur in the absence of the evidence above if specific therapy, 
such as infusion of donor lymphocytes, use of interferon, or second transplant, is initiated 
for relapse reversal. 
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3.2.10. Donor Lymphocyte Infusion (DLI) 
 
The indication for DLI will be collected, i.e., treatment of relapse of the original malignancy, 
treatment of a new malignancy, boost for immune reconstitution, reversal of graft failure, or 
others.  Pretreatment of the recipient with chemotherapy or irradiation will be recorded.  
Pretreatment of the donor with G-CSF will be recorded. 
 
3.2.11. Infections 
 
Microbiologically documented infections will be reported by site of disease, date of onset, 
severity and resolution, if any.  For definitions, see Chapter 6 and the BMT CTN MOP. 
 
3.2.12. Immune Reconstitution 
 
This will be measured in all patients by: 
1. The rate of peripheral blood repopulation by CD3, CD4, CD8 and γδ T cells, NK cells, 
DC1, DC2, monocytes and B cells. 
2. The rate of blood repopulation by EBV or CMV-specific T cells measured by tetramer 
staining, and response to CMV, tetanus and aspergillus antigens ex vivo. 
3. The rate of blood repopulation with recent thymus emigrants measured by T cell receptor 
excision circle-positive T cells. 
4. The serum levels of immunoglobulin G, A, and M and plasma levels of IL-2 and IL-7. 
5. Hepatitis B, Tetanus, Diphtheria and Pneumococcus antibody titers in response to 
immunization. 
 
3.2.13. Patient and Donor Quality of Life 
 
Details about these endpoints are given in Chapters 7 and 8. 
 
3.2.14. Three-year Survival 
 
The endpoint is three-year survival.  Two separate analyses will be conducted, one from time of 
randomization and one from time of transplant. 
 
3.2.15. Donor Recovery to Baseline Toxicity Scores 
 
Appropriate statistical methods to detect trends over the available spectrum of donor follow-up 
times will be employed for baseline toxicity recovery to baseline endpoints.  
 
3.2.16. Donor Recovery to Baseline CBC and WBC Differential Values 
 
Appropriate statistical methods to detect trends over the available spectrum of donor follow-up 
time will be employed for baseline CBC recovery to baseline endpoints. 
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CHAPTER 4 
 
 
4. PATIENT AND DONOR REGISTRATION, ENROLLMENT AND EVALUATION 
 
4.1. Donor Search Initiation 
 
Transplant centers will initiate the donor search by submitting patient demographics, HLA, and 
disease information to the NMDP coordinating center, using standard NMDP forms and 
additional data entry mechanisms developed for this trial.  It is anticipated that 50-90% of the 
patients will have suitable donors identified as defined by HLA type, transplant center donor 
matching preferences, patient age, disease risk, and financial coverage (see step (1) in Figure 
4.1).  It is anticipated that the duration of the search will vary between two months and more than 
one year with a median time of approximately four months. 
 
Figure 4.1 below highlights the event flow for recipients and donors in the trial.  The time scale 
is arbitrary beginning at the top and flowing downward.  Critical steps described in this Section 
are numbered (1) through (10). 
 
 
Figure 4.1 – Study Treatment 
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4.2. Approaching Patients About the Study 
 
Typically, transplant physicians first interact with the patient in a consultation session either 
before or, more likely, after initiation of the donor search, and in rare cases after a suitable donor 
has been identified.  During the initial consultation session, physicians explain the risks and 
benefits of transplant approaches and alternative therapies.  They also explain transplant 
modalities including the potential sources of hematopoietic cells for transplantation.  In such a 
setting, it will be appropriate for transplant physicians to approach eligible patients about their 
potential interest in the randomized trial of PBSC versus marrow transplantation.  Since most 
patients are affected by serious, rapidly progressing diseases and must proceed to transplantation 
as soon as possible, approaching patients for study participation at this stage will avoid ‘last 
minute’ pressure to obtain patient informed consent, and allow the required donor and patient 
procedures to be scheduled as soon as a suitable donor is identified. 
 
4.3. Screening for Patient Eligibility 
 
Transplant center physicians will evaluate the patient eligibility for randomization onto this study 
(Section 2.3).  For patients who cannot be seen at the transplant center, data to satisfy eligibility 
criteria will be obtained through direct communication with the patient and the patient's 
physician.  Patients that are not eligible will proceed off study and no further follow-up will be 
obtained. 
 
4.4. Patient Consent to Randomization 
 
Eligible patients who would like to participate in the trial will sign the appropriate Institutional 
Review Board (IRB) approved form, providing evidence of informed consent to proceed to 
randomization to PBSC or marrow, contingent upon finding a suitable donor willing to 
participate in the trial (see step (2) in Figure 4.1).  Patients will be informed that participation is 
dependent upon donor willingness to be randomized and upon the patient meeting specified 
eligibility criteria immediately prior to start of conditioning.  Alternate approaches in the event 
that either of these criteria is not met will be explained.  Patients who cannot travel to the 
transplant center because of medical contraindications or other reasons will be counseled by 
phone and will be allowed to mail the signed consent form.   
 
4.5. Patient Refusal 
 
Patients who decline randomization on this study will proceed towards transplant off study.   
 
4.6. Donor Selection and Work-Up 
 
As suitably matched donors are identified, the transplant center is notified. The transplant 
physician selects the best donor for the patient and requests donor ‘work-up’. Donor ‘work-up’ 
consists of a physical evaluation and an information session (see step (3) in Figure 4.1).  
Selection of the best donor occurs before the donor is approached for participation in this study. 
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4.7. Donor Deferral 
 
If a candidate donor is found unsuitable to donate, an alternative donor will be sought. 
 
4.8. Donor Consent 
 
During the donor information session, the donor center physician explains the cell harvest 
procedures to the candidate donor.  Donors for patients who have consented to this study will be 
asked to participate in the study at this time (see step (4) in Figure 4.1).  Donors will express 
their consent to participate by signing an IRB-approved consent form.  Documentation of donor 
consent, as well as documentation of donor eligibility, will be recorded on the Donor Form in 
AdvantageEDC by NMDP staff. 
 
4.9. Donor Refusal 
 
If a donor refuses to participate in the study, the patient will be off study.  The donor will be 
asked to donate either marrow or PBSC, according to transplant physician preference and 
standard NMDP policies.  
 
4.10. Transplant Protocol Registration 
 
Before randomization occurs, the transplant center must state through AdvantageEDC which 
conditioning regimen and GVHD prophylaxis regimen will be used (see step (5) in Figure 4.1).  
Such a registration step will avoid potential biases that preferential association of a certain 
regimen with one treatment arm could confer to the study.  At this stage, the transplant center 
will also verify that the patient is still a candidate for transplantation, is eligible for the trial and 
has consented to participate in the trial.  This data will be entered on the Enrollment Form in 
AdvantageEDC. 
 
4.11. Randomization 
 
Once both patient and donor are deemed eligible and have given written informed consent, and 
the transplant center has confirmed patient eligibility and registered the patient’s conditioning 
and GVHD prophylaxis regimens, randomization occurs (see step (6) in Figure 4.1). 
 
4.12. Treatment Scheduling 
 
Once the randomization arm is known, a transplant calendar is negotiated between the search-
coordinating unit, donor center and transplant center, and the transplant date is scheduled (see 
step (7) in Figure 4.1).  It is anticipated that 2-3 weeks will elapse between the randomization 
and the day of cell harvest and transplant.  This period is necessary to schedule the marrow or 
PBSC harvest.  During this period, donors may donate and store up to 3 autologous red cell units, 
if randomized to marrow, or receive G-CSF injections, if randomized to PBSC.  During this 
period, transplant center physicians will complete the patient evaluation. 
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4.13. Patient Evaluation 
 
The patient pre-transplant evaluation will be completed within four weeks of initiation of 
conditioning (see steps (8) and (9) in Figure 4.1).  This step is necessary because patient organ 
function, infection status and status of malignancy may vary over time.  This evaluation will 
protect patients with a new contraindication to transplant from initiating transplant therapy at an 
unsafe time.  Results of the pre-transplant evaluations as outlined in Section 4.15.4.1 will be 
entered on the Baseline Form in AdvantageEDC. 
 
4.14. Patient Deferral 
 
Patients who meet exclusion criteria will be deferred.  One option is remaining on study and 
rescheduling the transplant when eligibility criteria are again met, for example after clearance of 
a serious infection.  Another option is proceeding to transplant or other treatment off study, if 
that is the best treatment option determined by the transplant physician for the patient.  Patients 
deferred will continue to be followed for the primary endpoint. 
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4.15. Study Monitoring 
 
A visit schedule based on transplant date is displayed for printing in AdvantageEDC and is 
referred to as ‘Follow-up Schedule.’ 
 
Table 4.15:  Follow-Up Schedule 
 
Study Visit Target Day Post-Transplant 
1 week 7 ± 2 days 
2 week 14 ± 2 days 
3 week 21 ± 2 days 
4 week 28 ± 2 days 
5 week 35 ± 2 days 
6 week 42 ± 2 days 
7 week 49 ± 2 days 
8 week 56 ± 2 days 
60 days 60 ± 2 days 
9 week 63 ± 2 days 
10 week 70 ± 2 days 
11 week 77 ± 2 days 
12 week 84 ± 2 days 
13 week 91 ± 2 days 
14 week 98 ± 2 days 
100 day 100± 2 days 
4 month 120 ± 28 days 
6 month 180 ± 28 days 
7 month 210 ± 28 days 
9 month 270 ± 28  days 
11 month 330 ± 28 days 
12 month 365 ± 28 days 
24 month 730 ± 28 days 
36 month 1095 ± 28 days 
 
 
4.15.1. Case Report Forms 
 
A description of the forms, the procedures required for forms completion and timeliness of 
submission can be found in the Data Management Handbook and User’s Guide.  Forms that are 
not received within the specified time are considered delinquent.  Transplant Centers can view 
submitted, past due, and expected forms via AdvantageEDC.  A missing form will continue to be 
requested either until the form is reported, or until an exception is granted. 
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4.15.2. Reporting Patient Deaths 
 
Recipient death while at the transplant center must be reported to the BMT CTN Data 
Coordinating Center (DCC) within 24 hours of the event.  Death after the patient has left the 
transplant center must be reported within 24 hours of the event notification but no more than 30 
days after the event.  If the cause of death is unknown, it need not be recorded at the time of 
initial reporting.  However, once the cause of death is determined, the form must be updated. 
 
4.15.3. Reporting Serious Adverse Events 
 
4.15.3.1. Patient SAEs 
 
Unexpected, grade 3-5 adverse events (AE) will be reported through an expedited AE reporting 
system.  Unexpected, grade 4-5 AEs must be reported within 24 hours of knowledge of the 
event.  Unexpected, grade 3 AEs must be reported within three business days of knowledge of 
the event.  All grade 3-5 adverse reactions to vaccines should be reported within three working 
days.  Expected AEs will be reported using NCI’s Common Terminology Criteria for Adverse 
Events (CTCAE), Version 3.0 at regular intervals as defined on the Form Submission Schedule. 
 
4.15.3.2. Donor SAEs 
 
Marrow Donors - Reporting of SAEs following marrow donation will be consistent with 
standard BMT CTN procedures.  Serious and unexpected adverse events should be reported 
within three working days, and will include unexpected or life-threatening complications of 
anesthesia, and severe pain, debility, or incapacitation related to mechanical injury during 
marrow harvest.  Other SAEs, including prolonged hospitalization or hospital readmission, will 
be tracked, staged according to CTCAE, and reported on appropriate systems. 
 
PBSC Donors - Reporting of SAEs following G-CSF administration and apheresis donation will 
be consistent with NMDP policies and procedures.  Serious and unexpected adverse events 
should be reported within three working days, and will include complications of central line 
placement, and severe or life-threatening reactions to G-CSF administration or apheresis.  The 
Data and Safety Monitoring Board will receive summary reports of all adverse donor 
experiences on at least an annual basis. 
 
4.15.4. Patient Assessments 
 
Table 4.15.4 summarizes patient clinical assessments over the course of the study. 
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Table 4.15.4:  Summary of Patient Clinical Assessments 
 
Days Post-Transplant Study Assessments/ 
Testing Baseline 7 14 21 28 35 42 49 56 63 70 77 84 91 98 180 210 270 330 365 730 1095 1825 
History, physical exam, 
weight, height, and 
Karnofsky/Lansky 
performance status 
X X X X X X X X X X X X X X X X    X X X  
CBC1, differential, platelet 
count, and blood 
chemistries2 
X X X X X X X X X X X X X   X    X X X  
Infectious disease titers3 X                       
EKG X                       
DLCO, FEV1 and FVC X                       
Bone marrow aspirate for 
pathology and cytogenetics X            X       X X X  
Bone marrow biopsy for 
pathology             X       X X X  
Patient anti-donor 
lymphocyte cross match (in 
mismatched transplants 
only) 
X                       
Chest X-ray X                       
ß-HCG serum pregnancy 
test (females only) X                       
GVHD and other morbidity 
assessments4  X X X X X X X X X X X X X X X    X X X  
5 mL sample from allograft 
for graft characterization X                       
5 mL heparinized blood for 
HLA typing X                       
Blood samples for immune 
reconstitution assays5     0        0   0    0 0   
Plasma samples for IL-7 
and IL-2 levels             0   0    0 0   
dT vaccination6                X   X     
PCV7 vaccination6                 X X      
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Days Post-Transplant Study Assessments/ 
Testing Baseline 7 14 21 28 35 42 49 56 63 70 77 84 91 98 180 210 270 330 365 730 1095 1825 
PPV23 vaccination6                   X     
Hepatitis B vaccination6                X X  X     
Serum sample for 
immunoglobulin and 
antibody titers7, 8 
0               0   0 0 0   
Blood sample for natural 
killer cell receptors 
acquisition ancillary study 
0            0   0    0    
Peripheral blood T-cell 
chimerism9 X    X        X       X X   
Patient quality of life 
interviews 0               0    0 0  0
10 
 
1  CBC performed three times weekly from Day 0 until ANC >500 mcL for three days after nadir.  CBC performed twice weekly until Day 28. CBC performed weekly 
after Day 28 until 12 weeks post-transplant. 
2  Blood chemistries include: creatinine, bilirubin, alkaline phosphatase, AST, and ALT.  Blood chemistries performed twice weekly until Day 28. Blood chemistries 
performed weekly after Day 28 until 12 weeks post-transplant. 
3  Infectious disease titers include: CMV,  Hepatitis panel (HepB SAb, HepB SAg, HepB Core Ab, HepC Ab),  herpes simplex virus, varicella zoster virus, syphilis, HIV 
and HTLV ½ antibody. 
4  GVHD and other morbidity assessments performed weekly until Day 100 post-transplant. 
5  Immune reconstitution assays include: FACS analysis, tetramer assay, TREC analysis,  and T-cell responses to tetanus, CMV, and Aspergillus antigens, and CBC with 
differential. 
6  Vaccinations should be given ± 1 week of the scheduled date. 
7  Sample for antibody titers should be drawn just before vaccination.  Includes dT antibody titer, S. pneumoniae antibody and opsynophagoctyic titer, Hepatitis B antibody 
titer, and H. influenzae antibody titer. 
8  Quantitative Ig to include IgG, IgM, and IgA. 
9  Recommended, but not mandatory. 
10  Will not be analyzed as part of the randomized trial. 
 
X = Generally performed for transplant patients. 
0  = Required for this study. 
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4.15.4.1. Pre-Transplant Evaluations 
 
The following evaluations, which are generally performed for transplant eligibility, should be 
determined < 4 weeks before initiation of conditioning therapy: 
1. History, physical examination, height and weight. 
2. Karnofsky or Lansky performance status. 
3. CBC with differential and platelet count, creatinine, bilirubin, alkaline phosphatase, AST, 
ALT. 
4. CMV antibody test, Hepatitis panel (HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), 
herpes simplex virus, varicella zoster virus, syphilis, HIV and HTLV1/2 antibody. 
5. EKG. 
6. DLCO, FEV1, and FVC. 
7. Bone marrow aspirates for pathology and cytogenetics. 
8. If the donor is HLA mismatched, patient anti-donor lymphocyte cross match must be 
performed to rule out donor-directed sensitization (60, 61). 
9. Chest X-ray. 
10. β-HCG for serum pregnancy test (for women of childbearing potential). 
11. Heparinized blood sample for post-transplant chimerism assay (recommended but not 
mandatory). 
12. Heparinized blood sample for retrospective HLA typing to the NMDP repository. A 
separate NMDP consent form is used for blood sample acquisition for the NMDP 
repository and HLA typing. 
13. Sample from the marrow or PBSC allograft for graft characterization. 
 
The following evaluations, which are required for this study, should be determined < 4 weeks 
before initiation of conditioning therapy: 
1. Serum for quantification of IgG, IgM and IgA, and antibody titers to diphtheria and 
tetanus. 
2. Blood sample for natural killer cell receptors acquisition ancillary study. 
3. Quality of life survey. 
 
4.15.4.2. Post-Transplant Evaluations 
 
The following evaluations are generally performed for transplant recipients: 
1. History and physical exam to assess GVHD and other morbidity weekly until Day 100 
post-transplant, then at six months, one year and then yearly until three years post-
transplant. GVHD evaluation and grading to be in keeping with BMT CTN MOP. 
2. Data on occurrence of infections will be collected as specified in Chapter 6. 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 8.0 dated September 15, 2006 
4-10 
3. CBC at least three times a week from Day 0 until ANC > 500 mcL for 3 days after nadir 
reached. Thereafter CBC twice per week until Day 28, then weekly until 12 weeks, then 
six months, one year and then yearly until three years post-transplant. 
4. Creatinine, bilirubin, alkaline phosphatase, ALT, AST, twice a week until Day 28 (or 
four weeks) and then weekly until 12 weeks, six months, one year and then yearly until 
three years post-transplant. 
5. Bone marrow aspirate and biopsy to pathology, aspirate to cytogenetics at 12 weeks, one 
year and then yearly until three years post transplant. 
6. dT vaccine at 6 and 11 months post-transplant, Hepatitis B vaccine at 6, 7, and 11 months 
post transplant, PCV7 vaccine at 7 and 9 months post-transplant, and PPV23 vaccine at 
11 months post-transplant.  Vaccinations should be given ±1 week of scheduled date. 
7. Quantification of peripheral blood T cell chimerism at 1, 3, 12, and 24 months post-
transplant (recommended but not mandatory – see Appendix C). 
 
The following evaluations are required for this study: 
1. Heparinized blood for quantification of peripheral blood immune reconstitution at 1, 3, 6, 
12, and 24 months post-transplant. 
2. Serum for quantification of IgG, IgM and IgA, and antibody titers to diphtheria, tetanus, 
and pneumococcus at 6, 11, 12 and 24 months post-transplant.  Serum for antibody titers 
to H. influenzae type B and Hepatitis B at 6, 12, and 24 months post-transplant.  
Antibody titers should be drawn just before vaccination. 
3. Blood sample for natural killer cell receptors acquisition ancillary study at 3, 6, and 12 
months post-transplant. 
4. Quality of life surveys at 6 months, 1 year and 2 years. 
 
4.15.5. Required Observations for Donor  
 
Routine pre-allografting work-up in keeping with NMDP guidelines (see Donor Companion 
Manual for this protocol).  Work-up to include the following evaluations, which are generally 
performed for transplant donors: 
 
Pre-collection Evaluations: 
1. Complete history and physical examination. 
2. HLA typing of heparinized peripheral blood sample to determine compatibility. 
3. Serologic testing for Hepatitis B and C (HBsAg, anti-HBc, anti-HCV), CMV, syphilis, 
HIV1/2 and HTLV I/II. Molecular testing for HIV, HCV, and West Nile virus as 
recommended by the FDA. 
4. Sickle cell trait testing. 
5. ABO Rh blood typing.  In the case of donor-recipient ABO incompatibility, the graft 
should be manipulated according to institutional practices. 
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6. Heparinized blood samples for HLA typing to NMDP repository.  A separate NMDP 
consent form is used. 
7. Heparinized blood sample for Chimerism assays, if requested by the transplant center 
(not mandatory but recommended). 
8. Baseline toxicity scores, and CBC and WBC differential. 
9. Toxicity scores on each day of G-CSF administration. 
10. Number of autologous units collected prior to marrow donation. 
 
Collection Day Evaluations: 
11. Type and duration of anesthesia, volume of marrow collected, pre- and post-marrow 
donation CBC and WBC differential, and number of autologous units infused. 
12. Pre- and post-leukapheresis CBC and WBC differential and volume of whole blood 
processed. 
13. Toxicity scores on day of collection. 
14. Product CBC. 
 
Post-collection Evaluations: 
15. Toxicity scores post-donation at two days, weekly until donor reports recovery from 
donation, one month, six month, and annually for a minimum of three years. 
16. CBC post-donation at one month, six months, and annually for a minimum of three years. 
 
The following evaluations are required for this study: 
1. Serum for Hepatitis B antibody titer. 
2. Quality of life assessments as specified in Chapter 8. 
3. Blood sample for natural killer cell receptors acquisition ancillary study pre-donation 
(prior to G-CSF if PBSC). 
4. Product sample for cellular composition testing. 
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CHAPTER 5 
 
 
5. STATISTICAL CONSIDERATIONS 
 
5.1. Study Design 
 
The study is designed as a Phase III, randomized, multicenter, prospective comparative study of 
G-CSF mobilized PBSC versus marrow transplantation in HLA compatible unrelated donors.  
The target enrollment is initially 550 patients, with a provision to increase enrollment to 652 
patients depending on the observed rate of patients dropping out without receiving a transplant. 
 
5.1.1. Accrual 
 
It is estimated that three years of accrual will be necessary to enroll the targeted sample size.  
Both Core and non-Core Centers will enroll patients on this study.  Details of accrual estimates 
follow in the sample size section. 
 
5.1.2. Randomization 
 
All patient-donor pairs who have consented to the randomization as detailed earlier will be 
randomized once the donor has been cleared for donation.  Randomization will be performed in a 
1:1 ratio using random block sizes for the PBSC and marrow arms.  Randomization will be 
stratified by transplant center and by disease risk (see Table 5.4). 
 
5.1.3. Primary Endpoint 
 
The primary endpoint is the two-year survival probability. 
 
5.1.4. Primary Hypothesis 
 
The primary comparison of interest in this study is the two-year survival with PBSC 
transplantation as compared to marrow transplantation.  However, because this is a long-term 
endpoint, a monitoring rule comparing six-month survival between the two arms was put into 
place, to protect patients against unexpected (>10%) differences in six month mortality.  
Therefore, the primary hypothesis, accounting for both the primary comparison of two-year 
mortality as well as the stopping rule for six-month mortality, is a composite hypothesis which 
can be formally stated as: 
 
There will not be a difference in two-year survival with PBSC transplantation as compared to 
marrow transplantation AND the difference in six-month survival between PBSC transplantation 
and marrow transplantation will be ≤ 10%.   
 
The alternative statistical hypothesis is that two-year survival after PBSC versus marrow 
transplantation will differ OR six-month survival after PBSC versus marrow transplantation will 
differ by more than 10%. 
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5.2. Analysis of the Primary Hypothesis 
 
Because the primary hypothesis is a composite hypothesis, the analysis will split the overall type 
I error rate of 5% into 4.5% for the comparison of two-year survival and 0.5% for the 
comparison of six-month mortality.  This weighting reflects the primary interest on the two-year 
comparison.  The resulting procedure will control the overall type I error rate at 5% when there is 
no difference in two-year mortality and the true difference in six-month mortality is  ≤ 10%. 
 
5.2.1. Comparison of Two-year Survival 
 
The standard and experimental therapy arms will be compared using the stratified binomial 
comparison (Mantel-Haenszel test).  All patients who are randomized will be included in the 
analysis based on an intention to treat.  Survival times will be based on time since randomization, 
so that those patients who drop out of the study after randomization but before transplant can still 
be included.  The final analysis will be performed after all patients have been followed for a 
minimum of two years post-transplant.  In addition to this pointwise comparison, Kaplan-Meier 
survival curves will be constructed for each group.  Estimates of the difference between these 
survival curves and confidence bands for these differences will be constructed using the method 
of Zhang and Klein (62).  In the event that there are no significant differences between the two 
arms, a post hoc power analysis will be performed. 
 
5.2.2. Comparison and Interim Monitoring of Six-month Mortality 
 
There will be periodic interim analyses approximately every six months beginning nine months 
after the study opens to test whether the difference in six-month mortality rates is ≤ 10% against 
the alternative that the difference is > 10%.  An allowable difference, for which we would not 
stop early, of 10% is used because NMDP Phase II data indicates a potential for early survival 
differences between PBSC and marrow to dissipate by two years.  For example, Table 1.6.2 
gives an estimated relative risk of PB relative to marrow of 0.6 for the first 100 days followed by 
an estimated relative risk of 1.2 after 100 days.  This would result in a difference of 6.5% at six 
months, which is approximately 0% at two years; the allowable difference of 10% is chosen to 
reflect uncertainty in the Phase II data.   
 
A significance level of 0.5% is allocated to these interim analyses.  The stopping rule will only 
be applied to the estimated 495 patients who actually receive the randomized transplant, rather 
than the intent-to-treat population.  Because there are multiple looks at the data, a Pocock 
stopping boundary will be applied to control the type I error rate.  Therefore, at each interim 
analysis the hypothesis that the difference in six-month mortality rates is less than or equal to 
10% will be tested against the alternative that it is greater than 10%, using a two-sided 
alpha=0.005 level Pocock critical value with interim analysis schedule given in Table 5.2.  This 
test will be done by comparing the Kaplan-Meier estimates of six-month mortality, and using 
Greenwood’s formula for the variance in each group.   
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The final interim analysis procedure is to stop if  
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where 222.3005.0 =c  is the Pocock two-sided stopping boundary with significance level 0.005 
and stopping points given in Table 5.2.   
 
If this hypothesis is rejected, all analyses will be sent to the DSMB for expedited review.  
Operating characteristics of this interim analysis for safety are given below, as a function of the 
true difference in six-month survival (Delta), assuming an exponential survival curve with 55% 
or 55% + Delta survival at six months in the marrow or PB arms, respectively, and assuming 
uniform accrual over three years.  All estimates are based on 10,000 simulations.  As shown, this 
stopping rule will have good power to detect a large difference of 25-30% in six-month 
mortality, but will not stop often for smaller differences that may dissipate by two years. 
 
 
Table 5.2:  Probability of Stopping 
 
Interim Analysis 1 2 3 4 5   
Accrual Month 9 15 21 27 33   
Patients Enrolled 124 206 289 371 454   
Delta Probabilities of Stopping Total 
15% 0.6% 0.5% 0.8% 0.8% 0.9% 3.6% 
20% 1.5% 3.0% 4.4% 4.9% 5.7% 19.5% 
25% 4.2% 11.1% 14.4% 15.5% 14.6% 59.8% 
30% 10.7% 28.1% 26.8% 17.9% 9.5% 93.0% 
 
 
5.3. Sample Size and Power Considerations 
 
Sample size calculations are based on the analysis of the primary endpoint of two-year survival, 
conducted at the 4.5% significance level.  Based on the eligibility criteria, the estimated survival 
for the marrow transplant arm at two years is 35% as detailed in Table 5.3 below.  The study is 
powered to detect a 12.5% difference in the two-year survival of 35% among patients who 
actually receive a transplant.  Because randomization takes place prior to determination of a 
patient’s eligibility for transplant, NMDP experience indicates that between 5-15% of the 
randomized patients in each arm will never receive a transplant.  These patients are typically 
high risk and are assumed to all die within six months.  Therefore, the intent-to-treat populations 
to be compared in the primary analysis are assumed to be a mixture of 85-95% who receive the 
randomized stem cell source, and 5-15% who never receive a transplant.  The resulting two-year 
survival rates for the intent-to-treat populations are given in the table below, as well as the 
powers to detect these differences, for sample sizes of 275 per group (550 total) and 326 per 
group (652 total), and for differences of Delta=10%, 12.5%, and 15%.  A total sample size of 
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550 patients will have 80% power to detect the targeted difference of 12.5% in two-year survival 
rates for a 5% dropout rate using a two-sided binomial comparison with alpha=0.045. 
 
 
Table 5.3:  Power to Reject the Null Hypothesis under Various Scenarios1 
 
   Transplanted Intention to Treat Population 
Delta Source   Population 5% Dropout 10% Dropout 15% Dropout 
  Marrow 2 Yr. Survival 35.0% 33.3% 31.5% 29.7% 
12.5% PB 2 Yr. Survival 47.5% 45.1% 42.8% 40.4% 
  Power (N=550) 80% 76% 72% 
    Power (N=652) 86% 83% 80% 
10% PB 2 Yr. Survival 45.0% 42.8% 40.5% 38.3% 
  Power (N=550) 61% 57% 53% 
    Power (N=652) 69% 65% 61% 
15% PB 2 Yr. Survival 50.0% 47.5% 45.0% 42.5% 
  Power (N=550) 92% 89% 86% 
  Power (N=652) 95% 94% 91% 
1The table has been simplified for interpretability.  Power calculations are based on a two-sided test. 
 
 
5.4. Accrual 
 
This study will accrue patients from U.S. and Canadian Transplant Centers and donors from 
U.S., Canadian, and German Donor Centers, according to the eligibility criteria described in 
Chapter 2.  According to data from NMDP (based on 2002 numbers), there are approximately 
350 patients who would be potentially eligible for this protocol transplanted in 14 non-Pediatric 
Blood and Marrow Transplant Consortium (PBMTC) Core Centers per year.  Assuming an 
enrollment rate of 40%, the Network plans to accrue 140 patients annually from these Core 
Centers.  Among the PBMTC Centers doing at least 6 pediatric or at least 15 total unrelated 
donor peripheral blood or bone marrow transplants a year (N=9 centers), NMDP data indicate 
that there are about 125 potentially eligible for this study a year (70 under the age of 20 years).  
Assuming an enrollment rate of 40%, the Network plans to accrue an additional 50 patients 
annually.  The Network plans to accrue an additional 40 patients a year from non-Core NMDP 
Centers.  In summary, we estimate accruing 190 patients annually from 23 Core Centers and 40 
from 5-8 non-Core centers.  These estimates were corroborated by surveys of Core Centers and 
non-Core Centers asking for the number of unrelated donor transplants done in the 12-month 
period from March 2001-March 2002.  Although, this survey indicated a somewhat higher 
anticipated accrual, we chose to plan the study based on the conservative estimates given above 
because: 1) they are based on real data on actual numbers of NMDP-facilitated transplants in 
these centers; 2) participants may be lost based on either patient unwillingness to participate or 
donor unwillingness to participate; and, 3) about 20% of NMDP-facilitated transplants in the 
U.S. use donors from non-U.S. donor centers.   
 
Given these conservative estimates, it is anticipated that the accrual goal of 550 patients will be 
met in three years (see Figure 5.4 below).  Accrual will be closely monitored.  If necessary, the 
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DCC will identify additional U.S. and Canadian non-Core NMDP Centers that can contribute a 
minimum of three patients per year to the study.  Accrual will also be monitored to ascertain that 
enrolled patients reflect women, minorities and children in proportion to the numbers expected 
based on available NMDP data regarding general unrelated donor transplant recipients.  In 
addition, the rate of patients enrolling in the study and not receiving a transplant will be closely 
monitored and compared with our target rate of 5%.  If the observed rate appears to be as high as 
15%, increasing accrual to up to 652 patients will be considered.   
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Table 5.4:  Outcome of U.S. Unrelated Donor Blood or Marrow Transplants – 1996-2001 
 
Risk 
Stratum 
Disease / 
Stage^ N 
100-day 
survival
1-year 
survival
2-year 
survival
3-year 
survival
4-year 
survival 
5-year 
survival 
# Tx’s 
2001* 
NMDP 
     
Good CML-CP 1097 75±3 59±3 53±3 50±3 47±3 42±4 61 (10%)
 CML-AP/ CP2+ 401 67±5 41±5 31±5 28±5 26±5 22±6 44 (7%)
 AML-CR1 357 67±5 43±5 36±6 32±6 32±6 32±6 83 (13%)
 AML-CR2 381 74±4 47±5 40±5 38±6 34±6 33±7 67 (11%)
 ALL-CR1 287 73±5 54±6 44±6 41±6 38±7 38±7 42 (7%)
 ALL-CR2 431 74±4 46±5 37±5 34±5 33±5 31±5 77 (12%)
 ALL-CR3 125 70±8 43±9 33±9 29±9 29±9 25±11 15 (2%)
 MDS-RA 121 69±8 45±9 42±9 36±10 25±11 25±11 17 (3%)
 MDS-RAEB 143 60±8 36±8 30±8 29±8 27±8 27±8 30 (5%)
 JCML (JMML) 25 68±18 48±20 43±20 43±20 34±22 34±22 0 (0%)
 MFMM 37 59±16 45±16 41±17 41±17 41±17 41±17 7 (1%)
 Total Good Risk 3405 72±2 50±2 42±2 39±2 37±2 34±2 443 (70%)
Poor CML-BP 72 56±12 25±10 15±9 13±8 13±8 9±9 10 (2%)
 AML-CR>2 38 45±16 26±14 18±12 18±12 18±12 18±12 6 (1%)
 AML-Not in CR 648 57±4 23±3 15±3 14±3 12±3 11±4 100 (16%)
 ALL-Not in CR 275 48±6 18±5 10±4 9±4 7±3 6±3 50 (7%)
 MDS-RAEBT 114 69±9 39±9 24±8 23±8 21±8 17±10 18 (3%)
 CMML 34 73±15 25±18 25±18 25±18 25±18 25±18 9 (1%)
 Total Poor Risk 1199 56±3 24±3 15±2 14±2 12±2 11±3 193 (30%)
 TOTAL 4604 68±1 43±1 35±1 33±1 31±2 28±2 636 (100%)
* Includes all NMDP centers, U.S. and non-U.S., core and non-core centers. 
^ Abbreviations: CP = chronic phase; AP = accelerated phase; CR = complete remission; RA = 
refractory anemia; RAEB = refractory anemia with excess blasts; BP = blast phase; RAEBT = 
refractory anemia with excess blast in transformation. 
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Figure 5.4 – Anticipated Patient Accrual 
 
 
5.5. Interim Analyses  
 
Interim analyses will be conducted for safety at times coincident with regularly scheduled 
meetings of the National Heart, Lung, and Blood Institute (NHLBI)-appointed Data and Safety 
Monitoring Board (DSMB).  Policies and composition of the DSMB are described in the BMT 
CTN MOP. 
 
Toxicity, adverse experiences, and other safety endpoints will be monitored regularly and 
reported to the DSMB at each interim analysis.  Treatment will be coded for all analyses unless 
the DSMB requests that the code be revealed. 
 
5.6. Demographic and Baseline Characteristics 
 
Demographics and baseline characteristics will be summarized for all patients, and for all 
patients who actually receive a transplant.  Between group comparisons will be performed for 
continuous variables via a t-test and for categorical variables, via the chi-square test. 
 
5.7. Analysis of Secondary Endpoints 
 
Transplant-related event data will only be collected on patients who actually receive a transplant 
and will use event times calculated from the time of transplantation.  Therefore, these 
comparisons will be made using the actually transplanted populations.  Because of the potential 
for unequal drop out between the two arms, adjustment for covariates will be used to make these 
groups comparable, if necessary.  Covariates to be considered are transplant center, year of 
transplant, preparative regimen, GVHD prophylaxis, recipient characteristics (age, sex, body 
mass index [BMI], race, performance status, diagnosis, disease stage, time from diagnosis to 
transplant, CMV status, comorbid diseases) and donor characteristics (age, sex, BMI, race, CMV 
status and parity), and HLA match.  
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5.7.1. Two-year Survival among Transplanted Patients 
 
The two-year survival will be compared between patients actually receiving the randomized 
transplant stem cell source, using a stratified Mantel-Haenzel test.  In addition, logistic 
regression may be used to adjust for patient characteristics, which are unbalanced in the actually 
transplanted arms. 
 
5.7.2. Neutrophil Engraftment > 500/mcL 
 
Rates of neutrophil engraftment over time, treating death prior to engraftment as a competing 
risk, will be compared between the two groups using a stratified log-rank test, and the 
cumulative incidence curves will be estimated for each group.  Cox regression will be performed 
to compare the groups after adjusting for covariates, which may be imbalanced due to patient 
dropout. 
 
5.7.3. Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent 
 
Rates of platelet engraftment over time, treating death prior to engraftment as a competing risk, 
will be compared between the two groups using a stratified log-rank test, and the cumulative 
incidence curves will be estimated for each group.  Cox regression will be performed to compare 
the groups after adjusting for covariates that may be imbalanced due to patient dropout. 
 
5.7.4. Acute GVHD of Grades II-IV and III-IV 
 
The stratified log-rank test will be used to compare the cumulative incidence of acute GVHD of 
grades II-IV or III-IV by Day 100 between the treatment groups considering death as a 
competing risk.  Cox regression will be performed to compare the groups after adjusting for 
covariates, which may be imbalanced due to patient dropout. 
 
5.7.5. Chronic GVHD 
 
Rates of chronic GVHD, treating death prior to occurrence of chronic GVHD as a competing 
risk, will be compared between the two groups using a stratified log-rank test, and the 
cumulative incidence curves will be estimated for each group.  Cox regression will be performed 
to compare the groups after adjusting for covariates, which may be imbalanced due to patient 
dropout. 
 
5.7.6. Current Immunosuppressive (IS) Free Survival 
 
Patients on either arm may go off IS therapy, and then need to subsequently reinitiate therapy.  
The current immunosuppressive free survival is an estimate of the likelihood that a patient will 
be alive and not on immunosuppressive therapy at any given point in time.  Patients will be 
censored for this endpoint at the time of relapse. 
 
These survival curves will be compared between the two arms of the study across all time points 
using a technique found in Klein et al (63). 
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The probability that a patient is alive and off IS therapy at 2, 6, 9, 12, 15, 18, 21, 24, 30 and 36 
months will be estimated.  In the analysis at K months, the numerator for this estimate counts 
patients alive and off IS therapy, and the denominator counts all patients followed to K months, 
regardless of survival status.  These probabilities will be compared using standard tests for 
binomial proportions. 
 
5.7.7. Relapse of the Original Malignancy 
 
Rates of relapse, treating death prior to relapse as a competing risk, will be compared between 
the two groups using a stratified log-rank test, and the cumulative incidence curves will be 
estimated for each group.  Cox regression will be performed to compare the groups after 
adjusting for covariates that may be imbalanced due to patient dropout. 
 
5.7.8. Donor Lymphocyte Infusion 
 
The use of DLI will be recorded and analyzed as a secondary endpoint. DLI will be a competing 
risk for evaluation of acute and chronic GVHD. 
 
5.7.9. Bacterial, Viral and Invasive Fungal Infection 
 
Infectious complications will be analyzed in relation to patients’ clinical risk with comparison of 
the two treatment cohorts (PBSC versus marrow) and adjusted by other relevant clinical risk 
factors.  These may include, but will not be limited to: pre-transplant infectious history and 
serostatus, time to neutrophil engraftment, and acute and chronic GVHD.  Analysis of infection 
incidence (by cumulative incidence) and infection density (number of infections over time for 
patients with repeated infections), especially during later time periods, will be performed.  
Multivariate regression analysis will be performed to test for the contribution of stem cell source 
(PBSC versus marrow) and other relevant covariates to the incidence of infections.  Specific 
analyses using these techniques will be performed for bloodstream infections (bacteremia), 
systemic fungal infections, and viral infections (CMV, HSV, respiratory viruses), and infections 
that lead to added isolation precautions in the hospital setting (e.g., resistant enterococcus, 
Clostridium difficile, varicella zoster, adenovirus, rotavirus, respiratory viruses). 
 
5.7.10. Patient and Donor Quality of Life 
 
Details about these analyses will be given in the separate sections on quality of life. 
 
5.7.11. Three-Year Survival 
 
Same as for the primary and secondary two-year endpoints. 
 
5.8. Safety Analysis 
 
All entered patients will be included in the safety analysis. 
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5.8.1. Adverse Events 
 
All reported serious treatment related adverse events will be carefully examined with respect to 
the severity and relationship to study treatment.  Adverse events will be graded according to the 
NCI Common Terminology Criteria for Adverse Events, Version 3.0.  The incidence for each 
reported study group associated adverse experience delineated in Section 4.15 will be presented 
for each group. 
 
5.9. Laboratory Tests 
 
Graft Characterization - Descriptive statistics will be computed on the cellular constituents of 
the graft, separately for each graft type.  These will be compared between graft types using 
nonparametric Wilcoxon rank sum tests.  Counts of the immune cells of different types in the 
graft (including donor CD34 and dendritic cells) as well as the graft type will be used to model 
post-transplant GVHD, relapse, and various measures of immune reconstitution through Cox 
regression, treating death prior to immune reconstitution, GVHD, or relapse as a competing risk. 
 
Immune Reconstitution - Descriptive statistics will be computed on the cellular constituents and 
Ig types separately by treatment arm.  These will be compared between treatment arms using 
nonparametric Wilcoxon rank sum tests.  Levels of IL-2 and IL-7 will be correlated using 
nonparametric measures with the levels of T cells in the blood.  Response to vaccinations will be 
compared between treatment arms using the binomial comparison of proportions.   
 
Chimerism - Chimerism results will be compared between the treatment arms using 
nonparametric Wilcoxon rank sum tests. 
 
5.10. Donor Recovery 
 
Donor Recovery to Baseline Toxicity Scores - Appropriate statistical methods to detect trends 
over the available spectrum of donor follow-up time will be employed for baseline toxicity 
recovery to baseline endpoints.  Such methods may include, but not necessarily be limited to: 
analysis of variance with repeated measures techniques, non-parametric paired comparisons, or 
other methods suitable for comparisons of correlated data. 
 
Donor Recovery to Baseline CBC and WBC Differential Values - Appropriate statistical 
methods to detect trends over the available spectrum of donor follow-up time will be employed 
for baseline CBC recovery to baseline endpoints.  Such methods may include, but not necessarily 
be limited to: analysis of variance with repeated measures techniques, non-parametric paired 
comparisons, or other methods suitable for comparisons of correlated data. 
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5.11. Subgroup Analyses 
 
Subgroup analyses will be performed on the following subgroups: pediatric patients (<16), 
disease risk (High vs. low, as defined in Table 5.4), and HLA matching status (matched on HLA-
A, B, C, DRB1 vs. mismatched).  First the direction and magnitude of the treatment effect in the 
subgroup will be compared with the rest of the sample to look for qualitative differences.  In 
addition, statistical hypothesis testing will be performed on endpoints of interest to look for 
significant interactions between the treatment and each subgroup of interest.  However, because 
of the greatly reduced sample sizes in such subgroups, these tests are underpowered and not 
anticipated to reach statistical significance in most cases.  They will be used only to note very 
strong interactions and to generate hypotheses.   
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CHAPTER 6 
 
 
6. INFECTIOUS COMPLICATIONS OF TRANSPLANTATION 
 
The early neutropenia, mucocutaneous barrier disruption and extended period of 
immunodeficiency after allogeneic transplantation leave patients vulnerable to serious and life-
threatening infections.  Because engraftment as well as immune reconstitution rates may differ 
following PBSC versus marrow transplantation, in this trial individual infectious complications 
will be prospectively monitored and compared.  The primary question asked in this protocol 
component is whether there will be a significant difference in the incidence, severity and case-
fatality rate of microbiologically documented infections between the PBSC and the marrow arms 
of the trial. 
 
Regimens to prevent and treat infectious complications of transplantation have evolved over the 
last three decades and continue to evolve, as have diagnostic and monitoring tools.  Specific 
prophylactic, monitoring and therapeutic regimens also vary from center to center.  While the 
study randomization will be stratified by center, in part for this reason, knowledge of prevention 
regimens used at each center will assist with the interpretation of putative relationships between 
study arm and infectious complications on this trial. 
 
Infection prophylaxis and complication monitoring forms and instructions for completion of the 
forms are included in the Data Management Handbook and User's Guide. 
 
6.1. Required Data Elements for Collection 
 
6.1.1. Pre-transplant Infections that may have an Impact on the Transplant by Recurrence 
 
Information regarding clinically significant fungal infections that occurred before transplant will 
be obtained based on the expected possibility of their reactivation during transplantation.  In 
addition, cytomegalovirus (CMV) serostatus of the donor and recipient, and herpes simplex 
(HSV) and varicella zoster virus (VZV) serostatus of the recipient will be collected.  The 
presence of fungal, bacterial and viral infections requiring treatment will also be captured as part 
of the pre-treatment eligibility screening form, as these infections are grounds for delaying or 
deferring the transplant. 
 
6.1.2. Infectious Disease Prophylaxis 
 
To determine what infection preventive measures were used, centers will be surveyed annually to 
report their infection prophylaxis protocols applicable to patients enrolled on this trial.  These 
center-defined, rather than patient-specific, data will be compiled for analysis.  The survey will 
include questions on: systemic bacterial, viral, fungal and pneumocystis prophylaxis, pre-
emptive therapy for positive CMV pp65 antigen or PCR tests.  Infection prophylaxis varies by 
time period post-transplant.   
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The center infection prophylaxis survey will include the following periods: 
1. Early neutropenia combined with mucocutaneous barrier disruption, weeks –1 through 
week + 4 post-transplant; 
2. Resolution of early neutropenia combined with continuing recovery from mucocutaneous 
barrier disruption, from 4-12 weeks post-transplant; 
3. Extended period of immunodeficiency from 12-26 weeks post-transplant; and 
4. Extended period of immunodeficiency from 26-52 weeks post-transplant. 
 
Centers should indicate varying practices over time in their survey responses. 
 
6.1.3. Specific Reporting of Individual Infections 
 
6.1.3.1. Data of interest 
 
The objective of this protocol component is to capture microbiologically defined opportunistic 
infections.  These will include the following etiologies: 
1. Viruses 
2. Fungi 
3. Bacteria 
4. Protozoa 
5. Others 
 
For the case definition for each infectious syndrome please refer to the BMT CTN Infectious 
Diseases MOP.  Case definitions specify clinical manifestations of disease and microbiological 
data.  Microbiological data will be captured from evidence of microbiology isolates, as well as 
genetic or antibody probes tested on fluid or tissue samples.  Clinical manifestations specific for 
each infectious disease syndrome will be captured by the case report forms using data from 
clinical source documents. 
 
Specific microbiology information about Candida and Aspergillus species will be included in the 
MOP, as this emerging and serious infection class is now being managed with multiple alternate 
antifungal agents. 
 
6.1.3.2. Tempo of data acquisition and reporting 
 
To enhance the reporting of all individual infections, infections forms should be filed as soon as 
possible after diagnosis.  Patient charts should be reviewed on Days 28, 100, 180, 365 and 730 to 
ensure that all clinically significant infections were captured between these reporting time 
periods.  If no clinically significant infections have occurred, that negative information will be 
reported. 
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CHAPTER 7 
 
 
7. PATIENT QUALITY OF LIFE 
 
7.1. Background and Significance 
 
7.2. Overview and Rationale 
 
Quality of life (QOL) refers to every dimension of life except for its length, and includes 
physical abilities, symptoms, social well-being, psycho-emotional status, and spiritual/existential 
qualities.  It reflects how well people feel, what they can accomplish, how satisfied they are with 
their lives, and whether their lives have meaning and purpose.  Within this broad concept, health-
related quality of life (HRQOL) refers to aspects of QOL that are attributable to health, disease 
or medical treatment (for simplicity, the abbreviation QOL will be used in this protocol).  
Following hematopoietic stem cell transplantation (HSCT), QOL can range from perfect, with no 
physical, emotional or social sequelae and a greater appreciation for life, to severely 
compromised with physical disability, pain and psychological despair.  Of course, most patients 
who have undergone HSCT fall within this spectrum. 
 
The figure below shows an example of QOL taxonomy. Global QOL (“Overall, how is your 
quality of life?”) is made up of several domains such as physical symptoms and functioning, 
emotional well-being, social relationships etc.  HSCT survivors generally report high global 
quality of life following HSCT, but many specific symptoms (64, 65, 66, 67, 68, 69, 70) and 
limitations on their daily activities (71).  However, despite many problematic long-term 
complications, almost all patients indicate they would undergo the procedure again given similar 
circumstances (72, 73, 74, 75).  In addition, for some common problems after HSCT such as 
fatigue, sleep and sexual functioning, documented dissatisfaction is also high in the general 
population and chemotherapy-treated patients (76, 77). 
 
 
 
 
The purpose of the QOL component of this trial comparing unrelated PBSC versus marrow as a 
stem cell source is to understand the long-term QOL implications of one graft source versus 
another.  While the trial is powered with survival as the primary endpoint, QOL will be an 
especially important secondary endpoint if survival is not statistically different, or if the 
incidence of chronic GVHD is higher in one group.  It is also possible that immunologic 
recovery, peri-transplant experiences and complications, speed of physical recovery, and 
expectations may influence ultimate QOL. 
 
 
PHYSICAL 
fatigue 
pain 
SOCIAL
family
friends
EMOTIONAL
anxiety
depression
FUNCTIONAL
work
sleep
Global QOL 
SPIRITUAL
religion 
meaning 
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It is very important that data collection is centralized, patients’ response burden is minimized and 
QOL assessments are fully integrated into the trial to maximize the chance of complete data 
collection.  With this goal in mind, the number of data instruments will be minimized and 
focused on answering the research question, assuming that other psychological, social etc. 
factors are balanced by the randomization process.  Specifically, associations between QOL and 
specific clinical events or patient characteristics will not be investigated.  Other ongoing studies 
fully address those issues. 
 
7.3. Preliminary Work 
 
NHLBI has sponsored a randomized trial of T cell depletion vs. immunosuppressive medications 
for acute GVHD prophylaxis in unrelated donor marrow transplantation (TCD).  Accrual and 
follow-up are complete.  Dr. John Wingard and the International Bone Marrow Transplant 
Registry (IBMTR) have concluded a large, cross-sectional study of QOL and relationships 
incorporating patients, spouses and controls.  Both these studies have shown the feasibility of a 
centralized, telephone data collection strategy using mailed surveys followed by phone 
interviews.  Overall and item completion rates were excellent, and anecdotally, the personal 
contact was much appreciated by the patients.  Results are not yet available from these studies, 
but completion rates in the NHLBI trials were excellent (baseline – 91%, 100 days – 59%, 6 
months – 64%, one year – 73%, 3 years – 84%).  However, compliance varied and improved as 
the study progressed.  In addition, a pediatric component was planned but closed early due to 
poor compliance.  In order to facilitate comparison of the current study with the NHLBI and 
IBMTR studies, every effort has been made to include similar instruments and assessment times. 
 
7.4. Specific Aims 
 
The overall aim is to compare the QOL of patients undergoing unrelated donor marrow 
transplantation with that of patients undergoing unrelated donor PBSC transplantation.  Other 
aims include: 
1. To compare chronic GVHD symptom burden (as measured by the chronic GVHD 
symptom scale) between the two treatment groups. 
2. To compare physical, functional, and transplant-specific QOL modules (as measured by 
the Trial Outcome Index [TOI] of the Functional Assessment of Chronic Illness Therapy 
[FACT-BMT] and the rate of return to work) between the two groups. 
3. To compare the positive and negative psycho-emotional aspects of transplantation (as 
measured by the Mental Health Inventory) between the two groups. 
 
7.5. Hypotheses 
1. There will be greater chronic GVHD symptom burden in recipients of PBSC transplants 
at one-year post-transplantation. 
2. There will be no difference in the physical, functional, and transplant-specific QOL 
between the two groups over time through two years post-transplantation.  
3. There will be no difference in rate of return to work at two years. 
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4. There will be no difference in the positive and negative psycho-emotional aspects of 
transplantation, as measured by the Mental Health Inventory. 
 
7.6. Eligibility and Exclusion Criteria 
 
7.6.1. Inclusion Criteria 
1. Enrollment in the randomized clinical trial. 
2. At least 16 years of age. 
3. Signed informed consent. 
 
7.6.2. Exclusion Criteria 
1. Inability to communicate in English or Spanish. 
2. Inability to participate in interviews due to cognitive, linguistic or emotional difficulties. 
3. Current uncontrolled psychiatric illness. 
4. No telephone or access to a telephone. 
5. This study will not be offered to children and their parents based on the experience with 
the NHLBI TCD study.  In addition, QOL considerations and instruments differ between 
adult and pediatric patients necessitating a separate analysis.  It is anticipated that 
minority representation will mirror that in the randomized study. 
 
7.7. Study Procedures 
 
7.7.1. Study Design 
 
Patients will be enrolled in the QOL study at the time they provide first consent for the 
randomized trial.  Once a donor is confirmed, the patient will be sent a QOL study packet 
including a cover letter, copy of the QOL interview, and information to schedule the time for a 
pre-transplant interview. Interviews will be conducted in either English or Spanish.  
 
Interviewers will read the verbatim questions to the subject, who will indicate their answers.  
Interviewers will record those answers.  If a patient wishes to stop and continue later or another 
day, that is permissible.  Three contacts with the patient will be allowed with his/her permission 
to obtain complete data at each time point.  In addition, a toll-free line will be established for 
patient questions or in case it is easier for the patient to complete the surveys at another phone 
(e.g., at a clinic appointment or a friend’s house). 
 
Patients will be surveyed prior to transplantation (within 1 month of admission), and at 6 months, 
1 year and 2 years.  Post-transplant interviews may occur +/- 1 month from the scheduled time 
point.  Permission will also be sought for QOL assessment at 5 years post-transplantation, 
although these data will not be analyzed as part of the randomized controlled trial. 
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7.7.2. Study Endpoints 
 
The four study endpoints of the QOL component will be: 
1. The chronic GVHD symptom scale. 
2. The Trial Outcome Index of the FACT-BMT. 
3. Occupational functioning. 
4. The Psychological Distress and Psychological Well-Being Subscales of the Mental 
Health Inventory. 
 
7.7.3. Instruments 
 
Table 7.7.3:  Description of Instruments 
 
Instrument Domains Rationale 
Sociodemographics Race/ethnicity, Age, 
Gender, Education, 
Income 
 
Global quality of life Karnofsky 
performance status 
Perception of 
overall health, 
Perception of 
overall QOL, Rating 
scale 
Assesses patient self-perceived global quality of life 
and functioning. 
FACT-BMT Physical, 
Emotional, Social 
Functional, 
Transplant-specific 
Collected in NHLBI TCD and IBMTR QOL study. 
Allows comparison with other cancer populations. 
Mental Health Inventory 
(MHI) 
MHI Index, 
Psychological 
distress, 
Psychological well-
being 
Measures depression, anxiety, positive affect, 
emotional ties and loss of behavioral and emotional 
control.  Includes the mental subscale from the SF36. 
Occupational functioning Occupational 
functioning 
Only about 75% of surviving patients return to work, 
and return to work is associated with better QOL.  
This instrument was used in NHLBI study. 
Chronic GVHD module Chronic GVHD 
summary score 
Anticipated rates of cGVHD are 50-90%.  Measures 
cGVHD problems with skin, energy, lung, nutrition, 
psychological, eye, and mouth. 
Alternative contacts  Contact information for two alternative individuals. 
Distress assessment  Measures distress caused by survey administration. 
 
Sociodemographics: Eight standardized questions will assess ethnicity (Hispanic/Non-
Hispanic), race (White, Black, Asian, American Indian/Alaskan Native, Native Hawaiian or 
other Pacific Islander, Multiracial), age, sex, education, work status and occupation, and family 
income. 
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Global Quality of Life: Four standard questions will assess patient self-assessed Karnofsky 
performance status, overall health and overall quality of life (excellent, very good, good, fair, 
poor), and a rating scale for overall quality of life (where 0 equals death and 100 equals perfect 
quality of life). 
 
FACT-BMT: The FACT-BMT is a 37-item instrument composed of the FACT-G and 
transplant-specific subscale.  The FACT-G is comprised of 4 domains, physical (7 items), social 
(7 items, including sexual satisfaction), emotional (6 items) and functional (7 items, including 
work, sleep and leisure activities).  The transplant-specific module (10 scored items) includes 
appetite, appearance, mobility and fatigue (78,79).  Higher scores indicate better functioning.  
The Trial Outcome Index (TOI) is composed of the physical, functional, and transplant-specific 
modules (80).  Data from 132 observations in unrelated donor recipients post-transplantation (6-
60 months) showed a mean of 66.76, SD 19.53, range 11.8-96.0. 
 
Mental Health Inventory (MHI): Thirty-eight items divided into two summary scores and five 
subscales measure anxiety, depression, positive affect, emotional ties, and loss of behavioral and 
emotional control (this instrument includes the entire mental subscale of the SF36).  As 
transplantation has been associated with both positive and negative psycho-emotional sequelae, it 
is important that the instrument detects both.  Psychological well-being is measured by 14 items 
with a reported mean of 59.16 and SD 12.16 in a general population sample of 5,000 individuals.  
Cronbach’s alpha is 0.92, one year test-retest 0.63, and higher scores indicate better functioning. 
On the 24 item psychological distress scale, mean is 47.54, SD 15.39, Cronbach’s alpha 0.94, 
one-year test-retest 0.62, and higher scores indicate more distress (81, 82).  The MHI was 
sensitive to changes associated with azacytidine treatment in MDS patients, and baseline scores 
were very similar to that of the general population. 
 
Occupational Functioning: Occupational functioning was measured in the NHLBI TCD trial 
using 6 items that assess current job status, type of work (will be captured using Hollingshead 
categories), number of hours of paid and unpaid work, school, importance of work and change in 
work goals. 
 
Chronic GVHD Symptom Scale: The 30 item cGVHD symptom scale measures degree of 
bother of cGVHD manifestations in skin, energy, lung, nutrition, psychological, eye and mouth.  
Responses are captured on a five-point Likert scale (“no symptoms, or not bothered at all”, 
“slightly bothered,” “moderately bothered,” “bothered quite a bit,” or “extremely bothered”).  
Scores for each domain are converted to a 0-100 scale where higher scores indicate more bother.  
Mean (SD) was 12 (9) for patients with mild (N=55), 18 (13) for patients with moderate (N=39), 
and 34 (13) for patients with severe (N=13) disease.  Although the SF-36 and FACT-BMT were 
sensitive to changes in overall health, only the chronic GVHD symptom scale was sensitive to 
changes in patient-perceived chronic GVHD severity (83).  
 
Alternative Contact Information: The names of two people who do not live with the subject, 
but would be able to locate the patient in case of phone number change, move etc. will be 
obtained.  Names, addresses and phone numbers of these alternative contacts will be collected. 
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Distress Assessment: Two items will assess distress at the conclusion of each survey 
administration.  One question measures level of comfort with the questions (very comfortable, 
comfortable, a little uncomfortable, very uncomfortable) and degree of stress caused by the 
questions (a great deal, a lot, some, a little, none).  These questions were modified from studies 
of bereaved family members.  Responses of “very uncomfortable” with questions or “a great 
deal” or “a lot” of stress caused by the survey leads to follow-up questions and an offer of 
referral.  Actual referral or the need to notify the transplant center Principal Investigator due to 
distress caused by the survey administration will constitute an unexpected serious adverse event. 
 
7.7.4. Required Data 
 
Table 7.7.4:  Required Data 
 
Instrument N items Pre 6 mos 
1 & 2 
yrs 5 years
Sociodemographics 8 X    
Global quality of life 4 X X X X 
FACT-BMT 37 X X X X 
Mental Health Inventory (MHI) 38 X X X X 
Occupational functioning 6 X  X X 
Chronic GVHD module 30  X X  
Alternative contacts 2 X X X  
Distress assessment 2 X X X X 
TOTAL N ITEMS  97 114 120 87 
ANTICIPATED TIME  20 min 20 min 25 min 15 min 
 
 
7.8. Description of Study Process 
 
7.8.1. Identification of Eligible Patients 
 
Upon provision of informed consent for participation in the randomized clinical trial, patients 
will also complete a Patient Contact Form to allow the QOL interviewer to reach them.  This 
form will capture name, address, home phone number, email address, alternative contact 
information, preferred language, and preferred time to be contacted.  Site coordinators will 
provide transplant center name, type of transplant, date of admission, date of transplant, 
transplant center and patient NMDP identification numbers and patient’s study number.  This 
information will be faxed to the QOL coordinating center and entered into a password-protected 
database.  Upon receipt of this information, patients will be mailed a packet of information 
including a cover letter explaining more about the QOL survey procedures, the first survey for 
their review, and contact information for more questions. 
 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 8.0 dated September 15, 2006 
7-7 
7.8.2. Informed Consent 
 
Consent for QOL data collection is contained in the informed consent document for the trial.  
Procedures between the QOL coordinating center and the BMT CTN Data Coordinating Center 
(DCC) will ensure that a copy of the informed consent is on file before collection of the QOL 
data. 
 
7.8.3. Collection of QOL Data 
 
QOL interviewers will call the patient at a day and time that is convenient for them, or patients 
may call a toll-free number at a predetermined time.  Baseline data will be collected within one 
month prior to graft infusion and after an admission date is scheduled.  For each subsequent 
contact, the QOL coordinator will call or email the clinical contact person associated with the 
patient within a month of contact in order to prevent contact attempts with deceased patients.  
Once confirmation of survival is obtained, the QOL coordinator will mail the patient a packet of 
information, and call the patient to schedule the QOL interview.  The post-transplant interviews 
may occur +/- 1 month from the scheduled time.  At the conclusion of each survey 
administration, patients will be reminded of the next date of contact and the procedures that will 
be followed. 
 
7.8.4. Location of Missing Patients 
 
If patients cannot be located through the contact information provided, or through the transplant 
center, then the alternative contacts will be used to locate the patient.  With the patient’s 
permission, updated contact information will be forwarded to the transplant center for their 
records. 
 
7.8.5. Withdrawal of Consent for QOL Data Collection 
 
If patients wish to discontinue participation in the QOL study, the QOL interviewer will notify 
the Principal Investigator at the transplant center immediately.  In approximately one week, the 
Principal Investigator will call the patient back to make an attempt to keep the patient in the 
study by explaining the goals of the study and the required data needs.  Should the patient still 
wish to drop out of the QOL study, no further contact will be attempted.  However, QOL data 
will be removed from the database only when specifically requested by the patient. 
 
7.8.6. Fifth Year Contact 
 
Although the fifth year will not be officially part of the randomized controlled study or the 
analysis, consenting patients for long-term follow-up allows important long-term data to be 
collected.  Similar procedures as for the two-year survey will be followed. 
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7.8.7. Letter of Appreciation and Communication of Findings 
 
At the conclusion of the study, a letter of appreciation will be sent to all surviving patients 
thanking them for their participation.  If a patient dies, a letter will NOT be sent to the next of 
kin.   
 
7.8.8. Management of Adverse Reactions 
 
Patients enrolled in this study will undergo up to five interviews.  At the start of each interview, 
patients will be told clearly that they may skip over any interview questions they wish and may 
withdraw from the study at any time.  Despite our best efforts, it is conceivable that some 
patients may find the process upsetting.  Names and phone numbers of local people to contact 
will be listed in the consent form and provided at the end of each interview.  Notification of the 
transplant center Principal Investigator based on distress caused by participation in the study will 
be considered an unexpected, serious adverse event and will be reported to the Principal 
Investigator, the IRB and the DCC.  However, distress incidentally detected will be reported to 
physicians and noted in the research file, but will not be considered an adverse event.  Section 
7.11.1 details study procedures in case distress is detected with potential to cause injury to self or 
others. 
 
7.9. Statistical Considerations 
 
7.9.1. Sample Size 
 
As quality of life is a secondary endpoint for the randomized clinical trial, the available sample 
size is predetermined by the primary endpoint of survival.  Thus, statistical considerations will 
focus on the power to detect differences given the enrollment and likely survival of the treatment 
arms. 
 
The available sample size at two years will be 60 for marrow and 81 for PBSC, based on 
expected accrual and the following additional assumptions: 
1. 90% of patients are adults (age > 18 years) who communicate in English or Spanish. 
2. Compliance with QOL assessments is 80%. 
3. Survival is 45% in the PBSC and 35% in the marrow group at two years. 
 
The hypothesis related to chronic GVHD symptoms pertains only to the one-year time point, and 
return to work applies to the two-year assessment.  All other hypotheses address differences 
between the two groups (marrow versus PBSC) over four potential time points: pre-transplant, 
six months, one year and two years.  For illustrative purposes, there is 64% power to detect a 0.5 
SD difference in the scores of interest at the two year time point (assuming 81 PBSC and 60 
marrow eligible survivors) and with a Bonferroni correction p=0.01 and two-sided testing. These 
detectable differences are presented in Table 7.9.1. 
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Table 7.9.1:  Detectable Differences 
 
Outcome Raw scores 0.5 SD 
CGVHD Symptoms 12 vs. 18.5 6.5 
Trial Outcome Index 60 vs. 70 10 
Psychological Well-Being 56 vs. 62 6 
Psychological Distress 44 vs. 52 8 
 
 
Differences in QOL between the two groups will be assessed in two main ways.  First, the 
marginal QOL scores given that a patient is alive will be compared at the specific time points 
described above using simple t-tests/confidence intervals.  Each of these time point comparisons 
will be done using the patients alive at that time.  Additionally, a second analysis will be done 
using the Integrated Quality Adjusted Survival to compare the two treatments on an aggregated 
assessment of QOL over the entire period of observation.  This second analysis will account for 
potential differences in the survival rates between the two groups. 
 
7.9.2. Missing Data 
 
Missing data is a common problem in survey and/or longitudinal studies.  Reasons of missing 
data are multifold: death, relapse, drop-out, early termination, or missing assessments.  Death 
rates are expected to be substantial based on the underlying disease states and the nature of 
unrelated donor transplantation, and will be accounted for by the Quality Adjusted Survival, as 
discussed above.  For comparison of QOL among survivors, every effort will be made to collect 
all measurements from all eligible patients to minimize missing data from survivors.  However, 
as experience with the TCD trial suggests, there appear to be fewer problems with missing data 
at later time points because initial toxicity has diminished.  If missing data occur, we will 
diagnose the mechanism and pattern of missing data based on information provided by the site 
and we will perform missing data analysis.  Since prior studies suggest that missing data in 
HSCT studies is associated with poor QOL (84) (i.e., informative right censoring, non-ignorable 
missing), we will explore the generalized Schlucter model (85), which is a joint model for 
longitudinal and survival data, where the survival component of the model acts as a missing data 
mechanism using software developed at the Dana-Farber Cancer Institute (86).  This model 
essentially allows missing QOL measurements at a specific time point of interest to be imputed 
based on how soon after that time the patient dies.  Note that use of subsequent survival 
information to input the QOL scores is primarily useful when comparing QOL at earlier time 
points, because the survival times will be observed until two years for each patient, while at later 
time points there may be less additional time for which the patient’s survival status is recorded.  
Therefore this should be a reasonable approach to dealing with the missing data related to QOL. 
 
7.9.3. Modified Intent-to-Treat 
 
A modified intent-to-treat analysis is planned using all randomized patients who are transplanted 
according to their randomization assignment. 
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7.10. Risks and Discomforts 
 
No medical treatment will be delivered as part of the QOL component.  Participation is limited to 
completion of the surveys.  It is possible that some of the questions may be upsetting, although 
they are all validated instruments used on thousands of patients.  Patients will be reminded 
before every survey administration that they may skip items if they wish.  Distress will be 
assessed at the completion of each survey, and distress attributable to participation in the study 
(as opposed to distress detected incidentally) will be considered a severe adverse event 
reportable to the IRB. 
 
7.10.1. Potential Risks to Research Subjects 
 
As this is an observational study, there are no associated physical risks.  It is possible that the 
survey questions could cause emotional distress, but the risk is likely to be minimal.  Distress 
will be assessed after every contact with patients, and if we detect a high level of distress, the 
transplant center Principal Investigator will be notified. 
 
7.10.2. Adequacy of Protection Against Risks 
 
The informed consent document clearly outlines the QOL procedures, assessment points, time 
commitment and goals of this portion of the trial and must be signed by the patient.  Study 
participants may withdraw their consent to participate at any time or may refuse to participate in 
any aspect of the study.  This withdrawal will not compromise their medical care in any way. 
 
Confidential and emotionally sensitive material will be collected from the patients.  These data 
will be kept in locked research areas.  Access to all data will be limited to study personnel.   
 
7.10.3. Sources of Research Materials 
 
For the QOL component, potentially identifiable information on patients will consist of 
completed surveys.  Patient sociodemographics, quality of life, functional status, employment 
status, mental health and chronic GVHD symptoms will be measured.  Permission to collect all 
data will be obtained through the informed consent document, and will be obtained specifically 
for research purposes.  However, if a high level of emotional distress is detected, the transplant 
center Principal Investigator will be notified. 
 
7.10.4. Potential Benefits 
 
Patients participating in this study are not expected to obtain any direct benefit although some 
patients do report feeling better after participation in other QOL studies. 
 
7.10.5. Potential Benefits of the Proposed Research to the Subjects and Others 
 
This study will involve minimal risk to participants.  No benefits to the patients, as a result of 
participation in the study, are anticipated.  However it is hoped that future patients will benefit.  
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The risks of the study to participants are minimal whether measured absolutely or relative to 
what will be learned to benefit future patients. 
 
7.11. Monitoring and Quality Assurance 
 
7.11.1. Patient Tracking 
 
Patient tracking will be accomplished through a master file maintained by the QOL interviewers.  
Every four months, a progress report with total number of contacts attempted, total number of 
surveys successfully collected, and barriers to complete data collection will be produced.  In this 
way, response rates will be constantly monitored with the ability to enhance data collection 
procedures if inadequate QOL participation is detected. 
 
If serious distress is detected (suicidal, homicidal or psychotic features), the Principal 
Investigator at the patient’s transplant center will be notified for the patient’s own protection.  
This safeguard will be clearly outlined in the patient consent form, “Your answers to the quality 
of life interviews will be kept private and not included in your medical records nor shared with 
your physicians or other caregivers.  Your answers will be coded with a study number only and 
kept in password-protected electronic files or locked in file cabinets.  Only study personnel will 
have access to your information.  However, if any of your answers lead us to believe you are 
seriously depressed or in danger of hurting yourself, your physician will be notified.” 
 
7.11.2. Oversight of Project Staff 
 
Prior to patient contact, all study staff will be able to: 
1. Administer QOL surveys over the phone under appropriate supervision 
2. Demonstrate basic knowledge about the medical procedures under study and know where 
to refer patients who have questions about their medical conditions 
3. Explain and answer questions about the standardized instruments 
4. Know how to recognize and refer patients experiencing distress to the study investigators 
 
Ongoing quality will be maintained through random monitoring of interviews and additional 
training provided as necessary. 
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CHAPTER 8 
 
 
8. DONOR QUALITY OF LIFE 
 
8.1. Background and Significance 
 
Although both bone marrow harvest and PBSC collection are fairly well tolerated by donors (see 
Chapter 1), there may be significant differences between the procedures in terms of their impact 
on donor quality of life (QOL).  In a French study (87), researchers performed a prospective 
evaluation of anxiety, pain, and inconvenience.  Patients were randomly assigned to apheresis or 
bone marrow harvest for collection of stem cells in preparation for an autologous hematopoietic 
cell transplant.  Marrow donor patients experienced more anxiety and pain than PBSC patients.  
Patients undergoing PBSC collection experienced more positive judgments toward the collection 
procedure than bone marrow donor patients.  Patients who had a venous catheter placed for 
collection of stem cells experienced more pain than those from whom stem cells were collected 
by peripheral venous access. 
 
A group in Norway (88) also conducted a randomized study of safety and complaints of PBSC or 
marrow donation of stem cells.  They found a striking difference in the total burden of 
complaints, duration of hospital stay, and sick leave in the two groups of donors, favoring PBSC 
donors.  Interestingly, they found that PBSC donors used more analgesics than marrow donors.  
They hypothesized that these differences may have been due to the nature of the discomfort and 
the expectation that PBSC donors would continue to work during their daily injections of growth 
factor.  They indicated that the method used for informing donors may have influenced 
expectations, possibly impacting the post-procedure assessment.  However, they do not elaborate 
this point. 
 
Switzer et al., (89) compared the physical and psychosocial experiences of marrow and PBSC 
donors donating cells a second time.  Although the study was cross-sectional and retrospective, 
examination of quality of life outcomes from donors who have experienced both procedures 
makes this study unique.  Results were similar to the aforementioned studies; a greater 
proportion of marrow donors reported post-donation physical side effects as compared to PBSC 
donors.  A greater proportion of marrow donors reported using pain medications.  Individuals 
who donated marrow for their first donation and PBSCs for their second reported PBSC donation 
as less physically difficult, time-consuming, and inconvenient as compared to marrow donation. 
 
Rowley et al., (90) compared the experiences of marrow and PBSC donors participating in a 
randomized trial, and did not find significant differences in symptom burden or emotional status 
between collection methods.  They found that pain levels and duration were similar for the two 
groups, although they peaked at different times.  Both marrow and PBSC donors reported 
minimal fluctuations in emotional status.  However, as emotional status was measured with only 
a single, global item, these results should be interpreted with caution. The most significant 
difference between the groups was that recovery time was shorter for PBSC donors. 
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Given the few studies conducted and their somewhat contradictory results, further investigation 
is warranted to better describe the potential differences in quality of life following marrow versus 
PBSC donation. 
 
8.2. Specific Aims and Hypotheses 
 
Our overall goal is compare the QOL of marrow donors with PBSC donors.  We are interested in 
knowing if the physical and psychosocial symptom burdens, recovery time, inconvenience, 
concerns, and satisfaction levels of marrow and PBSC donors differ depending on the donation 
method.  Specific aims include: 
1. To compare the physical side effects, functional ability, and recovery time of donors 
randomized to PBSC or marrow donation. 
2. To compare the psychosocial side effects between the two donation methods. 
3. To compare the inconvenience and restriction of activities between the two groups. 
4. To compare the level of concern about donation of each group. 
5. To compare levels of satisfaction reported by each type of donor. 
 
8.2.1. Hypotheses 
1. PBSC donors will report fewer numbers of side effects and greater functional ability 
overall, but a greater degree of bone pain, than marrow donors.  PBSC donors will 
recover to baseline functioning faster than marrow donors. 
2. PBSC donors will report less anxiety about donation than marrow donors. 
3. PBSC donors will report lower levels of inconvenience and restriction of daily activities 
than marrow donors. 
4. PBSC donors will report fewer concerns about donation than marrow donors. 
5. PBSC donors will report greater satisfaction levels than marrow donors. 
 
8.3. Eligibility and Exclusionary Criteria 
 
Potential study participants will be the 550 donors (~275 each of PBSC and marrow) recruited to 
participate in the randomized clinical trial (RCT).  Donors must (a) meet the standard NMDP 
requirement for donor eligibility, (b) be selected for participation in the RCT, (c) meet the 
inclusion and exclusion criteria listed below, and (d) give signed informed consent to participate 
in both the RCT and the Donor Quality of Life study. 
 
8.3.1. Inclusion criteria 
1. Enrollment in the parent randomized clinical trial. 
2. Signed informed consent. 
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8.3.2. Exclusion Criteria 
1. Inability to read and speak in English, because the instruments to be used in the Quality 
of Life study have not all been validated in other languages. 
2. Inability to complete telephone interview due to cognitive or linguistic difficulties. 
3. Lack of telephone access. 
4. Age less than 18 years. 
 
8.4. Study Procedures 
 
8.4.1. Study Design 
 
Pre-donation.   Donors will be enrolled upon completion of their evaluations and agreement to 
the study randomization.   
 
Within four weeks prior to marrow donation or initiation of G-CSF administration for PBSC 
donors, participants will complete the baseline interview.  Every attempt will be made to 
administer the baseline interview as close to donation or G-CSF administration.  PBSC donors 
will have an additional assessment at Day 4 of G-CSF administration, since the preparatory 
procedures for PBSC donation are considered part of the donation process and include 
experiences that likely affect QOL. 
 
Post-donation.   Donors will be surveyed within 48 hours after donation, then weekly until they 
indicate normal functioning for a period of three consecutive weeks.  Long-term assessment will 
occur at 6 and 12 months.  All questionnaires will be administered by telephone by an 
independent interviewer.  Basic medical information will be obtained directly from donors by the 
donor center following standard NMDP procedures and forms.  Information will include the need 
for central venous catheter placement, hospitalization and reason, and any serious adverse event.   
 
Permission will be sought for repeated QOL and satisfaction assessment yearly for five years.  
These data will not be included as part of this randomized trial. 
 
8.4.2. Study Endpoints 
 
Study endpoints include physical recovery, including symptoms, functioning, and recovery time, 
psychological and social functioning, degree of inconvenience experienced, concerns about 
donation, and satisfaction with donation. 
 
8.4.3. Measures 
 
Sociodemographic Questions: Age, sex, marital status, education level, and work status will be 
assessed. Race/ethnicity will be identified using NIH categories. 
 
Physical Recovery: Physical side effects will be measured by a series of questions used by 
Switzer et al., in their 2001 study of second-time donors.  These questions include assessment of 
fever, overall pain, and specific side effects.  These questions will be supplemented with similar 
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questions contained on the standard NMDP forms, which assess side effects, complications, 
medication use, and discomfort in specific parts of the body, as well as evaluation of return to 
baseline functioning.  Four additional items will assess highest pain intensity, average pain, 
amount of pain, and pain’s effect on sleep using visual analog scales used previously by Rowley 
et al., (90).  Functional status will be measured by toxicity criteria, which is standard on the 
NMDP forms. 
 
General Physical, Social, and Emotional Functioning: Global physical, social, and emotional 
functioning will be assessed with the 12-item Medical Outcomes Survey Short-Form 12v2 (91).  
The SF-12v2 is widely used, reliable and a well-validated instrument that is appropriate for 
individuals with a broad range of functional limitations.  It has the advantage of being linked to a 
substantial body of normative data. 
 
Psychological Functioning: Psychological status will be measured by the Profile of Mood 
States-Short Form (92).  This is a 30-item measure that produces an overall distress score, as 
well as scores on six subscales: depression, anxiety, anger, confusion, fatigue, and vigor.  This 
scale has been shown to have good reliability and validity (92) and has been used extensively in 
the assessment of psychological aspects of quality of life. 
 
Convenience: The degree to which the procedure interferes with daily activities, and requires 
that special arrangements be made for coverage of work or domestic responsibilities, the number 
of days off from work, and the restriction of leisure activities will be assessed with items from 
the standard NMDP forms and items used in previous studies (89). 
 
Concerns about Donation: The degree to which donors are concerned about short- and long-
term health effects of donation will be assessed with questions used in previous studies (89). 
 
Satisfaction with Donation: Donors’ level of satisfaction with their donation experience will be 
assessed with questions used in previous studies (89). 
 
Clinical Data: Number of blood transfusions given, requirement for a central line and the 
number and duration of leukapheresis procedures will also be assessed via NMDP forms. 
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Table 8.4.3:  Data Collection Timeline 
 
Measures N items Pre 
Day 4-
PBSC only
Within 48 
hours 
donation 
Weekly 
until 3 
weeks 
after full 
recovery 
Final 
weekly 
assessment 
after full 
recovery 
6 & 12 
mos 
Sociodemographics and 
Background Information 
13 X      
Influence of Others 4 X    X  
Concerns about Donation 5 X 
(7 items) 
X X  X X 
Preparedness 5 X    X  
Physical Symptom Scale 12 X X X X X X 
Physical/Emotional Function: 
SF-12 
12 X  X  X X 
Pain 4 X X X X X X 
Profile of Mood States 30 X  X  X X 
Satisfaction and Feelings 
about Donation 
9   X  X X 
Response of Others 3   X  X X 
Side Effects 7  X 
(6 items) 
X X X X 
Inconvenience 5  X 
(4 items) 
  X X 
Concerns about the Recipient 5   X X X X 
TOTAL N ITEMS 105 87 35 87 28 92 88 
ANTICIPATED TIME  20 min 10 min 20 min 5 min 25 min 20 min 
 
 
8.5. Description of Study Process 
 
8.5.1. Contact Information 
 
Refer to Donor Center Companion Manual. 
 
8.5.2. Informed Consent 
 
A copy of the signed informed consent will be kept in a secure location to ensure confidentiality. 
 
8.5.3. Collection of QOL Data 
 
All interviews will be administered by telephone by a trained interviewer.  If donors wish, they 
can receive a mailed copy of the interviewer’s questionnaire to review before the telephone 
interview.  Medical information will be obtained by the donor center following standard NMDP 
procedures and forms. 
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8.5.4. Withdrawal of Consent for QOL Data Collection 
 
If a donor wishes to discontinue participation, every attempt will be made to ascertain the reason 
for discontinuation.  In general, the project coordinator or the study Principal Investigator will 
briefly review the procedures to make certain that the cause of withdrawal is not 
misunderstanding of study procedures. 
 
8.5.5. Letter of Appreciation and Summary of Results 
 
At the close of the study, thank you letters will be sent to each participant.  A summary of study 
results will be made available upon request. 
 
8.6. Statistical Considerations 
 
8.6.1. Sample Size 
 
As donor quality of life is a secondary endpoint for this randomized trial, the sample size is 
predetermined by the primary endpoint of patient survival.  A total sample size of 550 will 
provide more than adequate power to examine group-level differences between PSBC and 
marrow donors. 
 
8.6.2. Group Comparisons 
 
All demographic variables will be summarized and the PBSC and marrow groups will be 
compared with chi-squared tests as appropriate.  All outcome variables will be compared 
between the two groups at each time point using t-tests for continuous outcomes, nonparametric 
Wilcoxon tests for ordinal outcomes, chi-square tests for nominal categorical variables, and chi-
square trend tests for ordinal categorical variables, as appropriate.  A significance level of 0.01 
will be used as protection against multiplicity due to a large number of outcome variables and 
time points examined.  In addition, because physical recovery and psychological functioning are 
assessed both at baseline and subsequent times, adjustment for baseline measurements will be 
considered.  Symptom reporting (three categories) will be compared between the two groups at 
each time point using chi-squared tests, and may be adjusted for baseline symptom levels by 
treating them as strata variables.  Pain and psychological functioning will be compared between 
the two groups using mixed models for repeated measures data.  Clinical data will be compared 
between the two groups using nonparametric Wilcoxon tests or chi-squared tests as appropriate. 
 
8.6.3. Missing Data 
 
Missing data will initially be assumed to be missing at random, requiring no adjustment to the 
mixed models analysis across time.  If this is the case, separate tests performed at each time point 
will be done with the complete data at that time.  However, missing cases will be examined to 
determine whether data are missing systematically by key sociodemographic indicators. 
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8.7. Risks and Discomforts 
 
QOL data collection involves non-invasive survey procedures that pose no risk to the 
participants.  It is possible, although highly improbable, that completion of the survey items 
could elicit distress.  However, participants are instructed not to answer any questions that make 
them uncomfortable.  Donors also are informed that they may withdraw from study participation 
at any time without penalty.  Should high levels of distress be detected during donor contacts, the 
interviewer will attempt to determine the nature and intensity of the distress, and will ask the 
donor if they wish to receive a follow up call from their local donor coordinator, Principal 
Investigator of the RCT, or from a member of the Donor Services Staff at the NMDP.  If the 
donor says yes, the interviewer will contact the appropriate individual within 12 hours.  That 
individual, in turn, will make every attempt to contact the donor by telephone within 24 hours. 
 
8.8. Potential Benefits 
 
There are no direct benefits to participating in this study.  However, participants may experience 
positive feelings associated with sharing their experiences and/or contributing to research that 
may help others in the future. 
 
8.9. Monitoring and Quality Assurance 
 
The QOL data is confidential and will be kept in secure areas accessible only to study personnel.  
The study will be approved by the IRBs of all participating centers.  Standard operating 
procedures to respond to any adverse event are delineated above.   
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APPENDIX A 
 
RATIONALE FOR THE STUDY DESIGN 
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APPENDIX A – RATIONALE FOR THE STUDY DESIGN 
 
 
In creating this study, the protocol team held extensive discussions about the proper approach to 
donor and recipient enrollment.  The study is complicated because two research subjects, the 
hematopoietic stem cell (HSC) donor and the HSC recipient, must be managed 
contemporaneously.  Between these two, the recipients are inherently more unstable and more 
likely to shift in their eligibility status over short periods of time. 
 
The selected management schema is depicted in Figure 1.  Here the recipient eligibility is 
divided into two components, eligibility for randomization and eligibility for transplantation.  
The donor will be selected, enrolled and cleared for donation prior to randomization.  The 
recipient should be confirmed eligible for randomization prior to donor work-up (using the 
somewhat abbreviated criteria described in Section 2.3, with information that can be obtained by 
phone or mail for patients remote from the transplant center), but must be confirmed eligible on 
full evaluation at the transplant center after randomization but before conditioning therapy is 
initiated. 
 
Once the pair is randomized, the recipient will undergo work-up to determine final eligibility for 
transplantation.  Simultaneously, the donor will be prepared for the assigned donation, bone 
marrow or mobilized peripheral blood.  The donor’s preparation will require 2 – 3 weeks, during 
which time the recipient will be confirmed eligible for transplantation (Figure 1). 
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The major disadvantage of this approach is that a certain proportion of recipients will be found 
ineligible for transplant after randomization.  Based upon NMDP data, this is expected to be 15% 
or less, and has led to appropriate adjustment in the sample size (see Section 5.3).  The intent to 
treat analysis is discussed in the protocol. 
 
Several alternative approaches were considered.  The first of these involved performing work-up 
of both the donor and recipient prior to randomization (Figure 2).  
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This schema has the advantage of ensuring that the recipient is fully eligible for the study and 
transplantation prior to randomization.  The problem here is that following randomization the 
donor must still be prepared for donation.  During this 2 - 3 week preparation, the recipient will 
have ample time to change in status.  Complete or partial rework-ups would be needed for some 
recipients.  Also a consideration, long-distance recipients, i.e., those living far from the 
transplant center, would need to travel back and forth or stay in the transplant center city for 
several weeks before transplant. 
 
A modified version of schema II was also considered at the request of some donor center medical 
directors (Figure 3).  It was reasoned that donor enrollment would be greatly simplified if the 
randomization assignment was known at the time of donor work-up request. 
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Thus, the recipient would be randomized to a treatment arm and the donor invited to participate 
in the study by agreeing to provide the assigned product.  This model was discarded because it 
further aggravated the time delay for recipients between randomization and transplantation.  In 
addition, there were concerns because it could be argued (strongly) that donors were being 
randomized prior to their enrollment. 
 
The ideal randomization schema would place randomization as close as possible to the start of 
therapy.  This model is shown in Figure 4.  This model, unfortunately, would require that donors 
be prepared for both PBSC and marrow donation during the days prior to randomization.  Thus it 
would be necessary to schedule collection time in both the operating room and apheresis center.  
In all likelihood, donors eventually randomized to PBSC would still need to provide autologous 
blood before the randomization.  This model was rejected because it is too complex, it ties up 
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resources that do not belong to the donor centers (operating room and apheresis time) and it 
would be prohibitively costly (Figure 4). 
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APPENDIX B-1 
 
RECIPIENT CONSENT FORM and ATTACHMENTS 
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 Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell 
with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Institution  
Name/Title/Phone number/ 
 
3. Contact information for Emergencies after Hours or on Weekends or Holidays 
Name/Phone number/ 
 
4.  Sponsors and Source of Funding or Other Material Support 
The research in this study is paid for by the National Institutes of Health (NIH) and the National Marrow 
Donor Program ® (NMDP).  The NMDP and the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN) will direct the research study.  This study will be done at many different medical centers, 
including [Center Name/Location]. 
 
5. Introduction 
This is a consent form for a research study.  You are being invited to participate in this study because 
you have a disease that may be treated with a transplant of either bone marrow or peripheral blood 
stem cells (PBSC).  This form is intended to give you information to help you decide if you want to 
participate in this study.  You should read this form and ask any questions you may have before 
agreeing to be in the study. 
 
Doctors have been successfully treating blood disorders such as leukemia and myelodysplasia with a 
transplant of blood stem cells from either the bone marrow or the peripheral blood.  The goal of this 
study is to see if patients receiving a transplant from an unrelated donor have better results using 
blood stem cells from: 1) bone marrow or 2) peripheral blood.  The study may find that patients have 
similar results with either type of transplant.   
 
Important results of this study will include: 
 Survival 
 Quality of life 
 Blood counts after transplant 
 Number and severity of infections 
 Graft-versus-host disease (GVHD) 
 Relapse of disease (return of disease) 
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Other information about the study: 
 You will not be paid to be in this study. 
 You or your insurance company will pay the bills for your medical treatment. 
 You will not be charged for research tests. 
 You will face the same risks and benefits as any other bone marrow or peripheral blood stem 
cell (PBSC) transplant patient. 
 
It is your choice whether or not to participate in this study.  You and the medical staff at your 
transplant center will discuss other treatment options before you make your decision about 
participating in this study. 
 
6. Purpose of the Study 
This study will look at two kinds of blood stem cell transplants, bone marrow and peripheral blood 
stem cell (PBSC), and their side effects.  At this time, doctors use both types of blood stem cells for 
transplant.  Previous studies have compared the survival of patients who received an unrelated donor 
transplant from bone marrow with patients who received an unrelated donor transplant from PBSCs.  
In these studies there was no difference in survival between the bone marrow transplant patients and 
PBSC transplant patients.  This may have been because the patients in each group did not have the 
same characteristics (for example, different diseases, different ages). 
 
In this study, the patient and donor will be randomly assigned (much like the toss of a coin) to either 
the bone marrow or the PBSC transplant study group.  By randomly assigning the patients to receive 
either a bone marrow or PBSC transplant, the characteristics of each study group should be similar.  
The primary goal is to see which type of blood stem cell transplant (bone marrow or PBSC) has better 
survival results.  With similar patient characteristics in each study group, researchers should be able to 
find out if one type of blood stem cell transplant (bone marrow or PBSC) has better survival results 
for patients, or if both types of blood stem cell transplants have similar survival results.   
 
An important part of this study will look at how well you feel after your transplant.  Researchers want to 
know the effects from each type of stem cell used for the transplant and how long they last. 
 
Good effects might include: Bad effects might include: 
 Quick recovery of blood counts after 
transplant 
 Slow recovery or no recovery of 
blood counts after transplant 
 No relapse of disease  Relapse of disease 
 High cure rates  Severe graft-versus-host disease 
(GVHD) 
 Few infections  Serious infections 
 Able to return to important activities in life  Not able to return to important 
activities in life 
 
The information collected from this study will help doctors and future patients make better treatment 
choices.  About 550 patients will take part in this study at many centers around the country. 
 
7. Study Procedures 
If you agree to participate in the study, the transplant process has many steps.  A matched donor must 
be found.  Both you and the donor will need to to give permission to participate in this study.  A 
donor could refuse to participate in this study, but continue to be available for your transplant.  In that 
case, you may decide to have a transplant using this donor, but not participate in this study or another 
donor may be found who does want to participate in this study. 
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Since this study looks at the results of two different kinds of transplants, bone marrow and peripheral 
blood stem cell (PBSC), the kind of transplant you will receive will be decided randomly, like a coin 
toss.  Neither you nor your doctor chooses the type of transplant; the type of transplant you will 
receive is determined by a computer program.  Half of the patients in the study will have a bone 
marrow transplant.  The other half will receive a PBSC transplant.  Participation in the study means 
that you are willing to accept either type of transplant. 
 
One part of the study will involve collecting your medical information.  Your medical information 
will be collected for three years.  The study coordinators at your center will collect information from 
your medical record chart every week for 100 days, then at 6 months, 1 year, 2 years, and 3 years. 
 
Another part of the study will ask questions about your physical and emotional health.  This 
information will be collected for five years.  A trained interviewer will contact you by telephone 
before your transplant, then 6 months, 1 year, 2 years and 5 years after your transplant.  These 
interviews will last approximately 15-25 minutes and will be done at a convenient time for you.  They 
will include questions about side effects, health problems and how well you can do things that are 
important to you.  When you are contacted, you may skip any questions you don’t want to answer. 
 
As part of the standard transplant procedure, you will need to take many medications and have other 
medical treatments.  The medical staff will explain these during discussion of your medical care. 
 
8. Possible Discomforts and Risks 
You will face risks from the transplant itself, and from treatments given before and after the 
transplant.  Your doctor thinks these risks are less than the risk from the disease for which you are 
receiving a transplant.  
 
The bone marrow and PBSCs from the donor contain blood stem cells, which allow your blood 
counts (red blood cells, white blood cells, and platelets) to recover.  Blood stem cells make all the 
blood cells in the bone marrow and serve the entire body.  It is possible that even after the transplant 
your bone marrow will not work well enough, and you will be at an increased risk of infections and 
even death.  Infections after transplant can be from bacteria, viruses, parasites, or fungi.  Early after 
transplant, the risk of getting an infection might be less after a PBSC transplant, because the blood 
counts return faster than with bone marrow.  Later, the risk of infections might be increased in PBSC 
transplants, because graft-versus-host disease (GVHD) might be worse and last longer.  Blood counts 
will be done often to track recovery of the bone marrow.  You will get platelets and red cells as 
needed to keep your counts at a healthy level. 
 
There is a risk that stem cells may not grow after being given to you.  This is called graft failure.  
Graft failure can be fatal unless you have a second transplant.  Failure of the donor cells to grow 
(graft failure) may result from a mismatch with the donor, infection, a reduced effect of pre-transplant 
drugs on your body, or not enough cells in the product.  This risk may be less with PBSCs, since 
PBSCs contain more blood stem cells than bone marrow. 
 
Graft-versus-host disease (GVHD) is a frequent problem after unrelated donor transplantation.  After 
the cells in the product begin to grow, there is a risk that the donor cells may react against your body.  
GVHD may show up as a skin rash, or liver or stomach problems.  GVHD may cause nausea (feeling 
sick to your stomach), vomiting (throwing up), lack of appetite, stomach cramps, diarrhea (loose 
stools), and bleeding of the gut.  Chronic GVHD may occur later after transplantation and may 
involve problems with the eyes, mouth, lips, throat and liver.  Early (acute) or late (chronic) GVHD 
may be bad enough to cause death.  GVHD is treated with drugs that weaken the body’s defense 
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system, and thus make you more likely to get an infection.  The chance of getting GVHD may be 
increased with PBSCs, since PBSC transplants contain more donor cells. 
 
Relapse of your disease might occur after transplant, especially in patients with advanced disease.  
This risk may be decreased by PBSC transplantation. 
 
If one type of transplant does have better results, and you are not randomly assigned to that study 
group, you may not receive the same benefits as those in the study group with overall better results. 
 
Completion of the quality of life interviews will not cause you any physical discomfort, although it is 
possible that you will find some of the questions or topics upsetting.  If you do, there will be someone 
available to speak with you.  They will be able to refer you to appropriate counselors or other support 
people. 
 
Refer to Appendix A, B, C or D for additional risks and toxicities toxicities related to the specific 
transplant conditioning regimen you will receive, the drugs you will receive to help prevent graft-
versus-host disease (GVHD) and risks and toxicities related to the transplant procedure itself. 
 
9. Unknown or Unexpected Side Effects  
As with any treatment, there may be unknown and/or unexpected side effects from a bone marrow or 
PBSC transplant.  We may learn new things about bone marrow or PBSC transplants that might make 
you want to stop being in the study.  We will let you know if this happens and you can decide if you 
want to continue in the study. 
 
10. Alternative Treatments Available if You Don’t Want to be in the Study 
Participation in this study is entirely voluntary.  You don't have to be in this study.  What you decide 
will not affect current or future health care you receive at this institution.  Before you decide to be in 
this study, you and the medical staff will discuss other options available to you, including: 
 No treatment 
 Chemotherapy 
 A transplant using your own bone marrow or PBSCs 
 A transplant of bone marrow or PBSCs from a relative 
 A transplant of cord blood cells 
 A bone marrow or PBSC transplant from an unrelated donor without participation in this study 
 
11. Possible Benefits to Participating in the Study 
This research study is comparing the treatment results of bone marrow and PBSC transplants.  At this 
time doctors do not know if one type of transplant has better results than the other, or if they both 
have the same results.  If one type of transplant does have better results, and you are randomly 
assigned to that study group, you may benefit from participating in the study.  The knowledge gained 
from this study may help future patients who need a blood stem cell transplant, but there is no 
expectation that you will benefit from participating in the study. 
 
As a result of the bone marrow or PBSC transplant your disease may be put in remission or continue 
in remission. 
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12. Cost of Participating in the Study 
You and/or your insurance company will pay all medical expenses relating to, or arising from 
transplantation of either bone marrow or PBSC.  Research tests described in Section 20 will be paid 
by the NIH and the NMDP.  
 
For questions about your costs, financial responsibilities, and/or medical insurance coverage for your 
transplant and this study, please contact /Center/ Financial Counselor at /Number/. 
 
13. Reimbursement for Participating in the Study 
You will not be paid for participating in this study. 
 
14. In the Event of Injury While Participating in the Study 
If you are injured or become ill while taking part in this study, medical care will be provided at this 
center.  No funds have been set aside to pay you if you are injured.  You or your insurance company 
will be charged for ongoing medical care and/or hospitalization. 
 
Contact your doctor or one of the people listed at the start of this form if you are concerned about a 
research-related injury. 
 
15. Withdrawing from the Study 
You may decide to withdraw at any time, for any reason, without notice from this study that compares 
bone marrow transplant with PBSC transplant.  If you wish, you may withdraw from the study but 
still receive a blood stem cell transplant.  If you withdraw from the study after you have had some or 
all of the pre-transplant treatments and decide to have no transplant at all, then your blood counts may 
not return and you could die. 
 
If you decide to withdraw from the study, we ask that you tell [the Principal Investigator] in writing 
(his/her address is on the front page of this form).  If you withdraw, there will be no penalty or loss of 
benefit to which you are entitled and you will continue to receive medical care. 
 
If you withdraw from the study, the medical staff will continue to tell us about your progress for three 
years after your transplant.  If you do not want this, you must specifically tell your doctor. 
 
If you have any questions about your rights as a study subject, you may contact the Institutional Review 
Board (IRB) office at /number/. 
 
16. Reasons Your Doctor May Take You off the Study 
You can be taken off the study (with or without your consent) for any of these reasons: 
 You would be harmed by staying in the study. 
 You need treatment not allowed in this study. 
 You do not follow directions that are important to participating in the study. 
 The study is cancelled.  
 
17. Protection of your Privacy and Confidentiality of Your Research Records  
Your participation in this research study will be kept private and confidential.  All your medical, 
demographic (such as race and ethnicity, gender and household income) and quality of life 
information will be kept private and confidential. (Name of Transplant Center) and the organizations 
listed below will not disclose your participation by any means of communication to any person or 
organization, except by your written request, or permission, or unless required by federal, state or 
local laws, or regulatory agencies.  
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Individuals authorized by the organizations below will have access to your research and medical 
information for inspections or audits.  In agreeing to participate, you consent to such inspections and 
to the copying of excerpts from these records, if required by these authorized representatives. 
 
Organizations with access to your research and medical information:  
 /Institution/ 
 The National Institutes of Health (NIH) 
 Office of Human Research Protection (OHRP) 
 The Food and Drug Administration (FDA)  
 Institutional Review Boards (IRBs) responsible for this study 
 Data and Safety Monitoring Board (DSMB), not part of /Institution/ 
 The National Marrow Donor Program (NMDP) 
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 
 Quality of Life staff at Center on Outcomes, Research, and Education at Evanston Northwestern 
Healthcare 
 Laboratory staff at Dr. Edmund Waller’s laboratory at Emory Unversity, Esoterix, Inc., Dr. 
Jeffrey Miller’s laboratory at the Univerity of Minnesota 
 
Scientific and medical findings resulting from a study may be presented at meetings and published so 
that the information can be useful to others.  You would not be identified in these presentations and 
publications.  
 
For questions about access to your medical records, please contact /name / at/number/. 
 
18. Expiration Date for Keeping Your Records 
Study records will be kept indefinitely by the transplant center for re-analysis and follow-up. 
 
If you have questions about the keeping of your research records or access to your files, please call 
/name/at /number/. 
 
19. Benefit to Doctors for Your Participation in this Study 
Your doctors have no money invested in this study.  Presenting research results may help the career of a 
doctor.  Therefore, the doctors running this research study may benefit when the results are presented at 
scientific meetings or in the scientific press.  In addition, the hospital where you will receive your 
transplant is paid for participating in the study. 
 
20. Blood Samples for Research Purposes 
You will be asked to provide blood samples to see if infection-fighting cells are working and to help 
better understand tissue matching between donors and recipients in this study.  You do not have to 
participate in this part of the study. 
 
If you agree, you will provide blood samples up to 7 times (10-100 mL each time or approximately 1-
7 tablespoons) between the time transplant is initiated and two years after (up to a total for all 7 blood 
draws of 430 mL or approximately 2 cups).  The samples will be saved for future testing.  The blood 
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can usually be drawn from your central line at the time of other blood collections.  If this is not 
possible, then it will be drawn directly from a vein. 
 
As a standard part of the transplant procedure you will receive vaccinations for diphtheria, tetanus, 
Hepatitis B and pneumococcus.  The research studies on infection-fighting cells will include studies 
to look at how well these vaccinations are working.  You may still receive the vaccinations as part of 
your standard medical care even if you decide not to participate in the research on infection-fighting 
cells. 
 
The doctors conducting this study may choose to do some additional research tests on the blood 
samples.  These tests would only be done if the groups overseeing the safety and protection of 
subjects participating in this study approved these additional tests.  These tests would only be 
performed on blood samples that were left-over after the tests on infection-fighting cells, 
vaccinations, and tissue matching were done; no additional blood would be drawn for these tests.  
This research may include tests to determine and evaluate other factors that affect transplant outcome 
in this study. 
 
Any of your blood samples drawn for research purposes will be sent to laboratories that have a 
contract with the NMDP to conduct these research tests.  Your blood will be labeled with a unique 
code that contains no information that could identify you.  A link to this code does exist.  The link is 
stored at the Data Coordinating Center for the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN).  The staff at the laboratory where your blood is being tested does not have a link to this 
code.  Your blood will be stored at these laboratories until the entire sample has been used for the 
research tests or until the end of the study. 
 
If any of your blood samples are left over after the research studies are completed, these samples will 
either be destroyed or be sent to the National Heart Lung and Blood Institute (NHLBI) sample 
repository in Maryland.  If your left-over blood samples are sent to the repository, they will be given 
an anonymous code.  These left-over blood samples stored at the repository can never be linked to 
you.  Any research performed on these left-over blood samples must first be approved by an advisory 
panel at the NHLBI. 
 
You are free to not take part in this research and still participate in the other parts of the study.  
There will be no change in your care if you choose not to give blood samples for research purposes.  
Please mark your choice below (check only one box): 
 
 I agree to have blood drawn for research purposes. 
 
 I do not agree to have blood drawn for research purposes. 
 
 
_________________________________________  _________________________________  
Signature Date 
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21. Subject’s Consent  
 
I have been informed about this study’s purpose, procedures, possible benefits and risks.  I have been 
given a chance to ask questions and have had them answered to my satisfaction.  I understand that I 
can ask more questions at any time. 
 
I voluntarily agree to participate in this study. 
 
By signing this consent form, I have not given up any of the legal rights, which I otherwise would 
have as a subject in a research study. 
 
 
 
            
Signature of Subject     Date 
 
 
_________________________________________  
Print Name of Subject 
 
 
Certification of Counseling Healthcare Professional 
 
 I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this study have been explained to the above individual and that any questions about 
this information have been answered. 
 
 
_________________________________________  _________________________________  
Counseling Healthcare Professional Date 
 
  Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to  
  obtain consent: 
 
  Print name of interpreter: _________________________  Date: ______________________  
 
  Signature of interpreter: __________________________   
 
  An oral translation of this document was administered to the donor in ________________ (state  
  language) by an individual proficient in English and __________________ (state language).  See the  
  attached short form addendum for documentation. 
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Attachment A 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Total Body Irradiation and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications and irradiation therapy you will receive as part of the conditioning for the 
transplant, and risks related to the transplant itself.  Most of these risks and side effects are listed below, 
but they will vary from person to person.  There may be more risks involved with transplantation, and 
there may be more side effects.  Your doctor may give you medications to lessen some of the side-effects.  
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause you to have diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-term 
bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder damage and 
bleeding for a longer time.  You will be given large amounts of a sterile solution through your central line 
to protect your bladder.  A bladder catheter (thin plastic tube) may be inserted into your bladder, if your 
physician thinks that it can help you.  Cyclophosphamide slows the making of new red blood cells, white 
blood cells, and platelets.  This causes a risk of infection and/or severe bleeding until the transplanted 
donor cells begin to work in you.  You will get blood transfusions as needed.  Cyclophosphamide also 
lowers your defense system.  As a result, you may have more infections for several months after 
transplant.  In a small number of patients, cyclophosphamide can damage the heart muscle causing heart 
failure.  Sometimes cyclophosphamide causes abnormal heart function.  If this occurs you may have 
shortness of breath and have fluids build-up in your body.  This medication can also cause the lungs to 
become scarred. If scarring of the lungs occurs it will usually happen three to six months after you receive 
the medication.  Scarring of the lungs can cause you to die.  Cyclophosphamide can damage the male 
(testes) or female (ovaries) sex glands.  In men, the number of sperm may be reduced but you would still 
be able to have intercourse.  Women who are still menstruating may have irregular periods or may no 
longer have any periods.  Whether you are a man or woman, this medication will likely greatly decrease 
your chances of being able to have a child.  It is not known whether the use of cyclophosphamide will 
cause more side effects or problems with your health in the future. 
 
Total Body Irradiation (TBI):  TBI may cause you to have diarrhea (loose stools), nausea (feeling sick 
to your stomach), vomiting (throwing up), and painful swelling of the saliva gland for a few days.  You 
may also experience short-term hair loss.  TBI kills both sick and normal marrow, leading to a lack of red 
blood cells, white blood cells, and platelets.  The short-term loss of these blood cells could cause you to 
become anemic, develop an infection, and/or bleeding.  This will continue until the transplanted donor 
cells begin to work in you.  You will get blood transfusions as needed.  There is a risk that cataracts 
(cloudiness) may develop in your eyes.  This may mean partial loss of vision, and you may need contact 
lenses or surgery to remove the cataracts.  The TBI dose used will probably result in sterility (not being 
able to have children.)  It is not known whether the use of TBI will cause more side effects or problems 
with your health in the future. 
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Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cell (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness).   
 
 
Risks Related to the Medications Used to Help Prevent Graft-versus-host Disease (GVHD) 
 
Cyclosporine or Tacrolimus:  These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience include nausea 
(feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  Other 
side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects, 
they generally go away when the dose of the medication is decreased.  A few patients have had a seizure 
while on these medications.  You may experience a change of liver or kidney function, in which case the 
medication dose will be reduced or possibly even withheld.  The effect on kidneys seems to increase 
when other medications, which might cause kidney problems, are given at the same time, especially 
antibiotics.  Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate:  This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare you for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate and Steriods:  These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant.  
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but 
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more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets and may be at serious risk for bleeding.  
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy, irradiation 
therapy, or both.  VOD causes severe damage to the liver.  Symptoms include jaundice (yellowing of the 
skin and eyes), weight gain, and extra fluid build-up in the abdominal cavity and other parts of the body.  
It can often be managed successfully, and completely resolve.  However, complications can arise that may 
be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines and irradiation cause irritation in the lining of 
the mouth and intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth 
sores you will be given medicine to help control the pain.  If your mouth sores are severe you may not be 
able to eat normally until the sores are healed.  Mouth sores get better when the white blood count starts 
to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy and irradiation therapy.  The 
blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You 
may gain water weight and not go to the bathroom as often as you normally do.  Capillary leak syndrome 
can be difficult to manage if extra fluid enters the lungs and causes difficulty breathing.  You may die if 
there is continued fluid collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  Occasionally, the high 
doses of chemotherapy and radiation cause severe lung damage that cannot always be treated.  If this 
happens, you may need to use oxygen or even a respirator.  The lung damage may get worse and be life-
threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  As a result of irradiation, cataracts may occur earlier in life compared to a person who had 
not had a transplant.  If you develop cataracts (cloudiness in the eyes) they may require treatment.  It is 
rare, but your kidneys could be affected, causing anemia (low red blood cell count) or high blood 
pressure.  There is also a risk you may develop a second cancer as a result of the chemotherapy, 
irradiation and/or underlying disease.  If secondary cancers occur they generally do not occur until 10 to 
15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
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Attachment B 
 
Additional Risks and Toxicities Related to the Standard Transpant Procedure 
Busulfan and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications you will receive as part of the conditioning for the transplant, and risks 
related to the transplant itself.  Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your doctor may give you medications to lessen some of the side-effects.  
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause you to have diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-term 
bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder damage and 
bleeding for a longer time.  You will be given large amounts of a sterile solution through your central line 
to protect your bladder.  A bladder catheter (thin plastic tube) may be inserted into your bladder, if your 
physician thinks that it can help you.  Cyclophosphamide slows the making of new red blood cells, white 
blood cells, and platelets.  This causes a risk of infection and/or severe bleeding until the transplanted 
donor cells begin to work in you.  You will get blood transfusions as needed.  Cyclophosphamide also 
lowers your defense system.  As a result you may have more infections for several months after 
transplant.  In a small number of patients, cyclophosphamide can damage the heart muscle causing heart 
failure.  Sometimes cyclophosphamide causes abnormal heart function.  If this occurs you may have 
shortness of breath and have fluids build-up in your body.  This medication can also cause the lungs to 
become scarred.  If scarring of the lungs occurs it will usually happen three to six months after you 
receive the medication.  Scarring of the lungs can cause you to die.  Cyclophosphamide can damage the 
male (testes) or female (ovaries) sex glands.  In men, the number of sperm may be reduced but you would 
still be able to have intercourse.  Women who are still menstruating may have irregular periods or may no 
longer have any periods.  Whether you are a man or woman, this medication will likely greatly decrease 
your chances of being able to have a child.  It is not known whether the use of cyclophosphamide will 
cause more side effects or problems with your health in the future. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
you most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases your risk of infection, lower platelet count that 
increases your risk of bleeding, hair loss, stopping of menstrual periods in women, temporary reduced or 
no sperm production in men.  Less likely side effects that you may experiene are fatigue, sores in the 
mouth or on the lips, fever, rash, loss of appetite, changes in color of the skin, seizure.  Rare side effects 
that you may experience are damage to your lungs, which may cause you to cough, be short of breath and 
have trouble breathing.  It is rare, but busulfan can also cause changes in your liver function.  
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cell (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
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an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience include nausea 
(feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  Other 
side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects 
they generally go away when the dose of the medication is decreased.  A few patients have had a seizure 
while taking these medications.  You may experience a change of liver or kidney function, in which case 
the medication dose will be reduced or possibly even withheld.  The effect on kidneys seems to increase 
when other medications, which might cause kidney problems, are given at the same time, especially 
antibiotics.  Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare you for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant.  
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but 
more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets and may be at serious risk for bleeding. 
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Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth sores you will 
be given medicine to help control the pain.  If your mouth sores are severe you may not be able to eat 
normally until the sores are healed.  Mouth sores get better when the white blood count starts to rise, and 
engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You may gain water weight and 
not go to the bathroom as often as you normally do.  Capillary leak syndrome can be difficult to manage 
if extra fluid enters the lungs and causes difficulty breathing.  You may die if there is continued fluid 
collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  Occasionally, the high 
doses of chemotherapy cause severe lung damage that can not always be treated.  If this happens, you 
may need to use oxygen or even a respirator.  The lung damage may get worse and be life-threatening.  
Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  It is rare, but your kidneys could be affected, causing anemia (low red blood cell count) or 
high blood pressure.  There is also a risk you may develop a second cancer as a result of the 
chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur until 10 
to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
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Attachment C 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Melphalan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications you will receive as part of the conditioning for the transplant, and risks 
related to the transplant itself.  Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your doctor may give you medications to lessen some of the side effects.  
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects you may experience are low white 
blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects you may experience 
include confusion or coma, trouble seeing or problems with your eyes, trouble breathing, diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), pneumonia, agitation, numbness 
and tingling of the fingertips and toes, and kidney problems. 
 
Melphalan: This medication disrupts the growth of cancer cells and destroys them.  Side effects you 
most likely will experience include nausea (feeling sick to your stomach), hair loss, and low white blood 
cell count, which may lead to infection.  Less likely side effects you may experience include diarrhea 
(loose stools), mouth ulcers, and low platelet count with increased risk of bleeding.  It is rare, but you 
may experience a severe allergic reaction.  Symptoms of a severe allergic reaction include itching, hives 
(bumps on your skin), flushing (redness), wheezing, chest tightness, skin rashes, fever, chills, muscle 
stiffening, severe breathing problems, and loss of appetite. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cell (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness).   
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience may include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects 
they generally go away when the dose of the medication decreased.  A few patients have had a seizure 
while taking these medications.  You may experience a change of liver or kidney function, in which case 
the medication dose will be reduced or possibly withheld.  The effect on kidneys seems to increase when 
other medications that might cause kidney problems are given at the same time, especially antibiotics.  
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Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by-mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is a medication used to try to prevent GVHD.  Methotrexate causes damage to cells, 
and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth sores 
or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare ou for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all.   
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and as a result bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but more 
serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets, and may be at serious risk for bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It may often be managed 
successfully, and completely resolve.  However, complications can arise that can be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth sores you will 
be given medicine to help control the pain.  If your mouth sores are severe you may not be able to eat 
normally until they are healed.  Mouth sores get better when the white blood count starts to rise, and 
engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You may gain water weight and 
not go to the bathroom as often as you normally do.  Capillary leak syndrome can be difficult to manage 
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if extra fluid enters the lungs and causes difficulty breathing.  You may die if there is continued fluid 
collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of this the transplant.  Occasionally, the 
high doses of chemotherapy cause severe lung damage that can not always be treated.  If this happens, 
you may need to use oxygen or even a respirator.  The lung damage may get worse and be life-
threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  It is rare, but your kidneys could be affected, causing anemia (low red blood cell count) or 
high blood pressure.  There is also a risk you may develop a second cancer as a result of the 
chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur until 10 
to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating all of this fluid.  Furosemide is a medication that is often given to help eliminate 
this excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium 
and sodium. 
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Attachment D 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Busulfan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications you will receive as part of the conditioning for the transplant, and risks 
related to the transplant itself.  Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your doctor may give you medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects you may experience are low white 
blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects you may experience 
include confusion or coma, trouble seeing or problems with your eyes, trouble breathing, diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), pneumonia, agitation, numbness 
and tingling of the fingertips and toes, and kidney problems. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
you most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases your risk of infection, lower platelet count that 
increases your risk of bleeding, hair loss, stopping of menstrual periods in women, temporary reduced or 
no sperm production in men.  Less likely side effects that you may experience are fatigue, sores in the 
mouth or on the lips, fever, rash, loss of appetite, changes in color of the skin, seizure.  Rare side effects 
that you may experience are damage to your lungs, which may cause you to cough, be short of breath and 
have trouble breathing.  It is rare, but busulfan can also cause changes in your liver function.  
 
Antithymocyte Globulin (ATG): This medication is given pre-transplant with the conditioning regimen 
medications to try and prevent both acute and chronic graft-versus-host disease.  While taking ATG you 
most likely will have, a fever and chills, a lower white blood cell count that increases your risk of 
infection, a lower platelet count that increases your risk of bleeding, and a skin rash.  Less likely side 
effects you may experience are fatigue, diarrhea, vomiting, muscle aches and headaches.  Rare side 
effects that you may experience are changes in your blood pressures (either higher or lower blood 
pressure), rapid heart beat, be short of breath and have trouble breathing, chest pain and retention of 
fluids. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 8.0 dated September 15, 2006 
B-20 
Risks Related to the Medications Used to Help Prevent Graft versus Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus:  These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience include nausea 
(feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  Other 
side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects, 
they generally go away when the dose of the medication is decreased.  A few patients have had a seizure 
while on these medications.  You may experience a change of liver or kidney function, in which case the 
medication dose will be reduced or possibly even withheld.  The effect on kidneys seems to increase 
when other medications, which might cause kidney problems, are given at the same time, especially 
antibiotics.  Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate:  This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare you for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate and Steroids:  These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant.  
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but 
more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets and may be at serious risk for bleeding.  
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy, irradiation 
therapy, or both.  VOD causes severe damage to the liver.  Symptoms include jaundice (yellowing of the 
skin and eyes), weight gain, and extra fluid build-up in the abdominal cavity and other parts of the body.  
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It can often be managed successfully, and completely resolve.  However, complications can arise that may 
be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines and irradiation cause irritation in the lining of 
the mouth and intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth 
sores you will be given medicine to help control the pain.  If your mouth sores are severe you may not be 
able to eat normally until the sores are healed.  Mouth sores get better when the white blood count starts 
to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy and irradiation therapy.  The 
blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You 
may gain water weight and not go to the bathroom as often as you normally do.  Capillary leak syndrome 
can be difficult to manage if extra fluid enters the lungs and causes difficulty breathing.  You may die if 
there is continued fluid collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  Occasionally, the high 
doses of chemotherapy and radiation cause severe lung damage that cannot always be treated.  If this 
happens, you may need to use oxygen or even a respirator.  The lung damage may get worse and be life-
threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  It is rare, but your kidneys could be affected, causing anemia (low red blood cell count) or 
high blood pressure.  There is also a risk you may develop a second cancer as a result of the 
chemotherapy, irradiation and/or underlying disease.  If secondary cancers occur they generally do not 
occur until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are 
unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
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Legal Guardian Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell 
with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Child’s Institution 
Name/Title/Phone number/ 
 
3. Contact Information for Emergencies after Hours or on Weekends or Holidays: 
Name/Phone number/ 
 
4. Sponsors and Source of Funding or Other Material Support 
The research in this study is paid for by the National Institutes of Health (NIH) and the National Marrow 
Donor Program® (NMDP).  The NMDP and the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN) will direct the research study.  This study will be done at many different medical centers, 
including [Center Name/Location]. 
 
5. Introduction 
This is a consent form for a research study.  Your child is being invited to participate in this study 
because he/she has a disease that may be treated with a transplant of either bone marrow or peripheral 
blood stem cells (PBSC).  This form is intended to give you information to help you decide if you 
want your child to participate in this study.  You should read this form and ask any questions you may 
have before allowing your child to participate in the study. 
 
Doctors have been successfully treating blood disorders such as leukemia and myelodysplasia with a 
transplant of blood stem cells from either the bone marrow or the peripheral blood.  The goal of this 
study is to see if patients receiving a transplant from an unrelated donor have better results using 
blood stem cells from: 1) bone marrow or 2) peripheral blood.  The study may find that patients have 
similar results with either type of transplant.  
 
 Important results of this study will include: 
 Survival 
 Quality of life  
 Blood counts after transplant 
 Number and severity of infections 
 Graft-versus-host disease (GVHD) 
 Relapse of disease (return of disease) 
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 Other information about the study: 
 Your child will not be paid to be in this study. 
 You or your child’s insurance company will pay the bills for your child’s medical treatment. 
 You will not be charged for research tests. 
 Your child will face the same risks and benefits as any other bone marrow or peripheral blood 
stem cell (PBSC) transplant patient. 
 
You and your child have a choice whether or not to participate in this study.  The medical staff at 
your child’s transplant center will discuss other treatment options before you make a decision about 
allowing your child to participate in this study. 
 
6. Purpose of the Study 
This study will look at two kinds of blood stem cell transplants, bone marrow and peripheral blood 
stem cell (PBSC), and their side effects.  At this time, doctors use both types of blood stem cells for 
transplant.  Previous studies have compared the survival of patients who received an unrelated donor 
transplant from bone marrow with patients who received an unrelated donor transplant from PBSCs.  
In these studies there was no difference in survival between the bone marrow transplant patients and 
PBSC transplant patients.  This may have been because the patients in each group did not have the 
same characteristics (for example, different diseases and different ages).  
 
In this study, the patient and donor will be randomly assigned (much like the toss of a coin) to either 
the bone marrow or the PBSC transplant study group.  By randomly assigning the patients to receive 
either a bone marrow or PBSC transplant, the characteristics of each study group should be similar.  
The primary goal is to see which type of blood stem cell transplant (bone marrow or PBSC) has better 
survival results.  With similar patient characteristics in each study group, researchers should be able to 
find out if one type of blood stem cell transplant (bone marrow or PBSC) has better survival results 
for patients, or if both types of blood stem cell transplants have similar survival results. 
 
An important part of this study will look at how patients recover after transplant.  Researchers want to 
know what the effects are from each type of blood stem cells used for the transplant and how long they 
last. 
 
Good effects might include: 
 Quick recovery of blood counts after 
transplant 
 No relapse of disease 
 High cure rates 
 Few infections 
 Able to return to important activities in life 
 
Bad effects might include: 
 Slow recovery or no recovery of blood 
counts after transplant 
 Relapse of disease 
 Severe graft-versus-host disease (GVHD) 
 Serious infections 
 Not able to return to important activities in 
life 
 
The information collected from this study will help doctors and future patients make better treatment 
choices.  About 550 patients will take part in this study at many centers around the country. 
 
7. Study Procedures 
If you allow your child to participate in this study, the transplant process has many steps.  A matched 
donor must be found.  You will need to give permission for your child to participate in the study and 
the donor will also need to give permission to participate in this study.  A donor could refuse to 
participate in this study, but continue to be available for your child’s transplant.  In that case, you may 
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decide that your child will have a transplant using this donor, but not participate in this study, or 
another donor who does want to participate in this study may be found. 
Since this study looks at the results of two different kinds of transplants, bone marrow and peripheral 
blood stem cell (PBSC), the kind of transplant your child will receive will be decided randomly, like a 
coin toss.  Neither you, nor your child’s doctor, choose the type of transplant; the type of transplant 
your child will receive is determined by a computer program.  Half of the patients in the study will 
have a bone marrow transplant. The other half will receive a PBSC transplant.  Participation in the 
study means that you are willing to accept either type of transplant for your child. 
One part of the study will involve collecting your child’s medical information.  Your child’s medical 
information will be collected for three years.  The study coordinators at your child’s center will 
collect information from your child’s medical record chart every week for 100 days, then at 6 months, 
1 year, 2 years and 3 years. 
 
If your child is 16 or 17 years old, another part of the study will ask questions about his/her physical 
and emotional health.  This information will be collected for five years.  A trained interviewer will 
contact your child by telephone before his/her transplant, then 6 months, 1 year, 2 years and 5 years 
after the transplant.  These interviews will last approximately 15-25 minutes and will be done at a 
convenient time for your child.  They will include questions about side effects, health problems and 
how well your child can do things that are important to him/her.  When your child is contacted, your 
child may skip any questions he/she doesn’t want to answer. 
 
As part of the standard transplant procedure, your child will need to take many medications and have 
other medical treatments as part of the transplant.  The medical staff will explain these during 
discussion of your child’s medical care. 
 
8. Possible Discomforts and Risks 
Your child will face risks from the transplant itself and from treatments given before and after the 
transplant.  Your child’s doctor thinks these risks are less than the risk from the disease for which 
your child is receiving a transplant. 
 
The bone marrow and PBSCs from the donor contain blood stem cells, which allow your child’s 
blood counts (red blood cells, white blood cells, and platelets) to recover.  Blood stem cells make all 
the blood cells in the bone marrow and serve the entire body.  It is possible that even after the 
transplant your child’s bone marrow will not work well enough and he/she will be at an increased risk 
of infections and even death.  Infections after transplant can be from bacteria, viruses, parasites, or 
fungi.  Early after transplant, the risk of getting an infection might be less after a PBSC transplant, 
because the blood counts return faster than with bone marrow.  Later, the risk of infections might be 
increased in PBSC transplants, because graft-versus-host disease (GVHD) might be worse and last 
longer.  Blood counts will be done often to track recovery of the bone marrow.  Your child will get 
platelets and red cells as needed to keep his/her counts at a healthy level. 
 
There is a risk that stem cells may not grow after being given to your child.  This is called graft 
failure.  Graft failure can be fatal unless your child has a second transplant.  Failure of the donor cells 
to grow (graft failure) may result from a mismatch with the donor, infections, a reduced effect of pre-
transplant medications on your child’s body, or not enough cells in the product.  This risk may be less 
with PBSCs, since PBSCs contain more blood stem cells than bone marrow. 
 
Graft-versus-host disease (GVHD) is a frequent problem after unrelated donor transplantation.  After 
the cells in the product begin to grow, there is a risk that the donor cells may react against your 
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child’s body. GVHD may show up as a skin rash, or liver or stomach problems.  GVHD may cause 
nausea (feeling sick to your stomach), vomiting (throwing up), lack of appetite, stomach cramps, 
diarrhea (loose stools), and bleeding of the gut.  Chronic GVHD may occur later after transplantation 
and may involve problems with the eyes, mouth, lips, throat and liver.  Early (acute) or late (chronic) 
GVHD may be bad enough to cause death.  GVHD is treated with drugs that weaken the body’s 
defense system, and thus makes your child more likely to get an infection.  The chance of getting 
GVHD may be increased with PBSCs, since PBSC transplants contain more donor cells. 
 
Relapse of your child’s disease might occur after transplant, especially in patients with advanced 
disease.  This risk may be decreased by PBSC transplantation. 
 
If one type of transplant does have better results, and your child is not randomly assigned to that study 
group, your child may not receive the same benefits as those children in the study group with overall 
better results. 
 
Completion of the quality of life interviews will not cause your child any physical discomfort, 
although it is possible that your child will find some of the questions or topics upsetting.  If this 
occurs, there will be someone available to speak with your child.  They will be able to refer your child 
to appropriate counselors or other support people. 
 
Refer to Appendix A, B, C or D for additional risks and toxicities related to the specific transplant 
conditioning regimen your child will receive and the specific drugs your child will receive to help 
prevent graft-versus-host disease (GVHD). 
 
9. Unknown or Unexpected Side Effects 
As with any treatment, there may be unknown and/or unexpected side effects from a bone marrow or 
PBSC transplant.  We may learn new things about bone marrow or PBSC transplants that might make 
you or your child want to stop being in the study.  We will let you know if this happens and you can 
decide if you want to continue to allow your child to be in the study. 
 
10. Alternative Treatments Available if You Don’t Want Your Child to be in the Study 
Participation in this study is entirely voluntary.  You don’t have to allow your child to be in this 
study. What you and your child decide will not affect current or future health care your child receives 
at this institution.  Before you decide to allow your child to be in this study, you and the medical staff 
will discuss other options available to your child, including: 
 No treatment 
 Chemotherapy 
 A transplant using your child’s own bone marrow or PBSCs 
 A transplant of bone marrow or PBSCs from a relative 
 A transplant of cord blood cells 
 A bone marrow or PBSC transplant from an unrelated donor without participation in this study 
 
11. Possible Benefits to Participating in the Study  
This research study is comparing the treatment results of bone marrow and PBSC transplants.  At this 
time doctors do not know if one type of transplant has better results than the other, or if they both 
have the same results.  If one type of transplant does have better results, and your child is randomly 
assigned to that study group, he/she may benefit from participating in the study.  The knowledge 
gained from this study may help future patients who need a blood stem cell transplant, but there is no 
expectation that your child will benefit from participating in this study. 
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As a result of the bone marrow or PBSC transplant your child’s disease may be put in remission or 
continue in remission. 
 
12. Cost of Participating in the Study 
You and/or your child's insurance company will pay all medical expenses relating to, or arising from 
transplantation of either bone marrow or PBSC.  Research tests described in Section 20 will be paid 
by the NIH and the NMDP. 
 
For questions about your costs, financial responsibilities, and/or medical insurance coverage for your 
child’s transplant and this study, please contact /Center/ Financial Counselor at /Number/. 
 
13. Reimbursement for Participating in the Study 
You or your child will not be paid for participating in this study. 
 
14. In the Event of Injury While Participating in the Study 
If your child is injured or becomes ill while taking part in this study, medical care will be provided at 
this center.  No funds have been set aside to pay you or your child if injury occurs.  You or your 
insurance company will be charged for ongoing medical care and/or hospitalization. 
 
Contact your child’s doctor or one of the people listed at the start of this form if you are concerned about 
a research-related injury. 
 
15. Withdrawing from the Study 
You may decide to withdraw your child at any time, for any reason, without notice, from this study 
that compares bone marrow transplant with PBSC transplant.  If you wish, you may withdraw your 
child from the study but he/she may still receive a blood stem cell transplant.  If you decide to 
withdraw your child from the study after your child has had some or all of the pre-transplant 
treatments and decide to have no transplant at all, then your child’s blood counts may not return and 
he/she could die. 
 
If you decide to withdraw your child from the study, we ask that you tell [the Principal Investigator] 
in writing (his/her address is on the front page of this form).  If you withdraw your child, there will be 
no penalty or loss of benefit to which your child is entitled, and he/she will continue to receive 
medical care. 
 
If you withdraw your child from the study, the medical staff will continue to tell us about your child’s 
progress for three years after his/her transplant.  If you do not want this, you must specifically tell your 
child’s doctor. 
 
If you have any questions about your child’s rights as a study subject, you may phone the Institutional 
Review Board (IRB) office at /number/. 
 
16. Reasons Your Child’s Doctor May Take Your Child off the Study 
Your child can be taken off the study (with or without your consent) for any of these reasons: 
 Your child would be harmed by staying in the study. 
 Your child needs treatment not allowed in this study. 
 Your child does not follow directions that are important to participating in the study. 
 The study is cancelled. 
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17. Protection of Your Child’s Privacy and Confidentiality of Your Child’s Research Records 
Your child’s participation in this research study will be kept private and confidential.  All your child’s 
medical, demographic (such as race and ethnicity, gender and household income) and quality of life 
information will be kept private and confidential. (Name of Transplant Center) and the organizations 
listed below will not disclose your child’s participation by any means of communication to any 
person or organization, except by your written request, or permission, or unless required by federal, 
state or local laws, or regulatory agencies. 
 
Individuals authorized by the organizations below will have access to your child’s research and 
medical information for inspections or audits.  In allowing your child to participate, you consent to 
such inspections and to the copying of excerpts from your child’s records, if required by these 
authorized representatives. 
 
Organizations with access to your child’s research and medical information: 
 /Institution/ 
 The National Institutes of Health (NIH) 
 Office of Human Research Protection (OHRP) 
 The Food and Drug Administration (FDA) 
 Institutional Review Boards (IRBs) responsible for this study 
 Data and Safety Monitoring Board (DSMB), not part of /Institution/ 
 The National Marrow Donor Program (NMDP) 
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 
 Quality of Life staff at Center on Outcomes, Research, and Education at Evanston 
Northwestern Healthcare 
 Laboratory staff at Dr. Edmund Waller’s laboratory at Emory Unversity, Esoterix, Inc., and 
Dr. Jeffrey Miller’s laboratory at the Univerity of Minnesota 
 
Scientific and medical findings resulting from a study may be presented at meetings and published so 
that the information can be useful to others.  Your child would not be identified in these presentations 
and publications. 
 
For questions about access to your child’s medical records, please contact /name/ at /number/. 
 
18. Expiration Date for Keeping Your Child’s Records 
Study records will be kept indefinitely by the transplant center for re-analysis and follow-up.   
 
If you have questions about the keeping of your child’s research records or access to your child’s 
files, please call /name/ at /number/. 
 
19. Benefit to Doctors for Your Child’s Participation in the Study 
Your child’s doctors have no money invested in this study.  Presenting research results may help the 
career of a doctor.  Therefore, the doctors running this research study may benefit when the results are 
presented at scientific meetings or in the scientific press. In addition, the hospital where your child will 
receive his/her transplant is paid for participating in the study. 
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20. Blood Samples for Research Purposes 
You will be asked to allow your child to provide blood samples to see if infection-fighting cells are 
working and to help better understand tissue matching between donors and recipients in this study.  
You do not have to allow your child to participate in this part of the study. 
 
If you agree, your child will provide blood samples up to 7 times (10-100 mL each time or 
approximately 1-7 tablespoons) between the time transplant is initiated and two years after (up to a 
total for all 7 blood draws of 430 mL or approximately 2 cups).  The samples will be saved for future 
testing.  The amount of blood drawn will never be more than what is safe for your child to provide.  
The blood can usually be drawn from your child’s central line at the time of other blood collections.  
If this is not possible, then it will be drawn directly from a vein. 
 
As a standard part of the transplant procedure your child will receive vaccinations for diphtheria, 
tetanus, Hepatitis B and pneumococcus.  The research studies on infection fighting-cells will include 
studies to look at how well these vaccinations are working.  Your child may still receive the 
vaccinations as part of his/her standard medical care even if your child does not participate in the 
research on infection-fighting cells. 
 
The doctors conducting this study may choose to do some additional research tests on the blood 
samples.  These tests would only be done if the groups overseeing the safety and protection of 
subjects participating in this study approved these additional tests.  These tests would only be 
performed on blood samples that were left over after the tests on infection-fighting cells, 
vaccinations, and tissue matching were done; no additional blood would be drawn for these tests.  
This research may include tests to determine and evaluate other factors that affect transplant outcome 
in this study. 
 
Any of your child’s blood samples drawn for research purposes will be sent to laboratories that have a 
contract with the NMDP to conduct these research tests.  Your child’s blood will be labeled with a 
unique code that contains no information that could identify him/her.  A link to this code does exist. 
The link is stored at the Data Coordinating Center for the Blood and Marrow Transplant Clinical 
Trials Network (BMT CTN).  The staff at the laboratory where your child’s blood is being tested does 
not have a link to this code.  Your child’s blood will be stored at these laboratories until all the sample 
has been used for the research tests or until the end of the study. 
 
If any of your child’s blood samples are left over after the research studies are completed, these 
samples will either be destroyed or be sent to the National Heart Lung, and Blood Institute (NHLBI) 
sample repository in Maryland.  If your child’s left-over blood samples are sent to the repository, they 
will be given an anonymous code.  These left-over blood samples stored at the repository can never 
be linked to your child.  Any research performed on these left-over blood samples must first be 
approved by an advisory panel at the NHLBI. 
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You are free to not allow your child to take part in this research and still allow your child to 
participate in the other parts of the study.  There will be no change in your child’s care if you 
choose not to allow your child to give blood samples for research purposes.  Please mark your 
choice below (check only one box): 
 
 I agree to have blood drawn from my child for research purposes. 
 
 I do not agree to have blood drawn from my child for research purposes. 
 
___________________________________________  _______________________________  
Signature of Parent/Legal Guardian Date 
 
___________________________________________  _______________________________  
Signature of Parent/Legal Guardian Date 
 
The signatures of both parents (or legal guardians) are required. 
 
 
21. Parental/Legal Guardian Consent 
The signatures of both parents (or legal guardians) are required. 
 
I have been informed about this study’s purpose, procedures, possible benefits and risks.  I have been 
given a chance to ask questions and have had them answered to my satisfaction.  I understand that I 
can ask more questions at any time. 
 
I voluntarily agree to allow my child to participate in this study. 
 
By signing this consent form, I have not given up any of the legal rights, which I or my child 
otherwise would have as a subject in a research study. 
 
 
___________________________________________  _______________________________  
Signature of Parent/Legal Guardian Date 
 
___________________________________________  
Print Name of Parent/Legal Guardian 
 
 
___________________________________________  _______________________________  
Signature of Parent/Legal Guardian Date 
 
___________________________________________  
Print Name of Parent/Legal Guardian 
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Certification of Counseling Healthcare Professional 
 
I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this study have been explained to the above individual and that any questions about 
this information have been answered. 
 
___________________________________________  _______________________________  
Counseling Healthcare Professional Date 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to 
obtain consent: 
 
Print name of interpreter: __________________________  Date: ______________________  
 
Signature of interpreter: ___________________________   
 
An oral translation of this document was administered to the donor in ______________________ (state 
language) by an individual proficient in English and _____________________ (state language).  See the 
attached short form addendum for documentation. 
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Attachment A 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Total Body Radiation and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications and irradiation therapy your child will receive as part of the conditioning 
for the transplant and risks related to the transplant itself.  Most of these risks and side effects are listed 
below, but they will vary from person to person.  There may be more risks involved with transplantation, 
and there may be more side effects.  Your child’s doctor may give your child medications to lessen some 
of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause your child to have diarrhea 
(loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-
term bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder 
damage and bleeding for a longer time.  Your child will be given large amounts of a sterile solution 
through his/her central line to protect the bladder.  A bladder catheter (thin plastic tube) may be inserted 
into your child’s bladder, if your child’s physician thinks that it can help him/her.  Cyclophosphamide 
slows the making of new red blood cells, white blood cells, and platelets.  This causes a risk of infection 
and/or severe bleeding until the transplanted donor cells begin to work in your child.  Your child will get 
blood transfusions as needed.  Cyclophosphamide also lowers the defense system.  As a result your child 
may have more infections for several months after transplant.  In a small number of patients, 
cyclophosphamide can damage the heart muscle causing heart failure.  Sometimes cyclophosphamide 
causes abnormal heart function.  If this occurs your child may have shortness of breath and have fluids 
build-up in his/her body.  This medication can also cause the lungs to become scarred.  If scarring of the 
lungs occurs it will usually happen three to six months after your child receives the medication.  Scarring 
of the lungs can cause your child to die.  Cyclophosphamide can adversely affect the production of 
hormones responsible for the onset and completion of puberty and the number and function of eggs (girls) 
and sperm (boys) leading to decreased fertility and even sterility.  The onset of puberty can be delayed in 
your child and your child’s ultimate height can be decreased.  Since it is not possible to predict in a 
specific child the extent of these effects, it is important that your child has continuing, careful follow-up 
after the transplant.  It is not known whether the use of cyclophosphamide will cause more side effects or 
problems with your child’s health in the future. 
 
Total Body Irradiation (TBI): TBI may cause your child to have diarrhea (loose stools), nausea (feeling 
sick to your stomach), vomiting (throwing up), and painful swelling of the saliva glands for a few days.  
Your child may also experience short-term hair loss.  TBI kills both sick and normal marrow, leading to a 
lack of red blood cells, white blood cells, and platelets.  The short-term loss of these blood cells could 
cause your child to become anemic, develop an infection, and/or bleeding.  This will continue until the 
transplanted donor cells begin to work in your child.  Your child will get blood transfusions as needed.  
There is a risk that cataracts (cloudiness) may develop in your child’s eyes.  This may mean partial loss of 
vision, and your child may need contact lenses or surgery to remove the cataracts. TBI can adversely 
affect the production of hormones responsible for the onset and completion of puberty and the number 
and function of eggs (girls) and sperm (boys) leading to decreased fertility and even sterility.  The onset 
of puberty can be delayed in your child and your child’s ultimate height can be decreased.  Since it is not 
possible to predict in a specific child the extent of these effects, it is important that your child has 
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continuing, careful follow-up after the transplant.  It is not known whether the use of TBI will cause more 
side effects or problems with your child’s health in the future. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects they generally go away when the dose of the medication is decreased. A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 
given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your child’s body.  It may cause or can worsen the 
mouth sores or inflammation of the mouth which your child may have already developed from the 
procedures and medications used to prepare him/her for the transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation.  Methotrexate can cause kidney damage.  If your child’s 
kidneys are already damaged for other reasons, it can worsen kidney function.  If kidney damage does 
occur, the methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
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Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 
but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low.  Usually, there is success in preventing major bleeding problems with transfusions of platelets. 
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy, irradiation 
therapy, or both.  VOD causes severe damage to the liver. Symptoms include jaundice (yellowing of the 
skin and eyes), weight gain, and extra fluid build-up in the abdominal cavity and other parts of the body. 
It can often be managed successfully, and completely resolve.  However, complications can arise that may 
be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines and irradiation cause irritation in the lining of 
the mouth and intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe 
mouth sores he/she will be given medicine to help control the pain.  If your child’s mouth sores are 
severe, he/she may not be able to eat normally until the sores are healed.  Mouth sores get better when the 
white blood count starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy and irradiation therapy.  The 
blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your 
child may gain water weight and not go to the bathroom as often as he/she normally does.  Capillary leak 
syndrome can be difficult to manage if extra fluid enters the lungs and causes difficulty breathing.  Your 
child may die if there is continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy and irradiation cause severe lung damage that cannot 
always be treated.  If this happens, your child may need to use oxygen or even a respirator. The lung 
damage may get worse and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney 
failure) may occur, which is often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication.  As a result of irradiation, cataracts (cloudiness of the eyes) may occur earlier in life 
as compared to a person who had not had a transplant.  If your child develops cataracts they may require 
treatment. It is rare, but your child’s kidneys could be affected, causing anemia (low red blood cell count) 
or high blood pressure.  There is also a risk your child may develop a second cancer as a result of the 
chemotherapy, irradiation and/or underlying disease.  If secondary cancers occur they generally do not 
occur until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are 
unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
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Attachment B 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Busulfan and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications your child will receive as part of the conditioning for the transplant, and 
risks related to the transplant itself. Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your child’s doctor may give your child medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause your child to have diarrhea 
(loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-
term bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder 
damage and bleeding for a longer time.  Your child will be given large amounts of a sterile solution 
through the central line to protect his/her bladder.  A bladder catheter (thin plastic tube) may be inserted 
into your child’s bladder, if your child’s physician thinks that it can help him/her.  Cyclophosphamide 
slows the making of new red blood cells, white blood cells, and platelets.  This causes a risk of infection 
and/or severe bleeding until the transplanted donor cells begin to work in your child.  Your child will get 
blood transfusions as needed. Cyclophosphamide also lowers the defense system.  As a result your child 
may have more infections for several months after transplant. I n a small number of patients, 
cyclophosphamide can damage the heart muscle causing heart failure.  Sometimes cyclophosphamide 
causes abnormal heart function.  If this occurs your child may have shortness of breath and have fluids 
build-up in his/her body.  This medication can also cause the lungs to become scarred.  If scarring of the 
lungs occurs it will usually happen three to six months after your child receives the medication.  Scarring 
of the lungs can cause your child to die.  Cyclophosphamide can adversely affect the production of 
hormones responsible for the onset and completion of puberty and the number and function of eggs (girls) 
and sperm (boys) leading to decreased fertility and even sterility.  The onset of puberty can be delayed in 
your child and your child’s ultimate height can be decreased.  Since it is not possible to predict in a 
specific child the extent of these effects, it is important that your child has continuing careful follow-up 
after the transplant.  It is not known whether the use of cyclophosphamide will cause more side effects or 
problems with your child’s health in the future. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
your child most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases the risk of infection, lower platelet count that 
increases the risk of bleeding, hair loss, stopping of menstrual periods in girls who have reached puberty, 
temporary reduced or no sperm production in boys who have reached puberty.  Less likely side effects 
that your child may experience are fatigue, sores in the mouth or on the lips, fever, rash, loss of appetite, 
changes in color of the skin, seizure.  Rare side effects that your child may experience are damage to the 
lungs, which may cause him/her to cough, be short of breath, and have trouble breathing.  It is rare, but 
busulfan can also cause changes in your child’s liver function. 
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Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects they generally go away when the dose of the medication is decreased.  A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 
given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your child's body.  It may cause or can worsen the 
mouth sores or inflammation of the mouth which your child may have already developed from the 
procedures and medications used to prepare him/her for the transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation. Methotrexate can cause kidney damage.  If your child’s 
kidney is already damaged for other reasons, it can worsen kidney function.  If kidney damage does 
occur, the methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one drug or the transplanted donor cells, but they are 
risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 
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but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low. Usually, there is success in preventing major bleeding problems with transfusions of platelets.  
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe mouth sores 
he/she will be given medicine to help control the pain.  If your child’s mouth sores are severe, he/she may 
not be able to eat normally until the sores are healed.  Mouth sores get better when the white blood count 
starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your child may gain water weight 
and not go to the bathroom as often as she/she normally does.  Capillary leak syndrome can be difficult to 
manage if extra fluid enters the lungs and causes difficulty breathing.  Your child may die if there is 
continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy cause severe lung damage that can not always be treated.  
If this happens, your child may need to use oxygen or even a respirator.  The lung damage may get worse 
and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is 
often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication.  It is rare, but your child’s kidneys could be affected, causing anemia (low red blood 
cell count) or high blood pressure.  There is also a risk your child may develop a second cancer as a result 
of the chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur 
until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
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Attachment C 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Melphalan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell PBSC) transplant.  There 
are risks from the medications your child will receive as part of the conditioning for the transplant and 
risks related to the transplant itself.  Most of these risks and side effects are listed below, but they will 
vary from person to person.  There may be more risks involved with transplantation, and there may be 
more side effects.  Your child’s doctor may give your child medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects your child may experience are low 
white blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects your child may 
experience include confusion or coma, trouble seeing or problems with your child’s eyes, trouble 
breathing, diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), 
pneumonia, agitation, numbness and tingling of the fingertips and toes, and kidney problems. 
 
Melphalan: This medication disrupts the growth of cancer cells and destroys them.  Side effects your 
child most likely will experience include nausea (feeling sick to stomach), hair loss, and low white blood 
cell count, which may lead to infection.  Less likely side effects your child may experience include 
diarrhea (loose stools), mouth ulcers, and low platelet count with increased risk of bleeding.  It is rare, but 
your child may experience a severe allergic reaction.  Symptoms of a severe allergic reaction include 
itching, hives (bumps on the skin), flushing (redness), wheezing, chest tightness, skin rashes, fever, chills, 
muscle stiffening, severe breathing problems, and loss of appetite. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects, they generally go away when the dose of the medication is decreased.  A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 
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given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which your child may have already developed from the procedures 
and medications used to prepare him/her for the transplant.  Methotrexate may slow down the recovery of 
blood cells after transplantation.  Methotrexate can cause kidney damage.  If your child’s kidneys are 
already damaged for other reasons, it can worsen kidney function.  If kidney damage does occur, the 
methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 
but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low.  Usually, there is success in preventing major bleeding problems with transfusions of platelets.  
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe mouth sores 
he/she will be given medicine to help control the pain.  If your child’s mouth sores are severe, he/she may 
not be able to eat normally until the sores are healed.  Mouth sores get better when the white blood count 
starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your child may gain water weight 
and not go to the bathroom as often as he/she normally does.  Capillary leak syndrome can be difficult to 
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manage if extra fluid enters the lungs and causes difficulty breathing.  Your child may die if there is 
continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy cause severe lung damage that can not always be treated.  
If this happens, your child may need to use oxygen or even a respirator.  The lung damage may get worse 
and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is 
often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication. It is rare, but your child’s kidneys could be affected, causing anemia (low red blood 
cell count) or high blood pressure.  There is also a risk your child may develop a second cancer as a result 
of the chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur 
until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating all of this fluid.  Furosemide is a medication that is often given to help 
eliminate this excess fluid.  This medication may cause hearing loss and loss of body chemicals such as 
potassium and sodium. 
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Attachment D 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Busulfan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications your child will receive as part of the conditioning for the transplant, and 
risks related to the transplant itself.  Most of these risks and side effects are listed below, but they will 
vary from person to person.  There may be more risks involved with transplantation, and there may be 
more side effects.  Your child’s doctor may give your child medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects your child may experience are low 
white blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects your child may 
experience include confusion or coma, trouble seeing or problems with your child’s eyes, trouble 
breathing, diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), 
pneumonia, agitation, numbness and tingling of the fingertips and toes, and kidney problems. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
your child most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases the risk of infection, lower platelet count that 
increases the risk of bleeding, hair loss, stopping of menstrual periods in girls who have reached puberty, 
temporary reduced or no sperm production in boys who have reached puberty.  Less likely side effects 
that your child may experience are fatigue, sores in the mouth or on the lips, fever, rash, loss of appetite, 
changes in color of the skin, seizure.  Rare side effects that your child may experience are damage to the 
lungs, which may cause him/her to cough, be short of breath, and have trouble breathing.  It is rare, but 
busulfan can also cause changes in your child’s liver function. 
 
Antithymocyte Globulin (ATG): This medication is given pre-transplant with the conditioning regimen 
medications to try and prevent both acute and chronic graft-versus-host disease.  While taking ATG your 
child will most likely will have, a fever and chills, a lower white blood cell count that increases your 
child’s risk of infection, a lower platelet count that increases your child’s risk of bleeding, and a skin rash.  
Less likely side effects your child may experience are fatigue, diarrhea, vomiting, muscle aches and 
headaches.  Rare side effects that your child may experience are changes in your blood pressures (either 
higher or lower blood pressure), rapid heart beat, be short of breath and have trouble breathing, chest pain 
and retention of fluids. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
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Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects they generally go away when the dose of the medication is decreased.  A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 
given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your child's body.  It may cause or can worsen the 
mouth sores or inflammation of the mouth which your child may have already developed from the 
procedures and medications used to prepare him/her for the transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation. Methotrexate can cause kidney damage.  If your child’s 
kidney is already damaged for other reasons, it can worsen kidney function.  If kidney damage does 
occur, the methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one drug or the transplanted donor cells, but they are 
risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 
but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low.  Usually, there is success in preventing major bleeding problems with transfusions of platelets.  
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
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and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe mouth sores 
he/she will be given medicine to help control the pain.  If your child’s mouth sores are severe, he/she may 
not be able to eat normally until the sores are healed.  Mouth sores get better when the white blood count 
starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your child may gain water weight 
and not go to the bathroom as often as she/she normally does.  Capillary leak syndrome can be difficult to 
manage if extra fluid enters the lungs and causes difficulty breathing.  Your child may die if there is 
continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy cause severe lung damage that cannot always be treated.  If 
this happens, your child may need to use oxygen or even a respirator.  The lung damage may get worse 
and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is 
often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication.  It is rare, but your child’s kidneys could be affected, causing anemia (low red blood 
cell count) or high blood pressure.  There is also a risk your child may develop a second cancer as a result 
of the chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur 
until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
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APPENDIX B-2 
 
DONOR CONSENT FORM 
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NATIONAL MARROW DONOR PROGRAM® (NMDP) 
A PHASE III RANDOMIZED, MULTICENTER TRIAL COMPARING G-CSF MOBILIZED 
PERIPHERAL BLOOD STEM CELLS WITH MARROW TRANSPLANTATION FROM HLA 
COMPATIBLE UNRELATED DONORS 
 
DONOR/SUBJECT RESEARCH CONSENT FORM 
 
Would you be willing to take part in a research study?  
Because you have been matched with a recipient in seeking a blood stem cell transplant, you are being 
asked to take part in a clinical trial (a type of research study).  This research study is sponsored by the 
NMDP and the Blood and Marrow Clinical Trials Network (BMT CTN).  In this clinical trial the blood-
forming cells will be collected from either the donor’s bone marrow or the donor’s bloodstream.  This 
research study will only include people who choose to be in it.  
This form contains key facts about the study and what you will be asked to do if you take part.  Please 
read it in detail and take your time to decide.  You might want to view the PBSC vs. Marrow Randomized 
Clinical Trial Donor Consent video as well (also offered as a CD-ROM).  If you do not want to take part 
in this study, you may still be asked to donate for this recipient.  
If you have any questions, please ask your Donor Center Coordinator or the Donor Center Medical 
Director before you make your final choice.  If you agree to take part, you will be given a copy of this 
consent form for your records. 
 
1. Why is this study being done? 
The National Marrow Donor Program® (NMDP) uses bone marrow and blood-forming cells from the 
bloodstream for transplantation.  In the past, blood-forming cells were always taken from the bone 
marrow.  Now we know that a drug called “filgrastim” can increase the number of blood-forming cells in 
the bloodstream so much that these cells can be collected from the bloodstream of donors and used for 
transplant.  When these blood-forming cells are collected from the bloodstream they are called peripheral 
blood stem cells (PBSC). 
When the NMDP compared recipients who received bone marrow with recipients who received PBSCs, 
there was no difference in survival between the two groups.  But because the recipients in each group did 
not have the same characteristics (age, disease type and so on) more research is needed. 
This study will randomly assign recipients and donors into the two groups (bone marrow or PBSC).  This 
makes it fairer to compare the two groups. 
The NMDP and the BMT CTN hope what they learn from this study will help doctors and future 
recipients and donors make the best choice for the type of blood-forming cells to use for transplant; bone 
marrow or PBSC.  If you would like to know more about why this study is needed, read Attachment A. 
This study has two main goals: 
1. To see if recipients given blood-forming cells from a donor’s bone marrow do better or worse 
than recipients given PBSCs. 
2. To compare three things about donors who donate bone marrow to those who donate PBSCs: 
• What differences (if any) are there in physical side effects that donors feel? 
• What differences are there in the time it takes donors to recover? 
• How does the quality of life differ for the two types of donors?  For instance: how does a 
donor feel emotionally, how does donation affect a donor’s daily life, and what does the 
donor feel about the donation process? 
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2. What will happen if I take part in this research study? 
If you agree to take part in this research study, your donation will be different in these three ways: 
1. How you donate – from your bone marrow or your bloodstream – will be chosen at random.  A 
computer will make this choice.  
2. You will be asked to give four extra blood samples for research purposes. 
3. You will be asked to answer questions about how you feel emotionally after the donation.  
 
Your safety is important.  After you join the study, your health will be checked just like any donor.  To 
protect both you and the recipient, you will have: 
• A complete check-up. 
• Standard blood tests. 
• Blood tests for diseases like hepatitis, West Nile virus and HIV. 
• A check for sickle hemoglobin (hemoglobin S). 
• If you are a woman, a test to see if you are pregnant. 
 
These tests will help to make sure that donating is safe for both you and the recipient getting the donation.  
(If you have more questions about why the blood tests are needed, see Attachment B.)  All donors will 
have these tests.  You will have these tests before you know if you will donate bone marrow or PBSCs.  
You must be able to donate both ways – from your bone marrow or your bloodstream – to go forward in 
this study.  If you are able to donate only one way and cannot go forward in this study, you may still be 
asked to donate for this recipient. 
 
Either as part of your complete check-up or as part of some other scheduled blood draw, 9 teaspoons of 
blood will be drawn from a vein in your arm for research studies.  Your blood will be tested for antibodies 
specific to germs that cause infection, for example, Hepatitis B.  The antibody levels in your blood may 
be compared against the antibody levels in the recipient’s blood after the transplant.  These samples will 
also be used to better understand tissue matching between donors and recipients. 
 
If you are able to go forward in the study, you will be chosen at random to donate either from your bone 
marrow or your bloodstream.  This means that the way you donate will be picked by chance.  A computer 
program will make the choice.  You cannot choose how you will donate.  You will have an equal chance 
of giving blood-forming cells from bone marrow or from your bloodstream.  Your donation itself will be 
just the same as if you were not taking part in the study. 
 
If you are chosen to donate bone marrow: 
1. Getting Ready to Donate Bone Marrow 
You may be asked to donate blood for your own use (this is called “autologous” blood donation).  
Depending on how much bone marrow you are asked to donate, you may need to have one to 
three units (each unit is about a pint or about two cups) of your blood drawn and stored before the 
donation.  You will be asked to sign a separate consent form each time you give a unit of blood.  
If your blood counts are low after your marrow donation, your stored blood will be given back to 
you by transfusion. 
The doctors at the transplant center where the recipient is being treated may also ask for a sample 
of your blood before the transplant.  The blood will be used at the transplant center for tests 
needed in treating the recipient.  For instance, DNA from your blood may be stored to help see 
which blood cells growing in the recipient after the transplant come from your cells and which 
come from the recipient’s cells.  You will not be asked to give more than about 20 teaspoons of 
blood.  The blood will be drawn from a vein in your arm.  This blood cannot be used for research 
studies without further consent from you. 
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2. Donating Bone Marrow 
Bone marrow is collected in an operating room in a hospital.  You will be given either general 
anesthesia or spinal anesthesia.  Before the bone marrow donation, you will meet with a doctor to 
discuss the type of anesthesia that will be used.  (This consent form is not for the anesthesia or the 
actual bone marrow donation.  At the hospital you will be asked to sign another consent form for 
the anesthesia and the bone marrow donation.)  
The amount of bone marrow you will be asked to donate depends on the size of the recipient.  For 
safety reasons, no more than two teaspoons of bone marrow per pound of your body weight will 
be removed.  For instance: if you weigh 150 pounds, no more than 6 cups of bone marrow would 
be taken. 
You will lie on your stomach for the donation.  Your bone marrow will be taken out of your 
pelvic bone (iliac crest).  The doctor taking the bone marrow will make at least two, and maybe 
more, very small cuts in the skin of your back that covers the pelvic bones.  Hollow needles will 
be placed through these cuts and into the bone.  After a needle is put in the marrow space of the 
bone, a syringe will be attached to the needle and the marrow will be drawn out.  Once the bone 
marrow is taken, the anesthetic will be allowed to wear off and you will be returned to your 
hospital room. 
Your donated bone marrow may be tested to find out the number and types of cells, to make sure 
that it is sterile, and to learn other things that may be important to the transplant.  
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How much time will it take to donate bone marrow? 
A list of visits and calls is given in the following table (an X marks what will happen on each visit/call): 
Visit/Call 
Risks 
Assessed 
Unit of 
Blood 
Drawn and 
Stored  
Bone 
Marrow 
Donated 
Blood 
Drawn 
Quality of 
Life 
Assessed 
by Phone 
Screening check-up X   X  
1st Quality of Life contact     X 
Pre-donation appointment 1a  X  X  
Pre-donation appointment 2a  X    
Pre-donation appointment 3a  X    
Bone marrow donation X  X X  
2 days after donation (call) X    X 
1 week after donationb (call) X    X 
1 month after donation X   X  
6 months after donation X   X X 
1 year after donation X   X X 
2 years after donation  X   X  
3 years after donation 
(study ends) 
X   X 
 
Yearly visits after donation as 
part of the NMDP’s routine 
donor follow up 
X   X 
 
a The number of autologous blood units you give depends on how much bone marrow will be taken. 
b Calls will continue weekly until complete healing from donation is reported. 
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What are the possible risks of donating bone marrow? 
Caution:  You should not take aspirin or aspirin-containing drugs for two weeks before your donation, or 
for soreness after it, without a doctor’s approval.  
GIVING A SAMPLE OF BLOOD 
Risks Very small, may include: 
• Bruising where the needle was put in. 
• Fainting. 
• More rarely, infection where the needle was put in. 
DONATING BONE MARROW 
Risks From the anesthetic: For a few hours after your bone marrow has been taken, you 
may feel groggy and sick from the anesthetic.  You will not be allowed to eat food or 
to get out of bed until you are wide awake and all the anesthetic has worn off.  Even 
after the anesthetic has worn off, you may still be sick and faint for a period of time. 
From the collection: You should expect to feel some pain from the collection of the 
bone marrow.  Most donors go through soreness in their lower back, like a back 
strain, that lasts for a few weeks.  You may find it hard to sit in a chair for long 
periods of time or to climb stairs.  You will most likely be less active than normal for 
the first two weeks after your donation. 
 
There are certain risks with donating bone marrow.  
Serious problems from bone marrow collection are rare but could occur due to an 
unexpected reaction to the anesthetic or trouble with the process of taking the bone 
marrow.  
Possible risks with anesthetics include: 
• High fever. 
• Allergic reaction. 
• Low blood pressure and a slowed heart rate.  
• Not able to pass urine for a brief time (spinal anesthesia). 
• Headache (spinal anesthesia). 
 
Possible risks from donation include: 
• Infection where the skin was cut to collect your bone marrow (requires 
antibiotic treatment). 
• Pain or numbness in a leg. 
• Bleeding where the skin was cut. 
• More severe pain than normal. 
• Bone, nerve or other tissue damage (requires more medical treatment or 
physical therapy). 
Life-threatening problems are extremely rare.  But you should know, that as with any 
surgery, there is a risk of death. 
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Additional Risks 
Donating can cause intense feelings, especially if the transplant does not succeed.  These feelings may 
range from stress during the process to great joy or the blues after the donation.  By donating for this 
recipient, you are doing all you can to help them.  You cannot control the success of the transplant, or 
whether the recipient lives or dies.  You should not feel personally responsible for the outcome. 
You may be asked to donate again for the recipient if the donated cells do not grow in the recipient or if 
the recipient’s disease is not cured.  If you are asked to donate again, you are free to say no. 
 
If you are chosen to donate PBSCs: 
1. Getting Ready to Donate PBSCs 
The drug filgrastim has been shown to increase the number of blood-forming cells in the 
bloodstream.  You will get a shot of filgrastim under your skin once a day for five days.  Before 
each shot, you will be asked about any symptoms you may have.  You will have blood samples 
(1½ to 3 teaspoons) taken from a vein in your arm before your shots on Day 1 and on Day 5.  
These samples are used to see how the drug affects your blood cell counts. 
The doctors at the transplant center where the recipient is being treated may also ask for a sample 
of your blood before the transplant.  The blood will be used at the transplant center for tests 
needed in treating the recipient.  For instance, DNA from your blood may be stored to help see 
which blood cells growing in the recipient after the transplant come from your cells and which 
come from the recipient’s cells.  You will not be asked to give more than about 20 teaspoons of 
blood.  The blood will be drawn from a vein in your arm.  This blood cannot be used for research 
studies without further consent from you. 
2. Donating PBSCs 
PBSCs are donated in a hospital or blood center.  Before you donate, a needle will be placed in a 
vein in each of your arms.  Blood is removed through the needle in one arm and passed through a 
special machine called a blood cell separator.  This process is called “apheresis.”  The machine 
collects your PBSCs, and the rest of your blood is given back through the needle in your other 
arm.  You will make one or two PBSC donations, depending on the size of the recipient.  During 
each donation you will need to lie fairly still in a recliner chair for four to six hours. 
With each donation, 2 teaspoons of blood will be taken at the start and at the end of the process to 
measure your blood cell counts.  Your donation may be tested to find out the number and types of 
cells, to make sure that it is sterile, and to learn other things that may be important to the 
transplant. 
Needing a Central Line 
Sometimes, a donor’s arm veins are not big enough for the needles used in the apheresis process.  In the 
NMDP’s experience, this happens in about 18% of women and 3% of men.  If your veins are too small, 
you may be asked to have a special blood-drawing tube called a “central line” placed in a larger vein in 
your body.  The choice to use a central line may be made at your complete check-up (when your veins 
will be checked) or it could be made on the day you donate. 
Placing a central line requires a surgical procedure under local anesthesia.  A doctor does this in a 
hospital.  In this case, your collection will also take place in the hospital and, if you donate over two days, 
you will need to stay in the hospital the night between donations. 
If a central line is recommended in your case, you will be asked to sign a separate consent form that 
explains the risks of central line placement.  You are free to say no to having a central line placed.  If you 
choose to not have the central line placement, you may be asked to donate bone marrow instead.  
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How much time will it take to donate PBSCs? 
A list of visits and calls is given in the following table (an X marks what will happen on each visit/call): 
Visit/Call 
Risks 
Assessed
Filgrastim 
Shot Given 
PBSCs 
Donated 
Blood 
Drawn 
Quality of Life 
Assessed by 
Phone 
Screening check-up X   X  
1st Quality of Life contact     X 
Preparation, Day 1 X X  X  
Preparation, Day 2 X X    
Preparation, Day 3 X X    
Preparation, Day 4 X X   X 
First donation, Day 5 X X X X  
Second donationa X  X X  
2 days after donation (call) X    X 
1 week after donationb (call) X    X 
1 month after donation X   X  
6 months after donation X   X X 
1 year after donation X   X X 
2 years after donation  X   X  
3 years after donation 
(study ends)  
X   X  
Yearly visits after donation as 
part of the NMDP’s routine 
donor follow up 
X   X  
a If needed, based on size of the recipient. 
b Calls will continue weekly until complete healing from donation is reported. 
 
What are the possible risks of donating PBSCs? 
Cautions:  You should not take aspirin or drugs with aspirin in them while getting filgrastim and for two 
weeks after PBSC donation without a doctor’s approval.  During the PBSC donation, your platelet count 
may be lower because platelets are collected with the PBSCs.  Taking aspirin when your platelet count is 
lower may increase your chance of bleeding.  
You should not take filgrastim if you are pregnant.  You should not become pregnant while taking 
filgrastim and for 48 hours after the last shot.  This drug could cause serious problems for an unborn 
child. 
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The following table lists side effects and risks for receiving filgrastim and donating PBSCs. 
GIVING A SAMPLE OF BLOOD 
Risks Some people have: 
• Bruising where the needle was put in. 
• Fainting. 
Very few people have: 
• An infection where the needle was put in. 
 
GETTING SHOTS OF FILGRASTIM 
Risks Most people have: • Pain from the shot. 
• High white blood cell count. 
 White blood cell counts usually return to normal levels within a few days to a 
few weeks after you stop receiving filgrastim. 
• Aching pain in bones while getting the filgrastim. 
 The aching bone pain is usually relieved by acetaminophen (Tylenol™) or 
ibuprofen (Motrin™, Advil™).  If you have pain that is not relieved by these 
drugs, you should contact the Donor Center Coordinator, 
_____________________ at (       ) _______________, and the dose of filgrastim 
may be reduced.  
Some people have: 
• Headaches. 
• Muscle aches. 
• Being tired. 
• Nausea and vomiting. 
• Trouble sleeping. 
Very few people have: 
• Allergy symptoms:  
– rapid heart rate. 
– Dizziness. 
– shortness of breath. 
– itching or rash. 
 
All symptoms usually go away within two or three days after stopping filgrastim. 
• Lowered platelet count.  
Filgrastim may cause your platelet count to be lower than normal. Platelets help 
stop bleeding.  Two out of 1400 NMDP donors had very low platelet counts that 
needed to be watched closely.  Although one donor went into the hospital for this, 
neither had symptoms from the low platelet count and both got well.  
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GETTING SHOTS OF FILGRASTIM (cont’d) 
 Your platelet count will be measured on Day 5, before the first PBSC donation.  
You will be told if your platelet count is less than 80% of the lower limit of 
normal.  In this case, depending on the true value of your platelet count, a doctor 
will talk with you about other options, such as to: 
– Monitor your platelet count during the PBSCs donation. 
– Shorten the donation process. 
– Delay the donation for a day. 
– Cancel the PBSCs donation. 
– Ask you to consider a bone marrow donation. 
– Ask you to consider some other course of action that is okay with you. 
• There is a small (about 1 in 1,200) risk of being hospitalized for observation of 
side effects from the filgrastim (for example bone pain, nausea). 
• There is a small (about 1 in 10,000) risk of pain and bleeding from the spleen. 
The NMDP is aware of four non-NMDP donors who had pain and bleeding from 
the spleen while getting filgrastim.  In two cases the spleen was taken out by 
surgery.  All four got well.  Symptoms of bleeding from the spleen are pain in the 
upper left side just below the rib cage.  If you feel pain in this area you should 
contact your Donor Center right away, as this can be a risk. 
• Based on limited long-term data from healthy people who have received 
filgrastim, no long-term risks have been found so far.  
Normal individuals are at risk for developing cancer, including leukemia, 
lymphoma or other blood diseases throughout their life time.  It is unknown 
whether filgrastim increases or decreases an individuals risk of developing 
cancer.  The data being collected during follow-up will help establish if there are 
any positive or negative long-term effects from receiving filgrastim. 
 
If you think you are having any serious or unexpected symptoms, contact the 
Donor Center right away at (       ) ___________________________. 
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DONATING PBSCs 
Risks Most people have: 
• Pain and bruising where the needles are put into the arms. 
• Lowered platelet count. 
In addition to collecting PBSCs, the blood cell separator also collects platelets.  
Platelets help stop bleeding.  If your platelet count after the first donation is too 
low, the second donation may be cancelled.  Platelet counts usually return to 
normal levels within two to four weeks after collection of PBSCs. 
 
Some people have: 
• Lightheadedness. 
• Nausea. 
• Numbness and tingling. 
To prevent clotting, your blood will be mixed in the machine with a liquid called 
an “anticoagulant” during the PBSC collection.  When the blood is returned to 
you, the anticoagulant can cause numbness and tingling of the fingertips or 
around the mouth.  If you feel numbness and tingling, you must tell the nurse 
running the machine.  These symptoms are easily treated with calcium, but if not 
treated could progress to muscle cramps.  
 
Very few people: 
• Faint due to short-term low blood pressure. 
• Experience chills during the process. 
• Experience severe bleeding in the arm. 
• Have a loss of blood from a breakdown of the blood cell separator machine.  If 
the machine does breakdown you could lose about 1½ cups of blood.  This is 
unlikely to cause you harm. 
• There is a small (about 1 in 1,200) risk of being hospitalized for observation of 
side effects from the donation (for example lightheadedness, nausea). 
 
Additional Risks 
Donating for a recipient can cause strong feelings, especially if the transplant does not succeed.  These 
feelings may range from stress during the process to great joy or feeling sad after the donation.  By 
donating for this recipient, you are doing all you can to help them.  You cannot control the success of the 
transplant, or whether the recipient lives or dies.  You should not feel personally responsible for the 
outcome. 
 
You may be asked to donate again for the recipient if the donated cells do not grow in the recipient or if 
the recipient’s disease is not cured.  If you are asked to donate again, you are free to say no. 
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After You Donate Either Bone Marrow or PBSCs 
After your donation, you will be called on the phone and asked questions about how you are feeling 
physically.  These calls will start two days after the donation and will be made each week until you feel 
you are back to normal.  You will be called again at one month, six months and then yearly after that. 
You will also be asked to give a small blood sample (1½ teaspoons) at one month and six months after 
your donation, and then yearly after that.  These samples will be used to measure your blood cell counts 
and to see how you are healing from the donation. 
Quality of Life Surveys 
To see how donation has affected your life, and how you have dealt with it, this study also asks questions 
about the quality of your life.  
If you can answer the following three questions with a “yes,” you will be called and asked questions 
about your quality of life.  
• Do you read or speak English?  
• Do you have access to a phone?  
• Are you able to complete a survey?  
You can ask to have a written copy of the questions sent to you before you are called. The people calling 
will arrange a time that works for you.  The calls will take 30 minutes or less and will happen on this 
schedule: 
• Within four weeks before your donation. 
• On Day 4 of filgrastim injections (only for PBSC donors). 
• At two days after your donation. 
• Every week after your donation until you have reported that you are fully well again for four 
weeks in a row. 
• At six months after your donation. 
• At one year after the donation. 
The questions you will be asked include: 
• How are you recovering physically? 
• How well are you doing emotionally? 
• How has the donation affected your everyday activities? 
• How do you feel about the donation experience? 
• What is your age, gender, race, marital status, work status, and what level of schooling have you 
had? 
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What are the possible side effects and risks of answering questions? 
 
ANSWERING QUESTIONS FOR THE QUALITY OF LIFE STUDY 
There are no physical side effects or risks to being in the quality of life part of the study. It will take at 
least three extra hours of your time over one year.  Some people may feel awkward answering questions 
about themselves, but you may skip any questions that bother you.  
 
3. What do I do if I am injured in this study? 
The risk of serious injury to donors participating in this study is thought to be small.  If you are injured, 
treatment (to include first aid, emergency treatment and other needed care) will be on hand for you.  The 
NMDP will pay for this treatment.  Please call your Donor Center Coordinator right away at  
(       ) __________________ if you are injured. 
In the case of an injury resulting from this study, you do not lose any of your legal rights to seek payment 
by signing this form. 
 
4. Do I have to agree to be in this study?  
No, it is up to you if you want to participate in this study.  If you decline to participate, the NMDP will 
not remove you from the Registry unless you ask for this to be done.  Your decision to decline 
participation will not change your relationship with your Donor Center or the NMDP.  There will not be 
any penalty or loss of benefits.  Your decision to decline participation will not affect your right or access 
to health care or any other service that you are entitled to receive at your Donor Center. 
 
5. Are there alternatives to being in this study?  
Yes.  If you decide you do not want to take part in this study, you may be asked to donate either bone 
marrow or PBSCs for the recipient without participating in this study.  In that case, the type of donation 
will not be decided randomly. 
 
6. How long will I be in this study?  
As part of your normal donor follow-up, each year you will be asked to give a blood sample and answer 
some questions about how you are feeling physically.  This information will be shared with the study for 
three years.  You will be called with questions about your quality of life for one year. 
You will be informed of any new finding which may affect your decision to continue your participation in 
this research study. 
 
7. Can I stop being in this study? 
Yes, you may stop taking part in this study at any time.  If you want to withdraw, you are asked to tell 
your Donor Center Coordinator.  Your choice to stop will not change your relationship with your Donor 
Center or the NMDP.  There will not be any penalty or loss of benefits.  Your choice to stop will not 
affect your right or access to health care or any other service that you are entitled to receive at your Donor 
Center. 
If you choose to stop before you donate bone marrow or PBSCs: It is important you know that if you 
decline to donate after the intended recipient begins to get treatment to get ready for the transplant, he or 
she will most likely die. If you have any questions about this statement, please contact your Donor Center 
Medical Director. 
 
8. Will it cost me money to be in this study? 
No.  There is no cost to you for the check-ups, donating the cells or the surveys. 
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9. Will I be paid to be in this study? 
No.  You will not be given any payment for being in this study. 
 
10. Are there rewards to being in this study? 
You will not receive direct payment or reward for being in this study.  But, this study may help future 
recipients in need of transplants, as well as future donors. 
 
11. How does the NMDP use donor data? 
As part of your participation in this study, your demographic and health information will be entered into 
the NMDP Research Database.  The NMDP collects some data on all donors.  This helps the NMDP 
make sure it is doing the best job it can and learn how to improve where needed.  
By signing this consent form, you allow _____________________________ (Donor Center) to give the 
NMDP your demographic information (for instance: gender, age and ethnic background) and health 
information that was taken as part of the donation process (for instance: results from infectious disease 
testing and the physical exam and information on healing from the donation).  This information will be 
used by the NMDP to evaluate operation of the Registry, to report to its funding agencies, and to conduct 
research.  In addition, people doing studies approved by the NMDP may use this information for research. 
This authorization does not have an expiration date.  You have the right to cancel this authorization at any 
time by notifying the NMDP in writing that you are canceling the authorization.  The address for the 
NMDP is 3001 Broadway Street NE, Suite 500, Minneapolis, MN 55413.  If you cancel this 
authorization, any identifiable health information will be removed from the NMDP Research Database.  If 
you cancel your authorization, this will not affect your right or access to healthcare or any other services 
you are entitled to receive at _____________________________ (Donor Center). 
 
12. Will my health information and surveys be kept private? 
We will do our best to make sure that the personal information in your health record is kept private.  We 
cannot guarantee total privacy.  Your personal information may be given out if required by law.  If 
information from this study is published or presented at scientific meetings, your name and other personal 
information will not be used. 
Groups that may look at and/or copy health records for research, quality assurance and data analysis 
include: 
• The NMDP 
• The BMT CTN 
• The NMDP Institutional Review Board (IRB) 
• The National Institutes of Health (NIH) and other government agencies, like the Food & Drug 
Administration (FDA), involved in keeping research safe for people. 
 
Steps used to keep your data private are: 
• To label your data with a nine-digit identification (ID) number instead of your name.  This ID 
number is chosen at random and does not contain any identifying information about you. 
• To limit who sees your data. 
• To keep your data in locked files. 
• To destroy all papers when they are thrown away (for instance, by shredding). 
• To use special, protected computer systems. 
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13. Who can I contact with questions or concerns about this study? 
The doctors for this study are:  
Dr. _______________ ___________________ (       ) ________________________ 
(Donor Center Medical Director) 
Dr. John Miller     (800) 526-7809 
(NMDP Medical Director) 
For questions about your rights while taking part in this study, please contact Roberta King, Institutional 
Review Board (IRB) Administrator, at (800) 526-7809.  
 
14. Donor/Participant’s Signature (NMDP DID:______________) 
I have been given a copy of all 18 pages of this form. I have read it, or it has been read to me. I 
understand this information and have had my questions answered. I agree to take part in this study. 
 
______________________________________ ________________________________  
 Donor/Participant’s Signature     Date 
 
______________________________________ 
 Donor/Participant’s Name Printed 
 
 
Certification of Counseling Healthcare Professional 
I certify that the nature and purpose, the potential benefits, and possible risks associated with participation 
in this research study have been explained to the above individual and that any questions about this 
information have been answered. 
 
______________________________________ ________________________________  
 Counseling Healthcare Professional    Date 
 
 
 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to 
obtain consent. 
An oral translation of this document was administered to the subject in ______________ 
(name of language) by an individual proficient in English and ______________________ (name of 
language). See the attached short form addendum for documentation. 
 
______________________________________ ________________________________  
 Interpreter’s Signature     Date 
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ATTACHMENT A 
WHY IS THIS STUDY NEEDED? 
 
The main goal of this study is to find out if there are differences in the outcomes of unrelated donor 
transplants based on whether blood-forming cells are taken from the bloodstream (PBSCs) or from the 
bone marrow.  
Blood-forming cells are needed for transplantation.  The greatest number of blood-forming cells are found 
in the bone marrow, while only a few blood-forming cells are normally found in the blood.  In the past, 
blood-forming cells were always taken from the bone marrow.  However, it is now known that a drug 
called “filgrastim” can increase the number of blood-forming cells in the blood so much that transplants 
can be performed using these cells taken from the blood.  
When the NMDP compared the past survival of recipients who received an unrelated donor marrow 
transplant with recipients who received an unrelated donor PBSC transplant, there was no difference in 
survival between the two groups.  This may have been because the recipients in each group did not have 
the same characteristics (different ages, different disease stages). 
In this study, the donor and recipient will be randomly assigned (much like the toss of a coin) to either the 
PBSC group or the bone marrow group.  By randomly assigning the recipients to receive either PBSCs or 
bone marrow, the characteristics of the recipients in each group should be similar.  This makes it fairer to 
compare the two groups.  With similar types of recipients in each group, the study should be able to find 
out if recipients who receive one type of donation do better after transplant than recipients who receive 
the other type of donation, or if recipients in both groups have similar results from their transplant. 
There are also goals of this study specifically related to the donor.  These goals are: 1) to examine any 
difference in the physical side effects PBSC donors and bone marrow donors have; 2) to examine any 
difference in the time it takes donors to recover from PBSC donation and marrow donation; and 3) to 
examine any difference in quality of life issues between the two types of donations, such as how the 
donation affects donors emotionally, how the donation affects the daily activities of donors, and how the 
donors feel about the donation experience. 
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ATTACHMENT B 
WHY DO I NEED THESE BLOOD TESTS? 
 
Standard Blood Tests 
Tests are done on your blood to make sure it is safe for you to donate PBSCs or bone marrow.  Any 
increased risk might mean that you would not be allowed to donate, or that only one of the two methods 
of donating would be advisable for you.  These tests also protect the recipient getting your donation.  
Blood Tests for Diseases 
Your blood will be tested for infectious diseases including HIV, Hepatitis and West Nile Virus. 
If your check-up or blood tests reveal anything that is not normal, you will be told.  The NMDP or your 
Donor Center may also be required by law to notify your state public health agency if you test positive for 
Hepatitis B, Hepatitis C, the virus that causes AIDS (HIV) or other infectious diseases.  
Check for Sickle Hemoglobin 
Your blood will be tested for sickle hemoglobin.  This test may result in genetic information that is new 
to you.  There have been reports of severe reactions to filgrastim in persons with sickle cell disease.  If 
your blood test is positive for sickle hemoglobin, you will not be able to participate in this study.  
However, you may still be asked to donate bone marrow for this recipient. 
Pregnancy Test 
If you are a woman of childbearing years, you will be required to take a pregnancy test.  You must not 
donate bone marrow if you are pregnant.  You must not take filgrastim if you are pregnant.  This 
medication could cause serious problems for an unborn child.  You must make sure that you do not get 
pregnant while taking filgrastim and for 48 hours after the last shot. 
 
Extra Blood Samples for Research in this Study 
Your blood will be tested for antibodies specific to germs that cause infection, for example, Hepatitis B.  
The antibody levels in your blood may be compared against the antibody levels in the recipient’s blood 
after the transplant. 
These samples are also used to better understand tissue matching between donors and recipients. 
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ATTACHMENT C 
DEFINITIONS 
 
Anesthesia is the giving of a drug or drugs designed to relieve pain and/or cause loss of consciousness. 
Apheresis is a process where a machine divides blood into its separate parts.  Blood is removed from one 
arm of the donor, passed through the machine, which separates out the needed type of cell(s), and returns 
the remaining blood to the donor.  Over time, the donor’s body naturally replaces the blood cells that are 
removed. 
A Central Line is a sterile tube put into one of the larger veins, usually in the groin area (femoral vein), 
the neck area (internal jugular) or just below the collarbone (subclavian vein). 
Demographic Information are facts about the part of the country where you live; what sex, race and age 
you are, and what ethnic group(s) you belong to.  These facts help people study the health data.  It does 
not include your name. 
Filgrastim is a drug that causes the bone marrow to produce more blood forming cells than usual.  When 
these cells go into the bloodstream they are often called peripheral blood stem cells (PBSC).  They can be 
collected from the bloodstream.  Filgrastim is also called “G-CSF” and marketed in the U.S. as 
Neupogen®. Filgrastim has been approved by the Food & Drug Administration (FDA) to collect PBSCs 
from recipients getting transplants of their own cells.  It is also approved to treat recipients with cancer 
getting chemotherapy, for recipients getting bone marrow transplants and for recipients with diseases 
causing very low white blood counts. 
An Institutional Review Board (IRB) is a group of people who review research methods and results to 
protect your rights and safety. 
PBSC are “peripheral blood stem cells.” This is another term for the blood forming cells circulating in 
your bloodstream that can be taken by a machine. 
Platelets are special blood cells that help you stop bleeding by making clots. 
Blood forming cells are cells found in the bone marrow and bloodstream that rebuild your blood, bone 
marrow and the immune system. 
A Syringe is used to inject or withdraw a fluid.  It has a hollow needle to break the skin and fluid is either 
injected into the body through the needle or fluids such as blood are withdrawn from the body. 
A Teaspoon is a common unit of measurement.  One teaspoon is equal to about five milliliters. There are 
three teaspoons in a tablespoon, 48 teaspoons in a cup. 
 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 8.0 dated September 15, 2006 
B-61 
 
 
APPENDIX B-3 
 
ASSENT TO PARTICIPATE FORMS 
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Assent to Participate in Research (Ages 7 to 11 years old) 
 
 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cells 
with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Institution  
Name/Title/Phone number/ 
 
3. Contact information for Emergencies after Hours or on Weekends or Holidays 
Name/Phone number/ 
 
You are being invited to be in a research project.  This research project is about deciding which kinds of 
donor cells work better for transplants.  Donor cells can come from bone marrow or blood.  Your doctors 
want to learn whether it is better to use bone marrow or blood for other children who need a transplant in 
the future. 
 
You should talk to your parents about this research project.  If you have questions, ask your parents or 
your doctor. 
 
You have a disease in your blood cells and the disease makes you sick.  To help you get better, the 
doctors will give you strong medicines to make the bad blood cells go away.   
 
The medicines may make you throw up, lose your hair and have mouth sores.   
 
After these strong medicines, you will get a transplant of new cells from a donor who is a person you do 
not know.  The cells will come from the donor’s bone marrow or from the donor’s blood.  The cells 
should make new and healthy blood in your body.   
 
Your parents, doctors, and nurses will explain what happens with the transplant.  You should ask them 
about anything you do not understand.  They will answer your questions. 
 
You don't have to be in this research project.  Your doctors and nurses will not be mad at you if you don't 
want to be in the research project.  If you decide you don't want to be in this research project, you may 
still receive a transplant for your disease. 
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Sign your name on the line below if you want to be in this research project.  You can keep a copy of this 
form at home. 
 
 
 
_________________________________________________  _______________________________  
Minor’s Signature Date 
 
_________________________________________________  _______________________________  
Print Name of Minor Age of Minor 
 
 
 
 
Certification of Counseling Healthcare Professional 
 
I certify that the nature and purpose, the potential benefits, and possible risks associated with participation 
in this study have been explained to the above individual and that any questions about this information 
have been answered. 
 
________________________________  ____________________________ 
Counseling Healthcare Professional   Date 
 
 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was 
used to obtain assent: 
 
Print name of interpreter: ______________________  Date: ____________________  
 
Signature of interpreter: _______________________   
 
An oral translation of this document was administered to the donor in __________ (state 
language) by an individual proficient in English and _______________ (state language).  See the 
attached short form addendum for documentation. 
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Assent to Participate in Research (Ages 12 to 17 years old) 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell 
versus Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Institution  
Name/Title/Phone number/ 
 
3. Contact information for Emergencies after Hours or on Weekends or Holidays 
Name/Phone number/ 
 
4. Invitation to Participate in a Research Study 
 You are being invited to join a research study because you have a disease that may be treated with a 
transplant of bone marrow or blood cells from a healthy person not related to you.  This form gives 
you information to help you decide if you want to be in this study.  You should read this form and ask 
any questions you have before agreeing to be in the study. 
 
 It is your choice whether or not to join this study.  The medical staff at your transplant center will tell 
you about other treatment options before you make your decision about joining this study.  If you do 
not join this study, you may still have a transplant for your disease. 
 
5. Purpose of the Study 
This study will look at two kinds of blood stem cell transplants, bone marrow and peripheral blood 
stem cell (PBSC), and their side effects.  At this time, doctors use both types of blood stem cells for 
transplant.  If you join this study, the type of cells used for your transplant will be picked by a 
computer program.  The goal of this study is to see which type of blood stem cell transplant (bone 
marrow or PBSC) has better results. 
 
An important part of this study will look at how patients recover after transplants.  Researchers want to 
know what the effects are from each type of blood stem cell used for the transplant and how long they 
last. 
 
Good effects might include: 
 Quick recovery of blood counts after 
transplant 
 No relapse (return) of disease 
 High cure rates 
 Few infections 
 Able to return to important activities in 
life 
Bad effects might include: 
 Slow recovery or no recovery of blood counts 
after transplant 
 Relapse (return) of disease 
 Severe graft-versus-host disease (GVHD) 
 Serious infections 
 Not able to return to important activities in 
life 
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6. Study Procedures 
If you agree to join this study, the donor will also need to agree to join the study.  A donor could 
decide not to join this study, but still agree to give you cells for your transplant.  If that happens, you 
can still have your transplant without being in this study, or another donor who does want to join this 
study may be found. 
 
Since this study looks at the results of two different kinds of transplants, bone marrow and peripheral 
blood stem cell (PBSC), the kind of transplant you will receive will be decided randomly, like a coin 
toss.  Neither you nor your doctor chooses the type of transplant; the type of transplant you will 
receive is determined by a computer program.  Half of the patients in the study will have a bone 
marrow transplant.  The other half will receive a PBSC transplant.  Saying yes to joining the study 
means that you are willing to accept either type of transplant. 
 
One part of the study will involve collecting your medical information.  Your medical information 
will be collected for three years.  The study coordinators at your center will collect information from 
your medical record chart every week for 100 days, then at 6 months, 1 year, 2 years and 3 years. 
 
If you are 16 or 17 years old, another part of the study will ask questions about your physical and 
emotional health.  This information will be collected for five years.  A trained interviewer will contact 
you by telephone before your transplant, then 6 months, 1 year, 2 years and 5 years after your 
transplant.  These telephone interviews will last approximately 15-25 minutes and will be done at a 
convenient time for you.  They will include questions about side effects, health problems and how 
well you can do things that are important to you.  When you are contacted, you may skip any 
questions you don’t want to answer. 
 
As part of the standard transplant procedure, you will need to take many medications and have other 
medical treatments as part of your transplant.  Your doctors will explain these during discussion of 
your medical care.  Even if you decide not to join this research study, you will still need to take 
medications and have other medical treatments as part of your transplant. 
 
7. Possible Discomforts and Risks of Being in the Research Study 
The bone marrow and PBSCs from the donor contain blood stem cells, which allow your blood 
counts (red blood cells, white blood cells, and platelets) to recover.  Blood stem cells make all the 
blood cells in the bone marrow and serve the entire body.  It is possible that even after the transplant 
your bone marrow will not work well enough and you will be at an increased risk of infections and 
even death.  Early after transplant, the risk of getting an infection might be less after a PBSC 
transplant, because the blood counts return faster than with bone marrow.  Later, the risk of infections 
might be increased in PBSC transplants, because graft-versus-host disease (GVHD) might be worse 
and last longer. Blood counts will be done often to track recovery of the bone marrow.  You will get 
platelets and red cells as needed to keep your counts at a healthy level.   
 
There is a risk that the blood stem cells may not grow after being given to you.  This is called graft 
failure.  This risk may be less with PBSCs, since PBSCs contain more blood stem cells than bone 
marrow. 
Graft-versus-host disease (GVHD) is a common problem after unrelated donor transplantation.  After 
the cells in the product start to grow, there is a risk that the donor cells might react against your body. 
GVHD it can show up as a skin rash, or liver or stomach problems, like feeling sick to your stomach, 
throwing up, not feeling hungry, stomach cramps, diarrhea, and bleeding of the gut.  Chronic GVHD 
may occur later after transplantation and can cause problems with the eyes, mouth, lips, throat and 
liver.  You will get medicines to help prevent GVHD, but sometimes people get it anyway.  If you do, 
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there are other medicines used to help treat it.  The chance of getting GVHD might be more with 
PBSCs, because PBSC transplants have more donor cells. 
 
Relapse of your disease might occur after transplant, especially in patients with advanced disease.  
This risk may be decreased by PBSC transplantation. 
 
If one type of transplant does have better results, and you are not randomly assigned to that study 
group, you may not receive the same benefits as those in the study group with overall better results. 
 
If you are 16 or 17 years old, you will complete quality of life interviews.  These interviews will not 
cause you any physical discomfort, although it is possible that you will find some of the questions or 
topics upsetting.  If you do, there will be someone available to speak with you.  They will be able to 
refer you to appropriate counselors or other support people. 
 
8. Possible Risks and Discomforts from the Standard Transplant Procedure 
As part of the standard transplant procedures, you will face risks from the transplant itself and from 
treatments given before and after the transplant.  These risks are no different than the risks you would 
face if you had a transplant but did not join the study.  Your doctor thinks these risks are less than the 
risk from the disease for which you are receiving a transplant. 
 
Your organs may be damaged by the chemotherapy or irradiation given to you to prepare you for the 
transplant, or by other medications given to you after the transplant.  We expect these risks to be the 
same whether you receive bone marrow or PBSCs.  If you want more information about additional 
risks and the drugs that will be used for your conditioning regimen, it is available for you.  
 
As part of a standard transplant procedure you may develop an infection after the transplant.  The new 
cells from the donor may not grow in you (graft failure).  You may develop graft-versus-host disease 
(GVHD). Your disease could relapse. 
 
When the bone marrow or PBSC are given to you through the catheter, there are usually few side 
effects.  Sometimes people may have a headache, chest pain or trouble breathing, a slight fever, or 
blood in the urine.  Very rarely, it may cause an allergic reaction. 
 
9. Alternatives Treatments Available if You Don’t Want to be in the Study 
Participation in this study is entirely voluntary.  You don't have to join this study.  What you and your 
family decide will not affect current or future health care you receive at this institution.  If you are not 
in this study, you might have a transplant with marrow or blood stem cells anyway. 
 
10. Possible Benefits to Participating in the Study  
This research study is comparing the treatment results of bone marrow and PBSC transplants.  At this 
time doctors do not know if one type of transplant has better results than the other, or if they both 
have the same results.  If one type of transplant does have better results, and you are randomly 
assigned to that study group, you may benefit from participating in the study.  The knowledge gained 
from this study may help future patients who need a blood stem cell transplant. 
 
As a result of the bone marrow or PBSC transplant your disease may be put in remission or continue 
in remission. 
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11. Withdrawing From the Study 
You can decide to leave the study at any time, for any reason, without notice.  If you want you can 
withdraw from the study but still get a blood stem cell transplant.  If you leave the study after you 
have had some or all of the pre-transplant treatments and decide to have no transplant at all, then your 
blood counts may not return and you could die.  
 
12. Protection of Your Privacy and Confidentiality of Your Research Records  
 Your participation in this research study, and your medical and quality of life information, will be 
kept private and confidential. 
 
Scientific and medical findings resulting from a study may be presented at meetings and published so 
that the information can be useful to others.  Your name would not be used in these presentations and 
publications. 
 
For questions about access to your medical records, please contact /name / at/number/. 
 
13. Blood Samples for Research Purposes 
You will be asked to give blood samples to see if infection-fighting cells are working and to help 
better understand tissue matching between donors and recipients in this study.  You do not have to 
participate in this part of the study. 
 
If you agree, you will provide blood samples up to 7 times (10-100 mL each time or approximately  
1-7 tablespoons) between the time transplant is initiated and two years after (up to a total for all 7 
blood draws of 430 mL or approximately 2 cups).  The samples will be saved for future testing.  The 
blood can usually be drawn from your central line at the time of other blood collections.  If this is not 
possible, then it will be drawn directly from a vein. 
 
In addition, part of this study will look at if vaccinations after transplantation can help prevent infection.  
You will get vaccinations for diphtheria, tetanus, Hepatitis B and pneumococcus.  Blood will be 
drawn for medical tests to see if the vaccinations are working.  If you do not agree to give blood 
samples for research, your doctor may still recommend vaccinations as part of your medical 
treatment. 
 
The doctors conducting this study may choose to do some additional research tests on the blood 
samples. 
 
You don't have to be in this research.  If you don't want to give blood samples for research you can 
still be in the other parts of the study.  Your care will not be changed if you decide not to give these 
blood samples for research purposes.  Please mark your choice below (check only one box): 
 
 I agree to have blood drawn for research purposes. 
 
 I do not agree to have blood drawn for research purposes. 
 
 
____________________________________                     _______________________ 
  Signature                                                                               Date 
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14. Minor’s Assent 
 
I have been told about this study’s purpose, procedures, possible benefits and risks.  I have been given 
a chance to ask questions and they have been answered to my satisfaction.  I understand that I can ask 
more questions at any time. 
 
I voluntarily agree to participate in this study. 
 
By signing this consent form, I have not given up any of the legal rights, which I otherwise would 
have as a subject in a research study. 
 
 
            
Signature of Minor      Date 
 
 
        
Print Name of Minor  
 
 
 
 
Certification of Counseling Healthcare Professional 
 
 I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this study have been explained to the above individual and that any questions about 
this information have been answered. 
 
 
________________________________  ____________________________ 
Counseling Healthcare Professional   Date 
 
 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to 
obtain consent: 
 
Print name of interpreter: __________________________  Date: ______________________  
 
Signature of interpreter: ___________________________   
 
An oral translation of this document was administered to the donor in __________(state language) by an 
individual proficient in English and _______________(state language).  See the attached short form 
addendum for documentation. 
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APPENDIX C 
 
LABORATORY PROCEDURES 
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APPENDIX C – LABORATORY PROCEDURES 
 
 
 
The laboratory procedures performed under this protocol include: 
1. HLA Typing 
2. Characterization of Graft 
3. Immune Reconstitution 
4. Chimerism 
5. Acquisition of Natural Killer Cell Receptors in Recipients of Unrelated Transplants 
 
LABORATORY PROCEDURES 
 
1. HLA TYPING 
 
Before Transplantation: HLA typing will be performed for all patients and donors in American 
Society of Histocompatibility and Immunogenetics (ASHI)-approved laboratories designated by 
the transplant centers.  HLA typing must be performed by DNA methods for HLA-A, -B, and -C 
at intermediate resolution, and DRB1 at high resolution, consistent with NMDP standard 
procedures. 
 
After Transplantation: High resolution HLA typing of cryopreserved patient and donor 
samples is conducted as an ongoing research study by the NMDP.  Data will be shared with the 
BMT CTN. 
 
 
2. GRAFT CHARACTERISTICS 
 
2.1 Rationale: The impact of the cellular constituents of the graft on post-transplant outcome 
is likely a complex effect that is a function of the absolute numbers of immune cells in the graft 
(T cells, NK-cells, B-cells, monocytes, and dendritic cells) as well as interactions among these 
different donor cells, and their interactions with residual host cells.  Storek et al. has noted that 
the kinetics of CD45RAbright “naïve” CD4 T cells is most correlated to the numbers of 
CD45RAbright CD4 T cells in the allograft marrow or PBSC allo-graft from HLA matched 
siblings (Storek 2001).  A detailed analysis of the cellular constituents of the graft in patients 
receiving allogeneic marrow or PBSC could help validate or reject the hypothesis that the 
content of donor CD34 and donor dendritic cells are significant factors in regulating post-
transplant immune reconstitution and the incidences of post-transplant GVHD and relapse.  
Recent reports have suggested that the content of donor dendritic cells are associated with the 
incidences of chronic GVHD, and relapse (Waller, 2001), and that the number of transplanted 
CD34 cells is associated with the incidence of acute and chronic GVHD (Przepiorka, 1999).  
Other reports have shown that mobilization of PBSC with G-CSF results in a relative increase in 
the frequency of type 2 dendritic cell progenitors (DC2p) compared with un-stimulated blood 
mononuclear cells (Arpinati 2000).  Thus it is likely that the content of donor CD34 and type 2 
dendritic cells will vary significantly between allogeneic marrow grafts and PBSC grafts that are 
collected after G-CSF stimulation. 
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2.2 Assays: Studies will be conducted in keeping with the BMT CTN MOP on graft 
characterization.  Samples of the marrow or PBSC graft will be sent to a central reference 
laboratory for flow cytometric analysis of the content of CD34 cells, the CD38-negative subset 
of CD34 cells, ALDH-bright progenitor cells, T cells, B-cells, NK-cells, monocytes, and 
dendritic cells.  The test samples will be shipped to the reference laboratory at the same time that 
the graft is shipped from the collection center to the transplant center, so that the analysis of the 
cell content will be performed at approximately the same time as the graft is infused into the 
recipient.  Samples will be shipped at 2-8oC on “cold-packs” in order to prevent accidental over-
heating that may impair cell viability. Pilot experiments storing samples of marrow or PBSC 
grafts at 2-8oC versus 20oC have not shown any significant differences in recovery of viable 
CD34 cells or the recovery of various subsets of immune cells (Table 2).  The flow cytometric 
analysis will be performed using a panel of flow cytometry assays, each containing multiple 
fluorescently labeled monoclonal antibodies.  The FACS panel that will be used is shown in 
Table 3. 
 
2.3 Calculation of absolute cell counts for manipulated products: Some products are 
manipulated between the time of arrival at the transplant center and infusion.  In some cases, 
plasma or red cells are depleted, while in others a subset of the product is cryopreserved.  For 
such products, the doses of cell subsets transplanted can be estimated by adjusting the cell subset 
count at the reference lab multiplied by the proportion of total cells infused divided by the total 
cell received by the transplant center.  Such a method assumes that travel and manipulation of 
the product did not affect any cell subset in a selective manner. 
 
 
3. MEASUREMENTS OF POST-TRANSPLANT IMMUNE RECONSTITUTION 
 
3.1 Sample shipping and analysis: Blood samples will be shipped at 2o-8o C to a central 
reference laboratory for measurement of peripheral T cell subsets, the numbers of T cell receptor 
excision circles (TREC)-positive CD4 and CD8 T cells, and the frequencies of anti-viral T cells 
using the tetramer assay and the pattern of cytokine synthesis by intracellular staining and flow 
cytometric assays.  Plasma samples will be analyzed for IL2 and IL7 levels.  Serum samples will 
be shipped to the reference laboratory for quantitative immunoglobulin levels and analysis of 
standard antibody titers to diptheria toxin and tetanus antigen (dT).  Serum for measuring 
pneumococcal antibodies, Haemophilus influenzae type B-specific IgG antibodies, Hepatitis B 
antibody as well as the titers of opsonophagocytic antibodies to pneumococcus will be sent to the 
central reference laboratory.  The schedule for obtaining and shipping samples is listed in Tables 
6 and 7 of Appendix C below. 
 
3.2 Rationale and methods for measuring post-transplant T cell function: PBSC grafts 
contain more donor immune cells than marrow grafts and therefore may lead to improved 
reconstitution.  Storek, et al. compared the kinetics of immune reconstitution among 115 cancer 
patients randomly assigned to receive either marrow or PBSC allografts from HLA matched 
siblings (Storek 2001).  Recovery of CD4 T cells was slower among recipients of marrow versus 
PBSC allografts while proliferative responses of T cells to HSV, VZV, or PHA in vitro did not 
differ between recipients of marrow versus PBSC transplants.  There was a significant difference 
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in the incidence of post-transplant infections, with recipients of marrow grafts experiencing a 2.4 
fold higher rate of severe infections.  The rate of fungal infections was 10/46 among recipients of 
marrow grafts and 2/36 among recipients of PBSC grafts (Storek 2001).  The frequency of T 
cells, NK cell, B cells and dendritic cells will be measured in the blood of transplant recipients in 
order to test the hypothesis that the content of donor CD34 cells and donor immune cells in the 
graft has a material impact on the kinetics and quality of post-transplant immune reconstitution.  
Tetramer staining and flow cytometric assays will measure anti-CMV and anti-EBV CD8 T cells 
in samples from A2+ and/or B7+ recipients (circa 60% of patients).  The frequency of functional 
anti-CMV specific T cells will be measured by the frequency of T cells that synthesize TNF in 
response to in vitro exposure to CMV antigens.  The frequency of anti-aspergillus T cells will be 
assessed by measuring cytokine (γ-IFN and IL-4) synthesis following incubation with aspergillus 
antigen in-vitro.  Plasma IL-7 and IL-2 levels will be measured by ELISA or chemiluminescence 
assays from the heparinized tube of blood used to measure peripheral blood T cells.  The levels 
of IL-2 and IL-7 will be correlated with the levels of T cells in the blood to test the hypothesis 
that poor cellular immune reconstitution may be due, in part, to low blood levels of these 
cytokines (Okamoto 2002).  
 
3.3 Rationale and methods for measuring post-transplant B-cell function: Comparison 
of recovery of serum immunoglobulin levels among a 115 patients randomized to receive 
marrow or PBSC allo-grafts from HLA matched siblings did not reveal any significant difference 
in the levels of serum Ig or circulating B-cells post-transplant (Storek 2001).  Of note, this study 
did not compare humoral responses to vaccines, but did find lower rates of infections among the 
recipients of the PBSC grafts.  In order to compare in vivo functional humoral immunity between 
the PBSC and marrow recipients, the response to vaccination with the heptavalent pneumococcal 
conjugate vaccine and to Hepatitis B will be measured.  Pneumococcal infections are a long-term 
risk after transplant and, given the increased prevalence of penicillin resistant S. pneumonia, 
penicillin prophylaxis is not universally effective (Kulkarni 2000).  However, polysaccharide 
epitopes such as those in the 23-valent pneumovax vaccine, are T cell independent antigens.  As 
such, the pneumovax vaccine is not highly immunogenic, especially when administered in the 
first year after transplantation.  Conjugate vaccines, which are T cell dependent and provide 
longer lasting immunity have been found to be more immunogenic in both infants and bone 
marrow transplant recipients (Barra 1992).  A recent study administered the heptavalent 
pneumococcal conjugate vaccine (Prevnar, Wyeth Lederle Laboratories) to recipients (and half 
of the donors) at 3, 6, and 12 months after a T cell repleted allogeneic transplant (Molrine 2002).  
By month 12, over 60% of recipients had protective immunity to all 7 serotypes, although at 
month 3 and 6, humoral responses remained low in the half of patients whose donors had not 
been immunized.  An increase in the frequency of patients with protective antibodies was seen 
following the third vaccination with PPV23 at 12 months, indicating that multiple early 
vaccinations with the protein conjugate vaccine can elicit protective humoral antibody responses 
when given within the first year post-transplant (Molrine 2003).  Since the Wyeth vaccine is 
conjugated to a nontoxic variant of diphtheria toxin (CRM), an attractive strategy to augment 
humoral responses to the glycoprotein polysaccharide vaccines in adults within the first year 
post-transplant would be to sequentially immunize transplant recipients with the carrier protein 
(diptheria toxin) followed by vaccination with the pneumococcal conjugate vaccine (7 valent) 2 
weeks later, and finally the 23-valent polysaccharide pneumococcal vaccine a few months later.   
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Antibody response to the conjugated vaccine, however, represents a best-case scenario.  If 
patients do not respond to the conjugated vaccine, they will not respond to the unconjugated 
vaccine or wild type infection.  Unfortunately, the ability to respond to the conjugated vaccine 
does not predict for response to bacterial carbohydrate antigens.  To evaluate the recipient’s 
ability to produce an antibody response to wild type bacterial carbohydrate antigens, we will test 
for Haemophilus influenzae type B-specific IgG antibodies that cross-react against E. coli K-100 
present in gut flora. 
 
Immunization with Hepatitis B will serve as a potentially informative “neo-antigen” for the circa 
40-50% of donor-recipient pairs that are both sero-negative to test the integrity of the primary 
humoral immune response post-transplant and responding patients may be protected from 
infection.  The hypothesis would be that recipients of PBSC would receive more donor T cells 
and may respond to vaccinations starting at six months post-transplant at a higher frequency than 
recipients of marrow allografts.  Demonstration of immune-responsiveness among transplant 
recipients receiving vaccine starting at six months post-transplant could lead to a reduction of 
some of the morbidity and mortality due to infection seen within the first year post-transplant.   
 
3.4 Immunophenotype assays of lymphoid subsets and dendritic cells:  Blood samples 
will be obtained from patients at 1, 3, 6, 12 and 24 months post-transplant.  Aliquots of 
peripheral blood will be stained with the panels described in Table 4 by the central reference 
laboratory, and the percentage of nucleated cells with each phenotype determined using standard 
Cell-Quest (or similar) analysis templates.  The reference laboratory will send the coordinating 
center the results from a CBC with differential performed on the shipped sample as well as the 
calculated numbers of cells/mcL of each phenotype as determined by the results of the FACS 
analysis.  The reference laboratory will calculate the absolute numbers of subsets of immune 
cells in the blood based upon the absolute number of leukocytes in the blood and the percentage 
of leukocytes that are T, B, NK, monocyte, or dendritic cells subsets as defined by 
multiparameter flow cytometry.  
 
3.5 Assays for antigen-specific T cells: Blood samples from patients who receive 
transplants from donors who have the HLA A2 or B7 allele will be obtained at 3, 6, 12 and 24 
months post-transplant.  These will be shipped to the central reference laboratory for FACS 
analysis of the frequency of anti-CMV and anti-EBV specific T cells using a tetramer FACS 
assay on the mononuclear cell fraction obtained from fresh (not frozen) samples.  Tetramers will 
be incubated with PBMC obtained from transplant recipients at the time points described above, 
and the frequency of CD3, CD8, tetramer+ T cells will be assessed by flow cytometry (Altman, 
1996).  A subset of approximately 60% of transplant patients is predicted to be either A2+ and/or 
B7+, but they should be evenly distributed between the two arms.  Phycoerythrin-labeled HLA 
A2 and HLA B7 tetramers that stain antigen specific T cells that recognize immunogenic CMV 
peptides will be synthesized by the tetramer core facility at the central reference laboratory.  
HLA-B0702 tetramers loaded with (TPRVTGGGAM), the amino acid number 417-426 of lower 
matrix protein pp65-of CMV) and HLA-A 0201 tetramers, loaded with (NLVPMVATV), the 
amino acid number 495-503 of the pp65 protein will be used to identify CMV specific T cells 
from patients transplanted with HLA A2 and HLA B7 donors, respectively (Singhal, 2000; 
Keenan, 2001).  EBV specific T cells will be assayed using phycoerythrin-labeled HLA A2 
tetramers loaded with the EBV/BMLF1 peptide containing aa 280-288 (GLCTLVAML, Chen, 
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2001).  In addition, the presence and number of aspergillus-specific, CMV-specific and tetanus-
specific T cells will be determined by secreted cytokines measured by ELISA and FACS 
following in-vitro incubation with antigens at 3, 6,12 and 24 months after transplant (Centeno-
Lima 2002; Hebart 2002).  For CMV, the assays will include FACS for cytoplasmic IL2, IFN-g 
and TNF-a, and no ELISA.  For Aspergillus, the assays will only include ELISA for IL2, IL4, 
IL10 and IFN-g and no FACS.  For Tetanus, the assays will include FACS for cytoplasmic IL2 
and ELISA for IL-2, IL-4, IL-10 and IFN-g.  Appropriate controls should be included in the 
assays.  See Table 1 below.   
 
Table 1:  Cytokines for FACS and ELISA Assays 
 
 CMV Aspergillus Tetanus Control 
FACS IC Assay IL2 
INF-g 
TNF-a 
 IL-2 
 
IL-2 
IFN-g 
TNF-a 
ELISA Assay  IL-2 
IL-4 
IL-10, 
IFN-g 
IL-2 
IL-4 
IL-10 
IFN-g 
IL-2 
IL-4 
IL-10 
IFN-g 
IC = intracytoplasmatic 
 
 
3.6 TREC assay for de novo T cell generation: The central reference laboratory will 
prepare a mononuclear cell suspension from patient blood samples collected at 3, 6, 12 and 24 
months post-transplant.  Cell separations will be performed to isolate CD3+/CD4+ and 
CD3+/CD8+ cell subsets for batch analysis of signal joint T cell receptor excised circles 
(TRECs). IL-7 and IL-2 levels will be measured by the central reference laboratory using ELISA 
or chemiluminescence assays on samples of plasma obtained from the tubes of blood used to 
measure T cell numbers.  The levels of IL2 and IL7 will be correlated with the numbers TREC 
CD4 and CD8 (Okamoto 2002).  A summary of post-transplant studies in cellular immune 
reconstitution is shown in Table 5.  
 
3.7 Immunoglobulin levels: Quantitative immunoglobulin levels will be measured by the 
central reference laboratory on patient samples collected prior to transplant (baseline) and 6, 11, 
12 and 24 months post-transplant (Table 5).  
 
3.8 Vaccination schedule: In order to increase the effectiveness of the pneumococcal 23 
valent polysaccharide vaccine administered post-transplant, transplant recipients will receive 
sequential vaccination with dT (tetanus diphtheria toxoid) at 6 months post-transplant followed 
by the heptavalent pneumococcal conjugate vaccine (PCV7) four weeks later at 7 months, and 
again at 9 months post-transplant, and then the 23-valent polysaccharide vaccine (PPV23) and 
the dT (tetanus diptheria toxiod) vaccine at 11 months post-transplant (Table 5).  The goal will 
be to evaluate the immunogenicity of the pneumococcal vaccine conjugate when it is 
administered after boosting with the dT carrier vaccine followed by sequential vaccination using 
the PCV7 and PPPV23 vaccines. ELISA and functional type-specific pneumococcal antibodies 
will be measured.  Diphtheria and tetanus antibody will be measured prior to the first vaccination 
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and prior to the PPV23 vaccine.  Haemophilus influenzae type B-specific IgG antibody 
measurements will also be performed on samples collected at 6, 12 and 24 months post 
transplant to assist in evaluating the recipient’s ability to produce T cell independent immune 
responses to polysaccharide antigens.  Approximately 60% of recipients are predicted to be sero-
negative for Hepatitis A. Immunization with the Hepatitis B vaccine will be used a neo-antigen, 
in order to assess immune response to primary antigen.  The Hepatitis B vaccine will be 
administered at 6 months, 7 months, and 11 months after transplant, and antibody titers at 6, 12 
and 24 months will be determined to compare responses in the PBSC and bone marrow 
recipients.  All vaccinations should be given ± 1 week of the scheduled date.  Donor and pre-
transplant recipient serum will be collected to measure baseline antibody titers as specified in 
Table 5.  
 
3.9 Laboratory assays for antibody titers: 
 
i) ELISA for diphtheria antibody and tetanus antibody will be performed at the central 
reference laboratory. 
 
ii) ELISA for S. pneumoniae antibody. IgG antibody levels for specific serotypes of S. 
pneumoniae will be assayed by a protocol developed by George Carlone, Ph.D. at CDC.  
These studies will be conducted at the central reference laboratory.  Serotypes that are 
PCV7 heptavalent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F &23F) and 
a subset of serotypes present in the PPV23-valent polysaccharide vaccine (1, 3, 5, 7F, 
15B) vaccines will be measured at 6, 11, 12 and 24 months post-transplant. 
 
iii) Functional antibodies for S. pneumoniae.  Functional antibodies will be measured by 
an opsonophagocytic assay using HL-60 cells. Opsonophagocytic titers will be expressed 
as the reciprocal of the serum dilution with ≥ 50% killing compared with growth in the 
complement control wells.  These studies will be conducted at the central reference 
laboratory.  The opsonophagocytic assay will be performed only on 11 and 12 month 
post-transplant patient samples that show demonstrable IgG antibodies directed against 
one or more of the twelve S. pneumoniae serotypes evaluated in this study.  The 
measurement of functional antibodies will be limited to the analysis of the two serotype-
specific antibodies (one serotype, if IgG antibody detected to only one serotype) 
exhibiting the highest IgG titers. 
 
iv) Hepatitis B surface antigen antibody.  These will be measured using ELISA kits at the 
central reference laboratory.  Analysis will be performed on baseline donor serum 
samples and on patient serum samples collected at 6, 12 and 24 months post-transplant 
(Table 5). 
 
v) ELISA for Haemophilus influenzae antibodies.  Quantitative total IgG antibody levels 
against H. influenzae Type B (HIB) capsular polysaccharide will be measured using 
ELISA/EIA kits at the central reference laboratory.  Analysis will be performed on 
patient serum samples collected at 6, 12 and 24 months post-transplant. 
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vi) Stored serum and subsequent assays.  If, during the conduct of the study, investigators 
wish to analyze additional antibody assays, samples from frozen serum samples will be 
sent to the outside lab with no identifying information, except for a unique study number.  
All serum specimens will be stored for a 2-year period following enrollment of the last 
patient on the study.  Specimens will be stored in a locked freezer at –80°C. 
 
 
4. CHIMERISM 
 
Recommendations for chimerism assay: Demonstration of donor cells in lymphoid and 
myeloid lineages can assess the relative engraftment potential of PBSC compared to marrow.  
Since all patients on this trial will receive myeloablative conditioning regimens, we hypothesize 
that there will be little if any difference in donor chimerism between PBSC recipients and 
marrow recipients.  Therefore, chimerism testing will not be mandatory in this study. However, 
routine chimerism data generated by transplant center laboratories will be reported.  Chimerism 
results will be reported as “percent donor DNA.” 
 
 
5. ACQUISITION OF NATURAL KILLER CELL RECEPTORS IN RECIPIENTS 
OF UNRELATED TRANSPLANTS 
 
This is a supplemental study to this protocol conducted by Jeffrey S. Miller, Daniel Weisdorf, 
Claudio Anasetti, and Peter Parham. 
 
5.1 Background: Natural killer cells comprise approximately 10 – 15 % of resting normal 
donor blood.  Interestingly, they comprise a much higher proportion of blood lymphocytes early 
after bone marrow or peripheral blood stem cell transplantation.  There has been a growing 
interest in NK cells, given the discovery over the past five years of specific receptors that 
recognize Class I MHC molecules.  A recent publication by Ruggeri, et al, suggests that T-cell 
depleted haplo-identical transplant by donors who are mismatched at a known Killer 
Immunoglobulin-like Receptor (KIR) ligand (Cw3-group, Cw4-group or Bw4) correlates with 
protection from relapse, less GVHD and better survival.  The complexity of the KIR system is in 
part limited by the lack of known ligands for many of the receptors.  The Perugia analysis is 
clinically intriguing but leaves some complicated biologic questions unanswered.  Understanding 
this receptor status and how well it correlates with recipient KIR ligands may be of importance 
for better donor selection and improving unrelated donor (URD) transplant outcomes.  The 
principal study goal is to evaluate the NK cell receptor repertoire and the functional acquisition 
of these receptors on NK cells in patients who recover from unrelated donor transplant.  A 
functional NK repertoire may be associated with better protection from GVHD and infections 
and might differ in patients receiving PBSC or BM transplantation. 
 
5.2 Preliminary Data: We have already accessed donor/recipient samples from the National 
Marrow Donor Program Sample Repository.  From this repository, donor peripheral blood 
mononuclear cells (PBMNC) are available as well as cells from the recipient at approximately 
Day 100. We have used several approaches to analyze NK cell receptor acquisition after 
transplant including flow cytometry, quantitative RT-PCR, and intracellular cytokine staining. 
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Our current data on 36 donor/recipient sample pairs (collected retrospectively) can be 
summarized as follows: 1) KIR reconstitution early after transplant is diminished in a majority of 
patients, 2) KIR reconstitution is diminished to a greater extent in recipients of unmanipulated 
compared to T-cell depleted grafts, and 3) less KIR expression is associated with enhanced 
interferon-γ production in developing NK cells and CD94/NKG2A is reciprocally increased in 
those with low KIR expression.  Further study will correlate these laboratory endpoints with 
clinical outcomes after URD transplantation.  
 
5.3 Limitations to Current Retrospective Analysis and Samples Requested: Despite rapid 
progress in studies using retrospectively collected donor/recipient pairs, there are important 
limitations with this analysis.  Available repository samples are limited to a single, early post-
transplant time point.  Our in vitro studies predict that NK cell receptor acquisition develops 
progressively over time.  This is supported by studies from the Parham laboratory in allogeneic 
transplant patients.  Therefore, kinetic analyses are needed to study the completeness of NK cell 
receptor reconstitution.  To accomplish this goal, we propose prospective sample collection (30 
ml blood at each time point) from the donor and recipient pre-transplant and from the recipient at 
3, 6, and 12 months after transplant.  Applying this analysis to the randomized trial also provides 
the advantage of correlation with detailed immunologic and infectious disease outcomes that will 
be collected in conjunction with this trial. 
 
5.4 Objectives 
 
a. The primary objective of this study is to assess NK cell receptor acquisition (KIR, 
NKG2, LILR, NKp30/44/46, others) and NK cell function (cytotoxicity and cytokine 
production) during the first year after allogeneic URD transplantation.  Until the BMT 
CTN Protocol 0201 trial is complete, this objective will be met irrespective of knowledge 
of graft source, transplant variables or clinical outcomes.  
 
b. The secondary objective will not be reached until after completion of and reporting of 
the randomized study.  We plan to determine whether graft source (BM vs. PBSC) 
impacts on the frequency and completeness of NK cell receptor reconstitution and NK 
cell function.  In this large prospective cohort, we will determine whether NK cell 
receptor status correlates with clinical outcomes (infectious disease, relapse, GVHD) and 
the number of activating vs. inhibitory NK receptors.  We will test the hypothesis that 
KIR reconstitution is delayed by GVHD, favors CD56+bright NK cell (cytokine producing) 
reconstitution and this diminishes CD56+dim NK cell (directly cytotoxic) alloreactivity as 
a mechanism to protect against relapse.  These analyses will be performed in conjunction 
with the BMT CTN database for the BMT CTN Protocol 0201 trial, which will collect 
the relevant clinical endpoints. 
 
5.5 Experimental Plan: Paired donor /recipient samples will be thawed (including at least 2 
post-transplant time points) and analyzed in parallel.  We have a 2-tiered approach to analyze 
KIR expression.  The first is based on flow cytometry using antibodies recognizing one or more 
KIR gene products [(DX9 recognizes KIR3DL1), (GL183 recognizes KIR2DL2, KIR2DL3, 
KIR2DS2), (EB6 recognizes KIR2DL1, KIR2DS1)].  The limitations of this analysis are that 
some antibodies recognize more than one gene product and that monoclonal antibodies are not 
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currently available for all KIR.  Therefore, in addition to flow cytometry, RNA extracts will be 
amplified for KIR expression.  We have already validated real time quantitative PCR reactions 
for a majority of KIR genes.  To control for NK cell number, quantitative real time PCR will be 
performed from gene products expressed in all NK cells (KIR2DL4 and CD56/NCAM).  We will 
need genotyping studies to further investigate whether the absence of a KIR transcript is due to 
the absence of a gene or the absence of expression.  Control cell lines and a panel of known 
normal donors will be included with each analysis.  We have already established a good 
correlation between protein level by flow cytometry and real time quantitative PCR data using 
standard curves.  We will also analyze other NK receptors including NKG2, LILR, and 
NKp30/44/46 receptors and other families as reagents become available and validated.  Function 
will be measured by cytotoxicity or cytokine productions assays in the presence or absence of 
KIR ligands.  As new reagents or NK cell related genes or receptors are identified, these samples 
may be used for new studies.  However, within this study, analyses are limited to studies on NK 
cell expressed gene products and NK cell function.  They will not be used for other purposes. 
 
5.6 Samples: 
 
Donor:      30 mL heparinized blood (green top tubes), pre-donation (prior to G-CSF if PBSC) 
Recipient: 30 mL heparinized blood (green top tubes), pre-transplant (before conditioning) 
        30 mL heparinized blood (green top tubes) at 3, 6 and 12 months post-transplant 
 
To limit blood drawing volumes, if needed, the post-transplant samples can be collected a few 
days or up to 4 weeks before or after the requested times. 
 
For pediatric subjects, the volume requested is 15-20 mL heparinized blood at the same time 
points. 
 
Samples are to be sent by overnight express in a temperature certified shipping kit: 
 
Dr Jeffrey Miller  
Attn: Sue Fautsch 
University of Minnesota 
Cancer Center Research Building, Room 521 
425 E. River Road 
Minneapolis, MN  55455 
 
Phone: 612 625-6165 
 
 
6. LABORATORY SPECIMEN COLLECTION, STORAGE AND SHIPPING 
PROCEDURES 
 
Standard procedures for collection, storage, and shipping of specimens will be followed 
according to the NMDP and the NHLBI guidelines.  Samples will be given a unique 
alphanumeric code that contains no personal identifiers.  Transplant Center Coordinators will 
hold the link to the code.  Laboratory staff will not have access to the link. 
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7. LABORATORY CONTRACTS AND REMAINING SAMPLES 
 
All laboratory studies will be performed at laboratories under contract with the NMDP on behalf 
of the BMT CTN.  The laboratory contract specifies that any remaining serum must be stored at 
the laboratory for the duration of the study.  If the investigators choose to perform additional 
studies on these remaining samples, a formal amendment will be made to the protocol.  Any 
amendments to the protocol are subject to the DSMB and IRB approval process. 
 
At the end of the study, the BMT CTN will either instruct the laboratory to destroy any 
remaining samples or to transfer the remaining samples to the NHLBI sample repository in 
Maryland.  These samples will be paired with the respective donor or recipient sample and given 
unique bar code designations that cannot be linked back to the donor or the recipient.  An 
NHLBI Biologic Specimen Repository Utilization Committee will advise the Institute on 
requests for specimens to perform research with these anonymous samples.  If an investigator 
request for these samples is approved by the committee, the NHLBI may provide a panel of the 
specimens requested using unique code numbers.  Laboratory test results, clinical information, 
etc., associated with the coded samples are provided to the investigator only after completion of 
his/her research protocol.  Samples sent to researchers cannot be linked with any remaining 
sample at the repository. 
 
After completion of all cellular assays, the samples will be destroyed.  Only serum samples 
remaining from the laboratory assays for antibody titers will be shipped to the NHLBI sample 
repository.   
 
 
Table 2:  Effect of Storage Time and Storage Temperature on the Numbers of Viable CD34 
Cells, T cells and Dendritic Cells in Blood and Marrow Grafts 
 
Analyses after 72 
hours:  
Median percentages 
of initial value 
2-8°C Marrow 
HPC 
Room Temp 
Marrow HPC 
2-8°C Blood 
HPC 
Room Temp 
Blood PBSC 
Viable CD34 100% 100% 40% 16% 
Viable CD3 60% 51% 54% 48% 
Viable DC2p 74% 54% 67% 32% 
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Table 3:  Flow Cytometry for Graft Characterization 
 
Tube 
# 
Class of 
Cells Cell Types 
Measured Blood Cell 
Subsets Antibodies 
1 Progenitor 
Cell  
Viable CD34 
cells 
Viable nucleated cells 
CD34 cells 
CD34/CD38- cells/kg 
anti-CD45 (FITC) 
anti-CD34 (PE) 
anti-CD38(APC) 
7AAD 
2 Progenitor 
Cell  
ALDHbright 
cells 
ALDHbright CD34 cells 
ALDHbright CD34-negative 
cells/kg 
BAAA (FITC) 
anti-CD34 (APC) 
anti-CD45(PE) 
3 Progenitor 
Cell  
ALDH 
negative 
control 
Negative control for 
BAAA staining 
BAAA (FITC) + DEAB 
IgG1-(APC negative control) 
IgG1-(PE negative control) 
4 Progenitor 
Cell  
ALDH 
compensation 
BAAA control BAAA 
IgG1 (APC negative control) 
IgG1-(PE negative control) 
5 Progenitor 
Cell  
ALDH 
compensation 
PE control BAAA 
IgG1-(APC negative control) 
CD3-(PE) 
6 Progenitor 
Cell  
ALDH 
compensation 
APC control BAAA 
CD3-(APC) 
IgG1-(PE negative control) 
7 Lymphoid 
Subsets 
T cell subsets CD4 
CD8 
CD25+ 
anti-CD4 (PerCP) 
anti-CD8 (FITC) 
anti-CD25 (PE) 
anti-CD3 (APC) 
8 Lymphoid 
Subsets 
NK and γδ T 
cells 
CD56+ 
γδ  T cells 
anti-CD56 (PE) 
anti-γδ TCR (FITC) 
anti-CD16 (PerCP) 
anti-CD3 (APC) 
9 Lymphoid 
Subsets 
B-cells & 
monocytes 
CD5+ B-cells  
CD14+ monocytes 
anti-CD5 (PerCP) 
anti-CD14(PE) 
anti-CD2 (FITC) 
anti-CD19 (APC) 
10 Dendritic 
Cell 
Subsets 
DC subsets DC1 and DC2 subsets anti-lineage (FITC) 
anti-CD123(PE) 
anti-HLADR (PerCP) 
anti-CD11c(APC) 
11 Isotype 
Controls 
Isotype Ig Non-specific staining irrelevant (FITC) (PE) (PerCP) (APC) 
conjugates to murine monoclonal Ab 
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Table 4:  Flow Cytometry for Immune Reconstitution 
 
Tube 
# 
Class of 
Cells Cell Types 
Measured Blood Cell 
Subsets Antibodies 
1 Lymphoid 
Subsets 
T cells CD4 
CD8 
CD25+  
anti-CD4(PerCP) 
anti-CD8 (FITC) 
anti-CD25 (PE) 
anti-CD3(APC) 
2 Lymphoid 
Subsets 
NK and γδ T 
cells 
CD56+  
γδ T cells 
anti-CD56 (PE) 
anti-γδ TCR (FITC) 
anti-CD16 (PerCP) 
anti-CD3 (APC) 
3 Lymphoid 
Subsets 
CD8 T cell 
Subsets 
Naïve and activated 
CD8 T cells 
anti-CD8 (APC) 
anti-Ki67(FITC) 
anti-CD62L (PE) 
anti-CD45RA (TC) 
4 Lymphoid 
Subsets 
CD4 T cell 
Subsets 
Naïve and activated 
CD4 T cells 
anti-CD4 (APC) 
anti-Ki67(FITC) 
anti-CD62L(PE) 
anti-CD45RA (TC) 
5 Lymphoid 
Subsets 
B-cells & 
monocytes 
CD5+ 
CD27 
B cells 
CD14+ monocytes 
anti-CD5 (PerCP) 
anti-CD27 (FITC) 
anti-CD14(PE) 
anti-CD19 (APC) 
6 Dendritic 
Cell Subsets 
DC subsets DC1 and DC2 subsets anti-lineage (FITC) 
anti-CD123(PE) 
anti-HLADR (PerCP) 
anti-CD11c(APC) 
7 Isotype 
Controls 
Isotype Ig Non-specific staining irrelevant (FITC) (PE) (PerCP) 
(APC) conjugates to murine 
monoclonal Ab 
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Table 5:  Summary of Immune Reconstitution Assays for Donors and Patients 
and Post-transplant Vaccination Schedule for Patients  
 
 Baseline 
Donor 
Baseline 
Patient 1 m 3 m 6 m 7 m 9 m 11 m 12 m 24 m 
 
Measures of Cellular Immunity  
FACS analysis    X X X    X X 
Tetramers assay    X X    X X 
TREC analysis    X X    X X 
Plasma IL-7 and IL-2 
levels 
   X X    X X 
T cell responses to tetanus, 
CMV, and Aspergillus 
antigens  
   X X    X X 
 
Immunoglobulin and Antibody Titers1 
dT Antibodies   X   X   X X X 
S. pneum. Ab and ops     X   X X X 
Anti-HBsAg titer X    X    X X 
Quantitative Ig  X   X   X X X 
H. influenzae B Ab Titer     X    X X 
Natural Killer Cell 
Receptor Acquisition 
X X  X X    X  
1 Antibody titers should be drawn just before vaccination. 
 
 Baseline 
Donor 
Baseline 
Patient 1 m 3 m 6 m 7 m 9 m 11 m 12 m 24 m 
 
Vaccination Schedule2 
dT vaccine     X   X   
PCV7 vaccine      X X    
PPV23 vaccine        X   
Hep B vaccine     X X  X   
2 Vaccinations should be given ±1 week of the scheduled dates. 
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Table 6: Collection and Shipping Procedures and Collection Schedule for Patient Blood Samples 
 
 
TYPE OF  
SAMPLE 
TYPE OF PROCESSING AND 
STORAGE 
DATES SAMPLES 
OBTAINED SHIPPING SPECIFICATIONS 
LOCATION OF TEST 
PERFORMED 
FACS Analysis 17 mL peripheral blood 
((2) 8.5 mL fill ACD-A 
yellow top tubes) 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
1, 3, 6, 12, and 24 
months post-transplant. 
Ship priority overnight FedEx on frozen gel 
packs to Emory University; samples should 
not be in direct contact with the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
CBC with 
Differential 
3 mL peripheral blood 
((1) 3 mL fill EDTA 
lavendar top tube) 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
1, 3, 6, 12, and 24 
months post-transplant. 
Ship priority overnight FedEx on frozen gel 
packs to Emory University; samples should 
not be in direct contact with the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
TREC analysis; T 
cell responses to 
tetanus, CMV, and 
Aspergillus antigens; 
Tetramer FACS 
analysis 
34 mL peripheral blood 
sample for all analyses 
((4) 8.5 mL fill ACD-A 
yellow top tubes) 
 
 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
3, 6, 12, and 24 months 
post-transplant. 
Ship priority overnight FedEx on frozen gel 
packs to Emory University; samples should 
not be in direct contact with the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
Immunoglobulin and 
Antibody Titers 
10 mL peripheral blood 
((1) 10 mL fill red top 
tube, no anticoagulant) 
 
Sample should be placed upright in a 
sample rack and allowed to clot at 
room temperature for 30 minutes.  
Centrifuge red top tube at 900 x g or 
2100 rpm.  Extract serum carefully 
without disturbing the clot.  Transfer 
500 µL aliquots to 10 cryovials and 
freeze at –70ºC in a scientific grade 
freezer. 
At baseline prior to 
transplant and at 6, 11, 
12, and 24 months post-
transplant. 
Batch ship quarterly, frozen on dry ice in a 
provided shipping container, FedEx priority 
overnight to the NHLBI Repository. 
Esoterix Laboratory 
Plasma Il-7 and Il-2 
Levels 
6 mL peripheral blood 
((1) 7 mL fill EDTA 
lavendar top tube) 
Centrifuge the EDTA containing 
whole blood samples at 900 x g or 
2100 rpm for 10 minutes within 30 
minutes of collection.  Extract the 
separated plasma.  Transfer 500 µL 
aliquots to 6 cryovials and freeze at 
 -70ºC in a scientific grade freezer. 
3, 6, 12, and 24 months 
post-transplant. 
Batch ship quarterly, frozen on dry ice in a 
provided shipping container, FedEx priority 
overnight to the NHLBI Repository. 
Esoterix Laboratory 
Natural Killer Cell 
Receptor Acquisition 
30 mL peripheral blood 
((3) 10 mL fill sodium 
heparin green top tube) 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
At baseline prior to 
transplant and at 3, 6, 
and 12 monts post-
transplant. 
Ship priority overnight FedEx on frozen gel 
packs to University of Minnesota; samples 
should not be in direct contact with the gel 
packs. 
Dr. Jeffrey Miller’s Lab at 
University of Minnesota 
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Table 7: Collection and Shipping Procedures and Collection Schedule for Donor Blood and Product Samples 
 
TEST TYPE OF  SAMPLE 
TYPE OF PROCESSING AND 
STORAGE 
DATES SAMPLES 
OBTAINED SHIPPING SPECIFICATIONS 
LOCATION OF TEST 
PERFORMED 
Baseline Antibody 
Titer 
10 mL peripheral blood 
((1) 10 mL fill red top 
tube, no additive) 
 
Sample should be placed upright in a 
sample rack and allowed to clot at 
room temperature for a minimum of 
30 minutes prior to packaging the 
sample for shipment. 
At baseline: any time 
after donor signs 
consent and prior to 
first filgrastim 
injection/marrow 
collection. 
Ship priority overnight FedEx at room 
temperature to Esoterix Laboratory. 
Esoterix Laboratory 
Cellular Composition 2-4 mL product sample 
((2) 5 mL sterile 
polyethylene screw top 
tubes, no additive) 
 
Collect and package an aliquot of 
product for shipment.  If two day 
PBSC collection, first sample is 
stored overnight at 2-8° C and 
shipped with Day 2 sample. 
Day of collection. Ship priority overnight FedEx at 2-8° C on 
frozen gel packs to Emory University; 
samples should not be in direct contact with 
the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
Natural Killer Cell 
Receptor Acquisition 
30 mL peripheral blood 
((3) 10 mL fill sodium 
heparin green top tube) 
No additional processing; do not 
centrifuge.   
At baseline: any time 
after donor signs 
consent and prior to 
first filgrastim 
injection/marrow 
collection. 
Ship priority overnight FedEx at 2-8° C on 
frozen gel packs to University of Minnesota; 
samples should not be in direct contact with 
the gel packs. 
Dr. Jeffrey Miller’s Lab at 
University of Minnesota 
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APPENDIX D – HUMAN SUBJECTS 
 
 
Subject consent: Candidates for the study will be identified as described in Chapter 4.  The PI or 
his/her designee at each transplant or donor center will contact the candidates, provide 
information about the purpose of the study, obtain consent and register them onto the study.  A 
template of the consent form will be provided by the network for each center to customize to 
meet the local requirements and have reviewed and approved by the local IRB. 
 
Confidentiality: Confidentiality will be maintained by assigning patients and donors identifier 
codes.  The keys relaying to the patient’s or donor's identity with the ID code will be kept at each 
Center and at the NMDP separately from the research database.  
 
Participation of women and minorities, children and other populations: Women and ethnic 
minorities will be included in this study.  There is no lower age for participants. 
 
Justification for including minors: The transplant procedures described in this protocol are 
considered non-research, standard therapy at U.S. transplant centers.  Both bone marrow and 
peripheral blood stem cell (PBSC) transplants have been successfully used to treat blood 
disorders such as leukemias and myelodysplasia in pediatric and adult populations.  In addition, 
the conditioning regimens and GVHD prophylaxis regimens included in the protocol are non-
research, standard regimens.  Therefore, in this protocol, the transplant procedure itself is not 
considered a research procedure and was not included in the risk/benefit analysis for inclusion of 
minors in research. 
 
The following research procedures were included in the risk/benefit analysis: 
• Randomization 
• Quality of life interviews (16 and 17 years of age only) 
• Blood draws for immune reconstitution studies 
 
The research in this protocol satisfies the conditions set forth in 45 CFR 46.406: “Research 
involving greater than minimal risk and no prospect of direct benefit to individual subjects, but 
likely to yield generalizable knowledge about the subject’s disorder or condition.” 
 
The research meets the following conditions: 
 
1. The risk represents a minor increase over minimal risk. 
• In all likelihood, all children invited to participate in this protocol will receive a 
hematopoietic stem cell (HSC) transplant regardless of whether they participate in this 
protocol.  Since it is unknown if the overall survival from a HSC transplant differs 
depending on whether the source of the stem cells is bone marrow or peripheral blood, 
the randomization process represents a minor increase over minimal risk to the standard 
transplant procedure.  
• Quality of life (QOL) interviews will only be conducted on minors 16 and 17 years of 
age.  There are no physical risks associated with the QOL interviews, but there is a minor 
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increase over minimal risk as to loss of confidentiality or psychological distress caused 
by the questions.  There are procedures in place to decrease these risks. 
• Blood draws for immune reconstitution studies are an optional part of the study.  The 
minor may participate in the randomization, and if applicable, the QOL interviews, and 
opt-out of the blood draws for the immune reconstitution studies.  Although these blood 
draw volumes fall well within the minimal risk limits for healthy adults, the fact that 
these are pediatric, post-transplant patients slightly increases the risk of the blood draw.  
However, since these tests have no bearing whatsoever on patient care, the patient’s 
physician would eliminate the blood draw if it posed additional risk for the patient. 
 
2. The intervention or procedure presents experiences to subjects that are reasonably 
commensurate with those inherent in their actual or expected medical, dental, psychological, 
social, or educational situations. 
• In all likelihood, all children invited to participate in this protocol will receive a 
hematopoietic stem cell transplant regardless of whether they participate in this protocol.  
Randomly assigning the transplant product the minor will receive does not inherently 
alter the standard transplant procedure.  The transplant experience on the protocol is 
commensurate with the transplant experience off the protocol. 
• The majority of minors invited to participate on this protocol will not take part in the 
QOL portion of the study.  For those 16 and 17-year-old minors who will participate in 
the QOL interviews, the interviews are commensurate with the interviews these minors 
would have with Child Life Coordinators or other similar support staff at the transplant 
center following a standard transplant. 
• The blood drawn for the immune reconstitution studies will most likely be drawn at the 
time of other blood draws for the standard transplant procedure.  Since in most cases 
additional vein sticks will not be required, and the amount of blood drawn for these 
research tests is relatively minor in relation to all the other blood draws that are part of 
the standard transplant procedure, these blood draws are commensurate with those of the 
standard transplant procedure. 
 
3. The intervention or procedure is likely to yield generalizable knowledge about the subject’s 
disorder or condition, which is of vital importance for the understanding or amelioration of 
the subject’s disorder, or condition. 
• Within the transplant community there is shift in medical practice from performing bone 
marrow transplants to performing peripheral blood transplants despite the fact that there 
are presently no data to support this shift in practice.  This study is the first prospective, 
randomized clinical trial to compare the results of these two types of transplant using 
unrelated donors.  This study is of vital importance in understanding the best treatment 
options for patients in need of an unrelated donor hematopoietic stem cell transplant.  The 
results could well be different in pediatric populations than in adult populations; 
therefore, it is important to include pediatric patients in this study.  
• Since quality of life issues are an important aspect of evaluating the results of each type 
of transplant, the quality of life interviews in the 16 and 17 year olds will provide 
BMT CLINICAL TRIALS NETWORK  PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 8.0 dated September 15, 2006 
D-4 
valuable information in determining the impact each type of transplant has on the quality 
of life of older minors.  
• The additional research tests examining immune reconstitution after transplant will 
provide data on any differences the source of the hematopoietic stem cells may make in 
restoring immune reconstitution after a transplant.  Since immune reconstitution is 
directly related to post-transplant infections, a major contributor to transplant-related 
mortality, results of this portion of the study will be important to further understanding 
and treating this significant complication of unrelated donor hematopoietic stem cell 
transplantation. 
 
4. Adequate provisions are made for soliciting assent of the children and permission of their 
parents or guardians, as set forth in CFR 46.408. 
• The research procedures do not provide any direct benefit to the health and well being of 
the minors; therefore, assent will be sought from all minors aged 7 to 17 years old. 
• Age appropriate assent forms will be used to obtain assent from minors 7 to 11 years old 
and minors 12 to 17 years old.  Minor assent must be documented by a signature on the 
Assent Form for Participation in the study. 
• The research in this protocol is covered by 45 CFR 46.406; therefore, the signatures of 
both parents are required on the legal guardian consent form, unless one parent is 
deceased, unknown, incompetent, or not reasonably available, or when only one parent 
has legal responsibility for the care and custody of the child. 
• The minor may only participate in the research if the minor and both parents agree to the 
minor’s participation.  If either parent or the minor declines participation in the study, the 
minor shall not be enrolled in the study. 
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APPENDIX E – DONOR MANAGEMENT 
 
 
Donor eligibility will be confirmed as described in Section 2.5 of the protocol.  In addition, 
donor management will be in accordance with the NMDP Donor Center Manual of Operations. 
 
Donors’ eligibility determinations and enrollments will occur following issuance of a work-up 
request.  Because none of the work-up requirements are unique to the protocol, the donor consent 
decision may be made at any time prior to donor clearance.  However, the invitation to 
participate in the protocol must be extended at the donor information session.  At any time 
during the work-up procedure, if the donor declines to participate in the protocol, this decision 
must be communicated immediately to the NMDP Search and Transplant Services Department.  
At the donor information session, the following information will be provided: 
 
PURPOSE OF THE TRIAL 
This trial has been undertaken to compare the established blood stem cell source, bone marrow, 
against the newer source, PBSC.  In making this comparison, we are interested in both donor and 
recipient experiences (outcomes).  There is no foregone conclusion that one product is better 
than the other (for either donors or recipients), if that were the case, the trial would not be 
necessary.  While some experts may have opinions about the comparison, these opinions cannot 
be verified by facts.  The purpose of this trial is to provide scientifically valid information to 
allow a comparison. 
 
POTENTIAL ADVANTAGES OF EACH PRODUCT 
Donors will be informed about what is being compared to determine the potential advantages of 
each product for themselves and their recipients.  The major outcome for donors is the incidence 
of adverse events and serious adverse events.  We are also interested, however, in the donors’ 
quality of life experiences with each type of donation.  For transplant recipients, we will be 
measuring engraftment, graft-versus-host disease, risk of relapse and survival.  
 
The NMDP has been conducting a non-randomized comparison of bone marrow and PBSC since 
July 1999.  This comparison suggests, but does not prove, the following associations. 
 
For Donors1 –  
Symptoms from donation Similar in both groups. PBSC donors experience most 
of their symptoms before donation, but bone marrow 
donors have symptoms after donation. 
Recovery from donation PBSC donors recover faster after donation.  
Satisfaction with donation Both bone marrow and PBSC donors are comfortable 
with their decisions to donate and both groups feel the 
donation experience was positive. 
 
                                                 
1 Data provided by Galen Switzer who has conducted an NMDP-funded comparison of donor experiences following 
bone marrow and PBSC donation. 
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For Recipients –  
Engraftment of neutrophils and 
platelets 
Clearly occurs earlier with PBSC, but no difference in 
overall engraftment 
Risk of graft-versus-host 
disease 
May be higher with PBSC, particularly chronic GVHD 
Immune reconstitution May be faster with PBSC 
Risk of relapse No obvious differences 
Survival  No obvious differences 
 
 
RECIPIENT DROPOUT 
Donors should receive information about the enrollment process for donors and recipients.  They 
should understand that the recipient has consented to participate in the clinical trial, but will 
ultimately be confirmed eligible only in the days immediately preceding the start of conditioning 
therapy.  It is anticipated by the study investigators that up to 15% of enrolled donor-recipient 
pairs will be removed from study before the start of conditioning. In this instance, participation 
in the study will be terminated.  Donors should understand that they may still be asked to provide 
a blood stem cell product for the recipient if an alternative approach to transplantation is 
available.  But, in such cases, the transplant and the results of the transplant will not be included 
in the clinical study. 
 
DONOR EDUCATIONAL MATERIALS 
The NMDP has developed educational materials for donors considering the randomized clinical 
trial.  These materials should be provided prior to the donor’s consent decision.  Questions from 
donors may be directed to donor center personnel or to Dr. Dennis Confer, NMDP Chief Medical 
Officer (612-362-3425, dconfer@nmdp.org) or Dr. John Miller, NMDP Donor Center Medical 
Director (612-884-8534, jmiller5@nmdp.org). 
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